Famotidine	B-CHEMICAL
-	O
associated	O
delirium	B-DISEASE
Famotidine	B-CHEMICAL
is	O
a	O
histamine	B-CHEMICAL
Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	B-DISEASE
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	B-CHEMICAL
The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	B-CHEMICAL
-	O
associated	O
delirium	B-DISEASE
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	B-CHEMICAL
The	O
pharmacokinetics	O
of	O
famotidine	B-CHEMICAL
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	B-DISEASE
The	O
implications	O
of	O
using	O
famotidine	B-CHEMICAL
Indomethacin	B-CHEMICAL
induced	O
hypotension	B-DISEASE
in	O
sodium	B-CHEMICAL
After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
indomethacin	B-CHEMICAL
(	O
IDM	O
)	O
to	O
sodium	B-CHEMICAL
In	O
sodium	B-CHEMICAL
repleted	O
animals	O
indomethacin	B-CHEMICAL
Thus	O
,	O
indomethacin	B-CHEMICAL
by	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin	O
-	O
angiotensin	B-CHEMICAL
system	O
in	O
sodium	B-CHEMICAL
Late	O
-	O
onset	O
scleroderma	B-DISEASE
renal	B-DISEASE
crisis	O
induced	O
by	O
tacrolimus	B-CHEMICAL
and	O
prednisolone	B-CHEMICAL
Scleroderma	B-DISEASE
renal	B-DISEASE
crisis	O
(	O
SRC	O
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-DISEASE
sclerosis	I-DISEASE
(	O
SSc	O
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	B-DISEASE
Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
precipitated	O
by	O
cyclosporine	B-CHEMICAL
In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	O
induced	O
by	O
tacrolimus	B-CHEMICAL
and	O
corticosteroids	B-CHEMICAL
The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B-CHEMICAL
The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	B-CHEMICAL
psychosis	B-DISEASE
in	O
methamphetamine	B-CHEMICAL
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	B-CHEMICAL
-	O
induced	O
psychosis	B-DISEASE
in	O
patients	O
with	O
methamphetamine	B-CHEMICAL
dependence	B-DISEASE
The	O
association	O
between	O
psychiatric	B-DISEASE
co	B-CHEMICAL
-	O
morbidity	O
and	O
methamphetamine	B-CHEMICAL
-	O
induced	O
psychosis	B-DISEASE
METHODS	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
concurrently	O
at	B-DISEASE
Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	B-CHEMICAL
for	O
methamphetamine	B-CHEMICAL
-	O
induced	O
psychosis	B-DISEASE
and	O
other	O
Axis	O
I	O
psychiatric	B-DISEASE
RESULTS	O
:	O
Of	O
292	O
subjects	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	B-DISEASE
symptoms	I-DISEASE
and	O
13	O
.	O
0	O
%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	B-DISEASE
symptoms	I-DISEASE
Co	B-CHEMICAL
-	O
morbid	O
major	B-DISEASE
depressive	I-DISEASE
disorder	I-DISEASE
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
),	O
bipolar	B-DISEASE
disorder	I-DISEASE
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
),	O
antisocial	B-DISEASE
personality	I-DISEASE
disorder	I-DISEASE
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
heavy	O
methamphetamine	B-CHEMICAL
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	B-CHEMICAL
-	O
induced	O
psychosis	B-DISEASE
Major	B-DISEASE
depressive	I-DISEASE
disorder	I-DISEASE
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
antisocial	B-DISEASE
personality	I-DISEASE
disorder	I-DISEASE
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	B-DISEASE
CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	B-DISEASE
in	O
patients	O
with	O
methamphetamine	B-CHEMICAL
dependence	B-DISEASE
It	O
was	O
associated	O
with	O
co	B-CHEMICAL
-	O
morbid	O
affective	B-DISEASE
disorder	I-DISEASE
,	O
antisocial	B-DISEASE
personality	I-DISEASE
,	O
and	O
heavy	O
methamphetamine	B-CHEMICAL
It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	B-CHEMICAL
dependence	B-DISEASE
should	O
be	O
screened	O
for	O
psychotic	B-DISEASE
symptoms	I-DISEASE
Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
PD	B-DISEASE
)	O
and	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
(	O
LIDs	B-DISEASE
This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	B-DISEASE
The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	B-DISEASE
To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	B-DISEASE
changes	O
in	O
LIDs	B-DISEASE
The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	B-CHEMICAL
(	O
CYP	O
)-	O
induced	O
cystitis	B-DISEASE
injected	O
with	O
CYP	O
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	B-CHEMICAL
and	O
GR	B-CHEMICAL
82334	I-CHEMICAL
Spontaneous	O
pain	B-DISEASE
RESULTS	O
:	O
Cyclophosphamide	B-CHEMICAL
treatment	O
increased	O
the	O
spontaneous	O
pain	B-DISEASE
The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	B-DISEASE
Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	B-DISEASE
CONCLUSIONS	O
:	O
In	O
CYP	O
-	O
induced	O
cystitis	B-DISEASE
Acute	O
hepatitis	B-DISEASE
associated	O
with	O
clopidogrel	B-CHEMICAL
Drug	O
-	O
induced	O
hepatotoxicity	B-DISEASE
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	B-DISEASE
We	O
describe	O
a	O
case	O
of	O
clopidogrel	B-CHEMICAL
-	O
related	O
acute	O
hepatitis	B-DISEASE
The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	B-DISEASE
Reports	O
about	O
cases	O
of	O
hepatotoxicity	B-DISEASE
due	O
to	O
clopidogrel	B-CHEMICAL
In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
hepatic	B-DISEASE
injury	I-DISEASE
when	O
clopidogrel	B-CHEMICAL
Bortezomib	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-DISEASE
myeloma	I-DISEASE
Bortezomib	B-CHEMICAL
(	O
bort	O
)-	O
dexamethasone	B-CHEMICAL
(	O
dex	B-CHEMICAL
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-DISEASE
myeloma	I-DISEASE
This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	O
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-CHEMICAL
Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	O
-	O
dex	B-CHEMICAL
The	O
median	O
number	O
of	O
bort	O
-	O
dex	B-CHEMICAL
On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	B-DISEASE
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	B-CHEMICAL
and	O
35	O
%	O
achieved	O
at	B-DISEASE
The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	B-CHEMICAL
and	O
receiving	O
bort	O
-	O
dex	B-CHEMICAL
Bort	O
-	O
dex	B-CHEMICAL
Pubertal	O
exposure	O
to	O
Bisphenol	B-CHEMICAL
A	I-CHEMICAL
increases	O
anxiety	B-DISEASE
The	O
negative	O
effects	O
of	O
Bisphenol	B-CHEMICAL
A	I-CHEMICAL
Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	B-DISEASE
This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	O
exposure	O
during	O
puberty	B-DISEASE
Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	B-DISEASE
Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	O
exposure	O
increased	O
anxiety	B-DISEASE
Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	B-DISEASE
Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	B-DISEASE
Cardiovascular	B-DISEASE
diseases	I-DISEASE
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
The	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	B-DISEASE
an	O
interval	O
of	O
24	O
h	B-CHEMICAL
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	B-CHEMICAL
dehydrogenase	O
,	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
,	O
alanine	B-CHEMICAL
transaminase	I-CHEMICAL
,	O
aspartate	B-CHEMICAL
transaminase	O
,	O
and	O
angiotensin	B-CHEMICAL
-	O
converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	B-CHEMICAL
,	O
triglycerides	B-CHEMICAL
,	O
free	O
serum	O
fatty	O
acid	O
,	O
cardiac	O
tissue	O
malondialdehyde	B-CHEMICAL
(	O
MDA	O
),	O
and	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	B-CHEMICAL
and	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
Pretreatment	O
with	O
S	O
.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	B-DISEASE
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	B-CHEMICAL
Captopril	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
),	O
an	O
inhibitor	O
of	O
angiotensin	B-CHEMICAL
The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S	O
.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	O
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	B-CHEMICAL
"	O
Real	O
-	O
world	O
"	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-DISEASE
myeloma	I-DISEASE
Lenalidomide	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
(	O
RD	O
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed	O
/	O
refractory	O
multiple	B-DISEASE
myeloma	I-DISEASE
Objective	O
response	O
(>	O
PR	O
(	O
partial	O
response	O
))	O
rate	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
response	O
(	O
CR	B-CHEMICAL
Median	O
time	O
to	O
CR	B-CHEMICAL
when	O
RD	O
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)-	O
line	O
treatment	O
at	B-DISEASE
Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	B-CHEMICAL
or	O
bortezomib	B-CHEMICAL
Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease	B-DISEASE
Adverse	O
events	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
patients	O
(	O
myelosuppression	B-DISEASE
Peripheral	B-DISEASE
neuropathy	I-DISEASE
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
patients	O
and	O
deep	B-DISEASE
vein	I-DISEASE
thrombosis	I-DISEASE
Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	B-CHEMICAL
Our	O
study	O
confirms	O
that	O
RD	O
is	O
effective	O
and	O
safe	O
in	O
RRMM	O
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	B-DISEASE
The	O
cytogenetic	O
action	O
of	O
ifosfamide	B-CHEMICAL
,	O
mesna	B-CHEMICAL
Ifosfamide	B-CHEMICAL
(	O
IFO	O
)	O
is	O
an	O
alkylating	O
nitrogen	B-CHEMICAL
It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B-DISEASE
cystitis	B-DISEASE
This	O
side	O
effect	O
of	O
IFO	O
raises	O
the	O
requirement	O
for	O
the	O
co	B-CHEMICAL
-	O
administration	O
with	O
sodium	B-CHEMICAL
2	O
-	O
sulfanylethanesulfonate	O
(	O
Mesna	B-CHEMICAL
IFO	O
and	O
Mesna	B-CHEMICAL
Mesna	B-CHEMICAL
In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B-CHEMICAL
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	O
acting	O
at	B-DISEASE
Mesna	B-CHEMICAL
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesia	B-DISEASE
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
Chronic	O
pulsatile	O
levodopa	B-CHEMICAL
therapy	O
for	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
PD	B-DISEASE
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B-DISEASE
We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesia	B-DISEASE
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	B-DISEASE
METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	B-DISEASE
on	O
uninterrupted	O
levodopa	B-CHEMICAL
therapy	O
for	O
at	B-DISEASE
The	O
predictors	O
of	O
dyskinesia	B-DISEASE
The	O
median	O
disease	B-DISEASE
Dyskinesia	B-DISEASE
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B-CHEMICAL
Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	B-DISEASE
Patients	O
with	O
dyskinesia	B-DISEASE
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
longer	O
duration	O
of	O
levodopa	B-CHEMICAL
therapy	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
longer	O
disease	B-DISEASE
duration	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
higher	O
total	O
daily	O
levodopa	B-CHEMICAL
dose	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
patients	O
without	O
dyskinesia	B-DISEASE
The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B-DISEASE
were	O
duration	O
of	O
levodopa	B-CHEMICAL
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B-CHEMICAL
CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesia	B-DISEASE
The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B-CHEMICAL
therapy	O
,	O
total	O
daily	O
levodopa	B-CHEMICAL
An	O
unexpected	O
diagnosis	O
in	O
a	O
renal	B-DISEASE
-	O
transplant	O
patient	O
with	O
proteinuria	B-DISEASE
treated	O
with	O
everolimus	B-CHEMICAL
:	O
AL	O
amyloidosis	B-DISEASE
Proteinuria	B-DISEASE
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	B-DISEASE
and	O
tubular	O
atrophy	B-DISEASE
In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	B-DISEASE
in	O
a	O
renal	B-DISEASE
-	O
transplant	O
patient	O
with	O
pre	O
-	O
transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	B-DISEASE
after	O
conversion	O
from	O
tacrolimus	B-CHEMICAL
to	O
everolimus	B-CHEMICAL
An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	O
injury	O
in	O
HIV	O
-	O
positive	O
persons	O
exposed	O
to	O
tenofovir	B-CHEMICAL
The	O
potential	O
for	O
tenofovir	B-CHEMICAL
We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV	O
-	O
positive	O
persons	O
taking	O
tenofovir	B-CHEMICAL
Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
,	O
kidney	O
tubular	O
dysfunction	O
and	O
Fanconi	B-DISEASE
syndrome	I-DISEASE
Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF	O
-	O
related	O
kidney	B-DISEASE
disease	I-DISEASE
,	O
of	O
which	O
53	O
(	O
50	O
%)	O
had	O
features	O
of	O
kidney	O
tubular	O
dysfunction	O
,	O
35	O
(	O
33	O
%)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	O
dysfunction	O
and	O
18	O
(	O
17	O
%)	O
had	O
Fanconi	B-DISEASE
syndrome	I-DISEASE
The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	O
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	B-DISEASE
syndrome	I-DISEASE
Incidence	O
of	O
postoperative	O
delirium	B-DISEASE
PURPOSE	O
:	O
Postoperative	O
delirium	B-DISEASE
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	B-DISEASE
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	O
delirium	B-DISEASE
METHODS	O
:	O
An	O
observational	O
,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	B-DISEASE
least	O
24	O
h	B-CHEMICAL
Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	B-DISEASE
Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	B-DISEASE
Early	O
postoperative	O
delirium	B-DISEASE
RESULTS	O
:	O
According	O
to	O
the	O
confusion	B-DISEASE
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	O
delirium	B-DISEASE
The	O
use	O
of	O
thiopentone	B-CHEMICAL
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higher	O
risk	O
for	O
delirium	B-DISEASE
compared	O
to	O
propofol	B-CHEMICAL
CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	O
delirium	B-DISEASE
Thiopentone	B-CHEMICAL
A	O
single	O
neurotoxic	B-DISEASE
dose	O
of	O
methamphetamine	B-CHEMICAL
induces	O
a	O
long	O
-	O
lasting	O
depressive	B-DISEASE
Methamphetamine	B-CHEMICAL
(	O
METH	B-CHEMICAL
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	B-CHEMICAL
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	B-DISEASE
However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	B-CHEMICAL
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressive	B-DISEASE
Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive	B-DISEASE
-	O
like	O
behaviour	O
in	O
mice	O
at	B-DISEASE
early	O
and	O
long	O
-	O
term	O
periods	O
following	O
a	O
single	O
high	O
METH	B-CHEMICAL
METH	B-CHEMICAL
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	B-CHEMICAL
However	O
,	O
METH	B-CHEMICAL
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	B-DISEASE
This	O
depressive	B-DISEASE
-	O
like	O
profile	O
induced	O
by	O
METH	B-CHEMICAL
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	B-CHEMICAL
,	O
DOPAC	B-CHEMICAL
and	O
HVA	O
,	O
tyrosine	B-CHEMICAL
hydroxylase	O
and	O
serotonin	B-CHEMICAL
,	O
observed	O
at	B-DISEASE
In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	B-DISEASE
--	O
astroglial	O
dysfunction	O
--	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	B-CHEMICAL
fibrillary	I-CHEMICAL
acidic	I-CHEMICAL
protein	I-CHEMICAL
,	O
were	O
only	O
transiently	O
increased	O
at	B-DISEASE
These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	B-CHEMICAL
induces	O
long	O
-	O
lasting	O
depressive	B-DISEASE
Linezolid	B-CHEMICAL
-	O
induced	O
optic	B-DISEASE
neuropathy	I-DISEASE
We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	O
of	O
vision	B-DISEASE
associated	O
with	O
linezolid	B-CHEMICAL
A	O
45	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second	O
-	O
line	O
anti	O
-	O
tuberculous	O
drugs	O
including	O
linezolid	B-CHEMICAL
and	O
ethambutol	B-CHEMICAL
for	O
extensively	B-DISEASE
drug	I-DISEASE
-	I-DISEASE
resistant	I-DISEASE
tuberculosis	I-DISEASE
(	O
XDR	O
-	O
TB	B-DISEASE
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	O
of	O
vision	B-DISEASE
Color	O
vision	B-DISEASE
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	O
disc	O
edema	B-DISEASE
Ethambutol	B-CHEMICAL
-	O
induced	O
toxic	B-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
was	O
suspected	O
and	O
tablet	O
ethambutol	B-CHEMICAL
Deterioration	O
of	O
vision	B-DISEASE
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	B-CHEMICAL
Discontinuation	O
of	O
linezolid	B-CHEMICAL
resulted	O
in	O
marked	O
improvement	O
of	O
vision	B-DISEASE
Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long	O
-	O
term	O
linezolid	B-CHEMICAL
Resuscitation	O
with	O
lipid	O
,	O
epinephrine	B-CHEMICAL
,	O
or	O
both	O
in	O
levobupivacaine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
toxicity	I-DISEASE
BACKGROUND	O
:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	B-CHEMICAL
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	B-DISEASE
METHODS	O
:	O
Newborn	O
piglets	O
received	O
levobupivacaine	B-CHEMICAL
Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
),	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	B-CHEMICAL
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	B-CHEMICAL
Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	B-DISEASE
The	O
number	O
of	O
ECG	O
abnormalities	B-DISEASE
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	B-CHEMICAL
and	O
epinephrine	B-CHEMICAL
CONCLUSIONS	O
:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	B-CHEMICAL
,	O
or	O
epinephrine	B-CHEMICAL
Epinephrine	B-CHEMICAL
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	B-DISEASE
Incidence	O
of	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
type	O
II	O
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	B-DISEASE
BACKGROUND	O
:	O
Thrombocytopenia	B-DISEASE
in	O
patients	O
with	O
end	O
-	O
stage	O
liver	B-DISEASE
disease	I-DISEASE
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	O
hypertension	B-DISEASE
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	B-DISEASE
The	O
impact	O
of	O
immune	O
-	O
mediated	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
type	O
II	O
(	O
HIT	B-DISEASE
type	O
II	O
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	B-DISEASE
after	O
liver	B-DISEASE
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	B-DISEASE
after	O
liver	B-DISEASE
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	B-DISEASE
METHOD	O
:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full	O
-	O
size	O
liver	B-DISEASE
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	O
-	O
stage	O
or	O
malignant	O
liver	B-DISEASE
disease	I-DISEASE
Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	B-DISEASE
RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	B-DISEASE
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End	O
-	O
Stage	O
Liver	B-DISEASE
Disease	I-DISEASE
score	O
and	O
liver	B-DISEASE
cirrhosis	I-DISEASE
The	O
platelet	O
count	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	B-DISEASE
a	O
medium	O
of	O
7	O
d	O
.	O
Regarding	O
HIT	B-DISEASE
II	O
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%)	O
patients	O
with	O
a	O
background	O
of	O
HIT	B-DISEASE
CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
HIT	B-DISEASE
in	O
patients	O
with	O
end	O
-	O
stage	O
hepatic	B-DISEASE
failure	I-DISEASE
For	O
further	O
reduction	O
of	O
HIT	B-DISEASE
type	O
II	O
,	O
the	O
use	O
of	O
intravenous	O
heparin	B-CHEMICAL
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	B-CHEMICAL
Takotsubo	B-DISEASE
syndrome	I-DISEASE
(	O
or	O
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
)	O
secondary	O
to	O
Zolmitriptan	B-CHEMICAL
Takotsubo	B-DISEASE
syndrome	I-DISEASE
(	O
TS	O
),	O
also	O
known	O
as	O
broken	B-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	B-CHEMICAL
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-DISEASE
coronary	I-DISEASE
syndrome	I-DISEASE
We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B-DISEASE
valve	I-DISEASE
prolapse	I-DISEASE
and	O
migraines	O
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-DISEASE
pain	I-DISEASE
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	B-CHEMICAL
I	I-CHEMICAL
.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	B-DISEASE
Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	B-CHEMICAL
But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B-CHEMICAL
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-DISEASE
headache	B-DISEASE
Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
vasospasm	I-DISEASE
secondary	O
to	O
zolmitriptan	B-CHEMICAL
Depression	B-DISEASE
,	O
impulsiveness	O
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
,	O
ecstasy	B-CHEMICAL
RATIONALE	O
:	O
Ecstasy	B-CHEMICAL
(	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
,	O
MDMA	B-CHEMICAL
OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	B-CHEMICAL
METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
),	O
alcohol	B-CHEMICAL
/	O
nicotine	B-CHEMICAL
(	O
AN	O
),	O
cannabis	B-CHEMICAL
/	O
alcohol	B-CHEMICAL
/	O
nicotine	B-CHEMICAL
(	O
CAN	O
),	O
non	O
-	O
ecstasy	B-CHEMICAL
polydrug	O
(	O
PD	B-DISEASE
)),	O
and	O
two	O
ecstasy	B-CHEMICAL
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	B-CHEMICAL
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	B-CHEMICAL
Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	B-DISEASE
RESULTS	O
:	O
While	O
the	O
CAN	O
and	O
PD	B-DISEASE
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	B-CHEMICAL
and	O
EX	O
-	O
MDMA	B-CHEMICAL
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	B-DISEASE
Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
),	O
past	O
ecstasy	B-CHEMICAL
Compared	O
with	O
present	O
ecstasy	B-CHEMICAL
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	B-DISEASE
CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	O
memory	O
and	O
clinically	O
significant	O
levels	O
of	O
depression	B-DISEASE
,	O
impulsiveness	O
,	O
and	O
sleep	O
disturbance	O
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	B-CHEMICAL
Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	B-CHEMICAL
adverse	O
effects	O
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
Levodopa	B-CHEMICAL
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	B-CHEMICAL
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	B-DISEASE
and	O
visual	B-DISEASE
hallucinations	I-DISEASE
HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B-CHEMICAL
This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B-CHEMICAL
A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B-DISEASE
Parkinson	I-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B-DISEASE
(	O
prevalence	O
ratio	O
(	O
PR	O
)=	O
0	O
.	O
615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
visual	B-DISEASE
hallucinations	I-DISEASE
Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B-CHEMICAL
Crocin	B-CHEMICAL
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	B-CHEMICAL
exposure	O
through	O
ERK1	O
/	O
2	O
pathway	O
in	O
rat	O
liver	B-DISEASE
INTRODUCTION	O
:	O
Diazinon	B-CHEMICAL
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	O
insecticides	B-CHEMICAL
It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B-CHEMICAL
may	O
interfere	O
with	O
lipid	B-DISEASE
metabolism	I-DISEASE
Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B-CHEMICAL
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	B-DISEASE
metabolism	I-DISEASE
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	B-DISEASE
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	B-CHEMICAL
Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B-CHEMICAL
on	O
diazinon	B-CHEMICAL
induced	O
disturbed	O
cholesterol	B-CHEMICAL
METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	B-CHEMICAL
oil	I-CHEMICAL
(	O
control	O
),	O
diazinon	B-CHEMICAL
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	B-CHEMICAL
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B-CHEMICAL
The	O
levels	O
of	O
cholesterol	B-CHEMICAL
Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rat	O
liver	B-DISEASE
RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B-CHEMICAL
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B-CHEMICAL
Moreover	O
diazinon	B-CHEMICAL
Crocin	B-CHEMICAL
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	B-CHEMICAL
CONCLUSIONS	O
:	O
Crocin	B-CHEMICAL
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	B-CHEMICAL
GEM	B-CHEMICAL
-	O
P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	B-DISEASE
lymphoma	I-DISEASE
Hodgkin	B-DISEASE
lymphoma	I-DISEASE
(	O
HL	O
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	B-DISEASE
However	O
,	O
for	O
those	O
who	O
relapse	O
,	O
high	O
-	O
dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	B-DISEASE
Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	B-DISEASE
Gemcitabine	B-CHEMICAL
and	O
cisplatin	B-CHEMICAL
have	O
activity	O
in	O
HL	O
,	O
non	O
-	O
overlapping	O
toxicity	B-DISEASE
In	O
this	O
retrospective	O
single	O
-	O
centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	O
treated	O
with	O
gemcitabine	B-CHEMICAL
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	B-CHEMICAL
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	B-CHEMICAL
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM	B-CHEMICAL
Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	B-DISEASE
One	O
hundred	O
and	O
twenty	O
-	O
two	O
cycles	O
of	O
GEM	B-CHEMICAL
Twenty	O
of	O
41	O
(	O
48	O
%)	O
patients	O
received	O
GEM	B-CHEMICAL
Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM	B-CHEMICAL
-	O
P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	B-CHEMICAL
)	O
37	O
%,	O
partial	O
response	O
44	O
%)	O
with	O
14	O
/	O
15	O
CR	B-CHEMICAL
confirmed	O
as	O
a	O
metabolic	O
CR	B-CHEMICAL
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicities	B-DISEASE
were	O
haematological	O
:	O
neutropenia	B-DISEASE
54	O
%	O
and	O
thrombocytopenia	B-DISEASE
Median	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	B-CHEMICAL
Following	O
GEM	B-CHEMICAL
GEM	B-CHEMICAL
Basal	O
functioning	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	B-CHEMICAL
RATIONALE	O
:	O
Ecstasy	B-CHEMICAL
(	O
MDMA	B-CHEMICAL
OBJECTIVES	O
:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	B-CHEMICAL
-	O
polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	B-CHEMICAL
METHOD	O
:	O
Seventy	O
-	O
six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy	B-CHEMICAL
-	O
polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy	B-CHEMICAL
-	O
polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	B-DISEASE
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	B-CHEMICAL
RESULTS	O
:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	B-DISEASE
and	O
depression	B-DISEASE
On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	B-CHEMICAL
On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	B-CHEMICAL
Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	B-CHEMICAL
levels	O
and	O
in	O
overall	O
cortisol	B-CHEMICAL
CONCLUSIONS	O
:	O
The	O
increases	O
in	O
anxiety	B-DISEASE
and	O
depression	B-DISEASE
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	B-CHEMICAL
Dysregulated	O
diurnal	O
cortisol	B-CHEMICAL
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	B-DISEASE
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	B-CHEMICAL
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	B-CHEMICAL
Ifosfamide	B-CHEMICAL
related	O
encephalopathy	B-DISEASE
BACKGROUND	O
:	O
Ifosfamide	B-CHEMICAL
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	B-DISEASE
including	O
sarcomas	O
,	O
lymphoma	B-DISEASE
,	O
gynecologic	O
and	O
testicular	O
cancers	B-DISEASE
Encephalopathy	B-DISEASE
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
IV	O
ifosfamide	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	B-CHEMICAL
related	O
encephalopathy	B-DISEASE
METHODS	O
:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	B-DISEASE
Anderson	O
Cancer	B-DISEASE
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	B-CHEMICAL
related	O
acute	O
encephalopathy	B-DISEASE
RESULTS	O
:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	B-DISEASE
soon	O
after	O
(	O
within	O
12	O
h	B-CHEMICAL
-	O
2	O
days	O
)	O
receiving	O
ifosfamide	B-CHEMICAL
Two	O
patients	O
developed	O
generalized	O
convulsions	B-DISEASE
while	O
one	O
patient	O
developed	O
continuous	O
non	O
-	O
convulsive	B-DISEASE
status	B-DISEASE
epilepticus	I-DISEASE
CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	B-CHEMICAL
related	O
encephalopathy	B-DISEASE
We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	B-CHEMICAL
who	O
develop	O
features	O
of	O
encephalopathy	B-DISEASE
Incidence	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-DISEASE
in	O
hospitalised	O
patients	O
with	O
cancer	B-DISEASE
OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	O
-	O
induced	O
nephropathy	B-DISEASE
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	B-DISEASE
Patients	O
with	O
risk	O
factors	O
for	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	B-CHEMICAL
(	O
Cr	B-CHEMICAL
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	B-CHEMICAL
CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	O
/	O
irinotecan	B-CHEMICAL
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	B-DISEASE
CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	B-DISEASE
Hypertension	B-DISEASE
and	O
the	O
combination	O
of	O
bevacizumab	O
/	O
irinotecan	B-CHEMICAL
Contrast	O
-	O
induced	O
nephropathy	B-DISEASE
Hypertension	B-DISEASE
Syndrome	B-DISEASE
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	B-DISEASE
Her	O
medications	O
included	O
desvenlafaxine	O
,	O
and	O
symptoms	O
included	O
nausea	B-DISEASE
,	O
anxiety	B-DISEASE
and	O
confusion	B-DISEASE
The	O
serum	O
sodium	B-CHEMICAL
at	B-DISEASE
this	O
time	O
was	O
120	O
mmol	O
/	O
L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urine	B-DISEASE
osmolality	O
410	O
mosmol	O
/	O
kg	O
and	O
urine	B-DISEASE
sodium	B-CHEMICAL
After	O
4	O
days	O
the	O
sodium	B-CHEMICAL
During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	B-CHEMICAL
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatment	O
with	O
mirtazapine	B-CHEMICAL
DISCUSSION	O
:	O
SIADH	O
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	B-CHEMICAL
This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	O
might	O
cause	O
clinically	O
significant	O
hyponatremia	B-DISEASE
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	B-CHEMICAL
to	O
cause	O
hyponatremia	B-DISEASE
Oxidative	O
stress	O
on	O
cardiotoxicity	B-DISEASE
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	B-CHEMICAL
The	O
mechanism	O
of	O
doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
)-	O
induced	O
cardiotoxicity	B-DISEASE
Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B-CHEMICAL
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(-	O
24	O
h	B-CHEMICAL
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	B-CHEMICAL
after	O
(+	O
24	O
h	B-CHEMICAL
,	O
n	O
=	O
8	O
)	O
a	O
single	O
dose	O
of	O
DOX	B-CHEMICAL
(	O
4	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
)	O
to	O
determine	O
the	O
DOX	B-CHEMICAL
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	B-CHEMICAL
(	O
4	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
Animals	O
used	O
at	B-DISEASE
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	B-DISEASE
moment	O
-	O
24	O
h	B-CHEMICAL
Cardiac	O
total	O
antioxidant	O
performance	O
(	O
TAP	O
),	O
DNA	O
damage	O
,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	B-DISEASE
Single	O
dose	O
of	O
DOX	B-CHEMICAL
was	O
associated	O
with	O
increased	O
cardiac	O
disarrangement	O
,	O
necrosis	B-DISEASE
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	B-CHEMICAL
The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	B-DISEASE
weight	I-DISEASE
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
),	O
necrosis	B-DISEASE
DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
),	O
and	O
necrosis	B-DISEASE
Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	B-DISEASE
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	B-CHEMICAL
Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	B-CHEMICAL
Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	B-DISEASE
versus	O
chronic	O
toxicity	B-DISEASE
Tacrolimus	B-CHEMICAL
-	O
related	O
seizure	B-DISEASE
after	O
pediatric	O
liver	B-DISEASE
To	O
identify	O
the	O
risk	O
factors	O
for	O
new	O
-	O
onset	O
seizures	B-DISEASE
Patients	O
were	O
divided	O
into	O
seizures	B-DISEASE
group	O
and	O
a	O
non	O
-	O
seizures	B-DISEASE
Seizures	B-DISEASE
All	O
exhibited	O
generalized	O
tonic	B-DISEASE
-	O
clonic	O
seizures	B-DISEASE
Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	B-DISEASE
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end	O
-	O
stage	O
liver	B-DISEASE
disease	I-DISEASE
score	O
before	O
surgery	O
,	O
Child	O
-	O
Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	B-CHEMICAL
after	O
surgery	O
,	O
and	O
trough	O
TAC	B-CHEMICAL
Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	B-CHEMICAL
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	B-DISEASE
All	O
children	O
who	O
experienced	O
seizures	B-DISEASE
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	B-DISEASE
-	O
free	O
without	O
anti	O
-	O
epileptic	B-DISEASE
High	O
trough	O
TAC	B-CHEMICAL
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	B-DISEASE
High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post	O
-	O
operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	B-CHEMICAL
-	O
related	O
seizures	B-DISEASE
The	O
flavonoid	O
apigenin	B-CHEMICAL
The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	O
apigenin	B-CHEMICAL
),	O
1	O
h	B-CHEMICAL
before	O
acquisition	O
),	O
on	O
24	O
h	B-CHEMICAL
There	O
were	O
no	O
differences	O
between	O
saline	O
-	O
and	O
apigenin	B-CHEMICAL
-	O
treated	O
groups	O
in	O
the	O
24	O
h	B-CHEMICAL
Furthermore	O
,	O
apigenin	B-CHEMICAL
did	O
not	O
prevent	O
the	O
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
The	O
saline	O
-	O
and	O
apigenin	B-CHEMICAL
In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	B-DISEASE
At	B-DISEASE
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60	O
%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	B-CHEMICAL
These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	B-CHEMICAL
delays	O
the	O
long	O
-	O
term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	B-CHEMICAL
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	B-CHEMICAL
Cholecystokinin	B-CHEMICAL
-	O
octapeptide	O
restored	O
morphine	B-CHEMICAL
Cholecystokinin	B-CHEMICAL
We	O
have	O
previously	O
reported	O
that	O
CCK	O
-	O
8	O
significantly	O
alleviated	O
morphine	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-CHEMICAL
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	O
-	O
8	O
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)-	O
granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-CHEMICAL
Acute	O
morphine	B-CHEMICAL
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B-CHEMICAL
The	O
present	O
results	O
demonstrate	O
that	O
CCK	O
-	O
8	O
attenuates	O
the	O
effect	O
of	O
morphine	B-CHEMICAL
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	O
-	O
8	O
on	O
morphine	B-CHEMICAL
-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	B-DISEASE
:	O
the	O
key	O
events	O
in	O
Streptozotocin	B-CHEMICAL
(	O
ICV	O
)	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B-DISEASE
in	O
ICV	O
Streptozotocin	B-CHEMICAL
In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	O
deficit	O
was	O
found	O
in	O
Morris	O
water	B-CHEMICAL
STZ	O
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	O
,	O
Ca	B-CHEMICAL
Increased	O
expression	O
and	O
activity	O
of	O
Caspase	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	O
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	B-DISEASE
STZ	O
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	B-CHEMICAL
and	O
SNAP	O
-	O
25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B-DISEASE
Oral	O
treatment	O
with	O
Memantine	B-CHEMICAL
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	O
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	B-DISEASE
and	O
post	O
synaptic	O
neurotoxicity	B-DISEASE
On	O
the	O
other	O
hand	B-DISEASE
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca	B-CHEMICAL
Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B-DISEASE
are	O
the	O
key	O
factors	O
in	O
STZ	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
and	O
neuronal	O
cell	O
death	B-DISEASE
Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
with	O
diltiazem	B-CHEMICAL
in	O
prevention	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-DISEASE
INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	O
-	O
induced	O
nephropathy	B-DISEASE
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
with	O
sodium	B-CHEMICAL
bicarbonate	I-CHEMICAL
infusion	O
and	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
infusion	O
with	O
diltiazem	B-CHEMICAL
,	O
a	O
calcium	B-CHEMICAL
MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B-CHEMICAL
agent	I-CHEMICAL
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
),	O
all	O
with	O
creatinine	B-CHEMICAL
The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	O
and	O
sodium	B-CHEMICAL
bicarbonate	I-CHEMICAL
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B-CHEMICAL
All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B-CHEMICAL
urea	I-CHEMICAL
nitrogen	I-CHEMICAL
(	O
BUN	O
)	O
and	O
creatinine	B-CHEMICAL
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B-CHEMICAL
material	I-CHEMICAL
RESULTS	O
:	O
The	O
basal	O
creatinine	B-CHEMICAL
Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
ARF	O
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B-CHEMICAL
material	I-CHEMICAL
CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
,	O
sodium	B-CHEMICAL
bicarbonate	I-CHEMICAL
and	O
isotonic	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
with	O
diltiazem	B-CHEMICAL
Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	B-CHEMICAL
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
protocols	O
(	O
ACCL0131	O
):	O
a	O
methotrexate	B-CHEMICAL
Concerns	O
about	O
long	O
-	O
term	O
methotrexate	B-CHEMICAL
(	O
MTX	B-CHEMICAL
)	O
neurotoxicity	B-DISEASE
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	B-CHEMICAL
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	B-CHEMICAL
administration	O
in	O
children	O
with	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	B-DISEASE
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(	O
CNS	O
)-	O
directed	O
therapy	O
(	O
P9605	B-CHEMICAL
A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
"	O
standard	O
-	O
risk	O
"	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
years	O
at	B-DISEASE
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	B-DISEASE
at	B-DISEASE
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	B-CHEMICAL
Significantly	O
more	O
P9605	B-CHEMICAL
patients	O
developed	O
leukoencephalopathy	B-DISEASE
Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	O
problems	O
,	O
but	O
P9605	B-CHEMICAL
This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	B-CHEMICAL
Tranexamic	B-CHEMICAL
acid	I-CHEMICAL
overdosage	O
-	O
induced	O
generalized	O
seizure	B-DISEASE
in	O
renal	B-DISEASE
failure	I-DISEASE
We	O
report	O
a	O
45	O
-	O
year	O
-	O
old	O
lady	O
with	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	O
disease	B-DISEASE
She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	B-DISEASE
due	O
to	O
menorrhagia	B-DISEASE
and	O
deterioration	O
of	O
renal	B-DISEASE
Tranexamic	B-CHEMICAL
acid	I-CHEMICAL
(	O
TNA	O
)	O
1	O
g	O
8	O
-	O
hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	B-DISEASE
Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	O
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B-DISEASE
clonic	O
convulsions	B-DISEASE
Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	O
system	O
abnormalities	B-DISEASE
that	O
could	O
have	O
provoked	O
the	O
convulsions	B-DISEASE
She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	B-DISEASE
Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	B-DISEASE
was	O
believed	O
to	O
be	O
an	O
overdose	B-DISEASE
Pre	O
-	O
treatment	O
of	O
bupivacaine	B-CHEMICAL
-	O
induced	O
cardiovascular	O
depression	B-DISEASE
using	O
different	O
lipid	O
formulations	O
of	O
propofol	B-CHEMICAL
BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	B-CHEMICAL
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	B-CHEMICAL
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	B-CHEMICAL
may	O
alleviate	O
bupivacaine	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	B-CHEMICAL
in	O
intralipid	O
or	O
medialipid	O
emulsions	B-CHEMICAL
on	O
bupivacaine	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	B-CHEMICAL
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	B-CHEMICAL
in	O
intralipid	O
(	O
Group	O
P	O
),	O
propofol	B-CHEMICAL
Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	B-CHEMICAL
We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	O
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	B-DISEASE
and	O
total	O
amount	O
of	O
bupivacaine	B-CHEMICAL
Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B-DISEASE
RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	O
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	B-DISEASE
The	O
cumulative	O
bupivacaine	B-CHEMICAL
dose	O
given	O
at	B-DISEASE
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P	O
.	O
Plasma	O
bupivacaine	B-CHEMICAL
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C	O
.	O
Bupivacaine	B-CHEMICAL
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C	O
.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	B-CHEMICAL
in	O
intralipid	O
,	O
compared	O
with	O
propofol	B-CHEMICAL
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	B-CHEMICAL
-	O
induced	O
cardiotoxic	B-DISEASE
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	B-CHEMICAL
Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	B-CHEMICAL
levels	O
of	O
propofol	B-CHEMICAL
Drug	O
-	O
Induced	O
Acute	O
Liver	B-DISEASE
Injury	I-DISEASE
Within	O
12	O
Hours	O
After	O
Fluvastatin	B-CHEMICAL
Although	O
statins	B-CHEMICAL
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	O
-	O
induced	O
liver	B-DISEASE
injury	I-DISEASE
A	O
52	O
-	O
year	O
-	O
old	O
Chinese	O
man	O
reported	O
with	O
liver	B-DISEASE
damage	I-DISEASE
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	B-CHEMICAL
Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	B-DISEASE
,	O
anorexia	B-DISEASE
,	O
and	O
upper	O
abdominal	B-DISEASE
pain	I-DISEASE
His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	B-CHEMICAL
kinase	I-CHEMICAL
The	O
liver	B-DISEASE
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	B-CHEMICAL
Therefore	O
,	O
when	O
prescribing	O
statins	B-CHEMICAL
,	O
the	O
possibility	O
of	O
hepatic	B-DISEASE
damage	I-DISEASE
Fluconazole	B-CHEMICAL
associated	O
agranulocytosis	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	B-CHEMICAL
associated	O
agranulocytosis	B-DISEASE
with	O
thrombocytopenia	B-DISEASE
The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	B-CHEMICAL
of	O
administration	O
of	O
fluconazole	B-CHEMICAL
and	O
began	O
to	O
recover	O
with	O
48	O
h	B-CHEMICAL
CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
'	O
s	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
'	O
s	O
agranulocytosis	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	B-CHEMICAL
In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
to	O
the	O
initiation	O
of	O
fluconazole	B-CHEMICAL
Two	O
-	O
dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high	O
-	O
sensitive	O
cardiac	O
troponin	B-CHEMICAL
T	I-CHEMICAL
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	B-DISEASE
AIMS	O
:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	O
strain	O
and	O
high	O
-	O
sensitive	O
cardiac	O
troponin	B-CHEMICAL
T	I-CHEMICAL
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
in	O
patients	O
after	O
epirubicin	B-CHEMICAL
METHODS	O
:	O
Seventy	O
-	O
five	O
patients	O
with	O
non	O
-	O
Hodgkin	B-DISEASE
lymphoma	I-DISEASE
treated	O
with	O
epirubicin	B-CHEMICAL
Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	B-DISEASE
Cardiotoxicity	B-DISEASE
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symptoms	O
of	O
heart	B-DISEASE
failure	I-DISEASE
RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18	O
.	O
67	O
%)	O
developed	O
cardiotoxicity	B-DISEASE
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	B-DISEASE
A	O
>	O
15	O
.	O
9	O
%	O
decrease	O
in	O
GLS	O
[	O
sensitivity	O
,	O
86	O
%;	O
specificity	O
,	O
75	O
%;	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
elevation	O
in	O
cTnT	O
(	O
sensitivity	O
,	O
79	O
%;	O
specificity	O
,	O
64	O
%;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	B-DISEASE
The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	B-DISEASE
CONCLUSIONS	O
:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invasive	O
method	O
to	O
predict	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
in	O
patients	O
receiving	O
anthracycline	B-CHEMICAL
Prevention	O
of	O
etomidate	B-CHEMICAL
-	O
induced	O
myoclonus	B-DISEASE
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B-CHEMICAL
,	O
midazolam	B-CHEMICAL
BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B-CHEMICAL
,	O
midazolam	B-CHEMICAL
,	O
and	O
a	O
combination	O
of	O
fentanyl	B-CHEMICAL
and	O
midazolam	B-CHEMICAL
to	O
prevent	O
etomidate	B-CHEMICAL
-	O
induced	O
myoclonus	B-DISEASE
Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B-CHEMICAL
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
),	O
fentanyl	B-CHEMICAL
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Group	O
F	O
),	O
midazolam	B-CHEMICAL
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Group	O
M	O
),	O
and	O
midazolam	B-CHEMICAL
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fentanyl	B-CHEMICAL
Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
etomidate	B-CHEMICAL
Myoclonic	O
movements	O
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B-CHEMICAL
The	O
severity	O
of	O
pain	B-DISEASE
due	O
to	O
etomidate	B-CHEMICAL
RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B-DISEASE
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B-CHEMICAL
or	O
combination	O
of	O
fentanyl	B-CHEMICAL
and	O
midazolam	B-CHEMICAL
was	O
effective	O
in	O
preventing	O
etomidate	B-CHEMICAL
-	O
induced	O
myoclonus	B-DISEASE
Cholestatic	O
presentation	O
of	O
yellow	O
phosphorus	B-CHEMICAL
poisoning	B-DISEASE
Yellow	O
phosphorus	B-CHEMICAL
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	B-DISEASE
Poisoning	B-DISEASE
with	O
yellow	O
phosphorus	B-CHEMICAL
classically	O
manifests	O
with	O
acute	O
hepatitis	B-DISEASE
leading	O
to	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
which	O
may	O
need	O
liver	B-DISEASE
We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	B-CHEMICAL
poisoning	B-DISEASE
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	B-DISEASE
highlighting	O
the	O
fact	O
that	O
cholestasis	B-DISEASE
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	B-CHEMICAL
hepatotoxicity	B-DISEASE
Vasovagal	B-DISEASE
syncope	I-DISEASE
and	O
severe	O
bradycardia	B-DISEASE
following	O
intranasal	O
dexmedetomidine	B-CHEMICAL
We	O
report	O
syncope	B-DISEASE
and	O
bradycardia	B-DISEASE
in	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	B-CHEMICAL
The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	B-DISEASE
The	O
bradycardia	B-DISEASE
lasted	O
~	O
2	O
h	B-CHEMICAL
Paradoxical	O
severe	O
agitation	B-DISEASE
induced	O
by	O
add	O
-	O
on	O
high	O
-	O
doses	O
quetiapine	O
in	O
schizo	O
-	O
affective	B-DISEASE
disorder	I-DISEASE
We	O
report	O
the	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
schizo	O
-	O
affective	B-DISEASE
disorder	I-DISEASE
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first	O
-	O
generation	O
antipsychotics	B-CHEMICAL
,	O
zuclopenthixol	O
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithium	B-CHEMICAL
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
serum	O
lithium	B-CHEMICAL
This	O
patient	O
had	O
no	O
associated	O
personality	B-DISEASE
disorder	I-DISEASE
(	O
particularly	O
no	O
antisocial	O
disorder	O
)	O
and	O
no	O
substance	B-DISEASE
abuse	I-DISEASE
disorder	I-DISEASE
Within	O
the	O
48	O
h	B-CHEMICAL
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	O
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
),	O
the	O
patient	O
presented	O
severe	O
agitation	B-DISEASE
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	B-DISEASE
or	O
personality	B-DISEASE
disorder	I-DISEASE
The	O
diagnoses	O
of	O
manic	B-DISEASE
shift	O
and	O
akathisia	B-DISEASE
The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	O
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	B-DISEASE
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	B-DISEASE
Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
Dexamethasone	B-CHEMICAL
-	O
(	O
Dex	B-CHEMICAL
-)	O
induced	O
hypertension	B-DISEASE
Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	B-CHEMICAL
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B-DISEASE
upon	O
Dex	B-CHEMICAL
Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	B-CHEMICAL
In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	B-CHEMICAL
Plasma	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
Dexamethasone	B-CHEMICAL
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	O
level	O
and	O
decreased	O
thymus	O
and	O
body	B-DISEASE
weights	I-DISEASE
LF	O
lowered	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
LF	O
prevented	O
body	B-DISEASE
weight	I-DISEASE
Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
The	O
association	O
between	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
and	O
convulsive	B-DISEASE
seizures	B-DISEASE
Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B-DISEASE
A	O
convulsive	B-DISEASE
seizure	B-DISEASE
Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B-DISEASE
A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%)	O
patients	O
developed	O
postoperative	O
convulsive	B-DISEASE
seizures	B-DISEASE
Generalised	O
and	O
focal	O
seizures	B-DISEASE
The	O
median	O
(	O
IQR	O
[	O
range	O
])	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B-DISEASE
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
])	O
h	B-CHEMICAL
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
])	O
h	B-CHEMICAL
Independent	O
predictors	O
of	O
postoperative	O
seizures	B-DISEASE
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	B-DISEASE
of	O
ascending	O
aorta	O
,	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
,	O
deep	O
hypothermic	O
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B-DISEASE
Patients	O
with	O
convulsive	B-DISEASE
seizures	B-DISEASE
had	O
2	O
.	O
5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	B-DISEASE
seizures	B-DISEASE
Mean	O
(	O
IQR	O
[	O
range	O
])	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
])	O
h	B-CHEMICAL
in	O
patients	O
with	O
convulsive	B-DISEASE
seizures	B-DISEASE
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
])	O
h	B-CHEMICAL
in	O
patients	O
without	O
seizures	B-DISEASE
Convulsive	B-DISEASE
seizures	B-DISEASE
are	O
a	O
serious	O
postoperative	B-DISEASE
complication	I-DISEASE
As	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg	O
.	O
kg	O
(-	O
1	O
),	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B-DISEASE
Dysfunctional	O
overnight	O
memory	O
consolidation	O
in	O
ecstasy	B-CHEMICAL
Previous	O
studies	O
indicate	O
that	O
ecstasy	B-CHEMICAL
We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	B-CHEMICAL
Ecstasy	B-CHEMICAL
Additionally	O
,	O
ecstasy	B-CHEMICAL
We	O
suggest	O
that	O
ecstasy	B-CHEMICAL
-	O
associated	O
dysfunction	O
in	O
fronto	O
-	O
temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	O
impairments	O
in	O
regular	O
ecstasy	B-CHEMICAL
Normoammonemic	O
encephalopathy	B-DISEASE
:	O
solely	O
valproate	B-CHEMICAL
A	O
77	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	B-DISEASE
,	O
aggression	B-DISEASE
,	O
auditory	O
hallucinations	B-DISEASE
In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	O
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	B-CHEMICAL
for	O
presumed	O
hemiplegic	B-DISEASE
migraine	I-DISEASE
Valproate	B-CHEMICAL
Valproate	B-CHEMICAL
EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	B-DISEASE
,	O
and	O
low	O
titre	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
The	O
possible	O
aetiologies	O
of	O
valproate	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
and	O
NMDA	B-CHEMICAL
receptor	O
-	O
associated	O
encephalitis	B-DISEASE
Cerebellar	O
and	O
oculomotor	O
dysfunction	O
induced	O
by	O
rapid	O
infusion	O
of	O
pethidine	B-CHEMICAL
Pethidine	B-CHEMICAL
is	O
an	O
opioid	O
that	O
gains	O
its	O
popularity	O
for	O
the	O
effective	O
pain	B-DISEASE
However	O
,	O
rapid	O
pain	B-DISEASE
Common	O
side	O
effects	O
include	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
and	O
hypotension	B-DISEASE
In	O
patients	O
with	O
impaired	O
renal	B-DISEASE
and	O
liver	B-DISEASE
function	O
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
pain	B-DISEASE
control	O
,	O
pethidine	B-CHEMICAL
may	O
cause	O
excitatory	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
effects	O
through	O
its	O
neurotoxic	B-DISEASE
metabolite	O
,	O
norpethidine	O
,	O
resulting	O
in	O
irritability	B-DISEASE
and	O
seizure	B-DISEASE
On	O
the	O
contrary	O
,	O
though	O
not	O
clinically	O
apparent	O
,	O
pethidine	B-CHEMICAL
In	O
this	O
case	O
report	O
,	O
we	O
highlight	O
opioid	O
'	O
s	O
inhibitory	O
side	O
effects	O
on	O
the	O
cerebellar	O
structure	O
that	O
causes	O
dysmetria	O
,	O
dysarthria	B-DISEASE
Baboon	O
syndrome	B-DISEASE
induced	O
by	O
ketoconazole	B-CHEMICAL
A	O
27	O
-	O
year	O
-	O
old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	O
eruption	O
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	B-CHEMICAL
The	O
patient	O
was	O
diagnosed	O
with	O
drug	O
-	O
induced	O
baboon	O
syndrome	B-DISEASE
based	O
on	O
his	O
history	O
,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	B-CHEMICAL
Baboon	O
syndrome	B-DISEASE
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole	B-CHEMICAL
-	O
induced	O
baboon	O
syndrome	B-DISEASE
A	O
Case	O
of	O
Sudden	O
Cardiac	O
Death	B-DISEASE
due	O
to	O
Pilsicainide	B-CHEMICAL
-	O
Induced	O
Torsades	B-DISEASE
de	I-DISEASE
Pointes	I-DISEASE
An	O
84	O
-	O
year	O
-	O
old	O
male	O
received	O
oral	O
pilsicainide	B-CHEMICAL
,	O
a	O
pure	O
sodium	B-CHEMICAL
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
his	O
paroxysmal	B-DISEASE
atrial	I-DISEASE
fibrillation	I-DISEASE
to	O
a	O
sinus	O
rhythm	O
;	O
the	O
patient	O
developed	O
sudden	O
cardiac	O
death	B-DISEASE
The	O
Holter	O
electrocardiogram	O
,	O
which	O
was	O
worn	O
by	O
chance	O
,	O
revealed	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
Although	O
the	O
patient	O
'	O
s	O
renal	B-DISEASE
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	B-CHEMICAL
was	O
low	O
,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	B-CHEMICAL
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs	O
,	O
including	O
pilsicainide	B-CHEMICAL
,	O
is	O
effective	O
to	O
terminate	O
atrial	B-DISEASE
fibrillation	I-DISEASE
All	O
-	O
trans	O
retinoic	O
acid	O
-	O
induced	O
inflammatory	O
myositis	B-DISEASE
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	B-DISEASE
All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
),	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	O
promyelocytic	O
leukemia	B-DISEASE
Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA	O
-	O
induced	O
myositis	B-DISEASE
Tolerability	O
of	O
lomustine	B-CHEMICAL
in	O
combination	O
with	O
cyclophosphamide	B-CHEMICAL
in	O
dogs	O
with	O
lymphoma	B-DISEASE
This	O
retrospective	O
study	O
describes	O
toxicity	B-DISEASE
associated	O
with	O
a	O
protocol	O
of	O
lomustine	B-CHEMICAL
(	O
CCNU	O
)	O
and	O
cyclophosphamide	B-CHEMICAL
(	O
CTX	O
)	O
in	O
dogs	O
with	O
lymphoma	B-DISEASE
CCNU	O
was	O
administered	O
per	O
os	O
(	O
PO	O
)	O
at	B-DISEASE
a	O
targeted	O
dosage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
body	O
surface	O
area	O
on	O
day	O
0	O
,	O
CTX	O
was	O
administered	O
PO	O
at	B-DISEASE
Neutropenia	B-DISEASE
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	B-DISEASE
The	O
mean	O
body	B-DISEASE
weight	I-DISEASE
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	B-DISEASE
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	B-DISEASE
weight	I-DISEASE
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	B-DISEASE
One	O
dog	O
(	O
3	O
%)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	B-DISEASE
No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	B-DISEASE
toxicity	I-DISEASE
or	O
hemorrhagic	B-DISEASE
cystitis	B-DISEASE
On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein	O
,	O
a	O
dose	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CCNU	O
combined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	O
(	O
divided	O
over	O
5	O
days	O
)	O
q	O
4	O
wk	O
is	O
tolerable	O
in	O
tumor	B-DISEASE
Nelarabine	B-CHEMICAL
neurotoxicity	B-DISEASE
Severe	O
nelarabine	B-CHEMICAL
neurotoxicity	B-DISEASE
A	O
37	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T	O
-	O
cell	O
lymphoblastic	O
lymphoma	B-DISEASE
was	O
admitted	O
for	O
relapsed	O
disease	B-DISEASE
She	O
developed	O
relapsed	O
disease	B-DISEASE
She	O
was	O
re	O
-	O
induced	O
with	O
nelarabine	B-CHEMICAL
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	B-CHEMICAL
At	B-DISEASE
the	O
time	O
of	O
treatment	O
,	O
she	O
was	O
on	O
continuous	O
renal	B-DISEASE
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	B-DISEASE
lysis	I-DISEASE
syndrome	I-DISEASE
She	O
tolerated	O
therapy	O
well	O
,	O
entered	O
a	O
complete	O
remission	B-DISEASE
,	O
and	O
recovered	O
her	O
renal	B-DISEASE
She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	B-CHEMICAL
Predominantly	O
sensory	O
,	O
though	O
also	O
motor	O
and	O
autonomic	O
,	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
A	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
her	O
spine	O
demonstrated	O
changes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacute	B-DISEASE
combined	I-DISEASE
degeneration	I-DISEASE
Nelarabine	B-CHEMICAL
Her	O
neuropathy	B-DISEASE
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
reduced	O
-	O
intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission	B-DISEASE
,	O
but	O
relapsed	O
disease	B-DISEASE
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	B-DISEASE
caused	O
by	O
nelarabine	B-CHEMICAL
Valproate	B-CHEMICAL
-	O
induced	O
hyperammonemic	O
encephalopathy	B-DISEASE
in	O
a	O
renal	B-DISEASE
Neurological	O
complications	O
after	O
renal	B-DISEASE
Valproate	B-CHEMICAL
-	O
induced	O
hyperammonemic	O
encephalopathy	B-DISEASE
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	B-CHEMICAL
Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
therapy	O
with	O
valproate	B-CHEMICAL
due	O
to	O
epilepsy	B-DISEASE
and	O
revealed	O
impaired	O
consciousness	O
with	O
hyperammonemia	B-DISEASE
12	O
days	O
after	O
renal	B-DISEASE
After	O
withdraw	O
of	O
valproate	B-CHEMICAL
,	O
patients	O
'	O
symptoms	O
resolved	O
within	O
24	O
h	B-CHEMICAL
.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	B-CHEMICAL
Necrotising	O
fasciitis	B-DISEASE
after	O
bortezomib	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
Bortezomib	B-CHEMICAL
and	O
high	O
-	O
dose	O
dexamethasone	B-CHEMICAL
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B-DISEASE
infections	I-DISEASE
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	B-DISEASE
We	O
report	O
a	O
case	O
of	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
with	O
Waldenstrom	O
macroglobulinaemia	O
who	O
suffered	O
necrotising	O
fasciitis	B-DISEASE
without	O
neutropenia	B-DISEASE
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	B-CHEMICAL
,	O
high	O
-	O
dose	O
dexamethasone	B-CHEMICAL
Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	B-CHEMICAL
Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B-DISEASE
infections	I-DISEASE
related	O
to	O
bortezomib	B-CHEMICAL
plus	O
high	O
-	O
dose	O
dexamethasone	B-CHEMICAL
An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
Many	O
efficacious	O
cancer	B-DISEASE
treatments	O
cause	O
significant	O
cardiac	O
morbidity	O
,	O
yet	O
biomarkers	B-CHEMICAL
In	O
this	O
study	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
)-	O
induced	O
cardiomyopathy	B-DISEASE
,	O
applying	O
multiple	O
approaches	O
,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
),	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	B-DISEASE
Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	B-CHEMICAL
Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	O
degeneration	O
,	O
hypertrophy	B-DISEASE
Extensive	O
replacement	O
fibrosis	B-DISEASE
Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(	O
including	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
),	O
cardiac	B-DISEASE
output	I-DISEASE
Significant	O
increases	O
in	O
peak	O
myocardial	O
contrast	O
enhancement	O
and	O
serological	O
cardiac	O
troponin	B-CHEMICAL
I	I-CHEMICAL
Troponin	B-CHEMICAL
I	I-CHEMICAL
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	B-CHEMICAL
However	O
,	O
all	O
indices	O
predated	O
"	O
clinical	O
"	O
LV	O
dysfunction	O
and	O
thus	O
warrant	O
further	O
evaluation	O
as	O
predictive	O
biomarkers	B-CHEMICAL
Intradermal	O
glutamate	B-CHEMICAL
and	O
capsaicin	B-CHEMICAL
injections	O
:	O
intra	O
-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	B-DISEASE
Intradermal	O
injections	O
of	O
glutamate	B-CHEMICAL
and	O
capsaicin	B-CHEMICAL
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	B-DISEASE
models	O
because	O
hyperalgesia	B-DISEASE
and	O
allodynia	O
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	B-DISEASE
Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	B-CHEMICAL
and	O
capsaicin	B-CHEMICAL
Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	B-DISEASE
and	O
brush	O
-	O
evoked	O
allodynia	O
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(	O
gauges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brush	O
strokes	B-DISEASE
Areas	O
of	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
Two	O
identical	O
experiments	O
separated	O
by	O
at	B-DISEASE
Secondary	O
pinprick	O
hyperalgesia	B-DISEASE
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
glutamate	B-CHEMICAL
For	O
capsaicin	B-CHEMICAL
,	O
secondary	O
pinprick	O
hyperalgesia	B-DISEASE
Glutamate	B-CHEMICAL
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brush	O
strokes	B-DISEASE
Capsaicin	B-CHEMICAL
injection	O
was	O
reproducible	O
for	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
Intra	O
-	O
individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
In	O
conclusion	O
,	O
glutamate	B-CHEMICAL
and	O
capsaicin	B-CHEMICAL
Ocular	O
-	O
specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	B-DISEASE
in	O
murine	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-DISEASE
Administration	O
of	O
glucocorticoids	B-CHEMICAL
induces	O
ocular	B-DISEASE
hypertension	I-DISEASE
If	O
untreated	O
,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	B-DISEASE
that	O
resembles	O
primary	O
open	O
-	O
angle	O
glaucoma	B-DISEASE
The	O
underlying	O
pathology	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-DISEASE
Here	O
,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-DISEASE
that	O
exhibits	O
glaucoma	B-DISEASE
Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0	O
.	O
1	O
%	O
dexamethasone	B-CHEMICAL
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
),	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	O
ganglion	O
cells	O
,	O
and	O
axonal	O
degeneration	O
,	O
resembling	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-DISEASE
Furthermore	O
,	O
dexamethasone	B-CHEMICAL
-	O
induced	O
ocular	B-DISEASE
hypertension	I-DISEASE
Similar	O
to	O
patients	O
,	O
withdrawal	O
of	O
dexamethasone	B-CHEMICAL
Dexamethasone	B-CHEMICAL
induced	O
the	O
transcriptional	O
factor	O
CHOP	O
,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress	O
,	O
in	O
the	O
anterior	O
segment	O
tissues	O
,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone	B-CHEMICAL
-	O
induced	O
ocular	B-DISEASE
hypertension	I-DISEASE
Furthermore	O
,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	B-CHEMICAL
4	O
-	O
phenylbutyrate	O
prevented	O
dexamethasone	B-CHEMICAL
-	O
induced	O
ocular	B-DISEASE
hypertension	I-DISEASE
Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid	O
-	O
induced	O
ocular	B-DISEASE
hypertension	I-DISEASE
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-DISEASE
Effects	O
of	O
ginsenosides	B-CHEMICAL
on	O
opioid	O
-	O
induced	O
hyperalgesia	B-DISEASE
Opioid	O
-	O
induced	O
hyperalgesia	B-DISEASE
OIH	O
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	B-CHEMICAL
and	O
complicate	O
withdrawal	O
from	O
opioid	O
addiction	B-DISEASE
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	O
,	O
Rg1	B-CHEMICAL
,	O
and	O
Rb1	O
ginsenosides	B-CHEMICAL
OIH	O
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	B-CHEMICAL
During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
),	O
these	O
mice	O
were	O
administered	O
Re	O
,	O
Rg1	B-CHEMICAL
On	O
the	O
test	O
day	O
(	O
day	O
10	O
),	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
Re	O
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	O
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
However	O
,	O
the	O
Rg1	B-CHEMICAL
and	O
Rb1	O
ginsenosides	B-CHEMICAL
Furthermore	O
,	O
Rg1	B-CHEMICAL
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	O
in	O
the	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-CHEMICAL
Re	I-CHEMICAL
,	O
but	O
not	O
Rg1	B-CHEMICAL
A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	B-CHEMICAL
and	O
propofol	B-CHEMICAL
OBJECTIVE	O
:	O
Dexmedetomidine	B-CHEMICAL
and	O
propofol	B-CHEMICAL
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	B-DISEASE
The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	B-CHEMICAL
and	O
propofol	B-CHEMICAL
SETTING	O
:	O
Neurocritical	O
care	O
units	O
at	B-DISEASE
INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	B-CHEMICAL
or	O
propofol	B-CHEMICAL
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	B-CHEMICAL
and	O
237	O
propofol	B-CHEMICAL
The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	B-DISEASE
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	B-DISEASE
When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	B-DISEASE
or	O
bradycardia	B-DISEASE
CONCLUSIONS	O
:	O
Severe	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
occur	O
at	B-DISEASE
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	B-CHEMICAL
or	O
propofol	B-CHEMICAL
Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	B-DISEASE
or	O
bradycardia	B-DISEASE
Hydroxytyrosol	O
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
in	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
in	O
rats	O
with	O
breast	B-DISEASE
cancer	I-DISEASE
Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	B-DISEASE
,	O
aging	B-DISEASE
and	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	B-CHEMICAL
Doxorubicin	B-CHEMICAL
causes	O
significant	O
cardiotoxicity	B-DISEASE
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin	B-CHEMICAL
-	O
associated	O
chronic	O
cardiac	B-DISEASE
toxicity	I-DISEASE
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	O
in	O
rats	O
with	O
breast	B-DISEASE
cancer	I-DISEASE
Thirty	O
-	O
six	O
rats	O
bearing	O
breast	O
tumors	B-DISEASE
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	O
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
),	O
doxorubicin	B-CHEMICAL
(	O
1mg	O
/	O
kg	O
/	O
week	O
),	O
and	O
doxorubicin	B-CHEMICAL
Cardiac	O
disturbances	O
at	B-DISEASE
Hydroxytyrosol	O
improved	O
the	O
cardiac	O
disturbances	O
enhanced	O
by	O
doxorubicin	B-CHEMICAL
This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	O
protect	O
rat	O
heart	O
damage	O
provoked	O
by	O
doxorubicin	B-CHEMICAL
Amiodarone	B-CHEMICAL
-	O
induced	O
myxoedema	O
coma	B-DISEASE
A	O
62	O
-	O
year	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	B-DISEASE
,	O
hypothermia	B-DISEASE
and	O
respiratory	B-DISEASE
failure	I-DISEASE
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	B-CHEMICAL
therapy	O
for	O
atrial	B-DISEASE
fibrillation	I-DISEASE
Thyroid	B-DISEASE
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
thyroxine	B-CHEMICAL
He	O
received	O
intravenous	O
fluids	O
,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	B-CHEMICAL
He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	O
in	O
the	O
first	O
18	O
h	B-CHEMICAL
Haemodynamic	O
improvement	O
,	O
along	O
with	O
complete	O
recovery	O
of	O
mental	O
status	O
,	O
occurred	O
after	O
48	O
h	B-CHEMICAL
A	O
thyroid	B-DISEASE
The	O
24	O
hour	O
excretion	O
of	O
iodine	B-CHEMICAL
The	O
only	O
two	O
cases	O
of	O
amiodarone	B-CHEMICAL
-	O
induced	O
myxoedema	O
coma	B-DISEASE
in	O
the	O
literature	O
report	O
patient	O
death	B-DISEASE
despite	O
supportive	O
therapy	O
and	O
thyroid	B-DISEASE
This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone	B-CHEMICAL
-	O
induced	O
myxoedema	O
coma	B-DISEASE
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	B-DISEASE
disease	B-DISEASE
Use	O
of	O
argatroban	B-CHEMICAL
and	O
catheter	O
-	O
directed	O
thrombolysis	O
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
with	O
thrombosis	B-DISEASE
PURPOSE	O
:	O
The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
with	O
thrombosis	B-DISEASE
(	O
HITT	B-DISEASE
)	O
and	O
was	O
treated	O
with	O
argatroban	B-CHEMICAL
SUMMARY	O
:	O
A	O
63	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
with	O
renal	B-DISEASE
amyloidosis	B-DISEASE
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper	O
-	O
extremity	O
deep	B-DISEASE
venous	I-DISEASE
thrombosis	I-DISEASE
(	O
DVT	B-DISEASE
)	O
and	O
pulmonary	B-DISEASE
embolism	I-DISEASE
secondary	O
to	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
infusion	O
of	O
argatroban	B-CHEMICAL
After	O
one	O
week	O
of	O
therapy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	O
vena	O
cava	O
(	O
SVC	O
)	O
syndrome	B-DISEASE
A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted	O
,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	B-DISEASE
The	O
epistaxis	B-DISEASE
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	B-CHEMICAL
Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	B-CHEMICAL
Alteplase	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	B-CHEMICAL
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfarin	B-CHEMICAL
Although	O
the	O
patient	O
recovered	O
,	O
he	O
experienced	O
permanent	O
vision	B-DISEASE
and	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
as	O
well	O
as	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
CONCLUSION	O
:	O
A	O
63	O
-	O
year	O
-	O
old	O
man	O
with	O
renal	B-DISEASE
amyloidosis	B-DISEASE
and	O
SVC	O
syndrome	B-DISEASE
secondary	O
to	O
HITT	B-DISEASE
was	O
successfully	O
treated	O
with	O
argatroban	B-CHEMICAL
Effects	O
of	O
dehydroepiandrosterone	B-CHEMICAL
in	O
amphetamine	B-CHEMICAL
-	O
induced	O
schizophrenia	B-DISEASE
OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	B-CHEMICAL
(	O
DHEA	O
)	O
on	O
animal	O
models	O
of	O
schizophrenia	B-DISEASE
METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	B-CHEMICAL
-	O
free	O
(	O
control	O
),	O
amphetamine	B-CHEMICAL
Amphetamine	B-CHEMICAL
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
hyper	O
locomotion	O
,	O
apomorphine	B-CHEMICAL
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutaneously	O
[	O
sc	O
])	O
induced	O
climbing	O
,	O
and	O
haloperidol	B-CHEMICAL
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
induced	O
catalepsy	B-DISEASE
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	B-DISEASE
The	O
study	O
was	O
conducted	O
at	B-DISEASE
Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
hyper	O
locomotion	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	B-DISEASE
RESULTS	O
:	O
In	O
the	O
amphetamine	B-CHEMICAL
-	O
induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	B-CHEMICAL
Both	O
DHEA	O
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	B-CHEMICAL
There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	B-CHEMICAL
CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	O
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	B-DISEASE
at	B-DISEASE
We	O
suggest	O
that	O
DHEA	O
displays	O
typical	O
neuroleptic	O
-	O
like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	B-DISEASE
Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
),	O
which	O
can	O
express	O
QT	B-DISEASE
interval	I-DISEASE
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-CHEMICAL
(+)	O
channel	O
and	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
channel	O
blocker	O
effects	O
on	O
QT	B-DISEASE
interval	I-DISEASE
IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
),	O
whereas	O
Ca	B-CHEMICAL
Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	B-CHEMICAL
,	O
Paroxetine	B-CHEMICAL
,	O
Terfenadine	B-CHEMICAL
and	O
Citalopram	B-CHEMICAL
Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	B-CHEMICAL
and	O
Citalopram	B-CHEMICAL
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-DISEASE
de	I-DISEASE
Pointes	I-DISEASE
(	O
TdP	B-DISEASE
hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	B-DISEASE
interval	I-DISEASE
This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B-DISEASE
Dermal	O
developmental	O
toxicity	B-DISEASE
of	O
N	O
-	O
phenylimide	O
herbicides	B-CHEMICAL
BACKGROUND	O
:	O
S	O
-	O
53482	O
and	O
S	O
-	O
23121	O
are	O
N	O
-	O
phenylimide	O
herbicides	B-CHEMICAL
and	O
produced	O
embryolethality	O
,	O
teratogenicity	O
(	O
mainly	O
ventricular	O
septal	O
defects	O
and	O
wavy	O
ribs	O
),	O
and	O
growth	B-DISEASE
retardation	I-DISEASE
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	B-DISEASE
Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	B-DISEASE
METHODS	O
:	O
S	O
-	O
53482	O
was	O
administered	O
dermally	O
to	O
rats	O
at	B-DISEASE
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organogenesis	O
,	O
and	O
S	O
-	O
23121	O
was	O
administered	O
at	B-DISEASE
RESULTS	O
:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S	O
-	O
53482	O
at	B-DISEASE
300	O
mg	O
/	O
kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	B-DISEASE
Toxicity	B-DISEASE
included	O
embryolethality	O
,	O
teratogenicity	O
,	O
and	O
growth	B-DISEASE
retardation	I-DISEASE
Dermal	O
administration	O
of	O
S	O
-	O
23121	O
at	B-DISEASE
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	O
death	B-DISEASE
and	O
ventricular	B-DISEASE
septal	I-DISEASE
defect	I-DISEASE
Rates	O
of	O
Renal	B-DISEASE
Toxicity	I-DISEASE
in	O
Cancer	B-DISEASE
Patients	O
Receiving	O
Cisplatin	B-CHEMICAL
With	O
and	O
Without	O
Mannitol	B-CHEMICAL
BACKGROUND	O
:	O
Cisplatin	B-CHEMICAL
One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	B-CHEMICAL
use	O
is	O
dose	O
-	O
limiting	O
nephrotoxicity	B-DISEASE
There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	B-DISEASE
,	O
including	O
the	O
use	O
of	O
mannitol	B-CHEMICAL
OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
in	O
cancer	B-DISEASE
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	B-CHEMICAL
with	O
and	O
without	O
mannitol	B-CHEMICAL
METHODS	O
:	O
This	O
single	O
-	O
center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	B-CHEMICAL
Data	O
were	O
collected	O
on	O
adult	O
cancer	B-DISEASE
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	B-CHEMICAL
The	O
primary	O
outcome	O
was	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
RESULTS	O
:	O
We	O
evaluated	O
143	O
patients	O
who	O
received	O
single	O
-	O
agent	O
cisplatin	B-CHEMICAL
;	O
97	O
.	O
2	O
%	O
of	O
patients	O
had	O
head	O
and	O
neck	O
cancer	B-DISEASE
as	O
their	O
primary	O
malignancy	B-DISEASE
Patients	O
who	O
did	O
not	O
receive	O
mannitol	B-CHEMICAL
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	B-DISEASE
Patients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	B-DISEASE
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	B-DISEASE
CONCLUSIONS	O
:	O
When	O
limited	O
quantities	O
of	O
mannitol	B-CHEMICAL
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	B-DISEASE
particularly	O
high	O
risk	O
of	O
nephrotoxicity	B-DISEASE
Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-CHEMICAL
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	B-DISEASE
are	O
at	B-DISEASE
the	O
greatest	O
risk	O
of	O
nephrotoxicity	B-DISEASE
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	B-CHEMICAL
Metformin	B-CHEMICAL
protects	O
against	O
seizures	B-DISEASE
,	O
learning	O
and	O
memory	O
impairments	O
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole	B-CHEMICAL
Cognitive	B-DISEASE
impairment	I-DISEASE
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	B-DISEASE
However	O
,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	B-DISEASE
Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	B-DISEASE
Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B-DISEASE
deficits	I-DISEASE
,	O
and	O
antioxidants	B-CHEMICAL
Metformin	B-CHEMICAL
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	B-CHEMICAL
on	O
seizures	B-DISEASE
,	O
cognitive	B-DISEASE
impairment	I-DISEASE
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole	B-CHEMICAL
Male	O
C57BL	O
/	O
6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	B-CHEMICAL
Metformin	B-CHEMICAL
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	B-CHEMICAL
We	O
found	O
that	O
metformin	B-CHEMICAL
suppressed	O
the	O
progression	O
of	O
kindling	O
,	O
ameliorated	O
the	O
cognitive	B-DISEASE
impairment	I-DISEASE
Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	B-CHEMICAL
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	B-DISEASE
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	B-DISEASE
impairment	I-DISEASE
induced	O
by	O
seizures	B-DISEASE
P53	O
inhibition	O
exacerbates	O
late	O
-	O
stage	O
anthracycline	B-CHEMICAL
cardiotoxicity	B-DISEASE
AIMS	O
:	O
Doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
)	O
is	O
an	O
effective	O
anti	O
-	O
cancer	B-DISEASE
therapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late	O
-	O
stage	O
cardiotoxicity	B-DISEASE
Children	O
are	O
particularly	O
sensitive	O
to	O
DOX	B-CHEMICAL
-	O
induced	O
heart	B-DISEASE
failure	I-DISEASE
late	O
-	O
stage	O
DOX	B-CHEMICAL
cardiotoxicity	B-DISEASE
METHODS	O
AND	O
RESULTS	O
:	O
Two	O
-	O
week	O
-	O
old	O
MHC	O
-	O
CB7	O
mice	O
(	O
which	O
express	O
dominant	O
-	O
interfering	O
p53	O
in	O
cardiomyocytes	O
)	O
and	O
their	O
non	O
-	O
transgenic	O
(	O
NON	O
-	O
TXG	O
)	O
littermates	O
received	O
weekly	O
DOX	B-CHEMICAL
One	O
week	O
after	O
the	O
last	O
DOX	B-CHEMICAL
Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	B-CHEMICAL
p53	O
inhibition	O
blocked	O
transient	O
DOX	B-CHEMICAL
Mice	O
with	O
cardiomyocyte	O
-	O
restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function	O
,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	B-CHEMICAL
CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53	O
-	O
dependent	O
cardioprotective	O
pathway	O
,	O
mediated	O
via	O
STAT3	O
activation	O
,	O
mitigates	O
DOX	B-CHEMICAL
Furthermore	O
,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and	O
,	O
paradoxically	O
,	O
enhanced	O
cardiotoxicity	B-DISEASE
Metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
Metronidazole	B-CHEMICAL
We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	B-DISEASE
following	O
prolonged	O
metronidazole	B-CHEMICAL
Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	O
showed	O
abnormal	O
signal	O
intensity	O
involving	O
both	O
dentate	O
nuclei	O
of	O
cerebellum	O
and	O
splenium	O
of	O
corpus	B-DISEASE
callosum	I-DISEASE
The	O
diagnosis	O
of	O
metronidazole	B-CHEMICAL
toxicity	B-DISEASE
Aconitine	B-CHEMICAL
-	O
induced	O
Ca2	O
+	O
overload	O
causes	O
arrhythmia	B-DISEASE
Aconitine	B-CHEMICAL
Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	B-CHEMICAL
(+)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B-DISEASE
of	O
aconitine	B-CHEMICAL
However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
in	O
aconitine	B-CHEMICAL
poisoning	B-DISEASE
In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
signaling	O
in	O
aconitine	B-CHEMICAL
poisoning	B-DISEASE
We	O
found	O
that	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
overload	O
lead	B-CHEMICAL
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B-DISEASE
To	O
investigate	O
effects	O
of	O
aconitine	B-CHEMICAL
on	O
myocardial	B-DISEASE
injury	I-DISEASE
,	O
we	O
performed	O
cytotoxicity	O
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
),	O
as	O
well	O
as	O
measured	O
lactate	B-CHEMICAL
The	O
results	O
showed	O
that	O
aconitine	B-CHEMICAL
resulted	O
in	O
myocardial	B-DISEASE
injury	I-DISEASE
To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	B-CHEMICAL
The	O
results	O
showed	O
that	O
aconitine	B-CHEMICAL
The	O
expression	O
analysis	O
of	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	B-CHEMICAL
promoted	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	B-CHEMICAL
Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	B-CHEMICAL
significantly	O
aggravates	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
overload	O
and	O
causes	O
arrhythmia	B-DISEASE
Chronic	O
treatment	O
with	O
metformin	B-CHEMICAL
suppresses	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
following	O
myocardial	B-DISEASE
infarction	I-DISEASE
Acute	O
treatment	O
with	O
metformin	B-CHEMICAL
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-DISEASE
infarction	I-DISEASE
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP	B-CHEMICAL
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-CHEMICAL
on	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B-DISEASE
infarction	I-DISEASE
Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
):	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B-CHEMICAL
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	B-CHEMICAL
Isoproterenol	B-CHEMICAL
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
Isoproterenol	B-CHEMICAL
The	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	B-CHEMICAL
Metfromin	O
markedly	O
lowered	O
isoproterenol	B-CHEMICAL
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
,	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
),	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
Phosphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	B-CHEMICAL
Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-CHEMICAL
reduces	O
post	O
-	O
myocardial	B-DISEASE
infarction	I-DISEASE
cardiac	B-DISEASE
dysfunction	I-DISEASE
Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	B-CHEMICAL
and	O
tiapride	O
in	O
a	O
Japanese	O
patient	O
with	O
Huntington	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
at	B-DISEASE
the	O
terminal	O
stage	O
of	O
recurrent	B-DISEASE
breast	I-DISEASE
cancer	I-DISEASE
We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
with	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	O
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabenazine	B-CHEMICAL
(	O
12	O
.	O
5	O
mg	O
/	O
day	O
)	O
for	O
Huntington	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	O
or	O
tetrabenazine	B-CHEMICAL
She	O
also	O
had	O
advanced	O
breast	B-DISEASE
cancer	I-DISEASE
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
occurrence	O
of	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	B-CHEMICAL
Tetrabenazine	B-CHEMICAL
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	B-CHEMICAL
drugs	I-CHEMICAL
A	O
metoprolol	B-CHEMICAL
-	O
terbinafine	B-CHEMICAL
combination	O
induced	O
bradycardia	B-DISEASE
To	O
report	O
a	O
sinus	B-DISEASE
bradycardia	I-DISEASE
induced	O
by	O
metoprolol	B-CHEMICAL
and	O
terbinafine	B-CHEMICAL
A	O
63	O
year	O
-	O
old	O
Caucasian	O
man	O
on	O
metoprolol	B-CHEMICAL
200	O
mg	O
/	O
day	O
for	O
stable	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
was	O
prescribed	O
a	O
90	O
-	O
day	O
course	O
of	O
oral	O
terbinafine	B-CHEMICAL
250	O
mg	O
/	O
day	O
for	O
onychomycosis	B-DISEASE
On	O
the	O
49th	O
day	O
of	O
terbinafine	B-CHEMICAL
therapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status	O
,	O
confusion	B-DISEASE
The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats	O
/	O
min	O
sinus	B-DISEASE
bradycardia	I-DISEASE
A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
'	O
s	O
sinus	B-DISEASE
bradycardia	I-DISEASE
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	B-CHEMICAL
and	O
terbinafine	B-CHEMICAL
The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	B-CHEMICAL
It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	B-CHEMICAL
By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6	O
,	O
terbinafine	B-CHEMICAL
had	O
decreased	O
metoprolol	B-CHEMICAL
'	O
s	O
clearance	O
,	O
leading	O
in	O
metoprolol	B-CHEMICAL
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	B-DISEASE
bradycardia	I-DISEASE
Optochiasmatic	O
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
due	O
to	O
ethambutol	B-CHEMICAL
Ethambutol	B-CHEMICAL
is	O
known	O
to	O
cause	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
,	O
more	O
rarely	O
,	O
axonal	O
polyneuropathy	B-DISEASE
We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
visual	B-DISEASE
loss	I-DISEASE
and	O
paresthesias	O
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	B-CHEMICAL
This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	B-CHEMICAL
toxicity	B-DISEASE
Testosterone	B-CHEMICAL
ameliorates	O
streptozotocin	B-CHEMICAL
-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	B-CHEMICAL
on	O
streptozotocin	B-CHEMICAL
(	O
STZ	O
)-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
Testosterone	B-CHEMICAL
(	O
1	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
),	O
sc	O
),	O
the	O
androgen	O
receptor	O
antagonist	O
flutamide	B-CHEMICAL
(	O
10	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
),	O
ip	O
),	O
the	O
estrogen	B-CHEMICAL
receptor	O
antagonist	O
tamoxifen	B-CHEMICAL
(	O
1	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
),	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	B-CHEMICAL
Testosterone	B-CHEMICAL
Administration	O
of	O
flutamide	B-CHEMICAL
,	O
letrozole	B-CHEMICAL
or	O
tamoxifen	B-CHEMICAL
significantly	O
impaired	O
the	O
memory	O
in	O
intact	O
rats	O
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	B-CHEMICAL
replacement	O
in	O
improving	O
STZ	O
-	O
and	O
castration	O
-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
CONCLUSION	O
:	O
Testosterone	B-CHEMICAL
administration	O
ameliorates	O
STZ	O
-	O
and	O
castration	O
-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	B-CHEMICAL
FC	I-CHEMICAL
in	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Garcinielliptone	B-CHEMICAL
FC	I-CHEMICAL
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-DISEASE
diseases	I-DISEASE
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	O
and	O
inflammatory	O
diseases	B-DISEASE
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	O
effects	O
at	B-DISEASE
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B-DISEASE
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	B-CHEMICAL
acid	I-CHEMICAL
(	O
r	O
-	O
aminobutyric	O
acid	O
(	O
GABA	B-CHEMICAL
),	O
glutamine	B-CHEMICAL
,	O
aspartate	B-CHEMICAL
and	O
glutathione	B-CHEMICAL
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	B-DISEASE
GFC	O
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B-DISEASE
,	O
at	B-DISEASE
In	O
addition	O
,	O
GABA	B-CHEMICAL
In	O
aspartate	B-CHEMICAL
,	O
glutamine	B-CHEMICAL
and	O
glutamate	B-CHEMICAL
The	O
results	O
indicate	O
that	O
GFC	O
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B-DISEASE
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	O
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B-CHEMICAL
model	O
by	O
modulating	O
the	O
GABA	B-CHEMICAL
and	O
glutamate	B-CHEMICAL
Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
INTRODUCTION	O
:	O
Acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(	O
standard	O
operating	O
procedures	O
(	O
SOP	O
))	O
for	O
potentially	O
nephrotoxic	B-DISEASE
Data	O
collection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
days	O
in	O
three	O
ICUs	O
at	B-DISEASE
A	O
total	O
of	O
675	O
patients	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	B-CHEMICAL
,	O
gentamicin	B-CHEMICAL
,	O
or	O
tobramycin	B-CHEMICAL
Basic	O
characteristics	O
were	O
comparable	O
,	O
except	O
an	O
increased	O
rate	O
of	O
soft	B-DISEASE
tissue	I-DISEASE
infections	I-DISEASE
CONCLUSION	O
:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	B-DISEASE
Rhabdomyolysis	B-DISEASE
in	O
a	O
hepatitis	B-DISEASE
C	I-DISEASE
virus	O
infected	O
patient	O
treated	O
with	O
telaprevir	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
A	O
46	O
-	O
year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B-DISEASE
C	I-DISEASE
virus	I-DISEASE
infection	I-DISEASE
received	O
triple	O
therapy	O
with	O
ribavirin	B-CHEMICAL
,	O
pegylated	O
interferon	O
and	O
telaprevir	B-CHEMICAL
The	O
patient	O
also	O
received	O
simvastatin	B-CHEMICAL
One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B-DISEASE
At	B-DISEASE
admission	O
simvastatin	B-CHEMICAL
and	O
all	O
antiviral	B-CHEMICAL
drugs	I-CHEMICAL
were	O
discontinued	O
because	O
toxicity	B-DISEASE
The	O
creatine	B-CHEMICAL
kinase	I-CHEMICAL
peaked	O
at	B-DISEASE
The	O
patient	O
'	O
s	O
renal	B-DISEASE
Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	B-CHEMICAL
kinase	I-CHEMICAL
Telaprevir	B-CHEMICAL
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	B-CHEMICAL
The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4	O
-	O
mediated	O
simvastatin	B-CHEMICAL
Simvastatin	B-CHEMICAL
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	B-CHEMICAL
induced	O
muscle	O
toxicity	B-DISEASE
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	B-CHEMICAL
In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	B-CHEMICAL
as	O
well	O
as	O
statins	B-CHEMICAL
Combination	O
of	O
bortezomib	B-CHEMICAL
,	O
thalidomide	B-CHEMICAL
,	O
and	O
dexamethasone	B-CHEMICAL
(	O
VTD	O
)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	B-DISEASE
myeloma	I-DISEASE
Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	B-DISEASE
myeloma	I-DISEASE
In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	B-CHEMICAL
,	O
thalidomide	B-CHEMICAL
,	O
and	O
dexamethasone	B-CHEMICAL
VTD	O
consisted	O
of	O
bortezomib	B-CHEMICAL
at	B-DISEASE
a	O
dose	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	B-CHEMICAL
at	B-DISEASE
a	O
dose	O
of	O
40	O
mg	O
/	O
day	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
day	O
cycle	O
,	O
with	O
daily	O
oral	O
thalidomide	B-CHEMICAL
at	B-DISEASE
Grade	O
3	O
-	O
4	O
neutropenia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
Peripheral	B-DISEASE
neuropathy	I-DISEASE
was	O
common	O
(	O
63	O
%),	O
but	O
severe	O
grade	O
3	O
-	O
4	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Conversion	O
to	O
sirolimus	B-CHEMICAL
ameliorates	O
cyclosporine	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
,	O
urine	B-DISEASE
,	O
gene	O
,	O
and	O
protein	O
renal	B-DISEASE
expression	O
biomarkers	B-CHEMICAL
Protocols	O
of	O
conversion	O
from	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
(	O
CsA	B-CHEMICAL
)	O
to	O
sirolimus	B-CHEMICAL
(	O
SRL	B-CHEMICAL
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	B-CHEMICAL
of	O
CsA	B-CHEMICAL
-	O
to	O
-	O
SRL	B-CHEMICAL
Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	B-CHEMICAL
,	O
SRL	B-CHEMICAL
,	O
and	O
conversion	O
(	O
CsA	B-CHEMICAL
for	O
3	O
weeks	O
followed	O
by	O
SRL	B-CHEMICAL
Renal	B-DISEASE
lesions	O
were	O
analyzed	O
in	O
hematoxylin	B-CHEMICAL
and	O
eosin	O
,	O
periodic	B-CHEMICAL
acid	I-CHEMICAL
SRL	B-CHEMICAL
-	O
treated	O
rats	O
presented	O
proteinuria	B-DISEASE
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B-DISEASE
Short	O
CsA	B-CHEMICAL
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	O
lesions	O
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
mTOR	O
,	O
PCNA	B-CHEMICAL
Prolonged	O
CsA	B-CHEMICAL
exposure	O
aggravated	O
renal	B-DISEASE
damage	I-DISEASE
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TBARs	B-CHEMICAL
Conversion	O
to	O
SRL	B-CHEMICAL
prevented	O
CsA	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
damage	I-DISEASE
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
),	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	B-DISEASE
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	B-CHEMICAL
replacement	O
to	O
SRL	B-CHEMICAL
Kinin	O
B2	O
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
renal	I-DISEASE
injury	I-DISEASE
Cisplatin	B-CHEMICAL
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies	O
;	O
however	O
,	O
this	O
drug	O
can	O
induce	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	B-DISEASE
function	O
,	O
augment	O
serum	O
levels	O
of	O
creatinine	B-CHEMICAL
and	O
urea	B-CHEMICAL
,	O
increase	O
the	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
score	O
and	O
up	O
-	O
regulate	O
cytokines	B-CHEMICAL
The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	B-DISEASE
process	O
,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression	O
,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	B-CHEMICAL
Additionally	O
,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	B-CHEMICAL
B2	O
receptor	O
-	O
deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice	O
,	O
as	O
shown	O
by	O
reduced	O
weight	B-DISEASE
loss	I-DISEASE
,	O
better	O
preservation	O
of	O
kidney	O
function	O
,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	B-CHEMICAL
and	O
less	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
Moreover	O
,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	B-CHEMICAL
and	O
blood	O
urea	B-CHEMICAL
after	O
cisplatin	B-CHEMICAL
Thus	O
,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
by	O
mediating	O
the	O
necrotic	B-DISEASE
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines	B-CHEMICAL
,	O
thus	O
resulting	O
in	O
declined	O
renal	B-DISEASE
These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	B-DISEASE
induced	O
by	O
cisplatin	B-CHEMICAL
Safety	O
and	O
efficacy	O
of	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
PURPOSE	O
:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
intravitreal	O
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
patients	O
with	O
birdshot	O
retinochoroidopathy	O
whose	O
disease	B-DISEASE
Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
underwent	O
surgery	O
for	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	B-DISEASE
baseline	O
,	O
before	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
implant	O
,	O
and	O
then	O
at	B-DISEASE
Disease	B-DISEASE
activity	O
markers	O
,	O
including	O
signs	O
of	O
ocular	O
inflammation	B-DISEASE
,	O
evidence	O
of	O
retinal	B-DISEASE
vasculitis	I-DISEASE
Data	O
on	O
occurrence	O
of	O
cataract	B-DISEASE
RESULTS	O
:	O
Intraocular	O
inflammation	B-DISEASE
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
patients	O
at	B-DISEASE
Active	O
vasculitis	B-DISEASE
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
patients	O
at	B-DISEASE
baseline	O
and	O
0	O
%	O
at	B-DISEASE
More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	B-DISEASE
macular	I-DISEASE
edema	I-DISEASE
at	B-DISEASE
At	B-DISEASE
This	O
percentage	O
decreased	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	B-DISEASE
Adverse	O
events	O
included	O
increased	O
intraocular	O
pressure	O
(	O
54	O
.	O
5	O
%)	O
and	O
cataract	B-DISEASE
CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
control	O
inflammation	B-DISEASE
It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	B-DISEASE
and	O
ocular	B-DISEASE
hypertension	I-DISEASE
Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	B-CHEMICAL
to	O
decrease	O
fasciculation	B-DISEASE
and	O
myalgia	B-DISEASE
following	O
succinylcholine	B-CHEMICAL
BACKGROUND	O
:	O
Succinylcholine	B-CHEMICAL
commonly	O
produces	O
frequent	O
adverse	O
effects	O
,	O
including	O
muscle	O
fasciculation	B-DISEASE
and	O
myalgia	B-DISEASE
The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	B-CHEMICAL
to	O
prevent	O
succinylcholine	B-CHEMICAL
-	O
induced	O
fasciculation	B-DISEASE
and	O
myalgia	B-DISEASE
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	B-CHEMICAL
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	B-CHEMICAL
Patients	O
were	O
randomized	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rocuronium	B-CHEMICAL
All	O
patients	O
received	O
succinylcholine	B-CHEMICAL
1	O
.	O
5	O
mg	O
/	O
kg	O
at	B-DISEASE
2	O
minutes	O
after	O
the	O
precurarization	O
,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	O
,	O
while	O
myalgia	B-DISEASE
was	O
assessed	O
at	B-DISEASE
RESULTS	O
:	O
The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	O
fasciculation	B-DISEASE
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-CHEMICAL
Those	O
of	O
myalgia	B-DISEASE
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-CHEMICAL
The	O
onset	O
time	O
of	O
succinylcholine	B-CHEMICAL
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-CHEMICAL
CONCLUSIONS	O
:	O
Precurarization	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocuronium	B-CHEMICAL
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	B-DISEASE
and	O
myalgia	B-DISEASE
Absence	O
of	O
PKC	O
-	O
alpha	O
attenuates	O
lithium	B-CHEMICAL
-	O
induced	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
Lithium	B-CHEMICAL
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	B-DISEASE
is	O
likely	O
due	O
to	O
lithium	B-CHEMICAL
acutely	O
disrupting	O
the	O
cAMP	O
pathway	O
and	O
chronically	O
reducing	O
urea	B-CHEMICAL
transporter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
water	B-CHEMICAL
Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	B-CHEMICAL
-	O
induced	O
polyuria	B-DISEASE
PKC	O
-	O
alpha	O
null	O
mice	O
(	O
PKCa	O
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	B-CHEMICAL
WT	O
mice	O
had	O
increased	O
urine	B-DISEASE
output	O
and	O
lowered	O
urine	B-DISEASE
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	B-DISEASE
Animals	O
were	O
also	O
treated	O
with	O
lithium	B-CHEMICAL
Lithium	B-CHEMICAL
-	O
treated	O
WT	O
mice	O
had	O
19	O
-	O
fold	O
increased	O
urine	B-DISEASE
AQP2	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	B-CHEMICAL
Urinary	O
sodium	B-CHEMICAL
,	O
potassium	B-CHEMICAL
and	O
calcium	B-CHEMICAL
were	O
elevated	O
in	O
lithium	B-CHEMICAL
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	B-CHEMICAL
Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	B-CHEMICAL
-	O
induced	O
NDI	O
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B-DISEASE
associated	O
with	O
lithium	B-CHEMICAL
Is	O
Dysguesia	O
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side	O
-	O
effect	O
of	O
Amlodipine	B-CHEMICAL
A	O
very	O
rare	O
side	O
-	O
effect	O
of	O
amlodipine	B-CHEMICAL
We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	B-DISEASE
hypertension	I-DISEASE
on	O
drug	O
treatment	O
with	O
amlodipine	B-CHEMICAL
We	O
conclude	O
that	O
amlodipine	B-CHEMICAL
Here	O
,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	B-CHEMICAL
Rhabdomyolysis	B-DISEASE
in	O
association	O
with	O
simvastatin	B-CHEMICAL
and	O
dosage	O
increment	O
in	O
clarithromycin	B-CHEMICAL
Clarithromycin	B-CHEMICAL
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	B-CHEMICAL
This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	B-DISEASE
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	B-CHEMICAL
The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	B-CHEMICAL
without	O
any	O
obvious	O
cardiac	O
issues	O
,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	B-DISEASE
To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	B-DISEASE
Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	B-DISEASE
Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	B-CHEMICAL
induced	O
rhabdomyolysis	B-DISEASE
Characterization	O
of	O
a	O
novel	O
BCHE	O
"	O
silent	O
"	O
allele	O
:	O
point	O
mutation	O
(	O
p	O
.	O
Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B-DISEASE
with	O
suxamethonium	B-CHEMICAL
Butyrylcholinesterase	B-DISEASE
deficiency	I-DISEASE
is	O
characterized	O
by	O
prolonged	O
apnea	B-DISEASE
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	B-CHEMICAL
or	O
mivacurium	B-CHEMICAL
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	B-CHEMICAL
Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	B-CHEMICAL
(	O
BTC	O
)	O
and	O
benzoylcholine	B-CHEMICAL
,	O
and	O
values	O
of	O
dibucaine	B-CHEMICAL
Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	O
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B-CHEMICAL
Molecular	O
dynamic	O
(	O
MD	B-DISEASE
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	O
.	O
Val204Asp	O
is	O
disruption	O
of	O
hydrogen	B-CHEMICAL
MD	B-DISEASE
This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	O
.	O
Ala204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	B-CHEMICAL
Delayed	O
anemia	B-DISEASE
after	O
treatment	O
with	O
injectable	O
artesunate	B-CHEMICAL
Cases	O
of	O
delayed	O
hemolytic	B-DISEASE
anemia	I-DISEASE
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	B-CHEMICAL
,	O
the	O
current	O
World	O
Health	O
Organization	O
(	O
WHO	O
)-	O
recommended	O
first	O
-	O
line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	B-DISEASE
A	O
total	O
of	O
350	O
patients	O
(	O
215	O
[	O
61	O
.	O
4	O
%]	O
<	O
5	O
years	O
of	O
age	O
and	O
135	O
[	O
38	O
.	O
6	O
%]	O
>	O
5	O
years	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatment	O
with	O
injectable	O
artesunate	B-CHEMICAL
for	O
severe	O
malaria	B-DISEASE
For	O
five	O
patients	O
,	O
Hb	O
levels	O
decreased	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	B-DISEASE
All	O
cases	O
of	O
delayed	O
anemia	B-DISEASE
Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	B-CHEMICAL
attenuates	O
isoproterenol	B-CHEMICAL
-	O
induced	O
acute	O
myocardial	B-DISEASE
injury	I-DISEASE
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	B-CHEMICAL
on	O
acute	O
myocardial	B-DISEASE
ischemia	I-DISEASE
Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	B-CHEMICAL
Acute	O
myocardial	O
ischemic	O
injury	O
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-CHEMICAL
Oral	O
administration	O
of	O
betaine	B-CHEMICAL
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	B-DISEASE
ventricular	I-DISEASE
remodeling	I-DISEASE
Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	B-CHEMICAL
-	O
induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	B-CHEMICAL
Furthermore	O
,	O
betaine	B-CHEMICAL
The	O
protective	O
role	O
of	O
betaine	B-CHEMICAL
on	O
myocardial	B-DISEASE
damage	I-DISEASE
In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	B-CHEMICAL
pretreatment	O
attenuated	O
isoproterenol	B-CHEMICAL
-	O
induced	O
acute	O
myocardial	B-DISEASE
ischemia	I-DISEASE
Quetiapine	O
-	O
induced	O
neutropenia	B-DISEASE
in	O
a	O
bipolar	B-DISEASE
patient	O
with	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
OBJECTIVE	O
:	O
Quetiapine	O
is	O
a	O
dibenzothiazepine	O
derivative	O
,	O
similar	O
to	O
clozapine	B-CHEMICAL
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	O
dyscrasias	O
,	O
especially	O
neutropenia	B-DISEASE
A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
that	O
developed	O
neutropenia	B-DISEASE
CASE	O
REPORT	O
:	O
A	O
62	O
-	O
year	O
-	O
old	O
Taiwanese	O
widow	O
with	O
bipolar	B-DISEASE
disorder	I-DISEASE
was	O
diagnosed	O
with	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
at	B-DISEASE
CONCLUSIONS	O
:	O
Although	O
neutropenia	B-DISEASE
Hepatic	O
dysfunction	O
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors	O
,	O
and	O
concomitant	O
fever	B-DISEASE
Lateral	O
antebrachial	O
cutaneous	O
neuropathy	B-DISEASE
after	O
steroid	B-CHEMICAL
injection	O
at	B-DISEASE
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	B-DISEASE
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
steroid	B-CHEMICAL
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	B-DISEASE
epicondylitis	I-DISEASE
MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	B-DISEASE
over	O
her	O
right	O
lateral	O
forearm	O
;	O
the	O
paresthesia	B-DISEASE
had	O
occurred	O
after	O
a	O
steroid	B-CHEMICAL
Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	B-DISEASE
CONCLUSION	O
:	O
This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	B-CHEMICAL
injection	O
for	O
the	O
treatment	O
of	O
lateral	B-DISEASE
epicondylitis	I-DISEASE
Curcumin	B-CHEMICAL
prevents	O
maleate	O
-	O
induced	O
nephrotoxicity	B-DISEASE
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	B-CHEMICAL
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	B-CHEMICAL
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-DISEASE
injury	I-DISEASE
Tubular	O
proteinuria	B-DISEASE
Maleate	O
-	O
induced	O
renal	B-DISEASE
injury	I-DISEASE
included	O
increase	O
in	O
renal	B-DISEASE
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	B-CHEMICAL
,	O
sodium	B-CHEMICAL
,	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acetyl	O
b	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
),	O
upregulation	O
of	O
kidney	O
injury	O
molecule	O
(	O
KIM	O
)-	O
1	O
,	O
decrease	O
in	O
renal	B-DISEASE
blood	O
flow	O
and	O
claudin	O
-	O
2	O
expression	O
besides	O
of	O
necrosis	B-DISEASE
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h	B-CHEMICAL
.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	B-CHEMICAL
and	O
proteins	O
and	O
diminution	O
in	O
renal	B-DISEASE
Studies	O
were	O
also	O
conducted	O
in	O
renal	B-DISEASE
Maleate	O
induced	O
cell	O
damage	O
and	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
In	O
addition	O
,	O
maleate	O
treatment	O
reduced	O
oxygen	B-CHEMICAL
consumption	O
in	O
ADP	B-CHEMICAL
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	O
/	O
glutamate	B-CHEMICAL
All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	B-CHEMICAL
It	O
is	O
concluded	O
that	O
curcumin	B-CHEMICAL
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	O
-	O
induced	O
nephropathy	B-DISEASE
The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	B-CHEMICAL
Incidence	O
of	O
solid	O
tumours	O
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	O
insecticide	O
diazinon	B-CHEMICAL
OBJECTIVE	O
:	O
Diazinon	B-CHEMICAL
,	O
a	O
common	O
organophosphate	O
insecticide	O
with	O
genotoxic	O
properties	O
,	O
was	O
previously	O
associated	O
with	O
lung	B-DISEASE
cancer	I-DISEASE
in	O
the	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
cohort	O
,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon	B-CHEMICAL
-	O
associated	O
cancer	B-DISEASE
We	O
used	O
updated	O
diazinon	B-CHEMICAL
exposure	O
and	O
cancer	B-DISEASE
METHODS	O
:	O
Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	B-CHEMICAL
use	O
at	B-DISEASE
enrolment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
);	O
cancer	B-DISEASE
Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure	O
-	O
response	O
patterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cancer	B-DISEASE
RESULTS	O
:	O
We	O
observed	O
elevated	O
lung	B-DISEASE
cancer	I-DISEASE
risks	O
(	O
N	O
=	O
283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Ptrend	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
days	O
of	O
diazinon	B-CHEMICAL
Kidney	B-DISEASE
cancer	I-DISEASE
(	O
N	O
=	O
94	O
)	O
risks	O
were	O
non	O
-	O
significantly	O
elevated	O
(	O
RRLT	O
days	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Ptrend	O
=	O
0	O
.	O
09	O
;	O
RRIW	O
days	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Ptrend	O
=	O
0	O
.	O
50	O
),	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	B-DISEASE
cancer	I-DISEASE
CONCLUSIONS	O
:	O
Our	O
updated	O
evaluation	O
of	O
diazinon	B-CHEMICAL
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	B-DISEASE
cancer	I-DISEASE
Newly	O
identified	O
links	O
to	O
kidney	B-DISEASE
cancer	I-DISEASE
and	O
associations	O
with	O
aggressive	O
prostate	B-DISEASE
cancer	I-DISEASE
Associations	O
of	O
Ozone	B-CHEMICAL
and	O
PM2	O
.	O
5	O
Concentrations	O
With	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
Disease	I-DISEASE
OBJECTIVE	O
:	O
This	O
study	O
describes	O
associations	O
of	O
ozone	B-CHEMICAL
and	O
fine	O
particulate	B-CHEMICAL
matter	I-CHEMICAL
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
METHODS	O
:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self	O
-	O
reported	O
,	O
doctor	O
-	O
diagnosed	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
RESULTS	O
:	O
We	O
observed	O
positive	O
associations	O
of	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
with	O
ozone	B-CHEMICAL
(	O
odds	O
ratio	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fine	O
particulate	B-CHEMICAL
matter	I-CHEMICAL
CONCLUSIONS	O
:	O
The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
risk	O
is	O
supported	O
by	O
experimental	O
data	O
demonstrating	O
damage	O
to	O
dopaminergic	O
neurons	O
at	B-DISEASE
Low	O
functional	O
programming	O
of	O
renal	B-DISEASE
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B-DISEASE
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	B-CHEMICAL
UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	B-CHEMICAL
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B-DISEASE
growth	I-DISEASE
retardation	I-DISEASE
Recent	O
research	O
suggested	O
that	O
IUGR	O
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B-DISEASE
However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B-DISEASE
This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B-DISEASE
A	O
rat	O
model	O
of	O
IUGR	O
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	B-DISEASE
The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B-DISEASE
as	O
well	O
as	O
interstitial	O
fibrosis	B-DISEASE
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	B-CHEMICAL
and	O
urine	B-DISEASE
Renal	B-DISEASE
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	B-DISEASE
angiotensin	B-CHEMICAL
II	I-CHEMICAL
Moreover	O
,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	O
-	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)/	O
tyrosine	B-CHEMICAL
These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	O
of	O
fetal	O
kidneys	O
as	O
well	O
as	O
glomerulosclerosis	B-DISEASE
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	B-DISEASE
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B-DISEASE
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
Butadiene	I-CHEMICAL
,	O
CML	O
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
translocation	B-DISEASE
UNASSIGNED	O
:	O
Epidemiological	O
studies	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
butadiene	I-CHEMICAL
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	O
myeloid	O
leukemia	B-DISEASE
Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML	O
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
translocation	B-DISEASE
(	O
Philadelphia	B-DISEASE
chromosome	I-DISEASE
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemicals	B-CHEMICAL
We	O
have	O
proposed	O
that	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
butadiene	I-CHEMICAL
Results	O
described	O
here	O
demonstrate	O
that	O
this	O
agent	O
does	O
in	O
fact	O
induce	O
pathogenic	O
t	O
(	O
9	O
:	O
22	O
)	O
translocations	O
in	O
a	O
human	O
myeloid	O
cell	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	B-DISEASE
Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
butadiene	I-CHEMICAL
Cancer	B-DISEASE
incidence	O
and	O
metolachlor	B-CHEMICAL
UNASSIGNED	O
:	O
Metolachlor	B-CHEMICAL
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	B-DISEASE
neoplasms	I-DISEASE
Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	B-CHEMICAL
We	O
evaluated	O
cancer	B-DISEASE
incidence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
applicators	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	B-CHEMICAL
We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	B-CHEMICAL
use	O
(	O
lifetime	O
days	O
,	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
)	O
and	O
cancer	B-DISEASE
We	O
saw	O
no	O
association	O
between	O
metolachlor	B-CHEMICAL
use	O
and	O
incidence	O
of	O
all	O
cancers	B-DISEASE
combined	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
year	O
lag	O
)	O
or	O
most	O
site	O
-	O
specific	O
cancers	B-DISEASE
For	O
liver	B-DISEASE
cancer	I-DISEASE
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers	O
,	O
elevations	O
observed	O
at	B-DISEASE
A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	O
cell	O
lymphoma	B-DISEASE
,	O
but	O
no	O
other	O
lymphoma	B-DISEASE
An	O
earlier	O
suggestion	O
of	O
increased	O
lung	B-DISEASE
cancer	I-DISEASE
risk	O
at	B-DISEASE
high	O
levels	O
of	O
metolachlor	B-CHEMICAL
This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	B-CHEMICAL
and	O
liver	B-DISEASE
cancer	I-DISEASE
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	B-DISEASE
neoplasms	I-DISEASE
However	O
,	O
our	O
findings	O
for	O
both	O
liver	B-DISEASE
cancer	I-DISEASE
and	O
follicular	O
cell	O
lymphoma	B-DISEASE
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	B-CHEMICAL
Mechanisms	O
Underlying	O
Latent	O
Disease	B-DISEASE
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	B-CHEMICAL
BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	O
arsenic	B-CHEMICAL
(	O
iAs	O
)	O
in	O
their	O
drinking	B-CHEMICAL
water	I-CHEMICAL
There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	O
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	B-DISEASE
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B-DISEASE
OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B-DISEASE
DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B-DISEASE
CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	O
exposure	O
and	O
cancer	B-DISEASE
Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	O
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	B-DISEASE
On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N	O
-	O
substituted	O
piperazine	B-CHEMICAL
The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N	O
-(	O
trans	O
-	O
3	O
-	O
hydroxy	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
-	O
tetrahydro	O
-	O
2	O
-	O
naphthyl	O
)-	O
N	O
-(	O
3	O
-	O
oxo	O
-	O
3	O
-	O
phenyl	O
-	O
2	O
-	O
methylpropyl	O
)-	O
piperazine	B-CHEMICAL
Four	O
types	O
of	O
experimental	O
arrhythmia	B-DISEASE
are	O
used	O
--	O
with	O
BaCl2	B-CHEMICAL
,	O
with	O
chloroform	B-CHEMICAL
-	O
adrenaline	B-CHEMICAL
,	O
with	O
strophantine	O
G	O
and	O
with	O
aconitine	B-CHEMICAL
The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	B-DISEASE
used	O
,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	B-DISEASE
induced	O
by	O
chloroform	B-CHEMICAL
-	O
adrenaline	B-CHEMICAL
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	B-CHEMICAL
Experimental	O
progressive	O
muscular	B-DISEASE
dystrophy	I-DISEASE
We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	B-DISEASE
dystrophy	I-DISEASE
Myopathy	B-DISEASE
due	O
to	O
lack	O
of	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
and	O
myopathy	B-DISEASE
The	O
authors	O
induced	O
myodystrophy	O
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
.	O
The	O
pharmacological	O
characteristics	O
of	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	O
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	B-DISEASE
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	B-DISEASE
The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	O
patients	O
by	O
using	O
anabolizing	O
steroids	B-CHEMICAL
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	O
,	O
CIBA	O
)	O
at	B-DISEASE
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	O
by	O
a	O
diet	O
deficient	O
in	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
.	O
In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	B-DISEASE
weight	I-DISEASE
(	O
increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	B-DISEASE
The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	B-CHEMICAL
in	O
experimental	O
myopathic	O
disease	B-DISEASE
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field	O
,	O
where	O
high	O
dosage	O
cannot	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility	O
;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	B-DISEASE
an	O
irreversible	O
stage	O
vis	O
-	O
a	O
-	O
vis	O
the	O
"	O
regeneration	O
"	O
of	O
the	O
muscle	O
tissue	O
;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
Fetal	O
risks	O
due	O
to	O
warfarin	B-CHEMICAL
therapy	O
during	O
pregnancy	B-DISEASE
Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	B-CHEMICAL
during	O
pregnancy	B-DISEASE
In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	B-CHEMICAL
with	O
heparin	B-CHEMICAL
The	O
baby	O
died	O
of	O
cerebral	O
and	O
pulmonary	O
hemorrhage	B-DISEASE
The	O
second	O
mother	O
had	O
a	O
male	O
infant	B-DISEASE
The	O
baby	O
showed	O
warfarin	B-CHEMICAL
-	O
induced	O
embryopathy	O
with	O
nasal	O
hypoplasia	O
and	O
stippled	B-DISEASE
epiphyses	I-DISEASE
(	O
chondrodysplasia	B-DISEASE
punctata	I-DISEASE
Nasal	O
hypoplasia	O
with	O
or	O
without	O
stippled	B-DISEASE
epiphyses	I-DISEASE
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	B-CHEMICAL
In	O
view	O
of	O
the	O
risks	O
to	O
both	O
mother	O
and	O
fetus	O
in	O
women	O
with	O
prosthetic	O
cardiac	O
valves	O
it	O
is	O
recommended	O
that	O
therapeutic	O
abortion	B-DISEASE
Isradipine	B-CHEMICAL
treatment	O
for	O
hypertension	B-DISEASE
A	O
6	O
-	O
week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	B-CHEMICAL
303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	B-DISEASE
The	O
main	O
side	O
-	O
effects	O
were	O
headache	B-DISEASE
,	O
dizziness	B-DISEASE
,	O
palpitation	O
and	O
flushing	B-DISEASE
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	B-CHEMICAL
Supine	O
blood	O
pressure	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+/-	O
20	O
/	O
102	O
+/-	O
6	O
mmHg	O
to	O
153	O
+/-	O
19	O
/	O
92	O
+/-	O
8	O
,	O
147	O
+/-	O
18	O
/	O
88	O
+/-	O
7	O
and	O
144	O
+/-	O
14	O
/	O
87	O
+/-	O
6	O
mmHg	O
at	B-DISEASE
Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	B-DISEASE
hypotension	I-DISEASE
Normalization	O
and	O
responder	O
rates	O
at	B-DISEASE
at	B-DISEASE
Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-CHEMICAL
High	O
doses	O
of	O
inhaled	O
salbutamol	B-CHEMICAL
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	B-DISEASE
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-CHEMICAL
Twelve	O
asthmatic	O
patients	O
(	O
FEV1	O
,	O
81	O
+/-	O
4	O
%	O
predicted	O
),	O
requiring	O
only	O
occasional	O
inhaled	O
beta	O
-	O
agonists	O
as	O
their	O
sole	O
therapy	O
,	O
were	O
given	O
a	O
14	O
-	O
day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-CHEMICAL
(	O
HDS	O
),	O
4	O
,	O
000	O
micrograms	O
daily	O
,	O
low	O
dose	O
inhaled	O
salbutamol	B-CHEMICAL
During	O
the	O
14	O
-	O
day	O
run	O
-	O
in	O
and	O
during	O
washout	O
periods	O
,	O
inhaled	O
beta	O
-	O
agonists	O
were	O
withheld	O
and	O
ipratropium	B-CHEMICAL
At	B-DISEASE
the	O
end	O
of	O
each	O
14	O
-	O
day	O
treatment	O
,	O
a	O
dose	O
-	O
response	O
curve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
airway	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chronotropic	O
(	O
HR	O
),	O
tremor	B-DISEASE
,	O
and	O
metabolic	O
(	O
K	B-CHEMICAL
,	O
Glu	O
)	O
responses	O
were	O
measured	O
at	B-DISEASE
DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
K	B-CHEMICAL
Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS	O
:	O
tremor	B-DISEASE
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Increased	O
anxiogenic	O
effects	O
of	O
caffeine	B-CHEMICAL
in	O
panic	B-DISEASE
disorders	I-DISEASE
The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavioral	O
ratings	O
,	O
somatic	O
symptoms	O
,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3	O
-	O
methoxy	O
-	O
4	O
-	O
hydroxyphenethyleneglycol	O
(	O
MHPG	O
)	O
and	O
cortisol	B-CHEMICAL
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM	O
-	O
III	O
criteria	O
for	O
agoraphobia	B-DISEASE
with	O
panic	B-DISEASE
attacks	I-DISEASE
or	O
panic	B-DISEASE
disorder	I-DISEASE
Caffeine	B-CHEMICAL
produced	O
significantly	O
greater	O
increases	O
in	O
subject	O
-	O
rated	O
anxiety	B-DISEASE
,	O
nervousness	O
,	O
fear	O
,	O
nausea	B-DISEASE
,	O
palpitations	O
,	O
restlessness	B-DISEASE
,	O
and	O
tremors	B-DISEASE
In	O
the	O
patients	O
,	O
but	O
not	O
the	O
healthy	O
subjects	O
,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	B-CHEMICAL
Seventy	O
-	O
one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	B-CHEMICAL
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	B-DISEASE
attacks	I-DISEASE
Caffeine	B-CHEMICAL
Caffeine	B-CHEMICAL
increased	O
plasma	O
cortisol	B-CHEMICAL
Because	O
caffeine	B-CHEMICAL
is	O
an	O
adenosine	B-CHEMICAL
receptor	O
antagonist	O
,	O
these	O
results	O
suggest	O
that	O
some	O
panic	B-DISEASE
disorder	I-DISEASE
patients	O
may	O
have	O
abnormalities	B-DISEASE
in	O
neuronal	O
systems	O
involving	O
adenosine	B-CHEMICAL
Patients	O
with	O
anxiety	B-DISEASE
disorders	I-DISEASE
may	O
benefit	O
by	O
avoiding	O
caffeine	B-CHEMICAL
Human	O
and	O
canine	O
ventricular	O
vasoactive	O
intestinal	O
polypeptide	O
:	O
decrease	O
with	O
heart	B-DISEASE
failure	I-DISEASE
Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	B-DISEASE
failure	I-DISEASE
In	O
the	O
first	O
,	O
cobalt	B-CHEMICAL
cardiomyopathy	B-DISEASE
was	O
induced	O
in	O
eight	O
dogs	O
;	O
VIP	O
(	O
by	O
radioimmunoassay	O
)	O
decreased	O
from	O
35	O
+/-	O
11	O
pg	B-CHEMICAL
/	O
mg	O
protein	O
(	O
mean	O
+/-	O
SD	O
)	O
to	O
5	O
+/-	O
4	O
pg	B-CHEMICAL
In	O
six	O
dogs	O
with	O
doxorubicin	B-CHEMICAL
-	O
induced	O
heart	B-DISEASE
failure	I-DISEASE
,	O
VIP	O
decreased	O
from	O
31	O
+/-	O
7	O
to	O
11	O
+/-	O
4	O
pg	B-CHEMICAL
In	O
addition	O
,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(	O
five	O
with	O
rheumatic	O
disease	B-DISEASE
The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	B-DISEASE
disease	I-DISEASE
(	O
one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses	O
)	O
(	O
6	O
.	O
3	O
+/-	O
1	O
.	O
9	O
pg	B-CHEMICAL
The	O
other	O
patients	O
undergoing	O
transplantation	O
had	O
an	O
average	O
ejection	O
fraction	O
of	O
17	O
%	O
+/-	O
6	O
%	O
and	O
a	O
VIP	O
level	O
of	O
8	O
.	O
8	O
+/-	O
3	O
.	O
9	O
pg	B-CHEMICAL
The	O
hearts	O
without	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
(	O
average	O
ejection	O
fraction	O
of	O
this	O
group	O
62	O
%	O
+/-	O
10	O
%)	O
had	O
a	O
VIP	O
concentration	O
of	O
14	O
.	O
1	O
+/-	O
7	O
.	O
9	O
pg	B-CHEMICAL
/	O
mg	O
protein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	B-DISEASE
disease	I-DISEASE
Myocardial	O
catecholamines	B-CHEMICAL
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	B-CHEMICAL
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	B-CHEMICAL
Acute	O
toxic	O
dosage	O
-	O
dependent	O
behavioral	O
effects	O
of	O
caffeine	B-CHEMICAL
C57BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
mouse	O
strain	O
,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffeine	B-CHEMICAL
Five	O
phenotypic	O
characteristics	O
--	O
locomotor	O
activity	O
,	O
righting	O
ability	O
,	O
clonic	O
seizure	B-DISEASE
induction	O
,	O
stress	O
-	O
induced	O
lethality	O
,	O
death	B-DISEASE
without	O
external	O
stress	O
--	O
were	O
scored	O
at	B-DISEASE
various	O
caffeine	B-CHEMICAL
Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume	O
/	O
g	O
body	B-DISEASE
weight	I-DISEASE
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	B-CHEMICAL
Loss	O
of	O
righting	O
ability	O
was	O
scored	O
at	B-DISEASE
1	O
,	O
3	O
,	O
5	O
min	O
post	O
dosing	O
and	O
at	B-DISEASE
In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	O
seizures	B-DISEASE
When	O
these	O
proceeded	O
to	O
tonic	B-DISEASE
seizures	B-DISEASE
,	O
death	B-DISEASE
Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water	B-CHEMICAL
,	O
and	O
death	B-DISEASE
-	O
producing	O
tonic	B-DISEASE
seizures	B-DISEASE
In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	B-CHEMICAL
By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria	O
,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	B-CHEMICAL
These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	B-DISEASE
Invasive	O
carcinoma	B-DISEASE
of	O
the	O
renal	B-DISEASE
pelvis	O
following	O
cyclophosphamide	B-CHEMICAL
therapy	O
for	O
nonmalignant	O
disease	B-DISEASE
A	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
right	O
hydroureteronephrosis	O
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	B-DISEASE
hematuria	I-DISEASE
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	B-CHEMICAL
for	O
cerebral	O
vasculitis	B-DISEASE
A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	B-DISEASE
The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	B-DISEASE
of	O
the	O
renal	B-DISEASE
Although	O
the	O
ability	O
of	O
cyclophosphamide	B-CHEMICAL
to	O
cause	O
hemorrhagic	B-DISEASE
cystitis	B-DISEASE
and	O
urine	B-DISEASE
cytologic	O
abnormalities	B-DISEASE
indistinguishable	O
from	O
high	O
grade	O
carcinoma	B-DISEASE
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	B-DISEASE
Twenty	O
carcinomas	O
of	O
the	O
urinary	B-DISEASE
bladder	I-DISEASE
and	O
one	O
carcinoma	B-DISEASE
The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	B-DISEASE
of	O
the	O
renal	B-DISEASE
pelvis	O
reported	O
in	O
association	O
with	O
cyclophosphamide	B-CHEMICAL
It	O
is	O
the	O
third	O
urinary	O
tract	O
cancer	B-DISEASE
reported	O
in	O
association	O
with	O
cyclophosphamide	B-CHEMICAL
treatment	O
for	O
nonmalignant	O
disease	B-DISEASE
The	O
association	O
of	O
the	O
tumor	B-DISEASE
with	O
preexisting	O
hydroureteronephrosis	O
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	B-CHEMICAL
Patients	O
who	O
are	O
candidates	O
for	O
long	O
-	O
term	O
cyclophosphamide	B-CHEMICAL
Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carbetocin	B-CHEMICAL
(	O
a	O
long	O
-	O
acting	O
synthetic	O
analogue	O
of	O
oxytocin	B-CHEMICAL
),	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	B-DISEASE
MATERIALS	O
AND	O
METHODS	O
:	O
Carbetocin	B-CHEMICAL
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	B-DISEASE
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	B-DISEASE
Dosage	O
groups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
microg	O
carbetocin	B-CHEMICAL
Recorded	O
were	O
dose	O
-	O
limiting	O
adverse	O
events	O
:	O
hyper	O
-	O
or	O
hypotension	B-DISEASE
(	O
three	O
),	O
severe	O
abdominal	B-DISEASE
pain	I-DISEASE
(	O
0	O
),	O
vomiting	B-DISEASE
(	O
0	O
)	O
and	O
retained	O
placenta	B-DISEASE
Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B-DISEASE
loss	I-DISEASE
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	B-DISEASE
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	B-CHEMICAL
Maximum	O
blood	B-DISEASE
loss	I-DISEASE
was	O
greatest	O
at	B-DISEASE
Four	O
out	O
of	O
six	O
cases	O
with	O
blood	B-DISEASE
loss	I-DISEASE
The	O
majority	O
of	O
additional	O
administration	O
of	O
oxytocics	B-CHEMICAL
CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	B-DISEASE
200	O
microg	O
carbetocin	B-CHEMICAL
A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	B-CHEMICAL
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
STUDY	O
OBJECTIVE	O
:	O
Chest	B-DISEASE
pain	I-DISEASE
in	O
the	O
setting	O
of	O
cocaine	B-CHEMICAL
Dobutamine	B-CHEMICAL
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	B-DISEASE
ischemia	I-DISEASE
Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	B-CHEMICAL
in	O
the	O
setting	O
of	O
cocaine	B-CHEMICAL
use	O
,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
METHODS	O
:	O
A	O
prospective	O
case	O
series	O
was	O
conducted	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
in	O
the	O
ED	B-DISEASE
Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	B-CHEMICAL
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	B-DISEASE
pain	I-DISEASE
Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	B-CHEMICAL
toxicity	B-DISEASE
None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	O
(	O
excluding	O
sinus	O
tachycardia	B-DISEASE
Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
13	O
(	O
65	O
%)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	B-CHEMICAL
CONCLUSION	O
:	O
No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	B-CHEMICAL
was	O
administered	O
to	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
related	O
chest	B-DISEASE
pain	I-DISEASE
Amiodarone	B-CHEMICAL
-	O
induced	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(	O
within	O
4	O
days	O
)	O
development	O
of	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
(	O
TdP	B-DISEASE
)	O
associated	O
with	O
oral	O
amiodarone	B-CHEMICAL
Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	B-DISEASE
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	B-DISEASE
and	O
digoxin	B-CHEMICAL
Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP	B-DISEASE
It	O
is	O
well	O
known	O
that	O
bradycardia	B-DISEASE
exacerbates	O
acquired	O
TdP	B-DISEASE
The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	B-CHEMICAL
therapy	O
resulted	O
in	O
amiodarone	B-CHEMICAL
In	O
the	O
absence	O
of	O
amiodarone	B-CHEMICAL
therapy	O
,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	B-DISEASE
despite	O
hypokalemia	B-DISEASE
and	O
hypomagnesemia	B-DISEASE
Acute	B-DISEASE
renal	I-DISEASE
insufficiency	I-DISEASE
after	O
high	O
-	O
dose	O
melphalan	B-CHEMICAL
in	O
patients	O
with	O
primary	O
systemic	O
amyloidosis	B-DISEASE
BACKGROUND	O
:	O
Patients	O
with	O
primary	O
systemic	O
amyloidosis	B-DISEASE
High	O
-	O
dose	O
intravenous	O
melphalan	B-CHEMICAL
The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	B-DISEASE
renal	I-DISEASE
insufficiency	I-DISEASE
immediately	O
after	O
melphalan	B-CHEMICAL
Acute	B-DISEASE
renal	I-DISEASE
insufficiency	I-DISEASE
(	O
ARI	O
)	O
after	O
high	O
-	O
dose	O
melphalan	B-CHEMICAL
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
serum	O
creatinine	B-CHEMICAL
Urine	B-DISEASE
sediment	O
score	O
was	O
the	O
sum	O
of	O
the	O
individual	O
types	O
of	O
sediment	O
identified	O
on	O
urine	B-DISEASE
RESULTS	O
:	O
Of	O
the	O
80	O
patients	O
studied	O
,	O
ARI	O
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
patients	O
after	O
high	O
-	O
dose	O
melphalan	B-CHEMICAL
Univariate	O
analysis	O
identified	O
age	O
,	O
hypoalbuminemia	B-DISEASE
,	O
heavy	O
proteinuria	B-DISEASE
,	O
diuretic	O
use	O
,	O
and	O
urine	B-DISEASE
Age	O
and	O
urine	B-DISEASE
Patients	O
who	O
had	O
ARI	O
after	O
high	O
-	O
dose	O
melphalan	B-CHEMICAL
CONCLUSION	O
:	O
The	O
timing	O
of	O
renal	B-DISEASE
injury	I-DISEASE
strongly	O
suggests	O
melphalan	B-CHEMICAL
Ongoing	O
tubular	O
injury	O
may	O
be	O
a	O
prerequisite	O
for	O
renal	B-DISEASE
injury	I-DISEASE
by	O
melphalan	B-CHEMICAL
Impaired	O
fear	O
recognition	O
in	O
regular	O
recreational	O
cocaine	B-CHEMICAL
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	B-CHEMICAL
MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
groups	O
,	O
comprised	O
of	O
21	O
cocaine	B-CHEMICAL
naive	O
participants	O
(	O
CN	O
),	O
30	O
occasional	O
cocaine	B-CHEMICAL
(	O
OC	B-CHEMICAL
),	O
and	O
48	O
regular	O
recreational	O
cocaine	B-CHEMICAL
RESULTS	O
:	O
There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
"	O
eyes	O
task	O
"	O
performance	O
,	O
but	O
the	O
RC	O
group	O
,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	B-CHEMICAL
group	O
,	O
exhibited	O
impaired	O
fear	O
recognition	O
accuracy	O
compared	O
to	O
the	O
OC	B-CHEMICAL
The	O
RC	O
group	O
also	O
correctly	O
identified	O
anger	O
,	O
fear	O
,	O
happiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	B-CHEMICAL
The	O
OC	B-CHEMICAL
The	O
selective	O
deficit	O
in	O
fear	O
recognition	O
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
cannot	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	B-CHEMICAL
,	O
or	O
ecstasy	B-CHEMICAL
Corneal	O
ulcers	O
associated	O
with	O
aerosolized	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
PURPOSE	O
:	O
We	O
report	O
4	O
cases	O
of	O
corneal	O
ulcers	O
associated	O
with	O
drug	B-DISEASE
abuse	I-DISEASE
METHODS	O
:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	O
ulcers	O
associated	O
with	O
drug	B-DISEASE
abuse	I-DISEASE
seen	O
at	B-DISEASE
RESULTS	O
:	O
Four	O
patients	O
with	O
corneal	O
ulcers	O
associated	O
with	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
Each	O
patient	O
received	O
comprehensive	O
health	O
care	O
,	O
including	O
medical	O
and	O
substance	B-DISEASE
abuse	I-DISEASE
The	O
infections	B-DISEASE
CONCLUSIONS	O
:	O
Aerosolized	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
Drug	B-DISEASE
abuse	I-DISEASE
Not	O
only	O
treatment	O
of	O
their	O
infections	B-DISEASE
Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	B-DISEASE
abuse	I-DISEASE
Levetiracetam	B-CHEMICAL
as	O
an	O
adjunct	O
to	O
phenobarbital	B-CHEMICAL
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
OBJECTIVE	O
:	O
To	O
assess	O
pharmacokinetics	O
,	O
efficacy	O
,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	B-CHEMICAL
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B-CHEMICAL
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
ANIMALS	O
:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	B-CHEMICAL
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	B-CHEMICAL
PROCEDURES	O
:	O
Cats	O
were	O
treated	O
with	O
levetiracetam	B-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
],	O
PO	O
,	O
q	O
8	O
h	B-CHEMICAL
After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment	O
,	O
serum	O
levetiracetam	B-CHEMICAL
Seizure	B-DISEASE
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	B-CHEMICAL
RESULTS	O
:	O
Median	O
maximum	O
serum	O
levetiracetam	B-CHEMICAL
concentration	O
was	O
25	O
.	O
5	O
microg	O
/	O
mL	O
,	O
median	O
minimum	O
serum	O
levetiracetam	B-CHEMICAL
Median	O
seizure	B-DISEASE
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	B-CHEMICAL
(	O
2	O
.	O
1	O
seizures	B-DISEASE
/	O
mo	O
)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	B-DISEASE
frequency	O
after	O
initiation	O
of	O
levetiracetam	B-CHEMICAL
treatment	O
(	O
0	O
.	O
42	O
seizures	B-DISEASE
/	O
mo	O
),	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	B-CHEMICAL
treatment	O
(	O
ie	O
,	O
reduction	O
in	O
seizure	B-DISEASE
Two	O
cats	O
had	O
transient	O
lethargy	B-DISEASE
CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Results	O
suggested	O
that	O
levetiracetam	B-CHEMICAL
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B-CHEMICAL
treatment	O
in	O
cats	O
with	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
Bilateral	O
haemorrhagic	O
infarction	B-DISEASE
of	O
the	O
globus	O
pallidus	O
after	O
cocaine	B-CHEMICAL
and	O
alcohol	B-CHEMICAL
Cocaine	B-CHEMICAL
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	O
and	O
haemorrhagic	O
stroke	B-DISEASE
We	O
present	O
the	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
bilateral	O
ischemia	B-DISEASE
of	O
the	O
globus	O
pallidus	O
after	O
excessive	O
alcohol	B-CHEMICAL
and	O
intranasal	O
cocaine	B-CHEMICAL
Drug	O
-	O
related	O
globus	O
pallidus	O
infarctions	O
are	O
most	O
often	O
associated	O
with	O
heroin	B-CHEMICAL
Bilateral	O
basal	O
ganglia	O
infarcts	O
after	O
the	O
use	O
of	O
cocaine	B-CHEMICAL
,	O
without	O
concurrent	O
heroin	B-CHEMICAL
In	O
our	O
patient	O
,	O
transient	O
cardiac	B-DISEASE
arrhythmia	I-DISEASE
or	O
respiratory	O
dysfunction	O
related	O
to	O
cocaine	B-CHEMICAL
and	O
/	O
or	O
ethanol	B-CHEMICAL
Acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
high	O
-	O
dose	O
methotrexate	B-CHEMICAL
High	O
-	O
dose	O
methotrexate	B-CHEMICAL
(	O
HD	O
-	O
MTX	B-CHEMICAL
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	B-DISEASE
lymphoma	I-DISEASE
,	O
but	O
can	O
cause	O
hepatic	O
and	O
renal	B-DISEASE
toxicity	I-DISEASE
We	O
report	O
a	O
case	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
HD	O
-	O
MTX	B-CHEMICAL
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
,	O
The	O
patient	O
was	O
a	O
3	O
-	O
year	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
living	O
-	O
related	O
liver	B-DISEASE
transplantation	O
for	O
congenital	B-DISEASE
biliary	B-DISEASE
atresia	I-DISEASE
At	B-DISEASE
day	O
833	O
after	O
the	O
transplantation	O
,	O
he	O
was	O
diagnosed	O
with	O
PTLD	O
(	O
post	O
-	O
transplantation	O
lymphoproliferative	O
disorder	O
,	O
Burkitt	O
-	O
type	O
malignant	O
lymphoma	B-DISEASE
Subsequent	O
HD	O
-	O
MTX	B-CHEMICAL
therapy	O
caused	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
We	O
supposed	O
that	O
intravascular	O
hypovolemia	B-DISEASE
After	O
recovery	O
of	O
his	O
renal	B-DISEASE
function	O
,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD	O
-	O
MTX	B-CHEMICAL
Antithrombotic	O
drug	O
use	O
,	O
cerebral	O
microbleeds	O
,	O
and	O
intracerebral	B-DISEASE
hemorrhage	I-DISEASE
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	O
microbleeds	O
(	O
MB	O
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-DISEASE
hemorrhage	I-DISEASE
(	O
ICH	B-DISEASE
Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	O
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B-DISEASE
and	O
ischemic	B-DISEASE
stroke	I-DISEASE
(	O
IS	O
)/	O
transient	B-DISEASE
ischemic	I-DISEASE
attack	I-DISEASE
(	O
TIA	B-DISEASE
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B-DISEASE
or	O
TIA	B-DISEASE
to	O
compare	O
the	O
presence	O
of	O
MB	O
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B-DISEASE
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	O
/	O
TIA	B-DISEASE
;	O
and	O
(	O
3	O
)	O
ICH	B-DISEASE
We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B-DISEASE
RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B-DISEASE
and	O
3817	O
IS	O
/	O
TIA	B-DISEASE
,	O
MB	O
were	O
more	O
frequent	O
in	O
ICH	B-DISEASE
vs	O
IS	O
/	O
TIA	B-DISEASE
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2	O
.	O
8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfarin	B-CHEMICAL
There	O
was	O
also	O
an	O
excess	O
of	O
MB	O
in	O
warfarin	B-CHEMICAL
users	O
vs	O
nonusers	O
with	O
ICH	B-DISEASE
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
warfarin	B-CHEMICAL
users	O
with	O
IS	O
/	O
TIA	B-DISEASE
There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	O
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B-DISEASE
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	O
/	O
TIA	B-DISEASE
In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	O
at	B-DISEASE
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B-DISEASE
CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	O
in	O
warfarin	B-CHEMICAL
users	O
with	O
ICH	B-DISEASE
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	O
increase	O
the	O
risk	O
of	O
warfarin	B-CHEMICAL
-	O
associated	O
ICH	B-DISEASE
Verapamil	B-CHEMICAL
stimulation	O
test	O
in	O
hyperprolactinemia	B-DISEASE
:	O
loss	O
of	O
prolactin	B-CHEMICAL
AIM	O
:	O
Verapamil	B-CHEMICAL
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B-DISEASE
Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	B-CHEMICAL
Prolactin	B-CHEMICAL
responses	O
to	O
verapamil	B-CHEMICAL
in	O
65	O
female	O
patients	O
(	O
age	O
:	O
29	O
.	O
9	O
+/-	O
8	O
.	O
1	O
years	O
)	O
with	O
hyperprolactinemia	B-DISEASE
METHODS	O
:	O
Verapamil	B-CHEMICAL
was	O
administered	O
,	O
and	O
then	O
PRL	O
levels	O
were	O
measured	O
at	B-DISEASE
Verapamil	B-CHEMICAL
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	B-CHEMICAL
RESULTS	O
:	O
Verapamil	B-CHEMICAL
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%),	O
and	O
risperidone	B-CHEMICAL
-	O
induced	O
hyperprolactinemia	B-DISEASE
ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	B-CHEMICAL
defined	O
as	O
PRL	O
<	O
7	O
%,	O
discriminated	O
anatomical	O
or	O
functional	O
stalk	O
effect	O
(	O
sensitivity	O
:	O
74	O
%,	O
specificity	O
:	O
73	O
%,	O
AUC	O
:	O
0	O
.	O
855	O
+/-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pseudoprolactinoma	O
or	O
risperidone	B-CHEMICAL
-	O
induced	O
hyperprolactinemia	B-DISEASE
CONCLUSION	O
:	O
Verapamil	B-CHEMICAL
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B-DISEASE
However	O
,	O
verapamil	B-CHEMICAL
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(	O
i	O
.	O
e	O
.,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	B-DISEASE
Central	O
action	O
of	O
narcotic	O
analgesics	B-CHEMICAL
Noradrenergic	O
influences	O
on	O
the	O
activity	O
of	O
analgesics	B-CHEMICAL
The	O
effect	O
of	O
clonidine	B-CHEMICAL
,	O
naphazoline	B-CHEMICAL
and	O
xylometazoline	B-CHEMICAL
on	O
analgesia	O
induced	O
by	O
morphine	B-CHEMICAL
,	O
codeine	B-CHEMICAL
,	O
fentanyl	B-CHEMICAL
and	O
pentazocine	B-CHEMICAL
,	O
and	O
on	O
cataleptic	O
effect	O
of	O
morphine	B-CHEMICAL
,	O
codine	O
and	O
fentanyl	B-CHEMICAL
The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	B-CHEMICAL
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	B-CHEMICAL
(	O
NA	B-CHEMICAL
It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
NA	B-CHEMICAL
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	B-DISEASE
induced	O
by	O
morphine	B-CHEMICAL
and	O
fentanyl	B-CHEMICAL
Codeine	B-CHEMICAL
catalepsy	B-DISEASE
was	O
increased	O
by	O
clonidine	B-CHEMICAL
and	O
decreased	O
by	O
naphazoline	B-CHEMICAL
and	O
xylometazoline	B-CHEMICAL
The	O
brain	O
concentration	O
of	O
NA	B-CHEMICAL
was	O
not	O
changed	O
by	O
morphine	B-CHEMICAL
and	O
fentanyl	B-CHEMICAL
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	B-CHEMICAL
Pentazocine	B-CHEMICAL
dose	O
-	O
dependently	O
decreased	O
the	O
brain	O
level	O
of	O
NA	B-CHEMICAL
The	O
rate	O
of	O
NA	B-CHEMICAL
turnover	O
was	O
not	O
altered	O
by	O
analgesics	B-CHEMICAL
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	B-CHEMICAL
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearance	O
of	O
NA	B-CHEMICAL
It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
NA	B-CHEMICAL
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	O
in	O
the	O
behavioural	O
activity	O
of	O
potent	O
analgesics	B-CHEMICAL
Modification	O
by	O
propranolol	B-CHEMICAL
Eight	O
received	O
insulin	B-CHEMICAL
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulin	B-CHEMICAL
-	O
only	O
group	O
,	O
were	O
given	O
propranolol	B-CHEMICAL
and	O
insulin	B-CHEMICAL
In	O
the	O
insulin	B-CHEMICAL
In	O
the	O
propranolol	B-CHEMICAL
-	O
insulin	B-CHEMICAL
Typical	O
S	O
-	O
T	O
/	O
T	O
changes	O
occurred	O
in	O
the	O
insulin	B-CHEMICAL
-	O
group	O
but	O
in	O
none	O
of	O
the	O
propranolol	B-CHEMICAL
-	O
insulin	B-CHEMICAL
Hypertension	B-DISEASE
Prevention	O
and	O
treatment	O
of	O
endometrial	O
disease	B-DISEASE
The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	O
disease	B-DISEASE
Cystic	O
hyperplasia	B-DISEASE
Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	O
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	B-DISEASE
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	B-DISEASE
4	O
cases	O
of	O
endometrial	O
carcinoma	B-DISEASE
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	O
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	B-DISEASE
from	O
malignancy	B-DISEASE
Cyclical	O
low	O
-	O
dose	O
oestrogen	O
therapy	O
with	O
7	O
--	O
13	O
days	O
of	O
progestagen	O
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
or	O
carcinoma	B-DISEASE
Pure	O
red	O
cell	O
aplasia	O
,	O
toxic	O
dermatitis	B-DISEASE
and	O
lymphadenopathy	B-DISEASE
in	O
a	O
patient	O
taking	O
diphenylhydantoin	B-DISEASE
A	O
patient	O
taking	O
diphenylhydantoin	B-DISEASE
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	B-DISEASE
rash	B-DISEASE
,	O
lymphadenopathy	B-DISEASE
Skin	B-DISEASE
rash	B-DISEASE
is	O
a	O
well	O
-	O
known	O
complication	O
of	O
diphenylhydantoin	B-DISEASE
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	B-DISEASE
Pure	O
red	O
cell	O
aplasia	O
associated	O
with	O
diphenylhydantoin	B-DISEASE
The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	B-DISEASE
In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	B-DISEASE
and	O
the	O
occurrence	O
of	O
the	O
skin	B-DISEASE
rash	B-DISEASE
,	O
lymphadenopathy	B-DISEASE
Continuous	O
infusion	O
tobramycin	B-CHEMICAL
combined	O
with	O
carbenicillin	B-CHEMICAL
for	O
infections	B-DISEASE
in	O
cancer	B-DISEASE
The	O
cure	O
rate	O
of	O
infections	B-DISEASE
in	O
cancer	B-DISEASE
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	B-DISEASE
In	O
particular	O
,	O
patients	O
with	O
severe	O
neutropenia	B-DISEASE
To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	B-DISEASE
,	O
tobramycin	B-CHEMICAL
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	B-CHEMICAL
Tobramycin	B-CHEMICAL
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenicillin	B-CHEMICAL
was	O
given	O
at	B-DISEASE
a	O
dose	O
of	O
5	O
gm	B-CHEMICAL
There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	B-DISEASE
Pneumonia	B-DISEASE
was	O
the	O
most	O
common	O
infection	B-DISEASE
Gram	O
-	O
negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69	O
%	O
of	O
these	O
infections	B-DISEASE
The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	O
and	O
this	O
,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
gram	O
-	O
negative	O
bacillary	O
infections	B-DISEASE
Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62	O
%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	B-DISEASE
Azotemia	B-DISEASE
Major	O
azotemia	B-DISEASE
(	O
serum	O
creatinine	B-CHEMICAL
Azotemia	B-DISEASE
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	B-CHEMICAL
This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	B-DISEASE
toxicity	I-DISEASE
Recurrent	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
associated	O
with	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
therapy	O
and	O
acute	O
renal	B-DISEASE
artery	O
thrombosis	B-DISEASE
Epsilon	B-CHEMICAL
aminocaproic	I-CHEMICAL
acid	I-CHEMICAL
(	O
EACA	O
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding	O
,	O
several	O
reports	O
have	O
described	O
thrombotic	B-DISEASE
These	O
complications	O
have	O
included	O
clinical	B-DISEASE
deterioration	I-DISEASE
and	O
intracranial	O
vascular	O
thrombosis	B-DISEASE
in	O
patients	O
with	O
SAH	O
,	O
arteriolar	O
and	O
capillary	O
fibrin	O
thrombi	B-DISEASE
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	O
,	O
or	O
other	O
thromboembolic	B-DISEASE
Since	O
intravascular	O
fibrin	O
thrombi	B-DISEASE
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders	O
,	O
EACA	O
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	B-DISEASE
in	O
patients	O
with	O
disseminated	B-DISEASE
intravascular	I-DISEASE
coagulation	I-DISEASE
or	O
other	O
"	O
consumption	B-DISEASE
coagulopathies	I-DISEASE
This	O
report	O
describes	O
subtotal	O
infarction	B-DISEASE
of	O
the	O
kidney	O
due	O
to	O
thrombosis	B-DISEASE
of	O
a	O
normal	O
renal	B-DISEASE
The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	B-DISEASE
Long	O
-	O
term	O
propranolol	B-CHEMICAL
therapy	O
in	O
pregnancy	B-DISEASE
Propranolol	B-CHEMICAL
Its	O
use	O
in	O
pregnancy	B-DISEASE
Ten	B-DISEASE
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	B-CHEMICAL
Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	B-CHEMICAL
An	O
attempt	O
is	O
made	O
to	O
differentiate	O
drug	O
-	O
related	O
complications	O
from	O
maternal	O
disease	B-DISEASE
We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	B-DISEASE
,	O
hyperbilirubinemia	B-DISEASE
,	O
polycythemia	B-DISEASE
,	O
neonatal	O
apnea	B-DISEASE
,	O
and	O
bradycardia	B-DISEASE
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	B-CHEMICAL
Growth	B-DISEASE
retardation	I-DISEASE
Use	O
of	O
propranolol	B-CHEMICAL
in	O
the	O
treatment	O
of	O
idiopathic	B-DISEASE
orthostatic	I-DISEASE
hypotension	I-DISEASE
Five	O
patients	O
with	O
idiopathic	B-DISEASE
orthostatic	I-DISEASE
hypotension	I-DISEASE
They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	B-CHEMICAL
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	B-DISEASE
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	B-CHEMICAL
Chronic	O
oral	O
administration	O
of	O
propranolol	B-CHEMICAL
In	O
1	O
patient	O
,	O
marked	O
hypertension	B-DISEASE
was	O
induced	O
by	O
propranolol	B-CHEMICAL
Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	B-DISEASE
output	I-DISEASE
following	O
propranolol	B-CHEMICAL
The	O
studies	O
suggest	O
that	O
propranolol	B-CHEMICAL
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	B-DISEASE
orthostatic	I-DISEASE
hypotension	I-DISEASE
Total	O
intravenous	O
anesthesia	O
with	O
etomidate	B-CHEMICAL
An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	B-CHEMICAL
Premedication	O
of	O
diazepam	B-CHEMICAL
10	O
mg	O
and	O
atropine	B-CHEMICAL
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	B-CHEMICAL
A	O
mean	O
overall	O
dose	O
of	O
etomidate	B-CHEMICAL
The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side	O
-	O
effects	O
,	O
particularly	O
pain	B-DISEASE
It	O
is	O
considered	O
unlikely	O
that	O
etomidate	B-CHEMICAL
A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	B-DISEASE
A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	B-DISEASE
By	O
means	O
of	O
a	O
computer	O
program	O
,	O
periods	O
and	O
amplitudes	O
of	O
tremor	B-DISEASE
The	O
actions	O
of	O
fenoterol	B-CHEMICAL
At	B-DISEASE
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	B-DISEASE
At	B-DISEASE
the	O
same	O
time	O
,	O
the	O
mean	O
period	O
within	O
each	O
class	O
of	O
amplitudes	O
shortened	O
by	O
10	O
--	O
20	O
ms	B-DISEASE
After	O
the	O
end	O
of	O
fenoterol	B-CHEMICAL
-	O
hydrobromide	O
infusion	O
,	O
tremor	B-DISEASE
Bilateral	O
retinal	O
artery	O
and	O
choriocapillaris	O
occlusion	O
following	O
the	O
injection	O
of	O
long	O
-	O
acting	O
corticosteroid	O
suspensions	B-CHEMICAL
Two	O
well	O
-	O
documented	O
cases	O
of	O
bilateral	O
retinal	O
artery	O
and	O
choriocapillaris	O
occlusions	O
with	O
blindness	B-DISEASE
following	O
head	O
and	O
neck	O
soft	O
-	O
tissue	O
injection	O
with	O
methylprednisolone	B-CHEMICAL
acetate	I-CHEMICAL
in	O
combination	O
with	O
lidocaine	B-CHEMICAL
,	O
epinephrine	B-CHEMICAL
,	O
or	O
penicillin	B-CHEMICAL
The	O
acute	O
observations	O
included	O
hazy	O
sensorium	O
,	O
superior	O
gaze	B-DISEASE
palsy	I-DISEASE
,	O
pupillary	O
abnormalities	B-DISEASE
,	O
and	O
conjunctival	O
hemorrhages	O
with	O
edema	B-DISEASE
Follow	O
-	O
up	O
changes	O
showed	O
marked	O
visual	B-DISEASE
loss	I-DISEASE
,	O
constricted	O
visual	O
fields	O
,	O
optic	O
nerve	O
pallor	B-DISEASE
,	O
vascular	O
attenuation	O
,	O
and	O
chorioretinal	B-DISEASE
atrophy	I-DISEASE
Cephalothin	B-CHEMICAL
-	O
induced	O
immune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
A	O
patient	O
with	O
renal	B-DISEASE
disease	B-DISEASE
developed	O
Coombs	O
-	O
positive	O
hemolytic	B-DISEASE
anemia	I-DISEASE
while	O
receiving	O
cephalothin	B-CHEMICAL
An	O
anti	O
-	O
cephalothin	B-CHEMICAL
In	O
addition	O
,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient	O
'	O
s	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin	B-CHEMICAL
Skin	B-DISEASE
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	B-CHEMICAL
and	O
also	O
to	O
ampicillin	B-CHEMICAL
Kaliuretic	O
effect	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
treatment	O
in	O
parkinsonian	B-DISEASE
Hypokalemia	B-DISEASE
,	O
sometimes	O
severe	O
,	O
was	O
observed	O
in	O
some	O
L	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
-	O
treated	O
parkinsonian	B-DISEASE
The	O
influence	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
on	O
the	O
renal	B-DISEASE
excretion	O
of	O
potassium	B-CHEMICAL
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	B-DISEASE
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	B-DISEASE
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
,	O
plasma	O
concentration	O
of	O
potassium	B-CHEMICAL
and	O
sodium	B-CHEMICAL
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	B-CHEMICAL
,	O
sodium	B-CHEMICAL
and	O
aldosterone	B-CHEMICAL
L	B-CHEMICAL
-	I-CHEMICAL
Dopa	I-CHEMICAL
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	B-CHEMICAL
,	O
and	O
sometimes	O
also	O
of	O
sodium	B-CHEMICAL
This	O
effect	O
on	O
the	O
renal	B-DISEASE
It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	B-CHEMICAL
production	O
and	O
this	O
renal	B-DISEASE
effect	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
Phenytoin	B-CHEMICAL
encephalopathy	B-DISEASE
A	O
case	O
of	O
phenytoin	B-CHEMICAL
(	O
DPH	O
)	O
encephalopathy	B-DISEASE
with	O
increasing	O
seizures	B-DISEASE
The	O
encephalopathy	B-DISEASE
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	B-DISEASE
reaction	I-DISEASE
In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	O
was	O
normal	O
,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	B-DISEASE
The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	O
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	B-DISEASE
Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
The	O
exercise	O
-	O
isoproterenol	B-CHEMICAL
(	O
E	O
-	O
1	O
)	O
and	O
exercise	O
control	O
(	O
EC	O
)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	B-DISEASE
1	O
mph	O
,	O
2	O
%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary	O
-	O
isoproterenol	B-CHEMICAL
Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exercise	O
period	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-CHEMICAL
(	O
250	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
Animals	O
of	O
the	O
S	O
-	O
I	O
group	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	B-CHEMICAL
Serum	O
CPK	O
activity	O
for	O
E	O
-	O
I	O
animals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	B-CHEMICAL
No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	B-CHEMICAL
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions	O
,	O
changes	O
in	O
heart	O
weight	O
,	O
or	O
heart	O
weight	O
to	O
body	B-DISEASE
weight	I-DISEASE
The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	B-CHEMICAL
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	B-DISEASE
Effect	O
of	O
D	O
-	O
Glucarates	O
on	O
basic	O
antibiotic	O
-	O
induced	O
renal	B-DISEASE
damage	I-DISEASE
Dehydrated	O
rats	O
regularly	O
develop	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
single	O
injection	O
of	O
aminoglycoside	B-CHEMICAL
antibiotics	O
combined	O
with	O
dextran	B-CHEMICAL
Oral	O
administration	O
of	O
2	O
,	O
5	O
-	O
di	O
-	O
O	O
-	O
acetyl	O
-	O
D	O
-	O
glucaro	O
-	O
1	O
,	O
4	O
-	O
6	O
,	O
3	O
-	O
dilactone	O
protected	O
rats	O
against	O
renal	B-DISEASE
failure	I-DISEASE
induced	O
by	O
kanamycin	B-CHEMICAL
-	O
dextran	B-CHEMICAL
The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D	O
-	O
glucarates	O
,	O
and	O
also	O
to	O
other	O
saccharic	B-CHEMICAL
acid	I-CHEMICAL
,	O
hexauronic	O
acids	B-CHEMICAL
and	O
hexaaldonic	O
acids	B-CHEMICAL
,	O
although	O
to	O
a	O
lesser	O
degree	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
sugar	B-CHEMICAL
alcohols	I-CHEMICAL
D	O
-	O
Glucarates	O
were	O
effective	O
against	O
renal	B-DISEASE
damage	I-DISEASE
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	B-CHEMICAL
With	O
a	O
D	O
-	O
glucarate	O
of	O
a	O
fixed	O
size	O
of	O
dose	O
,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	B-DISEASE
D	O
-	O
Glucarates	O
had	O
the	O
ability	O
to	O
prevent	O
renal	B-DISEASE
damage	I-DISEASE
Rats	O
excreted	O
acidic	O
urine	B-DISEASE
when	O
they	O
were	O
spared	O
from	O
renal	B-DISEASE
lesions	O
by	O
monosaccharides	B-CHEMICAL
The	O
reduction	O
effect	O
of	O
D	O
-	O
glucarates	O
against	O
nephrotoxicity	B-DISEASE
Paraplegia	B-DISEASE
following	O
intrathecal	O
methotrexate	B-CHEMICAL
A	O
patient	O
who	O
developed	O
paraplegia	B-DISEASE
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	B-CHEMICAL
The	O
ten	B-DISEASE
The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication	O
:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	O
nervous	O
system	O
leukemia	B-DISEASE
,	O
and	O
epidural	O
cerebrospinal	O
leakage	O
;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	O
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	B-CHEMICAL
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults	O
;	O
the	O
presence	O
of	O
neurotoxic	B-DISEASE
preservatives	O
in	O
commercially	O
available	O
methotrexate	B-CHEMICAL
preparations	O
and	O
diluents	O
;	O
and	O
the	O
use	O
of	O
methotrexate	B-CHEMICAL
The	O
role	O
of	O
methotrexate	B-CHEMICAL
contaminants	O
,	O
local	O
folate	B-CHEMICAL
deficiency	O
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	B-CHEMICAL
toxicity	B-DISEASE
The	O
incidence	O
of	O
neurotoxicity	B-DISEASE
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	B-CHEMICAL
in	O
the	O
presence	O
of	O
central	O
nervous	O
system	O
leukemia	B-DISEASE
Only	O
preservative	O
-	O
free	O
methotrexate	B-CHEMICAL
in	O
Elliott	O
'	O
s	O
B	O
Solution	O
at	B-DISEASE
Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	B-CHEMICAL
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	B-DISEASE
Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	B-CHEMICAL
injection	O
of	O
carbachol	B-CHEMICAL
injection	O
of	O
guanethidine	B-CHEMICAL
(	O
5	O
mg	O
),	O
hexamethonium	B-CHEMICAL
(	O
10	O
mg	O
)	O
or	O
phentolamine	B-CHEMICAL
desmethylimipramine	O
(	O
0	O
.	O
3	O
mg	O
),	O
while	O
propranolol	B-CHEMICAL
selectively	O
inhibited	O
the	O
enlargement	O
of	O
pulse	O
pressure	O
and	O
the	O
tachycardia	B-DISEASE
carbachol	B-CHEMICAL
On	O
the	O
other	O
hand	B-DISEASE
carbachol	B-CHEMICAL
atropine	B-CHEMICAL
(	O
3	O
mug	O
)	O
or	O
hexamethonium	B-CHEMICAL
chlorpromazine	B-CHEMICAL
carbachol	B-CHEMICAL
carbachol	B-CHEMICAL
The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
diet	O
weight	O
)	O
of	O
certain	O
amino	O
derivatives	O
of	O
caproate	O
resulted	O
in	O
hyperglycemia	B-DISEASE
,	O
an	O
elevated	O
glucose	B-CHEMICAL
Effective	O
compounds	O
included	O
norleucine	B-CHEMICAL
,	O
norvaline	B-CHEMICAL
,	O
glutamate	B-CHEMICAL
,	O
epsilon	O
-	O
aminocaproate	O
,	O
methionine	B-CHEMICAL
,	O
and	O
leucine	B-CHEMICAL
Fatty	B-DISEASE
liver	I-DISEASE
induced	O
by	O
tetracycline	B-CHEMICAL
Dose	O
-	O
response	O
relationships	O
,	O
biochemical	O
mechanisms	O
,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	B-DISEASE
liver	I-DISEASE
induced	O
by	O
tetracycline	B-CHEMICAL
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	B-DISEASE
In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B-CHEMICAL
With	O
provision	O
of	O
adequate	O
oleic	B-CHEMICAL
acid	I-CHEMICAL
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver	B-DISEASE
,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B-CHEMICAL
and	O
both	O
accumulation	O
of	O
triglyceride	O
in	O
the	O
liver	B-DISEASE
and	O
depression	B-DISEASE
Accumulation	O
of	O
hepatic	O
triglyceride	O
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values	O
,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	B-CHEMICAL
However	O
,	O
livers	O
from	O
female	O
,	O
and	O
especially	O
pregnant	O
female	O
rats	O
,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	B-CHEMICAL
on	O
depression	B-DISEASE
These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	B-CHEMICAL
or	O
altered	O
uptake	O
of	O
oleic	B-CHEMICAL
acid	I-CHEMICAL
Depressed	B-DISEASE
hepatic	O
secretion	O
of	O
triglyceride	O
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepatic	O
triglyceride	O
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	O
-	O
rich	O
fatty	B-DISEASE
liver	I-DISEASE
in	O
response	O
to	O
tetracycline	B-CHEMICAL
Fatal	O
myeloencephalopathy	O
due	O
to	O
intrathecal	O
vincristine	B-CHEMICAL
Vincristine	B-CHEMICAL
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	O
,	O
producing	O
sensory	O
and	O
motor	O
dysfunction	O
followed	O
by	O
encephalopathy	B-DISEASE
and	O
death	B-DISEASE
Separate	O
times	O
for	O
administering	O
vincristine	B-CHEMICAL
Progesterone	B-CHEMICAL
potentiation	O
of	O
bupivacaine	B-CHEMICAL
arrhythmogenicity	O
in	O
pentobarbital	B-CHEMICAL
The	O
effects	O
of	O
progesterone	B-CHEMICAL
treatment	O
on	O
bupivacaine	B-CHEMICAL
After	O
determining	O
the	O
bupivacaine	B-CHEMICAL
AD50	O
(	O
the	O
concentration	O
of	O
bupivacaine	B-CHEMICAL
that	O
caused	O
50	O
%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	O
),	O
we	O
determined	O
the	O
effect	O
of	O
1	O
-	O
hour	O
progesterone	B-CHEMICAL
Each	O
concentration	O
of	O
progesterone	B-CHEMICAL
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
micrograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
concentration	O
-	O
dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	B-CHEMICAL
Estradiol	B-CHEMICAL
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	B-CHEMICAL
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	B-CHEMICAL
Neither	O
progesterone	B-CHEMICAL
nor	O
estradiol	B-CHEMICAL
effects	O
on	O
bupivacaine	B-CHEMICAL
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	B-CHEMICAL
Chronic	O
progesterone	B-CHEMICAL
pretreatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
days	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	B-CHEMICAL
arrhythmogenicity	O
in	O
intact	O
pentobarbital	B-CHEMICAL
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	B-DISEASE
30	O
.	O
8	O
+/-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+/-	O
SE	B-DISEASE
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	B-CHEMICAL
can	O
potentiate	O
bupivacaine	B-CHEMICAL
Potentiation	O
of	O
bupivacaine	B-CHEMICAL
arrhythmia	B-DISEASE
in	O
myocyte	O
cultures	O
suggests	O
that	O
this	O
effect	O
is	O
at	B-DISEASE
least	O
partly	O
mediated	O
at	B-DISEASE
Acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
occurring	O
during	O
intravenous	O
desferrioxamine	B-CHEMICAL
A	O
patient	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	B-DISEASE
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	B-CHEMICAL
Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump	O
,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	B-DISEASE
insufficiency	I-DISEASE
Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values	O
,	O
despite	O
adequate	O
medical	O
treatment	O
,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	B-DISEASE
From	O
the	O
results	O
obtained	O
,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
caused	O
by	O
desferrioxamine	B-CHEMICAL
Neuroleptic	O
-	O
associated	O
hyperprolactinemia	B-DISEASE
Can	O
it	O
be	O
treated	O
with	O
bromocriptine	B-CHEMICAL
Six	O
stable	O
psychiatric	B-DISEASE
outpatients	O
with	O
hyperprolactinemia	B-DISEASE
and	O
amenorrhea	B-DISEASE
/	O
oligomenorrhea	B-DISEASE
associated	O
with	O
their	O
neuroleptic	O
medications	O
were	O
treated	O
with	O
bromocriptine	B-CHEMICAL
Daily	O
dosages	O
of	O
5	O
-	O
10	O
mg	O
corrected	O
the	O
hyperprolactinemia	B-DISEASE
One	O
woman	O
,	O
however	O
,	O
developed	O
worsened	O
psychiatric	B-DISEASE
symptoms	O
while	O
taking	O
bromocriptine	B-CHEMICAL
Thus	O
,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	B-CHEMICAL
This	O
suggests	O
that	O
bromocriptine	B-CHEMICAL
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic	O
-	O
associated	O
hyperprolactinemia	B-DISEASE
and	O
amenorrhea	B-DISEASE
/	O
galactorrhea	B-DISEASE
Ethacrynic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
Intracerebroventricular	O
injection	O
of	O
ethacrynic	B-CHEMICAL
acid	I-CHEMICAL
(	O
50	O
%	O
convulsive	B-DISEASE
dose	O
;	O
50	O
micrograms	O
/	O
mouse	O
)	O
accelerated	O
the	O
synthesis	O
/	O
turnover	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
and	O
acetylcholine	B-CHEMICAL
These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate	B-CHEMICAL
/	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
In	O
ethacrynic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
Pharmacology	O
of	O
gamma	O
-	O
aminobutyric	O
acidA	O
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta	O
-	O
carboline	O
derivative	O
abecarnil	B-CHEMICAL
In	O
rodents	O
,	O
the	O
effect	O
of	O
the	O
beta	O
-	O
carboline	O
derivative	O
isopropyl	O
-	O
6	O
-	O
benzyloxy	O
-	O
4	O
-	O
methoxymethyl	O
-	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
abecarrnil	O
),	O
a	O
new	O
ligand	O
for	O
benzodiazepine	B-CHEMICAL
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties	O
,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation	O
,	O
abecarnil	B-CHEMICAL
increased	O
[	O
3H	O
]	O
GABA	B-CHEMICAL
binding	O
,	O
enhanced	O
muscimol	B-CHEMICAL
These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	B-CHEMICAL
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	O
16	O
-	O
6028	O
(	O
tert	O
-	O
butyl	O
-(	O
S	O
)-	O
8	O
-	O
bromo	O
-	O
11	O
,	O
12	O
,	O
13	O
,	O
13a	O
-	O
tetrahydro	O
-	O
9	O
-	O
oxo	O
-	O
9H	O
-	O
imidazo	O
[	O
1	O
,	O
5	O
-	O
a	O
]-	O
pyrrolo	O
-[	O
2	O
,	O
1	O
-	O
c	O
][	O
1	O
,	O
4	O
]	O
benzodiazepine	B-CHEMICAL
injection	O
to	O
rats	O
,	O
abecarnil	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
Moreover	O
,	O
both	O
drugs	O
at	B-DISEASE
as	O
well	O
as	O
the	O
increase	O
of	O
[	O
35S	O
]	O
TBPS	O
binding	O
induced	O
by	O
foot	O
-	O
shock	B-DISEASE
To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects	O
,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	B-CHEMICAL
on	O
[	O
35S	O
]	O
TBPS	O
binding	O
,	O
exploratory	O
motility	O
and	O
on	O
isoniazid	B-CHEMICAL
In	O
these	O
animals	O
,	O
abecarnil	B-CHEMICAL
Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
beta	O
-	O
carboline	O
reduced	O
markedly	O
the	O
increase	O
of	O
[	O
35S	O
]	O
TBPS	O
binding	O
and	O
the	O
convulsions	B-DISEASE
induced	O
by	O
isoniazid	B-CHEMICAL
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Recurrent	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	B-CHEMICAL
Myocardial	B-DISEASE
infarction	I-DISEASE
Spasm	B-DISEASE
Bromocriptine	B-CHEMICAL
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,"	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	B-CHEMICAL
Asterixis	B-DISEASE
induced	O
by	O
carbamazepine	B-CHEMICAL
There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	B-DISEASE
In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	B-CHEMICAL
drugs	I-CHEMICAL
,	O
in	O
whom	O
asterixis	B-DISEASE
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	B-CHEMICAL
(	O
CBZ	B-CHEMICAL
Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	B-CHEMICAL
We	O
consider	O
asterixis	B-DISEASE
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-DISEASE
,	O
which	O
may	O
occur	O
even	O
at	B-DISEASE
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	B-CHEMICAL
or	O
clozapine	B-CHEMICAL
are	O
used	O
in	O
combination	O
with	O
CBZ	B-CHEMICAL
Pharmacodynamics	O
of	O
the	O
hypotensive	B-DISEASE
effect	O
of	O
levodopa	B-CHEMICAL
in	O
parkinsonian	B-DISEASE
levodopa	B-CHEMICAL
were	O
examined	O
in	O
parkinsonian	B-DISEASE
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	B-CHEMICAL
The	O
magnitude	O
of	O
the	O
hypotensive	B-DISEASE
effect	O
of	O
levodopa	B-CHEMICAL
Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	B-DISEASE
Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients	O
;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	B-DISEASE
Antiparkinsonian	O
effects	O
of	O
levodopa	B-CHEMICAL
Phenylalanine	B-CHEMICAL
,	O
a	O
large	O
neutral	O
amino	B-CHEMICAL
acid	I-CHEMICAL
(	O
LNAA	O
)	O
competing	O
with	O
levodopa	B-CHEMICAL
for	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
reduced	O
the	O
hypotensive	B-DISEASE
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	B-CHEMICAL
We	O
conclude	O
that	O
levodopa	B-CHEMICAL
has	O
a	O
central	O
hypotensive	B-DISEASE
The	O
hypotensive	B-DISEASE
Syndrome	B-DISEASE
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
after	O
infusional	O
vincristine	B-CHEMICAL
A	O
77	O
-	O
year	O
-	O
old	O
woman	O
with	O
refractory	O
multiple	B-DISEASE
myeloma	I-DISEASE
was	O
treated	O
with	O
a	O
4	O
-	O
day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	B-CHEMICAL
and	O
doxorubicin	B-CHEMICAL
and	O
4	O
days	O
of	O
oral	O
dexamethasone	B-CHEMICAL
Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	B-DISEASE
and	O
weakness	B-DISEASE
associated	O
with	O
hyponatremia	B-DISEASE
Evaluation	O
revealed	O
the	O
syndrome	B-DISEASE
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	B-CHEMICAL
After	O
normal	O
serum	O
sodium	B-CHEMICAL
levels	O
returned	O
,	O
further	O
doxorubicin	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
chemotherapy	O
without	O
vincristine	B-CHEMICAL
Heart	B-DISEASE
failure	I-DISEASE
Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	B-CHEMICAL
In	O
patients	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
digoxin	B-CHEMICAL
For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	B-DISEASE
failure	I-DISEASE
Digoxin	B-CHEMICAL
Also	O
,	O
digoxin	B-CHEMICAL
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands	O
,	O
and	O
causing	O
arrhythmias	B-DISEASE
More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	B-CHEMICAL
Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	B-CHEMICAL
may	O
increase	O
mortality	O
after	O
myocardial	B-DISEASE
infarction	I-DISEASE
Angiotensin	B-CHEMICAL
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
level	O
monitoring	O
,	O
modify	O
progression	O
of	O
disease	B-DISEASE
Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	B-CHEMICAL
Until	O
then	O
digoxin	B-CHEMICAL
Intravascular	O
hemolysis	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
intermittent	O
rifampin	B-CHEMICAL
Renal	B-DISEASE
failure	I-DISEASE
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	B-CHEMICAL
Intravascular	O
hemolysis	B-DISEASE
leading	O
to	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
rifampin	B-CHEMICAL
Two	O
patients	O
with	O
leprosy	B-DISEASE
who	O
developed	O
hemolysis	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
rifampin	B-CHEMICAL
Zidovudine	B-CHEMICAL
-	O
induced	O
hepatitis	B-DISEASE
A	O
case	O
of	O
acute	O
hepatitis	B-DISEASE
induced	O
by	O
zidovudine	B-CHEMICAL
in	O
a	O
38	O
-	O
year	O
-	O
old	O
patient	O
with	O
AIDS	B-DISEASE
The	O
mechanism	O
whereby	O
the	O
hepatitis	B-DISEASE
Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	B-DISEASE
A	O
high	O
index	O
of	O
suspicion	O
may	O
lead	B-CHEMICAL
Mania	B-DISEASE
associated	O
with	O
fluoxetine	B-CHEMICAL
Fluoxetine	B-CHEMICAL
,	O
a	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	B-DISEASE
Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults	O
,	O
fluoxetine	B-CHEMICAL
has	O
been	O
reported	O
to	O
induce	O
mania	B-DISEASE
The	O
cases	O
of	O
five	O
depressed	B-DISEASE
adolescents	O
,	O
14	O
-	O
16	O
years	O
of	O
age	O
,	O
who	O
developed	O
mania	B-DISEASE
during	O
pharmacotherapy	O
with	O
fluoxetine	B-CHEMICAL
Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	B-DISEASE
or	O
hypomania	O
during	O
fluoxetine	B-CHEMICAL
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention	O
-	O
deficit	O
hyperactivity	B-DISEASE
disorder	O
and	O
affective	O
instability	O
;	O
major	B-DISEASE
depression	I-DISEASE
with	O
psychotic	O
features	O
;	O
a	O
family	O
history	O
of	O
affective	B-DISEASE
disorder	I-DISEASE
,	O
especially	O
bipolar	B-DISEASE
disorder	I-DISEASE
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	B-DISEASE
disorder	I-DISEASE
Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	B-CHEMICAL
induced	O
mania	B-DISEASE
Gemfibrozil	B-CHEMICAL
-	O
lovastatin	B-CHEMICAL
therapy	O
for	O
primary	O
hyperlipoproteinemias	B-DISEASE
The	O
specific	O
aim	O
of	O
this	O
retrospective	O
,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long	O
-	O
term	O
(	O
21	O
months	O
/	O
patient	O
),	O
open	O
-	O
label	O
,	O
gemfibrozil	B-CHEMICAL
-	O
lovastatin	B-CHEMICAL
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	B-DISEASE
(	O
68	O
%	O
of	O
whom	O
had	O
atherosclerotic	B-DISEASE
vascular	O
disease	B-DISEASE
Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B-CHEMICAL
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B-CHEMICAL
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cholesterol	B-CHEMICAL
/	O
HDL	O
cholesterol	B-CHEMICAL
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
diet	O
plus	O
a	O
single	O
drug	O
,	O
gemfibrozil	B-CHEMICAL
(	O
1	O
.	O
2	O
g	O
/	O
day	O
)-	O
lovastatin	B-CHEMICAL
Follow	O
-	O
up	O
visits	O
were	O
scheduled	O
with	O
2	O
-	O
drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
average	O
of	O
10	O
.	O
3	O
visits	O
per	O
patient	O
,	O
with	O
741	O
batteries	O
of	O
6	O
liver	B-DISEASE
function	O
tests	O
and	O
714	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
Only	O
1	O
of	O
the	O
4	O
,	O
446	O
liver	B-DISEASE
Of	O
the	O
714	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
With	O
2	O
-	O
drug	O
therapy	O
,	O
mean	O
total	O
cholesterol	B-CHEMICAL
decreased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyceride	O
levels	O
decreased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesterol	B-CHEMICAL
decreased	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesterol	B-CHEMICAL
/	O
HDL	O
cholesterol	B-CHEMICAL
Myositis	B-DISEASE
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
in	O
1	O
%	O
with	O
concurrent	O
high	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
(	O
769	O
U	O
/	O
liter	O
);	O
no	O
patients	O
had	O
rhabdomyolysis	B-DISEASE
or	O
myoglobinuria	B-DISEASE
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Hepatocellular	B-DISEASE
carcinoma	I-DISEASE
in	O
Fanconi	O
'	O
s	O
anemia	B-DISEASE
The	O
case	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi	O
'	O
s	O
anemia	B-DISEASE
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	B-CHEMICAL
,	O
corticosteroids	B-CHEMICAL
Two	O
weeks	O
before	O
his	O
death	B-DISEASE
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	O
and	O
marked	O
abnormalities	B-DISEASE
in	O
liver	B-DISEASE
function	O
and	O
died	O
of	O
hemorrhagic	B-DISEASE
bronchopneumonia	B-DISEASE
At	B-DISEASE
autopsy	O
peliosis	O
and	O
multiple	O
hepatic	O
tumors	B-DISEASE
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well	O
-	O
differentiated	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non	O
-	O
metastasizing	O
hepatic	B-DISEASE
neoplasms	I-DISEASE
and	O
peliosis	O
can	O
develop	O
in	O
patients	O
with	O
androgen	O
-	O
and	O
corticosteroid	O
-	O
treated	O
Fanconi	O
'	O
s	O
anemia	B-DISEASE
Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	B-DISEASE
We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
neurogenic	O
tone	O
in	O
conscious	O
,	O
unrestrained	O
spontaneously	O
hypertensive	B-DISEASE
The	O
lesions	O
were	O
placed	O
via	O
bilateral	O
microinjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	O
-	O
methyl	O
-	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartic	I-CHEMICAL
acid	I-CHEMICAL
The	O
restimulation	O
of	O
this	O
area	O
with	O
N	O
-	O
methyl	O
-	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartic	I-CHEMICAL
acid	I-CHEMICAL
The	O
ganglionic	O
blocker	O
trimethaphan	B-CHEMICAL
The	O
trimethaphan	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	B-DISEASE
in	O
lesioned	O
rats	O
(-	O
32	O
+/-	O
13	O
beats	O
per	O
minute	O
)	O
but	O
a	O
tachycardia	B-DISEASE
Therefore	O
,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	B-DISEASE
in	O
conscious	O
spontaneously	O
hypertensive	B-DISEASE
Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	B-DISEASE
Damage	O
of	O
substantia	O
nigra	O
pars	O
reticulata	O
during	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	B-DISEASE
seizure	B-DISEASE
Additionally	O
,	O
in	O
models	O
of	O
prolonged	O
status	B-DISEASE
epilepticus	I-DISEASE
In	O
this	O
study	O
,	O
status	B-DISEASE
epilepticus	I-DISEASE
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	B-CHEMICAL
Animals	O
surviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	B-DISEASE
epilepticus	I-DISEASE
Nissl	O
-	O
staining	O
and	O
antibodies	O
against	O
the	O
neuron	O
-	O
specific	O
calcium	B-CHEMICAL
-	O
binding	O
protein	O
,	O
parvalbumin	O
,	O
served	O
to	O
detect	O
neuronal	B-DISEASE
damage	I-DISEASE
Antibodies	O
against	O
the	O
astroglia	O
-	O
specific	O
cytoskeletal	O
protein	O
,	O
glial	B-CHEMICAL
fibrillary	I-CHEMICAL
acidic	I-CHEMICAL
protein	I-CHEMICAL
(	O
GFAP	O
),	O
and	O
against	O
the	O
glial	O
calcium	B-CHEMICAL
Immunohistochemical	O
staining	O
for	O
serum	O
-	O
albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood	O
-	O
brain	O
barrier	O
disturbances	O
and	O
vasogenic	O
edema	B-DISEASE
Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP	O
-	O
staining	O
already	O
at	B-DISEASE
30	O
min	O
after	O
induction	O
of	O
seizures	B-DISEASE
At	B-DISEASE
1	O
h	B-CHEMICAL
By	O
2	O
hours	O
,	O
parvalbumin	O
-	O
staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	B-DISEASE
damage	I-DISEASE
By	O
6	O
h	B-CHEMICAL
,	O
vasogenic	O
edema	B-DISEASE
By	O
24	O
h	B-CHEMICAL
By	O
48	O
-	O
72	O
h	B-CHEMICAL
In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days	O
,	O
conventional	O
paraffin	B-CHEMICAL
Both	O
cell	O
elements	B-CHEMICAL
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	O
dysfunction	O
as	O
occur	O
during	O
massive	O
status	B-DISEASE
epilepticus	I-DISEASE
Reduced	O
cardiotoxicity	B-DISEASE
of	O
doxorubicin	B-CHEMICAL
given	O
in	O
the	O
form	O
of	O
N	B-CHEMICAL
-(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxypropyl	I-CHEMICAL
)	I-CHEMICAL
methacrylamide	I-CHEMICAL
A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	B-DISEASE
and	O
the	O
late	O
cardiotoxicity	B-DISEASE
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N	B-CHEMICAL
-(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxypropyl	I-CHEMICAL
)	I-CHEMICAL
methacrylamide	I-CHEMICAL
In	O
these	O
HPMA	O
copolymers	O
,	O
DOX	B-CHEMICAL
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non	O
-	O
biodegradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly	B-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
-	I-CHEMICAL
Leu	I-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	B-CHEMICAL
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	B-DISEASE
administration	O
of	O
free	O
and	O
polymer	O
-	O
bound	O
DOX	B-CHEMICAL
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	B-DISEASE
weight	I-DISEASE
However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	B-DISEASE
weight	I-DISEASE
seen	O
in	O
animals	O
that	O
received	O
polymer	O
-	O
bound	O
DOX	B-CHEMICAL
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B-CHEMICAL
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	O
copolymer	O
and	O
free	O
DOX	B-CHEMICAL
Throughout	O
the	O
study	O
(	O
20	O
weeks	O
),	O
deaths	B-DISEASE
related	O
to	O
cardiotoxicity	B-DISEASE
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	B-CHEMICAL
or	O
the	O
mixture	O
of	O
HPMA	O
copolymer	O
and	O
free	O
DOX	B-CHEMICAL
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
Sequential	O
measurements	O
of	O
cardiac	B-DISEASE
output	I-DISEASE
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	B-CHEMICAL
or	O
the	O
mixture	O
of	O
HPMA	O
copolymer	O
and	O
free	O
DOX	B-CHEMICAL
showed	O
a	O
reduction	O
of	O
approximately	O
30	O
%	O
in	O
function	O
beginning	O
at	B-DISEASE
Animals	O
that	O
were	O
given	O
the	O
HPMA	O
copolymer	O
conjugates	O
containing	O
DOX	B-CHEMICAL
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	B-DISEASE
output	I-DISEASE
In	O
addition	O
,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	B-CHEMICAL
in	O
the	O
form	O
of	O
HPMA	O
copolymer	O
conjugates	O
and	O
were	O
killed	O
at	B-DISEASE
However	O
,	O
these	O
animals	O
had	O
shown	O
a	O
significant	O
increase	O
in	O
heart	O
rate	O
beginning	O
at	B-DISEASE
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Topical	O
0	O
.	O
025	O
%	O
capsaicin	B-CHEMICAL
in	O
chronic	O
post	O
-	O
herpetic	O
neuralgia	B-DISEASE
In	O
order	O
to	O
evaluate	O
the	O
efficacy	O
,	O
time	O
-	O
course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	B-CHEMICAL
,	O
39	O
patients	O
with	O
chronic	O
post	O
-	O
herpetic	O
neuralgia	B-DISEASE
(	O
PHN	O
),	O
median	O
duration	O
24	O
months	O
,	O
were	O
treated	O
with	O
0	O
.	O
025	O
%	O
capsaicin	B-CHEMICAL
During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	B-DISEASE
Nineteen	O
patients	O
(	O
48	O
.	O
7	O
%)	O
substantially	O
improved	O
after	O
the	O
8	O
-	O
week	O
trial	O
;	O
5	O
(	O
12	O
.	O
8	O
%)	O
discontinued	O
therapy	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
intolerable	O
capsaicin	B-CHEMICAL
-	O
induced	O
burning	O
sensations	O
(	O
4	O
)	O
or	O
mastitis	B-DISEASE
Of	O
the	O
responders	O
72	O
.	O
2	O
%	O
were	O
still	O
improved	O
at	B-DISEASE
Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient	O
'	O
s	O
age	O
,	O
duration	O
or	O
localization	O
of	O
PHN	O
(	O
trigeminal	O
involvement	O
was	O
excluded	O
),	O
sensory	O
disturbance	O
or	O
pain	B-DISEASE
Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence	O
,	O
time	O
-	O
course	O
or	O
severity	O
of	O
capsaicin	B-CHEMICAL
If	O
confirmed	O
in	O
controlled	O
trials	O
,	O
the	O
long	O
-	O
term	O
results	O
of	O
this	O
open	O
,	O
non	O
-	O
randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	B-CHEMICAL
in	O
PHN	O
is	O
mediated	O
by	O
both	O
interference	O
with	O
neuropeptide	O
metabolism	B-DISEASE
Serotonin	B-CHEMICAL
Antidepressants	B-CHEMICAL
have	O
previously	O
been	O
associated	O
with	O
paranoid	O
reactions	O
in	O
psychiatric	B-DISEASE
Five	O
cases	O
of	O
paranoid	O
exacerbation	O
with	O
the	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
fluoxetine	B-CHEMICAL
and	O
amitriptyline	B-CHEMICAL
Elements	B-CHEMICAL
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	O
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	B-DISEASE
and	O
psychotic	B-DISEASE
symptoms	I-DISEASE
Complicated	O
depressive	B-DISEASE
disorders	I-DISEASE
(	O
including	O
atypicality	O
of	O
course	O
and	O
symptomatology	O
,	O
chronicity	O
,	O
psychosis	B-DISEASE
,	O
bipolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	B-DISEASE
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	O
exacerbations	O
associated	O
with	O
serotonin	B-CHEMICAL
Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	O
remain	O
cryptic	O
,	O
several	O
mechanisms	O
,	O
including	O
5HT3	O
receptor	O
-	O
mediated	O
dopamine	B-CHEMICAL
These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	O
exacerbations	O
with	O
serotonin	B-CHEMICAL
Five	O
cases	O
of	O
encephalitis	B-DISEASE
during	O
treatment	O
of	O
loiasis	B-DISEASE
with	O
diethylcarbamazine	B-CHEMICAL
Five	O
cases	O
of	O
encephalitis	B-DISEASE
following	O
treatment	O
with	O
diethylcarbamazine	B-CHEMICAL
(	O
DEC	O
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	B-DISEASE
The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	B-DISEASE
Delirium	B-DISEASE
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	B-CHEMICAL
Misoprostol	B-CHEMICAL
has	O
been	O
associated	O
with	O
adverse	O
reactions	O
,	O
including	O
gastrointestinal	O
symptoms	O
,	O
gynecologic	O
problems	O
,	O
and	O
headache	B-DISEASE
We	O
present	O
a	O
case	O
in	O
which	O
an	O
89	O
-	O
year	O
-	O
old	O
woman	O
in	O
a	O
long	O
-	O
term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	B-CHEMICAL
Her	O
delirium	B-DISEASE
significantly	O
improved	O
after	O
misoprostol	B-CHEMICAL
Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly	O
,	O
the	O
delirium	B-DISEASE
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	B-CHEMICAL
Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	B-DISEASE
ischemia	I-DISEASE
-	O
reperfusion	B-DISEASE
injury	I-DISEASE
Reperfusion	O
of	O
ischemic	O
intestine	O
results	O
in	O
acute	O
liver	B-DISEASE
dysfunction	O
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma	O
,	O
reduction	O
in	O
bile	O
flow	O
rate	O
,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver	B-DISEASE
The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	B-DISEASE
injury	I-DISEASE
This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	B-CHEMICAL
are	O
associated	O
with	O
the	O
hepatic	B-DISEASE
injury	I-DISEASE
Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	B-DISEASE
ischemia	I-DISEASE
-	O
reperfusion	B-DISEASE
injury	I-DISEASE
Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	O
and	O
reduced	O
glutathione	B-CHEMICAL
There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	B-CHEMICAL
following	O
intestinal	B-DISEASE
ischemia	I-DISEASE
-	O
reperfusion	B-DISEASE
injury	I-DISEASE
Oxidized	O
glutathione	B-CHEMICAL
Diphenhydramine	B-CHEMICAL
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	B-CHEMICAL
Cimetidine	B-CHEMICAL
,	O
a	O
histamine	B-CHEMICAL
This	O
may	O
be	O
because	O
cimetidine	B-CHEMICAL
acts	O
as	O
a	O
histamine	B-CHEMICAL
We	O
,	O
therefore	O
,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	B-CHEMICAL
1	O
(	O
H1	O
)	O
receptor	O
antagonist	O
,	O
diphenhydramine	B-CHEMICAL
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	B-CHEMICAL
In	O
a	O
random	O
fashion	O
,	O
they	O
received	O
cimetidine	B-CHEMICAL
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatment	O
of	O
diphenhydramine	B-CHEMICAL
40	O
mg	O
iv	O
with	O
cimetidine	B-CHEMICAL
In	O
the	O
non	O
-	O
pretreatment	O
group	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
decreased	O
from	O
107	O
.	O
4	O
+/-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+/-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
minutes	O
after	O
cimetidine	B-CHEMICAL
We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	B-DISEASE
caused	O
by	O
iv	O
cimetidine	B-CHEMICAL
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	B-CHEMICAL
Acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
A	O
23	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	O
tuberculosis	B-DISEASE
Rifampicin	O
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
and	O
fever	B-DISEASE
with	O
chills	B-DISEASE
The	O
last	O
such	O
episode	O
was	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
at	B-DISEASE
Severe	O
polyneuropathy	B-DISEASE
and	O
motor	O
loss	O
after	O
intrathecal	O
thiotepa	B-CHEMICAL
Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	B-DISEASE
toxicity	B-DISEASE
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(	O
IT	O
)	O
combination	O
chemotherapy	O
including	O
thiotepa	B-CHEMICAL
Both	O
cases	O
developed	O
axonal	O
neuropathy	B-DISEASE
Neurologic	B-DISEASE
toxicities	B-DISEASE
have	O
been	O
described	O
with	O
IT	O
-	O
methotrexate	B-CHEMICAL
,	O
IT	O
-	O
cytosine	B-CHEMICAL
To	O
our	O
knowledge	O
,	O
however	O
,	O
axonal	O
neuropathy	B-DISEASE
In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	O
is	O
a	O
useful	O
IT	O
agent	O
,	O
its	O
combination	O
with	O
MTX	B-CHEMICAL
,	O
ara	O
-	O
C	O
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	B-DISEASE
Effects	O
of	O
cromakalim	B-CHEMICAL
and	O
pinacidil	B-CHEMICAL
bolus	O
administration	O
of	O
cromakalim	B-CHEMICAL
(	O
1	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
and	O
pinacidil	B-CHEMICAL
(	O
3	O
-	O
100	O
micrograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumflex	O
artery	O
)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	B-CHEMICAL
Nitroglycerin	B-CHEMICAL
In	O
contrast	O
,	O
cromakalim	B-CHEMICAL
and	O
pinacidil	B-CHEMICAL
at	B-DISEASE
all	O
doses	O
and	O
nitroglycerin	B-CHEMICAL
at	B-DISEASE
Cromakalim	B-CHEMICAL
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pinacidil	B-CHEMICAL
Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	B-DISEASE
induced	O
by	O
cromakalim	B-CHEMICAL
and	O
pinacidil	B-CHEMICAL
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	O
adrenergic	O
and	O
muscarinic	O
receptors	O
blockade	O
but	O
drug	O
-	O
induced	O
tachycardia	B-DISEASE
When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant	O
,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	B-CHEMICAL
(	O
10	O
micrograms	O
/	O
kg	O
),	O
pinacidil	B-CHEMICAL
(	O
30	O
micrograms	O
/	O
kg	O
)	O
and	O
nitroglycerin	B-CHEMICAL
Thus	O
,	O
whereas	O
nitroglycerin	B-CHEMICAL
preferentially	O
and	O
flow	O
-	O
independently	O
dilates	O
large	O
coronary	O
arteries	O
,	O
cromakalim	B-CHEMICAL
and	O
pinacidil	B-CHEMICAL
Finally	O
,	O
two	O
mechanisms	O
at	B-DISEASE
least	O
,	O
direct	O
vasodilation	O
and	O
flow	O
dependency	O
,	O
are	O
involved	O
in	O
the	O
cromakalim	B-CHEMICAL
-	O
and	O
pinacidil	B-CHEMICAL
Mefenamic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
neutropenia	B-DISEASE
and	O
renal	B-DISEASE
failure	I-DISEASE
in	O
elderly	O
females	O
with	O
hypothyroidism	B-DISEASE
We	O
report	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
non	O
-	O
oliguric	O
renal	B-DISEASE
failure	I-DISEASE
and	O
severe	O
neutropenia	B-DISEASE
The	O
neutropenia	B-DISEASE
Both	O
patients	O
were	O
also	O
hypothyroid	B-DISEASE
However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
in	O
hypothyroid	B-DISEASE
patients	O
until	O
the	O
hypothyroidism	B-DISEASE
Etiology	O
of	O
hypercalcemia	B-DISEASE
in	O
hemodialysis	O
patients	O
on	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
Fourteen	O
of	O
39	O
dialysis	O
patients	O
(	O
36	O
%)	O
became	O
hypercalcemic	O
after	O
switching	O
to	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
as	O
their	O
principal	O
phosphate	B-CHEMICAL
In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	B-DISEASE
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	B-CHEMICAL
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
length	O
of	O
time	O
on	O
dialysis	O
,	O
and	O
etiology	O
of	O
renal	B-DISEASE
disease	B-DISEASE
In	O
addition	O
to	O
experiencing	O
hypercalcemic	O
episodes	O
with	O
peak	O
calcium	B-CHEMICAL
values	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
),	O
patients	O
in	O
the	O
hypercalcemic	O
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	B-CHEMICAL
In	O
contrast	O
,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	B-CHEMICAL
CaCO3	O
dosage	O
,	O
calculated	O
dietary	O
calcium	B-CHEMICAL
intake	O
,	O
and	O
circulating	O
levels	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Methyldopa	B-CHEMICAL
-	O
induced	O
hemolytic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near	O
-	O
syncope	B-DISEASE
Methyldopa	B-CHEMICAL
Methyldopa	B-CHEMICAL
causes	O
an	O
autoimmune	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
We	O
report	O
a	O
case	O
of	O
methyldopa	B-CHEMICAL
-	O
induced	O
hemolytic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
near	O
-	O
syncope	B-DISEASE
The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	B-CHEMICAL
during	O
a	O
trauma	B-DISEASE
Emergency	O
physicians	O
treating	O
children	O
must	O
be	O
aware	O
of	O
this	O
syndrome	B-DISEASE
A	O
brief	B-DISEASE
The	O
long	O
-	O
term	O
safety	O
of	O
danazol	B-CHEMICAL
in	O
women	O
with	O
hereditary	O
angioedema	B-DISEASE
Although	O
the	O
short	O
-	O
term	O
safety	O
(	O
less	O
than	O
or	O
equal	O
to	O
6	O
months	O
)	O
of	O
danazol	B-CHEMICAL
We	O
therefore	O
investigated	O
the	O
long	O
-	O
term	O
safety	O
of	O
danazol	B-CHEMICAL
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	O
angioedema	B-DISEASE
treated	O
with	O
danazol	B-CHEMICAL
Menstrual	O
abnormalities	B-DISEASE
(	O
79	O
%),	O
weight	B-DISEASE
gain	I-DISEASE
(	O
60	O
%),	O
muscle	B-DISEASE
cramps	I-DISEASE
We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions	O
,	O
danazol	B-CHEMICAL
Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	B-CHEMICAL
diphosphanilate	I-CHEMICAL
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	B-DISEASE
Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	B-DISEASE
Chlorhexidine	B-CHEMICAL
phosphanilate	I-CHEMICAL
Twenty	O
-	O
nine	O
burn	O
patients	O
,	O
each	O
with	O
two	O
similar	O
burns	B-DISEASE
which	O
could	O
be	O
separately	O
treated	O
,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	B-DISEASE
successive	O
12	O
-	O
h	B-CHEMICAL
One	O
burn	O
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	O
concentrations	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicle	O
,	O
and	O
1	O
per	O
cent	O
silver	B-CHEMICAL
sulphadiazine	O
(	O
AgSD	O
)	O
cream	O
,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	O
wounds	B-DISEASE
There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	O
concentration	O
and	O
patients	O
'	O
ratings	O
of	O
pain	B-DISEASE
The	O
0	O
.	O
25	O
per	O
cent	O
CHP	O
cream	O
was	O
closest	O
to	O
AgSD	O
in	O
pain	B-DISEASE
It	O
was	O
concluded	O
that	O
formulations	O
at	B-DISEASE
Dose	O
-	O
dependent	O
neurotoxicity	B-DISEASE
of	O
high	O
-	O
dose	O
busulfan	B-CHEMICAL
Busulfan	B-CHEMICAL
is	O
known	O
to	O
be	O
neurotoxic	B-DISEASE
in	O
animals	O
and	O
humans	O
,	O
but	O
its	O
acute	O
neurotoxicity	B-DISEASE
We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(	O
median	O
age	O
,	O
6	O
.	O
5	O
years	O
)	O
receiving	O
high	O
-	O
dose	O
busulfan	B-CHEMICAL
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	B-DISEASE
,	O
brain	O
tumors	B-DISEASE
Busulfan	B-CHEMICAL
Ninety	O
-	O
six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis	O
;	O
7	O
(	O
7	O
.	O
5	O
%)	O
developed	O
seizures	B-DISEASE
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	B-CHEMICAL
course	O
or	O
within	O
24	O
h	B-CHEMICAL
When	O
the	O
total	O
busulfan	B-CHEMICAL
dose	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	B-DISEASE
Twenty	O
-	O
seven	O
patients	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
busulfan	B-CHEMICAL
infusion	O
of	O
clonazepam	B-CHEMICAL
Busulfan	B-CHEMICAL
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	O
nervous	O
system	O
disease	B-DISEASE
under	O
600	O
mg	O
/	O
m2	O
busulfan	B-CHEMICAL
with	O
clonazepam	B-CHEMICAL
:	O
busulfan	B-CHEMICAL
This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dose	O
of	O
busulfan	B-CHEMICAL
This	O
study	O
shows	O
that	O
busulfan	B-CHEMICAL
neurotoxicity	B-DISEASE
is	O
dose	O
-	O
dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	B-CHEMICAL
A	O
busulfan	B-CHEMICAL
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children	O
,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	B-DISEASE
,	O
close	O
to	O
neurotoxicity	B-DISEASE
Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	B-CHEMICAL
The	O
busulfan	B-CHEMICAL
Histamine	B-CHEMICAL
antagonists	I-CHEMICAL
and	O
d	O
-	O
tubocurarine	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
Hemodynamic	O
effects	O
and	O
histamine	B-CHEMICAL
release	O
by	O
bolus	O
injection	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	O
-	O
tubocurarine	B-CHEMICAL
H1	O
-	O
and	O
H2	O
-	O
histamine	B-CHEMICAL
antagonists	I-CHEMICAL
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d	O
-	O
tubocurarine	B-CHEMICAL
in	O
a	O
randomized	O
double	O
-	O
blind	O
fashion	O
to	O
four	O
groups	O
:	O
group	O
1	O
--	O
placebo	O
;	O
group	O
2	O
--	O
cimetidine	B-CHEMICAL
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
group	O
3	O
--	O
chlorpheniramine	B-CHEMICAL
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
and	O
group	O
4	O
--	O
cimetidine	B-CHEMICAL
plus	O
chlorpheniramine	B-CHEMICAL
Histamine	B-CHEMICAL
release	O
occurred	O
in	O
most	O
patients	O
,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d	O
-	O
tubocurarine	B-CHEMICAL
Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	B-CHEMICAL
These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d	O
-	O
tubocurarine	B-CHEMICAL
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	B-CHEMICAL
Convulsant	O
effect	O
of	O
lindane	B-CHEMICAL
and	O
regional	O
brain	O
concentration	O
of	O
GABA	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
Lindane	B-CHEMICAL
(	O
gamma	O
-	O
hexachlorocyclohexane	B-CHEMICAL
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	B-DISEASE
Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	B-CHEMICAL
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagonist	O
at	B-DISEASE
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
We	O
studied	O
the	O
effect	O
of	O
lindane	B-CHEMICAL
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	B-CHEMICAL
,	O
dopamine	B-CHEMICAL
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	B-DISEASE
the	O
onset	O
of	O
seizures	B-DISEASE
All	O
animals	O
suffered	O
tonic	B-DISEASE
convulsions	B-DISEASE
at	B-DISEASE
18	O
.	O
3	O
+/-	O
1	O
.	O
4	O
min	O
after	O
lindane	B-CHEMICAL
The	O
concentration	O
of	O
GABA	B-CHEMICAL
The	O
concentration	O
of	O
dopamine	B-CHEMICAL
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	B-CHEMICAL
Two	O
cases	O
of	O
propylthiouracil	B-CHEMICAL
-	O
associated	O
acute	O
hepatitis	B-DISEASE
,	O
one	O
case	O
of	O
fatal	O
methimazole	B-CHEMICAL
-	O
associated	O
hepatocellular	O
necrosis	B-DISEASE
and	O
one	O
case	O
of	O
propylthiouracil	B-CHEMICAL
-	O
associated	O
lupus	B-DISEASE
-	O
like	O
syndrome	B-DISEASE
The	O
literature	O
related	O
to	O
antithyroid	O
drug	O
side	O
effects	O
and	O
the	O
mechanisms	O
for	O
their	O
occurrence	O
are	O
reviewed	O
and	O
the	O
efficacy	O
and	O
complications	O
of	O
thyroidectomy	O
and	O
radioiodine	O
compared	O
to	O
those	O
of	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	B-DISEASE
Anticonvulsant	O
actions	O
of	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
on	O
the	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-CHEMICAL
model	O
of	O
status	B-DISEASE
epilepticus	I-DISEASE
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
,	O
a	O
noncompetitive	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
)	O
receptor	O
antagonist	O
,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	B-DISEASE
models	O
,	O
coadministration	O
of	O
lithium	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	B-CHEMICAL
First	O
,	O
pretreatment	O
with	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
produced	O
an	O
effective	O
and	O
dose	O
-	O
dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-CHEMICAL
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	B-CHEMICAL
alone	O
,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	B-DISEASE
Second	O
,	O
the	O
anticonvulsant	O
effect	O
of	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
in	O
the	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-CHEMICAL
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	B-DISEASE
This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
binding	O
requires	O
agonist	O
-	O
induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	B-CHEMICAL
Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	B-DISEASE
induced	O
by	O
lithium	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
by	O
administration	O
of	O
anticonvulsants	B-CHEMICAL
prior	O
to	O
pilocarpine	B-CHEMICAL
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	B-DISEASE
epilepticus	I-DISEASE
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	B-DISEASE
Administration	O
of	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
30	O
or	O
60	O
min	O
after	O
pilocarpine	B-CHEMICAL
,	O
i	O
.	O
e	O
.,	O
during	O
status	B-DISEASE
epilepticus	I-DISEASE
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	B-DISEASE
These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	B-CHEMICAL
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	B-DISEASE
epilepticus	I-DISEASE
and	O
brain	B-DISEASE
damage	I-DISEASE
in	O
the	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-CHEMICAL
This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
were	O
synergistic	O
,	O
resulting	O
in	O
status	B-DISEASE
epilepticus	I-DISEASE
Nifedipine	B-CHEMICAL
induced	O
bradycardia	B-DISEASE
in	O
a	O
patient	O
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
An	O
80	O
year	O
old	O
diabetic	B-DISEASE
male	O
with	O
evidence	O
of	O
peripheral	O
and	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
was	O
admitted	O
with	O
chest	B-DISEASE
pain	I-DISEASE
He	O
was	O
found	O
to	O
have	O
atrial	B-DISEASE
flutter	I-DISEASE
at	B-DISEASE
a	O
ventricular	O
rate	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifedipine	B-CHEMICAL
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doses	O
,	O
during	O
which	O
he	O
was	O
paced	O
at	B-DISEASE
This	O
is	O
inconsistent	O
with	O
the	O
well	O
-	O
established	O
finding	O
that	O
nifedipine	B-CHEMICAL
induces	O
tachycardia	B-DISEASE
However	O
,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive	O
,	O
it	O
may	O
lead	B-CHEMICAL
to	O
bradycardia	B-DISEASE
The	O
effect	O
of	O
haloperidol	B-CHEMICAL
in	O
cocaine	B-CHEMICAL
and	O
amphetamine	B-CHEMICAL
The	O
effectiveness	O
of	O
haloperidol	B-CHEMICAL
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
injection	O
of	O
amphetamine	B-CHEMICAL
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
death	B-DISEASE
rate	O
)	O
or	O
cocaine	B-CHEMICAL
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
death	B-DISEASE
Haloperidol	B-CHEMICAL
failed	O
to	O
prevent	O
amphetamine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	B-DISEASE
Haloperidol	B-CHEMICAL
decreased	O
the	O
incidence	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
at	B-DISEASE
the	O
two	O
highest	O
doses	O
,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	B-DISEASE
These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	B-CHEMICAL
blocker	O
haloperidol	B-CHEMICAL
against	O
death	B-DISEASE
from	O
high	O
-	O
dose	O
amphetamine	B-CHEMICAL
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	B-DISEASE
In	O
contrast	O
,	O
haloperidol	B-CHEMICAL
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Autoradiographic	O
evidence	O
of	O
estrogen	B-CHEMICAL
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	O
induced	O
hamster	O
renal	B-DISEASE
Estrogen	B-CHEMICAL
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	O
induced	O
renal	B-DISEASE
Radiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H	O
-	O
17	O
beta	O
estradiol	B-CHEMICAL
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	B-DISEASE
cells	O
;	O
stereologic	O
analysis	O
revealed	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
higher	O
concentration	O
of	O
reduced	O
silver	B-CHEMICAL
Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	B-CHEMICAL
which	O
peaked	O
in	O
less	O
than	O
1	O
h	B-CHEMICAL
This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	B-CHEMICAL
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	B-CHEMICAL
induced	O
hamster	O
renal	B-DISEASE
Bradycardia	B-DISEASE
due	O
to	O
biperiden	B-CHEMICAL
In	O
a	O
38	O
-	O
year	O
-	O
old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	O
trigeminal	B-DISEASE
neuralgia	I-DISEASE
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	B-CHEMICAL
lactate	I-CHEMICAL
led	O
to	O
a	O
long	O
-	O
lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	B-DISEASE
,	O
dysarthria	B-DISEASE
,	O
and	O
dysphagia	B-DISEASE
Bradycardia	B-DISEASE
induced	O
by	O
biperiden	B-CHEMICAL
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose	O
-	O
related	O
dual	O
effect	O
of	O
atropine	B-CHEMICAL
-	O
like	O
drugs	O
on	O
muscarine	B-CHEMICAL
Deliberate	O
hypotension	B-DISEASE
induced	O
by	O
labetalol	B-CHEMICAL
with	O
halothane	B-CHEMICAL
,	O
enflurane	B-CHEMICAL
or	O
isoflurane	B-CHEMICAL
The	O
feasibility	O
of	O
using	O
labetalol	B-CHEMICAL
,	O
an	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
as	O
a	O
hypotensive	B-DISEASE
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	B-CHEMICAL
,	O
enflurane	B-CHEMICAL
or	O
isoflurane	B-CHEMICAL
mean	O
)	O
mmHg	O
to	O
52	O
+/-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+/-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+/-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+/-	O
10	O
min	O
in	O
the	O
halothane	B-CHEMICAL
(	O
H	B-CHEMICAL
)	O
group	O
,	O
from	O
79	O
+/-	O
5	O
to	O
53	O
+/-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+/-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+/-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+/-	O
11	O
min	O
in	O
the	O
enflurane	B-CHEMICAL
(	O
E	O
)	O
group	O
,	O
and	O
from	O
80	O
+/-	O
4	O
to	O
49	O
+/-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+/-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+/-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+/-	O
15	O
min	O
in	O
the	O
isoflurane	B-CHEMICAL
The	O
mean	O
H	B-CHEMICAL
concentration	O
during	O
hypotension	B-DISEASE
In	O
addition	O
,	O
the	O
patients	O
received	O
fentanyl	B-CHEMICAL
and	O
d	O
-	O
tubocurarine	B-CHEMICAL
The	O
initial	O
dose	O
of	O
labetalol	B-CHEMICAL
During	O
hypotension	B-DISEASE
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy	O
-	O
or	O
bradycardia	B-DISEASE
The	O
operating	O
conditions	O
regarding	O
bleeding	B-DISEASE
During	O
hypotension	B-DISEASE
,	O
the	O
serum	O
creatinine	B-CHEMICAL
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	B-DISEASE
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups	O
,	O
except	O
the	O
isoflurane	B-CHEMICAL
After	O
hypotension	B-DISEASE
These	O
results	O
indicate	O
that	O
labetalol	B-CHEMICAL
induces	O
easily	O
adjustable	O
hypotension	B-DISEASE
without	O
compensatory	O
tachycardia	B-DISEASE
and	O
rebound	O
hypertension	B-DISEASE
Convulsion	B-DISEASE
following	O
intravenous	O
fluorescein	B-CHEMICAL
Tonic	B-DISEASE
-	O
clonic	O
seizures	B-DISEASE
followed	O
intravenous	O
fluorescein	B-CHEMICAL
Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re	O
-	O
exposure	O
to	O
intravenous	O
fluorescein	B-CHEMICAL
Pharmacology	O
of	O
ACC	O
-	O
9653	O
(	O
phenytoin	B-CHEMICAL
ACC	O
-	O
9653	O
,	O
the	O
disodium	O
phosphate	B-CHEMICAL
ester	O
of	O
3	O
-	O
hydroxymethyl	O
-	O
5	O
,	O
5	O
-	O
diphenylhydantoin	B-DISEASE
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	B-CHEMICAL
ACC	O
-	O
9653	O
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	B-CHEMICAL
ACC	O
-	O
9653	O
and	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	B-DISEASE
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
ACC	O
-	O
9653	O
and	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	B-CHEMICAL
-	O
induced	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
The	O
total	O
doses	O
of	O
ACC	O
-	O
9653	O
or	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
necessary	O
to	O
convert	O
the	O
arrhythmia	B-DISEASE
Only	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin	B-CHEMICAL
-	O
induced	O
arrhythmias	B-DISEASE
In	O
anesthetized	O
dogs	O
,	O
a	O
high	O
dose	O
of	O
ACC	O
-	O
9653	O
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
The	O
ACC	O
-	O
9653	O
and	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	B-DISEASE
the	O
time	O
of	O
maximum	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
Acute	O
toxicity	B-DISEASE
studies	O
of	O
ACC	O
-	O
9653	O
and	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
The	O
systemic	O
toxic	O
signs	O
of	O
both	O
agents	O
were	O
similar	O
and	O
occurred	O
at	B-DISEASE
Importantly	O
,	O
the	O
local	O
irritation	O
of	O
ACC	O
-	O
9653	O
was	O
markedly	O
less	O
than	O
phenytoin	B-CHEMICAL
sodium	B-CHEMICAL
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Phenytoin	B-CHEMICAL
induced	O
fatal	O
hepatic	B-DISEASE
injury	I-DISEASE
A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	B-DISEASE
failure	I-DISEASE
after	O
phenytoin	B-CHEMICAL
A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	B-DISEASE
injury	I-DISEASE
The	O
hematologic	O
,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	O
damage	O
due	O
to	O
drug	B-DISEASE
hypersensitivity	I-DISEASE
In	O
a	O
patient	O
receiving	O
phenytoin	B-CHEMICAL
Treatment	O
of	O
lethal	O
pertussis	B-CHEMICAL
vaccine	I-CHEMICAL
reaction	O
with	O
histamine	B-CHEMICAL
H1	I-CHEMICAL
antagonists	I-CHEMICAL
We	O
studied	O
mortality	O
after	O
pertussis	B-DISEASE
Without	O
treatment	O
,	O
73	O
of	O
92	O
animals	O
(	O
80	O
%)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	B-CHEMICAL
albumin	I-CHEMICAL
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	B-DISEASE
After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	B-CHEMICAL
,	O
2	O
mg	O
mianserin	B-CHEMICAL
,	O
or	O
2	O
mg	O
chlorpheniramine	B-CHEMICAL
Blockade	O
of	O
histamine	B-CHEMICAL
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	B-DISEASE
immunization	O
-	O
induced	O
encephalopathy	B-DISEASE
Support	O
for	O
adrenaline	B-CHEMICAL
-	O
hypertension	B-DISEASE
hypothesis	O
:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	B-CHEMICAL
In	O
a	O
double	O
blind	O
,	O
crossover	O
study	O
6	O
h	B-CHEMICAL
infusions	O
of	O
adrenaline	B-CHEMICAL
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
),	O
noradrenaline	B-CHEMICAL
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
),	O
and	O
a	O
5	O
%	O
dextrose	O
solution	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	B-CHEMICAL
),	O
were	O
given	O
to	O
ten	B-DISEASE
By	O
means	O
of	O
intra	O
-	O
arterial	O
ambulatory	O
monitoring	O
the	O
haemodynamic	O
effects	O
were	O
followed	O
for	O
18	O
h	B-CHEMICAL
Adrenaline	B-CHEMICAL
,	O
but	O
not	O
noradrenaline	B-CHEMICAL
Thus	O
,	O
"	O
stress	O
"	O
levels	O
of	O
adrenaline	B-CHEMICAL
(	O
230	O
pg	B-CHEMICAL
/	O
ml	O
)	O
for	O
6	O
h	B-CHEMICAL
These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline	B-CHEMICAL
-	O
hypertension	B-DISEASE
Effect	O
of	O
alkylxanthines	O
on	O
gentamicin	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
Adenosine	B-CHEMICAL
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	O
and	O
nephrotoxic	B-DISEASE
models	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	O
with	O
different	O
potencies	O
as	O
adenosine	B-CHEMICAL
antagonists	O
8	B-CHEMICAL
-	I-CHEMICAL
phenyltheophylline	I-CHEMICAL
,	O
theophylline	B-CHEMICAL
and	O
enprofylline	B-CHEMICAL
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
4	O
daily	O
injections	O
of	O
gentamicin	B-CHEMICAL
Renal	B-DISEASE
function	O
was	O
assessed	O
by	O
biochemical	O
(	O
plasma	O
urea	B-CHEMICAL
and	O
creatinine	B-CHEMICAL
),	O
functional	O
(	O
urine	B-DISEASE
analysis	O
and	O
[	O
3H	O
]	O
inulin	B-CHEMICAL
and	O
[	O
14C	O
]	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippuric	I-CHEMICAL
acid	I-CHEMICAL
clearances	O
)	O
and	O
morphological	O
(	O
degree	O
of	O
necrosis	B-DISEASE
The	O
various	O
drug	O
treatments	O
produced	O
improvements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measurements	O
of	O
renal	B-DISEASE
However	O
,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	B-CHEMICAL
The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	O
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	B-CHEMICAL
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiological	O
role	O
in	O
gentamicin	B-CHEMICAL
Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	B-CHEMICAL
A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	B-CHEMICAL
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	B-DISEASE
Blepharoconjunctivitis	O
,	O
subjective	O
complaints	O
of	O
dry	B-DISEASE
eyes	I-DISEASE
,	O
blurred	O
vision	B-DISEASE
More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	B-DISEASE
,	O
pseudotumor	B-DISEASE
cerebri	I-DISEASE
Isotretinoin	B-CHEMICAL
is	O
contraindicated	O
in	O
pregnancy	B-DISEASE
because	O
of	O
the	O
many	O
reported	O
congenital	B-DISEASE
abnormalities	I-DISEASE
after	O
maternal	O
use	O
(	O
including	O
microphthalmos	B-DISEASE
,	O
orbital	O
hypertelorism	B-DISEASE
,	O
and	O
optic	B-DISEASE
nerve	I-DISEASE
hypoplasia	I-DISEASE
Procaterol	B-CHEMICAL
and	O
terbutaline	B-CHEMICAL
in	O
bronchial	O
asthma	B-DISEASE
Procaterol	B-CHEMICAL
,	O
a	O
new	O
beta	O
-	O
2	O
adrenoceptor	O
stimulant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
trial	O
in	O
patients	O
with	O
bronchial	O
asthma	B-DISEASE
Oral	O
procaterol	B-CHEMICAL
50	O
micrograms	O
b	O
.	O
d	O
.,	O
procaterol	B-CHEMICAL
100	O
micrograms	O
b	O
.	O
d	O
.,	O
and	O
terbutaline	B-CHEMICAL
The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	B-CHEMICAL
Both	O
anti	O
-	O
asthmatic	O
and	O
tremorgenic	O
effects	O
of	O
procaterol	B-CHEMICAL
Procaterol	B-CHEMICAL
Subacute	O
effects	O
of	O
propranolol	B-CHEMICAL
and	O
B	O
24	O
/	O
76	O
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
rat	O
heart	O
hypertrophy	B-DISEASE
1	O
-(	O
2	O
,	O
4	O
-	O
dichlorophenoxy	O
)-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimethoxyphenyl	O
)	O
ethanolamino	O
]-	O
prop	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
characterized	O
by	O
beta	O
1	O
-	O
adrenoceptor	O
blocking	O
and	O
beta	O
2	O
-	O
adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	B-CHEMICAL
The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
heart	O
hypertrophy	B-DISEASE
A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	O
hypertrophy	B-DISEASE
Both	O
beta	O
-	O
blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	B-DISEASE
It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	B-CHEMICAL
Neither	O
propranolol	B-CHEMICAL
Thus	O
,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta	O
-	O
receptor	O
blockers	O
propranolol	B-CHEMICAL
and	O
B	O
24	O
/	O
76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	B-CHEMICAL
from	O
producing	O
heart	O
hypertrophy	B-DISEASE
Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	B-CHEMICAL
bromide	O
and	O
of	O
slow	O
-	O
release	O
theophylline	B-CHEMICAL
on	O
nocturnal	O
asthma	B-DISEASE
The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug	O
,	O
oxitropium	B-CHEMICAL
bromide	O
,	O
and	O
of	O
a	O
slow	O
-	O
release	O
theophylline	B-CHEMICAL
preparation	O
upon	O
nocturnal	O
asthma	B-DISEASE
Two	O
samples	O
were	O
studied	O
:	O
12	O
patients	O
received	O
oxitropium	B-CHEMICAL
at	B-DISEASE
600	O
micrograms	O
(	O
6	O
subjects	O
)	O
or	O
at	B-DISEASE
(	O
6	O
subjects	O
)	O
whereas	O
11	O
received	O
theophylline	B-CHEMICAL
at	B-DISEASE
No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug	O
,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	B-CHEMICAL
No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	B-CHEMICAL
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
and	O
tremors	B-DISEASE
after	O
theophylline	B-CHEMICAL
Oxitropium	B-CHEMICAL
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	B-CHEMICAL
in	O
nocturnal	O
asthma	B-DISEASE
Penicillin	B-CHEMICAL
anaphylaxis	B-DISEASE
A	O
case	O
of	O
oral	O
penicillin	B-CHEMICAL
anaphylaxis	B-DISEASE
is	O
described	O
,	O
and	O
the	O
terminology	O
,	O
occurrence	O
,	O
clinical	O
manifestations	O
,	O
pathogenesis	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
anaphylaxis	B-DISEASE
Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	B-CHEMICAL
anaphylaxis	B-DISEASE
Reversible	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
dementia	B-DISEASE
Reversible	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
dementia	B-DISEASE
was	O
documented	O
in	O
a	O
21	O
-	O
year	O
-	O
old	O
man	O
with	O
epilepsy	B-DISEASE
Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxic	O
effect	O
of	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
hyperammonemia	B-DISEASE
Reversal	O
of	O
scopolamine	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
of	O
passive	O
avoidance	O
by	O
pre	O
-	O
and	O
post	O
-	O
training	O
naloxone	B-CHEMICAL
In	O
a	O
series	O
of	O
five	O
experiments	O
,	O
the	O
modulating	O
role	O
of	O
naloxone	B-CHEMICAL
on	O
a	O
scopolamine	B-CHEMICAL
Scopolamine	B-CHEMICAL
,	O
but	O
not	O
methyl	O
scopolamine	B-CHEMICAL
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
),	O
induced	O
an	O
amnesia	B-DISEASE
Naloxone	B-CHEMICAL
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	O
deficit	O
with	O
a	O
peak	O
of	O
activity	O
at	B-DISEASE
The	O
effect	O
of	O
naloxone	B-CHEMICAL
could	O
be	O
antagonized	O
with	O
morphine	B-CHEMICAL
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
),	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	B-CHEMICAL
Post	O
-	O
training	O
administration	O
of	O
naloxone	B-CHEMICAL
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	B-DISEASE
sensitivity	O
(	O
pre	O
-	O
training	O
naloxone	B-CHEMICAL
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(	O
post	O
-	O
training	O
naloxone	B-CHEMICAL
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	B-CHEMICAL
on	O
the	O
scopolamine	B-CHEMICAL
Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
lesions	O
of	O
the	O
urinary	B-DISEASE
bladder	I-DISEASE
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	B-CHEMICAL
Fully	O
developed	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium	O
,	O
severe	O
submucosal	O
edema	B-DISEASE
The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	B-CHEMICAL
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	B-CHEMICAL
This	O
damages	O
the	O
cellular	O
barrier	O
against	O
the	O
hypertonic	O
urine	B-DISEASE
Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells	O
,	O
intercellular	O
and	O
intracellular	O
edema	B-DISEASE
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	B-CHEMICAL
These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	B-CHEMICAL
Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium	B-CHEMICAL
-	O
induced	O
muscle	O
fasciculations	O
in	O
children	O
:	O
inhibition	O
by	O
alfentanil	B-CHEMICAL
Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	B-CHEMICAL
were	O
studied	O
in	O
32	O
children	O
(	O
mean	O
age	O
6	O
.	O
9	O
yr	O
)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	B-CHEMICAL
Anaesthesia	O
was	O
induced	O
with	O
thiopentone	B-CHEMICAL
The	O
incidence	O
and	O
intensity	O
of	O
muscle	O
fasciculations	O
caused	O
by	O
suxamethonium	B-CHEMICAL
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	B-CHEMICAL
The	O
intragastric	O
pressure	O
during	O
muscle	O
fasciculations	O
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(	O
16	O
+/-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	B-DISEASE
H2O	B-CHEMICAL
)	O
than	O
in	O
the	O
alfentanil	B-CHEMICAL
group	O
(	O
7	O
.	O
7	O
+/-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	B-DISEASE
H2O	B-CHEMICAL
It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	O
fasciculations	O
caused	O
by	O
suxamethonium	B-CHEMICAL
Alfentanil	B-CHEMICAL
50	O
micrograms	O
kg	O
-	O
1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium	B-CHEMICAL
-	O
induced	O
muscle	O
fasciculations	O
;	O
moreover	O
,	O
intragastric	O
pressure	O
remains	O
at	B-DISEASE
Acute	O
insulin	B-CHEMICAL
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	B-DISEASE
effect	O
of	O
isoproterenol	B-CHEMICAL
in	O
streptozotocin	B-CHEMICAL
diabetic	B-DISEASE
A	O
morphometric	O
study	O
of	O
isoproterenol	B-CHEMICAL
induced	O
myocardial	O
fibrosis	B-DISEASE
The	O
acute	O
effect	O
of	O
insulin	B-CHEMICAL
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	B-CHEMICAL
diabetes	B-DISEASE
against	O
the	O
cardiotoxic	B-DISEASE
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	B-CHEMICAL
(	O
ISO	B-CHEMICAL
Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	B-CHEMICAL
,	O
ISO	B-CHEMICAL
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	B-CHEMICAL
induced	O
fibrosis	B-DISEASE
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	B-CHEMICAL
glucose	I-CHEMICAL
after	O
insulin	B-CHEMICAL
The	O
myocardial	O
content	O
of	O
catecholamines	B-CHEMICAL
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	B-DISEASE
The	O
norepinephrine	B-CHEMICAL
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	B-CHEMICAL
An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta	O
-	O
adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	B-CHEMICAL
The	O
rapid	O
reversion	O
after	O
insulin	B-CHEMICAL
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	B-CHEMICAL
in	O
itself	O
causes	O
the	O
ISO	B-CHEMICAL
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	B-CHEMICAL
effect	O
on	O
myocardial	O
catecholamine	B-CHEMICAL
sensitivity	O
in	O
diabetic	B-DISEASE
The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	B-DISEASE
Differential	O
effects	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	B-CHEMICAL
induces	O
in	O
rats	O
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
sodium	B-CHEMICAL
salicylate	I-CHEMICAL
,	O
phenylbutazone	B-CHEMICAL
,	O
indomethacin	B-CHEMICAL
,	O
ibuprofen	B-CHEMICAL
and	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
on	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
Pretreatment	O
of	O
rats	O
with	O
sodium	B-CHEMICAL
salicylate	I-CHEMICAL
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
),	O
and	O
phenylbutazone	B-CHEMICAL
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
convulsant	O
dose	O
of	O
pilocarpine	B-CHEMICAL
Indomethacin	B-CHEMICAL
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuprofen	B-CHEMICAL
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modulate	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
Mefenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seizures	B-DISEASE
and	O
protected	O
rats	O
from	O
seizure	B-DISEASE
-	O
related	O
brain	B-DISEASE
damage	I-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
These	O
results	O
indicate	O
that	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Acute	O
neurologic	B-DISEASE
dysfunction	O
after	O
high	O
-	O
dose	O
etoposide	B-CHEMICAL
therapy	O
for	O
malignant	O
glioma	B-DISEASE
Etoposide	B-CHEMICAL
(	O
VP	O
-	O
16	O
-	O
213	O
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	B-DISEASE
and	O
hematologic	O
malignancies	B-DISEASE
When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment	O
-	O
resistant	O
cancers	B-DISEASE
including	O
malignant	O
glioma	B-DISEASE
In	O
six	O
of	O
eight	O
patients	O
(	O
75	O
%)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	B-DISEASE
,	O
sudden	O
severe	O
neurologic	B-DISEASE
This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
etoposide	B-CHEMICAL
Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	B-DISEASE
,	O
papilledema	B-DISEASE
,	O
somnolence	B-DISEASE
,	O
exacerbation	O
of	O
motor	O
deficits	O
,	O
and	O
sharp	O
increase	O
in	O
seizure	B-DISEASE
These	O
abnormalities	B-DISEASE
resolved	O
rapidly	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
intravenous	O
dexamethasone	B-CHEMICAL
In	O
all	O
patients	O
,	O
computerized	O
tomographic	O
(	O
CT	O
)	O
brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	B-DISEASE
size	O
and	O
peritumor	O
edema	B-DISEASE
This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	B-DISEASE
of	O
high	O
-	O
dose	O
etoposide	B-CHEMICAL
therapy	O
for	O
malignant	O
glioma	B-DISEASE
Progressive	O
bile	O
duct	O
injury	O
after	O
thiabendazole	B-CHEMICAL
A	O
27	O
-	O
yr	O
-	O
old	O
man	O
developed	O
jaundice	B-DISEASE
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	B-CHEMICAL
Cholestasis	B-DISEASE
persisted	O
for	O
3	O
yr	O
,	O
at	B-DISEASE
which	O
time	O
a	O
liver	B-DISEASE
Two	O
liver	B-DISEASE
Prominent	O
fibrosis	B-DISEASE
This	O
case	O
represents	O
an	O
example	O
of	O
"	O
idiosyncratic	O
"	O
drug	O
-	O
induced	O
liver	B-DISEASE
damage	I-DISEASE
Differential	O
effects	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydropyridine	I-CHEMICAL
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	B-CHEMICAL
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	B-CHEMICAL
channel	O
blocking	O
agents	O
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	B-DISEASE
diseases	I-DISEASE
Clinical	O
applications	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
In	O
contrast	O
to	O
verapamil	B-CHEMICAL
and	O
diltiazem	B-CHEMICAL
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle	O
,	O
the	O
dihydropyridine	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	B-CHEMICAL
agents	I-CHEMICAL
As	O
the	O
first	O
dihydropyridine	O
available	O
for	O
use	O
in	O
the	O
United	O
States	O
,	O
nifedipine	B-CHEMICAL
controls	O
angina	B-DISEASE
and	O
hypertension	B-DISEASE
with	O
minimal	O
depression	B-DISEASE
Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	B-CHEMICAL
and	O
nisoldipine	B-CHEMICAL
offers	O
a	O
convenient	O
administration	O
schedule	O
,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long	O
-	O
term	O
therapy	O
of	O
hypertension	B-DISEASE
The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	B-CHEMICAL
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	B-DISEASE
Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	B-CHEMICAL
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
,	O
migraine	B-DISEASE
headache	B-DISEASE
,	O
dementia	B-DISEASE
,	O
and	O
stroke	B-DISEASE
In	O
general	O
,	O
the	O
dihydropyridine	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
are	O
usually	O
well	O
tolerated	O
,	O
with	O
headache	B-DISEASE
,	O
facial	O
flushing	B-DISEASE
,	O
palpitations	O
,	O
edema	B-DISEASE
,	O
nausea	B-DISEASE
,	O
anorexia	B-DISEASE
,	O
and	O
dizziness	B-DISEASE
The	O
enhancement	O
of	O
aminonucleoside	B-CHEMICAL
nephrosis	B-DISEASE
by	O
the	O
co	B-CHEMICAL
An	O
experimental	O
model	O
of	O
focal	O
segmental	O
glomerular	B-DISEASE
sclerosis	I-DISEASE
(	O
FSGS	B-DISEASE
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin	B-CHEMICAL
-	O
aminonucleoside	B-CHEMICAL
The	O
series	O
of	O
injections	O
were	O
repeated	O
another	O
three	O
times	O
at	B-DISEASE
They	O
developed	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
and	O
finally	O
renal	B-DISEASE
failure	I-DISEASE
The	O
time	O
-	O
course	O
curve	O
of	O
creatinine	B-CHEMICAL
Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	B-DISEASE
The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	B-CHEMICAL
red	I-CHEMICAL
Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	O
enhances	O
the	O
toxicity	B-DISEASE
of	O
AMNS	O
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	B-DISEASE
in	O
rats	O
resulting	O
in	O
the	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
Theophylline	B-CHEMICAL
neurotoxicity	B-DISEASE
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	B-DISEASE
of	O
theophylline	B-CHEMICAL
is	O
altered	O
in	O
advanced	O
pregnancy	B-DISEASE
Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	B-CHEMICAL
until	O
onset	O
of	O
maximal	O
seizures	B-DISEASE
Theophylline	B-CHEMICAL
concentrations	O
at	B-DISEASE
Theophylline	B-CHEMICAL
Fetal	O
serum	O
concentrations	O
at	B-DISEASE
onset	O
of	O
seizures	B-DISEASE
It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	B-DISEASE
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	B-DISEASE
response	O
to	O
theophylline	B-CHEMICAL
Hyperkalemia	B-DISEASE
induced	O
by	O
indomethacin	B-CHEMICAL
and	O
naproxen	B-CHEMICAL
and	O
reversed	O
by	O
fludrocortisone	B-CHEMICAL
We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
and	O
a	O
history	O
of	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
nephropathy	B-DISEASE
in	O
whom	O
hyperkalemia	B-DISEASE
and	O
inappropriate	O
hypoaldosteronism	B-DISEASE
were	O
caused	O
by	O
both	O
indomethacin	B-CHEMICAL
and	O
naproxen	B-CHEMICAL
,	O
without	O
major	O
decline	O
in	O
renal	B-DISEASE
It	O
is	O
likely	O
that	O
preexisting	O
renal	B-DISEASE
disease	B-DISEASE
predisposed	O
this	O
patient	O
to	O
type	O
IV	O
renal	B-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
,	O
fludrocortisone	B-CHEMICAL
was	O
added	O
,	O
correcting	O
the	O
hyperkalemia	B-DISEASE
and	O
allowing	O
indomethacin	B-CHEMICAL
Hypotension	B-DISEASE
as	O
a	O
manifestation	O
of	O
cardiotoxicity	B-DISEASE
in	O
three	O
patients	O
receiving	O
cisplatin	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
Cardiac	O
symptoms	O
,	O
including	O
hypotension	B-DISEASE
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	O
carcinoma	B-DISEASE
while	O
being	O
treated	O
with	O
cisplatin	B-CHEMICAL
(	O
CDDP	O
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
In	O
two	O
patients	O
,	O
hypotension	B-DISEASE
was	O
associated	O
with	O
severe	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
The	O
presentation	O
and	O
cardiac	O
evaluation	O
(	O
hemodynamic	O
,	O
echocardiographic	O
,	O
and	O
scintigraphic	O
)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
cardiotoxicity	B-DISEASE
Fatal	O
aplastic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	B-CHEMICAL
A	O
case	O
of	O
fatal	O
aplastic	B-DISEASE
anemia	I-DISEASE
due	O
to	O
carbamazepine	B-CHEMICAL
treatment	O
in	O
an	O
epileptic	B-DISEASE
Despite	O
concerns	O
of	O
fatal	O
bone	O
marrow	O
toxicity	B-DISEASE
due	O
to	O
carbamazepine	B-CHEMICAL
Carbamazepine	B-CHEMICAL
Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
The	O
effects	O
of	O
microinjection	O
of	O
clonidine	B-CHEMICAL
(	O
1	O
-	O
10	O
micrograms	O
in	O
1	O
microliter	O
)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane	B-CHEMICAL
Intramedullary	O
administration	O
of	O
clonidine	B-CHEMICAL
The	O
clonidine	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
On	O
the	O
other	O
hand	B-DISEASE
,	O
the	O
clonidine	B-CHEMICAL
-	O
induced	O
bradycardia	B-DISEASE
Furthermore	O
,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
nerves	O
,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5	B-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dihydroxytryptamine	I-CHEMICAL
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	O
responses	O
to	O
clonidine	B-CHEMICAL
The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
The	O
induced	O
hypotension	B-DISEASE
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity	O
,	O
whereas	O
the	O
induced	O
bradycardia	B-DISEASE
Hypertension	B-DISEASE
in	O
neuroblastoma	B-DISEASE
induced	O
by	O
imipramine	B-CHEMICAL
Hypertension	B-DISEASE
is	O
a	O
well	O
-	O
known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	B-DISEASE
However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	B-CHEMICAL
We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	B-DISEASE
(	O
blood	O
pressure	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
year	O
-	O
old	O
girl	O
with	O
neuroblastoma	B-DISEASE
who	O
was	O
given	O
Imipramine	B-CHEMICAL
It	O
was	O
determined	O
later	O
that	O
this	O
patient	O
'	O
s	O
tumor	B-DISEASE
was	O
recurring	O
at	B-DISEASE
the	O
time	O
of	O
her	O
hypertensive	B-DISEASE
Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	B-DISEASE
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	B-CHEMICAL
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
),	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	B-DISEASE
alone	O
caused	O
her	O
hypertension	B-DISEASE
The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	B-CHEMICAL
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	B-CHEMICAL
From	O
this	O
experience	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	B-CHEMICAL
in	O
children	O
with	O
active	O
neuroblastoma	B-DISEASE
Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	B-DISEASE
candidiasis	I-DISEASE
or	O
hoarseness	B-DISEASE
with	O
beclomethasone	B-CHEMICAL
Of	O
158	O
asthmatic	O
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	B-CHEMICAL
,	O
15	O
(	O
9	O
.	O
5	O
%)	O
developed	O
either	O
hoarseness	B-DISEASE
(	O
8	O
),	O
oral	B-DISEASE
thrush	I-DISEASE
When	O
their	O
adverse	O
reactions	O
subsided	O
,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	B-CHEMICAL
These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	B-DISEASE
and	O
three	O
who	O
developed	O
Candidiasis	B-DISEASE
Oral	B-DISEASE
thrush	I-DISEASE
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
patients	O
with	O
hoarseness	B-DISEASE
had	O
recurrence	B-DISEASE
We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	B-CHEMICAL
when	O
clinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	B-DISEASE
rate	O
,	O
patients	O
who	O
develop	O
hoarseness	B-DISEASE
Concomitant	O
use	O
of	O
oral	O
prednisone	B-CHEMICAL
and	O
topical	O
beclomethasone	B-CHEMICAL
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	B-DISEASE
or	O
candidiasis	B-DISEASE
Cyclophosphamide	B-CHEMICAL
cardiotoxicity	B-DISEASE
Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	B-CHEMICAL
At	B-DISEASE
these	O
high	O
doses	O
of	O
CYA	O
,	O
serious	O
cardiotoxicity	B-DISEASE
may	O
occur	O
,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	B-DISEASE
Since	O
chemotherapeutic	O
agent	O
toxicity	B-DISEASE
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	O
in	O
patients	O
transplanted	O
at	B-DISEASE
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	O
cardiotoxicity	B-DISEASE
Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	O
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	B-DISEASE
anemia	I-DISEASE
,	O
Wiskott	B-DISEASE
-	I-DISEASE
Aldrich	I-DISEASE
syndrome	I-DISEASE
,	O
or	O
severe	B-DISEASE
combined	I-DISEASE
immunodeficiency	I-DISEASE
syndrome	I-DISEASE
Fourteen	O
of	O
84	O
(	O
17	O
%)	O
patients	O
had	O
symptoms	B-DISEASE
and	I-DISEASE
signs	I-DISEASE
consistent	O
with	O
CYA	O
cardiotoxicity	B-DISEASE
within	O
ten	B-DISEASE
Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
Cardiotoxicity	B-DISEASE
Congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
caused	O
or	O
contributed	O
to	O
death	B-DISEASE
We	O
conclude	O
that	O
the	O
CYA	O
cardiotoxicity	B-DISEASE
correlates	O
with	O
CYA	O
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area	O
,	O
and	O
that	O
patients	O
with	O
aplastic	B-DISEASE
anemia	I-DISEASE
and	O
immunodeficiencies	O
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	B-DISEASE
a	O
CYA	O
dose	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	B-DISEASE
This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	B-DISEASE
Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	B-CHEMICAL
nephrotoxicity	B-DISEASE
The	O
epidemiology	O
of	O
aminoglycoside	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	B-CHEMICAL
Clinical	O
trials	O
of	O
aminoglycosides	B-CHEMICAL
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy	O
,	O
plasma	O
aminoglycoside	B-CHEMICAL
levels	O
,	O
liver	B-DISEASE
disease	I-DISEASE
,	O
advanced	O
age	O
,	O
high	O
initial	O
estimated	O
creatinine	B-CHEMICAL
clearance	O
and	O
,	O
possibly	O
,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	B-DISEASE
Other	O
causes	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
such	O
as	O
shock	B-DISEASE
Predictive	O
models	O
have	O
been	O
developed	O
from	O
these	O
analyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patients	O
at	B-DISEASE
These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
Flurothyl	B-CHEMICAL
seizure	B-DISEASE
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	O
glutamate	B-CHEMICAL
(	O
MSG	O
):	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	B-CHEMICAL
seizure	B-DISEASE
Monosodium	O
glutamate	B-CHEMICAL
(	O
MSG	O
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	B-DISEASE
These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	O
produced	O
permanent	O
alterations	O
in	O
seizure	B-DISEASE
A	O
flurothyl	B-CHEMICAL
ether	B-CHEMICAL
seizure	B-DISEASE
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	B-DISEASE
MSG	O
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	B-DISEASE
A	O
naloxone	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	B-DISEASE
Flurothyl	B-CHEMICAL
ether	B-CHEMICAL
produced	O
hypothermia	B-DISEASE
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	B-CHEMICAL
exposure	O
;	O
however	O
,	O
the	O
relationship	O
of	O
hypothermia	B-DISEASE
to	O
seizure	B-DISEASE
Flurothyl	B-CHEMICAL
seizure	B-DISEASE
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	B-DISEASE
Susceptibility	O
to	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	B-CHEMICAL
or	O
gamma	O
-	O
vinyl	O
-	O
GABA	B-CHEMICAL
Pilocarpine	B-CHEMICAL
,	O
given	O
intraperitoneally	O
to	O
rats	O
,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	B-DISEASE
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	B-DISEASE
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
)-	O
mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	B-CHEMICAL
,	O
150	O
micrograms	O
,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA	B-CHEMICAL
-	O
synthesizing	O
enzyme	O
,	O
L	O
-	O
glutamic	B-CHEMICAL
acid	I-CHEMICAL
decarboxylase	O
,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(	O
SNR	O
),	O
bilaterally	O
,	O
non	O
-	O
convulsant	O
doses	O
of	O
pilocarpine	B-CHEMICAL
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	B-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure	B-DISEASE
-	O
related	O
damage	O
to	O
the	O
hippocampal	O
formation	O
,	O
thalamus	O
,	O
amygdala	O
,	O
olfactory	O
cortex	O
,	O
substantia	O
nigra	O
and	O
neocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	B-CHEMICAL
Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	B-CHEMICAL
did	O
not	O
augment	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	B-CHEMICAL
transaminase	O
,	O
gamma	O
-	O
vinyl	O
-	O
GABA	B-CHEMICAL
(	O
D	O
,	O
L	O
-	O
4	O
-	O
amino	O
-	O
hex	O
-	O
5	O
-	O
enoic	O
acid	O
),	O
5	O
micrograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	B-DISEASE
damage	I-DISEASE
Microinjections	O
of	O
gamma	O
-	O
vinyl	O
-	O
GABA	B-CHEMICAL
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	B-DISEASE
produced	O
by	O
pilocarpine	B-CHEMICAL
The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA	B-CHEMICAL
Non	O
-	O
invasive	O
detection	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	B-CHEMICAL
Electrocardiographic	O
changes	O
after	O
dipyridamole	B-CHEMICAL
infusion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
Patients	O
were	O
divided	O
into	O
three	O
groups	O
;	O
19	O
patients	O
without	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
non	O
-	O
MI	O
group	O
),	O
14	O
with	O
anterior	O
infarction	B-DISEASE
(	O
ANT	O
-	O
MI	O
)	O
and	O
eight	O
with	O
inferior	O
infarction	B-DISEASE
After	O
dipyridamole	B-CHEMICAL
,	O
ischemic	O
ST	O
-	O
segment	O
depression	B-DISEASE
Exercise	O
-	O
induced	O
ST	O
depression	B-DISEASE
For	O
individual	O
patients	O
,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	B-DISEASE
The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	B-CHEMICAL
The	O
data	O
suggest	O
that	O
the	O
dipyridamole	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
We	O
conclude	O
that	O
the	O
dipyridamole	B-CHEMICAL
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
Bradycardia	B-DISEASE
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	B-CHEMICAL
In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
who	O
received	O
intravenous	O
high	O
-	O
dose	O
methylprednisolone	B-CHEMICAL
In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	B-DISEASE
Electrocardiographic	O
registrations	O
showed	O
sinus	B-DISEASE
bradycardia	I-DISEASE
No	O
significant	O
changes	O
in	O
plasma	O
concentrations	O
of	O
electrolytes	B-CHEMICAL
High	O
-	O
dose	O
MP	O
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	B-DISEASE
disease	I-DISEASE
Two	O
cases	O
of	O
downbeat	O
nystagmus	B-DISEASE
and	O
oscillopsia	O
associated	O
with	O
carbamazepine	B-CHEMICAL
Downbeat	O
nystagmus	B-DISEASE
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	B-DISEASE
We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	O
nystagmus	B-DISEASE
related	O
to	O
carbamazepine	B-CHEMICAL
The	O
nystagmus	B-DISEASE
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	B-CHEMICAL
In	O
patients	O
with	O
downbeat	O
nystagmus	B-DISEASE
Improvement	O
by	O
denopamine	B-CHEMICAL
(	O
TA	O
-	O
064	O
)	O
of	O
pentobarbital	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
failure	I-DISEASE
in	O
the	O
dog	O
heart	O
-	O
lung	B-DISEASE
The	O
efficacy	O
of	O
denopamine	B-CHEMICAL
,	O
an	O
orally	O
active	O
beta	O
1	O
-	O
adrenoceptor	O
agonist	O
,	O
in	O
improving	O
cardiac	B-DISEASE
failure	I-DISEASE
was	O
assessed	O
in	O
dog	O
heart	O
-	O
lung	B-DISEASE
Cardiac	O
functions	O
depressed	B-DISEASE
by	O
pentobarbital	B-CHEMICAL
(	O
118	O
+/-	O
28	O
mg	O
;	O
mean	O
value	O
+/-	O
SD	O
)	O
such	O
that	O
cardiac	B-DISEASE
output	I-DISEASE
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
reduced	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	B-CHEMICAL
With	O
100	O
micrograms	O
denopamine	B-CHEMICAL
No	O
arrhythmias	B-DISEASE
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	B-CHEMICAL
The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	B-CHEMICAL
in	O
the	O
treatment	O
of	O
cardiac	B-DISEASE
failure	I-DISEASE
Clonazepam	B-CHEMICAL
monotherapy	O
for	O
epilepsy	B-DISEASE
Sixty	O
patients	O
(	O
age	O
-	O
range	O
one	O
month	O
to	O
14	O
years	O
)	O
with	O
other	O
types	O
of	O
epilepsy	B-DISEASE
than	O
infantile	O
spasms	B-DISEASE
were	O
treated	O
with	O
clonazepam	B-CHEMICAL
Disappearance	O
of	O
seizures	B-DISEASE
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	B-DISEASE
Seizures	B-DISEASE
disappeared	O
in	O
71	O
%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	B-DISEASE
and	O
89	O
%	O
of	O
partial	O
seizures	B-DISEASE
The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	O
and	O
ataxia	B-DISEASE
Postmarketing	O
study	O
of	O
timolol	B-CHEMICAL
-	O
hydrochlorothiazide	B-CHEMICAL
A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed	O
-	O
ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	B-CHEMICAL
maleate	O
and	O
25	O
mg	O
of	O
hydrochlorothiazide	B-CHEMICAL
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	B-DISEASE
Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	B-CHEMICAL
-	O
hydrochlorothiazide	B-CHEMICAL
The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	B-DISEASE
Overall	O
,	O
1	O
,	O
453	O
patients	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
adverse	O
events	O
,	O
the	O
most	O
common	O
being	O
fatigue	B-DISEASE
,	O
dizziness	B-DISEASE
,	O
and	O
weakness	B-DISEASE
Salicylate	O
nephropathy	B-DISEASE
in	O
the	O
Gunn	O
rat	O
:	O
potential	O
role	O
of	O
prostaglandins	B-CHEMICAL
We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	B-CHEMICAL
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	B-DISEASE
The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	B-DISEASE
due	O
to	O
the	O
absence	O
of	O
glucuronyl	O
transferase	O
,	O
leading	O
to	O
marked	O
bilirubin	B-CHEMICAL
deposition	O
in	O
renal	B-DISEASE
These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	O
necrosis	B-DISEASE
Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	B-CHEMICAL
Aspirin	B-CHEMICAL
PGF2	O
alpha	O
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	B-CHEMICAL
The	O
changes	O
in	O
renal	B-DISEASE
prostaglandin	O
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	B-DISEASE
damage	I-DISEASE
in	O
aspirin	B-CHEMICAL
-	O
treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by	O
:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	B-DISEASE
(	O
p	O
less	O
than	O
0	O
.	O
01	O
);	O
increased	O
serum	O
creatinine	B-CHEMICAL
(	O
p	O
less	O
than	O
0	O
.	O
05	O
);	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
compared	O
to	O
either	O
sham	O
-	O
treated	O
jj	O
or	O
aspirin	B-CHEMICAL
These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	O
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	B-DISEASE
function	O
and	O
morphological	O
integrity	O
,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
may	O
lead	B-CHEMICAL
to	O
pathological	O
renal	B-DISEASE
medullary	O
lesions	O
and	O
deterioration	O
of	O
renal	B-DISEASE
Prophylactic	O
lidocaine	B-CHEMICAL
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	B-DISEASE
infarction	I-DISEASE
Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	B-DISEASE
infarction	I-DISEASE
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double	O
-	O
blind	O
randomized	O
trial	O
of	O
lidocaine	B-CHEMICAL
During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
or	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
among	O
the	O
204	O
patients	O
with	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
Lidocaine	B-CHEMICAL
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously	O
,	O
did	O
not	O
prevent	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	B-DISEASE
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	B-CHEMICAL
The	O
average	O
plasma	O
lidocaine	B-CHEMICAL
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	B-DISEASE
The	O
mean	O
plasma	O
lidocaine	B-CHEMICAL
During	O
the	O
1	O
-	O
hour	O
study	O
period	O
,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	B-CHEMICAL
group	O
,	O
hypotension	B-DISEASE
occurred	O
in	O
11	O
patients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	B-CHEMICAL
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	B-DISEASE
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	B-CHEMICAL
We	O
cannot	O
advocate	O
the	O
administration	O
of	O
lidocaine	B-CHEMICAL
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	B-DISEASE
infarction	I-DISEASE
Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	B-DISEASE
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	O
-	O
induced	O
catalepsy	B-DISEASE
Large	O
doses	O
of	O
the	O
cholinomimetic	O
,	O
pilocarpine	B-CHEMICAL
,	O
could	O
induce	O
catalepsy	B-DISEASE
Low	O
doses	O
of	O
pilocarpine	B-CHEMICAL
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	B-DISEASE
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker	O
,	O
haloperidol	B-CHEMICAL
A	O
muscarinic	O
receptor	O
blocker	O
,	O
atropine	B-CHEMICAL
,	O
disrupted	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
Intracranial	O
injection	O
of	O
an	O
acetylcholine	B-CHEMICAL
-	O
synthesis	O
inhibitor	O
,	O
hemicholinium	O
,	O
prevented	O
the	O
catalepsy	B-DISEASE
that	O
is	O
usually	O
induced	O
by	O
haloperidol	B-CHEMICAL
These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	B-DISEASE
that	O
is	O
produced	O
by	O
neuroleptics	B-CHEMICAL
such	O
as	O
haloperidol	B-CHEMICAL
Alternatively	O
,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	B-DISEASE
Cardiovascular	O
dysfunction	O
and	O
hypersensitivity	B-DISEASE
to	O
sodium	B-CHEMICAL
pentobarbital	B-CHEMICAL
induced	O
by	O
chronic	O
barium	B-CHEMICAL
chloride	I-CHEMICAL
Barium	B-CHEMICAL
-	O
supplemented	O
Long	O
-	O
Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	B-DISEASE
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	B-CHEMICAL
(	O
100	O
micrograms	O
/	O
ml	O
mineral	O
fortified	O
water	B-CHEMICAL
Analysis	O
of	O
in	O
vivo	O
myocardial	O
excitability	O
,	O
contractility	O
,	O
and	O
metabolic	O
characteristics	O
at	B-DISEASE
16	O
months	O
revealed	O
other	O
significant	O
barium	B-CHEMICAL
The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	B-CHEMICAL
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	B-DISEASE
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-CHEMICAL
pentobarbital	B-CHEMICAL
Under	O
barbiturate	O
anesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	B-DISEASE
significantly	O
in	O
barium	B-CHEMICAL
The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	B-CHEMICAL
and	O
xylazine	B-CHEMICAL
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	B-CHEMICAL
pentobarbital	B-CHEMICAL
in	O
barium	B-CHEMICAL
Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	B-CHEMICAL
The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium	B-CHEMICAL
Similarly	O
,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	B-DISEASE
were	O
detected	O
in	O
the	O
barium	B-CHEMICAL
In	O
addition	O
,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	B-DISEASE
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium	B-CHEMICAL
Overall	O
,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics	O
,	O
the	O
myocardial	O
metabolic	O
disturbances	O
,	O
and	O
the	O
hypersensitivity	B-DISEASE
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-CHEMICAL
pentobarbital	B-CHEMICAL
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	O
disorder	O
induced	O
by	O
chronic	O
barium	B-CHEMICAL
These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life	O
-	O
long	O
barium	B-CHEMICAL
Propranolol	B-CHEMICAL
antagonism	O
of	O
phenylpropanolamine	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
Phenylpropanolamine	B-CHEMICAL
(	O
PPA	B-CHEMICAL
)	O
overdose	B-DISEASE
can	O
cause	O
severe	O
hypertension	B-DISEASE
,	O
intracerebral	B-DISEASE
hemorrhage	I-DISEASE
,	O
and	O
death	B-DISEASE
We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	B-CHEMICAL
in	O
the	O
treatment	O
of	O
PPA	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
Subjects	O
received	O
propranolol	B-CHEMICAL
either	O
by	O
mouth	B-DISEASE
for	O
48	O
hours	O
before	O
PPA	B-CHEMICAL
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	B-CHEMICAL
PPA	B-CHEMICAL
,	O
75	O
mg	O
alone	O
,	O
increased	O
blood	O
pressure	O
(	O
31	O
+/-	O
14	O
mm	O
Hg	O
systolic	O
,	O
20	O
+/-	O
5	O
mm	O
Hg	O
diastolic	O
),	O
and	O
propranolol	B-CHEMICAL
Intravenous	O
propranolol	B-CHEMICAL
after	O
PPA	B-CHEMICAL
Left	O
ventricular	O
function	O
(	O
assessed	O
by	O
echocardiography	O
)	O
showed	O
that	O
PPA	B-CHEMICAL
increased	O
the	O
stroke	B-DISEASE
volume	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+/-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+/-	O
22	O
.	O
4	O
ml	O
),	O
the	O
ejection	O
fraction	O
9	O
%	O
(	O
from	O
64	O
%	O
+/-	O
10	O
%	O
to	O
70	O
%	O
+/-	O
7	O
%),	O
and	O
cardiac	B-DISEASE
output	I-DISEASE
Intravenous	O
propranolol	B-CHEMICAL
Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	B-CHEMICAL
28	O
%	O
(	O
from	O
1710	O
+/-	O
200	O
to	O
2190	O
+/-	O
700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	B-CHEMICAL
We	O
conclude	O
that	O
PPA	B-CHEMICAL
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	B-DISEASE
output	I-DISEASE
,	O
and	O
that	O
propranolol	B-CHEMICAL
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	B-CHEMICAL
on	O
cardiac	B-DISEASE
output	I-DISEASE
That	O
propranolol	B-CHEMICAL
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	B-CHEMICAL
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	B-CHEMICAL
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	B-CHEMICAL
This	O
is	O
probably	O
because	O
PPA	B-CHEMICAL
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	B-CHEMICAL
Mesangial	O
function	O
and	O
glomerular	B-DISEASE
sclerosis	I-DISEASE
in	O
rats	O
with	O
aminonucleoside	B-CHEMICAL
nephrosis	B-DISEASE
The	O
possible	O
relationship	O
between	O
mesangial	O
dysfunction	O
and	O
development	O
of	O
glomerular	B-DISEASE
sclerosis	I-DISEASE
was	O
studied	O
in	O
the	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
PAN	B-CHEMICAL
Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	B-CHEMICAL
After	O
4	O
weeks	O
the	O
PAN	B-CHEMICAL
rats	O
were	O
severely	O
proteinuric	O
(	O
190	O
+/-	O
80	O
mg	O
/	O
24	O
hr	O
),	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	B-CHEMICAL
(	O
CC	B-CHEMICAL
At	B-DISEASE
5	O
months	O
glomerular	B-DISEASE
sclerosis	I-DISEASE
was	O
found	O
in	O
7	O
.	O
6	O
+/-	O
3	O
.	O
4	O
%	O
of	O
the	O
glomeruli	O
of	O
PAN	B-CHEMICAL
Glomeruli	O
of	O
PAN	B-CHEMICAL
rats	O
contained	O
significantly	O
more	O
CC	B-CHEMICAL
Glomeruli	O
with	O
sclerosis	B-DISEASE
contained	O
significantly	O
more	O
CC	B-CHEMICAL
CC	B-CHEMICAL
Since	O
mesangial	O
CC	B-CHEMICAL
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	B-CHEMICAL
treatment	O
,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	B-CHEMICAL
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	B-CHEMICAL
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	B-DISEASE
Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	B-CHEMICAL
Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	B-CHEMICAL
nephrosis	B-DISEASE
the	O
development	O
of	O
glomerular	B-DISEASE
sclerosis	I-DISEASE
Relationship	O
between	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design	O
,	O
a	O
relationship	O
between	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	B-CHEMICAL
had	O
greater	O
alpha	O
-	O
bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	B-DISEASE
The	O
binding	O
sites	O
from	O
seizure	B-DISEASE
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	B-CHEMICAL
Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	B-DISEASE
The	O
role	O
of	O
p	O
-	O
aminophenol	O
in	O
acetaminophen	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
:	O
effect	O
of	O
bis	O
(	O
p	O
-	O
nitrophenyl	O
)	O
phosphate	B-CHEMICAL
on	O
acetaminophen	B-CHEMICAL
and	O
p	O
-	O
aminophenol	O
nephrotoxicity	B-DISEASE
and	O
metabolism	B-DISEASE
Acetaminophen	B-CHEMICAL
(	O
APAP	O
)	O
produces	O
proximal	O
tubular	B-DISEASE
necrosis	I-DISEASE
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	O
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	O
-	O
induced	O
nephrotoxicity	B-DISEASE
Therefore	O
,	O
the	O
effect	O
of	O
bis	O
(	O
p	O
-	O
nitrophenyl	O
)	O
phosphate	B-CHEMICAL
(	O
BNPP	O
),	O
an	O
acylamidase	O
inhibitor	O
,	O
on	O
APAP	O
and	O
PAP	O
nephrotoxicity	B-DISEASE
and	O
metabolism	B-DISEASE
BNPP	O
(	O
1	O
to	O
8	O
mM	O
)	O
reduced	O
APAP	O
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	B-DISEASE
Pretreatment	O
of	O
animals	O
with	O
BNPP	O
prior	O
to	O
APAP	O
or	O
PAP	O
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	O
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxicity	B-DISEASE
but	O
not	O
PAP	O
nephrotoxicity	B-DISEASE
This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	O
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	B-DISEASE
Therefore	O
,	O
the	O
BNPP	O
-	O
induced	O
reduction	O
in	O
APAP	O
-	O
induced	O
nephrotoxicity	B-DISEASE
It	O
is	O
concluded	O
that	O
PAP	O
formation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	B-DISEASE
least	O
in	O
part	O
,	O
for	O
APAP	O
-	O
induced	O
renal	B-DISEASE
tubular	B-DISEASE
necrosis	I-DISEASE
Morphine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	B-DISEASE
during	O
the	O
course	O
of	O
intravenous	O
morphine	B-CHEMICAL
They	O
received	O
morphine	B-CHEMICAL
in	O
doses	O
of	O
32	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micrograms	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6	O
-	O
24	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizures	B-DISEASE
Plasma	O
concentrations	O
of	O
morphine	B-CHEMICAL
Other	O
known	O
reasons	O
for	O
seizures	B-DISEASE
were	O
ruled	O
out	O
and	O
the	O
convulsions	B-DISEASE
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	B-CHEMICAL
It	O
is	O
suggested	O
that	O
post	O
-	O
operative	O
intravenous	O
morphine	B-CHEMICAL
Effect	O
of	O
vincristine	B-CHEMICAL
sulfate	O
on	O
Pseudomonas	B-DISEASE
infections	I-DISEASE
Leukocytosis	B-DISEASE
Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vincristine	B-CHEMICAL
sulfate	O
was	O
followed	O
by	O
leukopenia	B-DISEASE
Intravenous	O
inoculation	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
pyocin	O
type	O
6	O
Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	B-CHEMICAL
sulfate	O
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	B-DISEASE
These	O
studies	O
suggest	O
that	O
an	O
antimetabolite	O
-	O
induced	O
leukopenia	B-DISEASE
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	B-DISEASE
Central	O
excitatory	O
actions	O
of	O
flurazepam	B-CHEMICAL
Toxic	B-CHEMICAL
actions	I-CHEMICAL
of	O
flurazepam	B-CHEMICAL
High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	B-DISEASE
,	O
superimposed	O
on	O
general	O
depression	B-DISEASE
Following	O
a	O
lethal	O
dose	O
,	O
death	B-DISEASE
was	O
always	O
associated	O
with	O
convulsions	B-DISEASE
Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	B-DISEASE
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	B-DISEASE
at	B-DISEASE
Signs	O
of	O
FZP	O
toxocity	O
in	O
cats	O
included	O
excessive	O
salivation	O
,	O
extreme	O
apprehensive	O
behavior	O
,	O
retching	O
,	O
muscle	O
tremors	B-DISEASE
and	O
convulsions	B-DISEASE
An	O
interaction	O
between	O
FZP	O
and	O
pentylenetetrazol	O
(	O
PTZ	B-CHEMICAL
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	O
before	O
PTZ	B-CHEMICAL
As	O
a	O
function	O
of	O
dose	O
,	O
FZP	O
first	O
protected	O
against	O
convulsions	B-DISEASE
and	O
death	B-DISEASE
At	B-DISEASE
higher	O
doses	O
,	O
however	O
,	O
convulsions	B-DISEASE
These	O
doses	O
of	O
FZP	O
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	B-DISEASE
These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	O
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability	O
,	O
such	O
as	O
epilepsy	B-DISEASE
We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	B-CHEMICAL
(	O
cardioselective	O
),	O
40	O
mg	O
propranolol	B-CHEMICAL
(	O
nonselective	O
),	O
and	O
placebo	O
on	O
both	O
exercise	O
-	O
and	O
isoproterenol	B-CHEMICAL
-	O
induced	O
tachycardia	B-DISEASE
Maximal	O
exercise	O
heart	O
rate	O
was	O
reduced	O
from	O
187	O
+/-	O
4	O
(	O
SEM	O
)	O
after	O
placebo	O
to	O
146	O
+/-	O
7	O
bpm	O
after	O
atenolol	B-CHEMICAL
and	O
138	O
+/-	O
6	O
bpm	O
after	O
propranolol	B-CHEMICAL
The	O
effects	O
on	O
isoproterenol	B-CHEMICAL
tachycardia	B-DISEASE
were	O
determined	O
before	O
and	O
after	O
atropine	B-CHEMICAL
Isoproterenol	B-CHEMICAL
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
increased	O
from	O
1	O
.	O
8	O
+/-	O
0	O
.	O
3	O
micrograms	O
after	O
placebo	O
to	O
38	O
.	O
9	O
+/-	O
8	O
.	O
3	O
micrograms	O
after	O
propranolol	B-CHEMICAL
and	O
8	O
.	O
3	O
+/-	O
1	O
.	O
7	O
micrograms	O
after	O
atenolol	B-CHEMICAL
After	O
atropine	B-CHEMICAL
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(	O
2	O
.	O
3	O
+/-	O
0	O
.	O
3	O
micrograms	O
)	O
and	O
atenolol	B-CHEMICAL
(	O
7	O
.	O
7	O
+/-	O
1	O
.	O
3	O
micrograms	O
);	O
it	O
was	O
reduced	O
after	O
propranolol	B-CHEMICAL
(	O
24	O
.	O
8	O
+/-	O
5	O
.	O
0	O
micrograms	O
),	O
but	O
remained	O
different	O
from	O
atenolol	B-CHEMICAL
This	O
change	O
with	O
propranolol	B-CHEMICAL
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka	O
,	O
this	O
was	O
unchanged	O
by	O
atropine	B-CHEMICAL
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise	O
-	O
induced	O
tachycardia	B-DISEASE
results	O
largely	O
from	O
beta	O
1	O
-	O
receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	B-CHEMICAL
Hormones	B-CHEMICAL
and	O
risk	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
The	O
majority	O
(	O
29	O
)	O
had	O
surgical	O
menopause	B-DISEASE
It	O
was	O
hypothesized	O
that	O
progestins	B-CHEMICAL
The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	O
estrogens	B-CHEMICAL
(	O
Premarin	O
)	O
1	O
.	O
25	O
mg	O
/	O
day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	B-CHEMICAL
acetate	I-CHEMICAL
Mastodynia	B-DISEASE
Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	B-DISEASE
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	B-DISEASE
Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	B-CHEMICAL
Early	O
infections	B-DISEASE
in	O
kidney	O
,	O
heart	O
,	O
and	O
liver	B-DISEASE
transplant	O
recipients	O
on	O
cyclosporine	B-CHEMICAL
Eighty	O
-	O
one	O
renal	B-DISEASE
,	O
seventeen	O
heart	O
,	O
and	O
twenty	O
-	O
four	O
liver	B-DISEASE
transplant	O
patients	O
were	O
followed	O
for	O
infection	B-DISEASE
Seventeen	O
renal	B-DISEASE
patients	O
received	O
azathioprine	B-CHEMICAL
(	O
Aza	O
)	O
and	O
prednisone	B-CHEMICAL
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine	B-CHEMICAL
-	O
and	O
-	O
prednisone	B-CHEMICAL
-	O
treated	O
renal	B-DISEASE
All	O
others	O
received	O
cyclosporine	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
The	O
randomized	O
Aza	O
patients	O
had	O
more	O
overall	O
infections	B-DISEASE
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nonviral	O
infections	B-DISEASE
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
randomized	O
cyclosporine	B-CHEMICAL
Heart	O
and	O
liver	B-DISEASE
patients	O
had	O
more	O
infections	B-DISEASE
than	O
cyclosporine	B-CHEMICAL
renal	B-DISEASE
patients	O
but	O
fewer	O
infections	B-DISEASE
than	O
the	O
Aza	O
renal	B-DISEASE
There	O
were	O
no	O
infectious	O
deaths	B-DISEASE
in	O
renal	B-DISEASE
transplant	O
patients	O
on	O
cyclosporine	B-CHEMICAL
or	O
Aza	O
,	O
but	O
infection	B-DISEASE
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	B-DISEASE
and	O
in	O
8	O
out	O
of	O
9	O
liver	B-DISEASE
transplant	O
deaths	B-DISEASE
Renal	B-DISEASE
patients	O
on	O
cyclosporine	B-CHEMICAL
Analysis	O
of	O
site	O
of	O
infection	B-DISEASE
showed	O
a	O
preponderance	O
of	O
abdominal	O
infections	B-DISEASE
in	O
liver	B-DISEASE
patients	O
,	O
intrathoracic	O
infections	B-DISEASE
in	O
heart	O
patients	O
,	O
and	O
urinary	B-DISEASE
tract	I-DISEASE
infections	I-DISEASE
in	O
renal	B-DISEASE
Pulmonary	O
infections	B-DISEASE
were	O
less	O
common	O
in	O
cyclosporine	B-CHEMICAL
-	O
treated	O
renal	B-DISEASE
Aza	O
patients	O
had	O
significantly	O
more	O
staphylococcal	B-DISEASE
infections	I-DISEASE
than	O
all	O
other	O
transplant	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
),	O
and	O
systemic	O
fungal	O
infections	B-DISEASE
occurred	O
only	O
in	O
the	O
liver	B-DISEASE
Cytomegalovirus	O
(	O
CMV	O
)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cyclosporine	B-CHEMICAL
Of	O
the	O
cyclosporine	B-CHEMICAL
patients	O
,	O
15	O
%	O
had	O
symptoms	O
related	O
to	O
CMV	O
infection	B-DISEASE
Serological	O
evidence	O
for	O
Epstein	O
Barr	O
Virus	O
infection	B-DISEASE
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporine	B-CHEMICAL
Three	O
had	O
associated	O
symptoms	O
,	O
and	O
one	O
developed	O
a	O
lymphoma	B-DISEASE
Structure	O
-	O
activity	O
and	O
dose	O
-	O
effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
by	O
cholecystokinin	B-CHEMICAL
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	B-CHEMICAL
Intraperitoneal	O
administration	O
of	O
cholecystokinin	B-CHEMICAL
octapeptide	O
sulphate	O
ester	O
(	O
CCK	O
-	O
8	O
-	O
SE	B-DISEASE
)	O
and	O
nonsulphated	O
cholecystokinin	B-CHEMICAL
octapeptide	O
(	O
CCK	O
-	O
8	O
-	O
NS	O
)	O
enhanced	O
the	O
latency	O
of	O
seizures	B-DISEASE
induced	O
by	O
picrotoxin	B-CHEMICAL
The	O
analogues	O
CCK	O
-	O
8	O
-	O
SE	B-DISEASE
The	O
peptide	O
CCK	O
-	O
5	O
-	O
8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides	O
,	O
3	O
.	O
2	O
mumol	O
/	O
kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug	O
,	O
diazepam	B-CHEMICAL
,	O
totally	O
prevented	O
picrotoxin	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
The	O
maximum	O
effect	O
of	O
the	O
peptides	B-CHEMICAL
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	B-CHEMICAL
Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta	O
-	O
alanyl	O
derivatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK	O
-	O
8	O
-	O
SE	B-DISEASE
Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
analogues	O
,	O
Ser	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	B-DISEASE
and	O
Thr	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	B-DISEASE
and	O
Hyp	O
(	O
SO3H	O
)-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	B-DISEASE
were	O
slightly	O
more	O
active	O
than	O
CCK	O
-	O
8	O
-	O
SE	B-DISEASE
Vasopressin	B-CHEMICAL
as	O
a	O
possible	O
contributor	O
to	O
hypertension	B-DISEASE
The	O
role	O
of	O
vasopressin	B-CHEMICAL
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	B-DISEASE
Vasopressin	B-CHEMICAL
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA	O
-	O
salt	B-CHEMICAL
hypertension	B-DISEASE
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium	B-CHEMICAL
-	O
treated	O
diabetes	B-DISEASE
insipidus	I-DISEASE
after	O
DOCA	O
-	O
salt	B-CHEMICAL
Administration	O
of	O
DDAVP	O
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	B-CHEMICAL
Furthermore	O
,	O
the	O
pressor	O
action	O
of	O
vasopressin	B-CHEMICAL
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	B-DISEASE
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	B-DISEASE
Increased	O
secretion	O
of	O
vasopressin	B-CHEMICAL
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	B-DISEASE
An	O
unproportional	O
release	O
of	O
vasopressin	B-CHEMICAL
compared	O
to	O
plasma	O
osmolality	O
may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	B-CHEMICAL
However	O
,	O
the	O
role	O
of	O
vasopressin	B-CHEMICAL
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	B-DISEASE
hypertension	I-DISEASE
Toxic	B-DISEASE
hepatitis	I-DISEASE
induced	O
by	O
disulfiram	B-CHEMICAL
A	O
reversible	O
toxic	O
liver	B-DISEASE
damage	I-DISEASE
was	O
observed	O
in	O
a	O
non	O
-	O
alcoholic	O
woman	O
treated	O
with	O
disulfiram	B-CHEMICAL
Atrial	O
thrombosis	B-DISEASE
involving	O
the	O
heart	O
of	O
F	O
-	O
344	O
rats	O
ingesting	O
quinacrine	B-CHEMICAL
Quinacrine	B-CHEMICAL
Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	B-CHEMICAL
hydrochloride	O
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	O
thrombosis	B-DISEASE
The	O
lesion	O
was	O
associated	O
with	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
and	O
dilatation	B-DISEASE
Rats	O
died	O
from	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs	O
,	O
liver	B-DISEASE
Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	B-CHEMICAL
hydrochloride	O
and	O
1	O
,	O
000	O
ppm	O
sodium	B-CHEMICAL
nitrite	I-CHEMICAL
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	B-DISEASE
of	O
the	O
atria	O
of	O
the	O
heart	O
,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	O
thrombosis	B-DISEASE
Sodium	B-CHEMICAL
nitrite	I-CHEMICAL
in	O
combination	O
with	O
quinacrine	B-CHEMICAL
Alternating	O
sinus	O
rhythm	O
and	O
intermittent	O
sinoatrial	B-DISEASE
block	I-DISEASE
induced	O
by	O
propranolol	B-CHEMICAL
Alternating	O
sinus	O
rhythm	O
and	O
intermittent	O
sinoatrial	O
(	O
S	O
-	O
A	O
)	O
block	O
was	O
observed	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	B-DISEASE
with	O
80	O
mg	O
propranolol	B-CHEMICAL
Atropine	B-CHEMICAL
The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	B-CHEMICAL
This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	B-CHEMICAL
Antitumor	O
effect	O
,	O
cardiotoxicity	B-DISEASE
,	O
and	O
nephrotoxicity	B-DISEASE
of	O
doxorubicin	B-CHEMICAL
Antitumor	O
activity	O
,	O
cardiotoxicity	B-DISEASE
,	O
and	O
nephrotoxicity	B-DISEASE
induced	O
by	O
doxorubicin	B-CHEMICAL
Animals	O
with	O
a	O
tumor	B-DISEASE
(	O
diameter	O
,	O
15	O
.	O
8	O
+/-	O
3	O
.	O
3	O
mm	O
)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	B-CHEMICAL
Tumor	B-DISEASE
regression	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
doxorubicin	B-CHEMICAL
Complete	O
disappearance	O
of	O
the	O
tumor	B-DISEASE
was	O
induced	O
with	O
1	O
.	O
0	O
mg	O
doxorubicin	B-CHEMICAL
Histologic	O
evidence	O
of	O
cardiotoxicity	B-DISEASE
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	B-DISEASE
a	O
dose	O
of	O
1	O
.	O
0	O
mg	O
doxorubicin	B-CHEMICAL
Light	O
microscopic	O
evidence	O
of	O
renal	B-DISEASE
damage	I-DISEASE
was	O
seen	O
above	O
a	O
dose	O
of	O
0	O
.	O
5	O
mg	O
doxorubicin	B-CHEMICAL
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuria	B-DISEASE
and	O
very	O
low	O
serum	B-CHEMICAL
albumin	I-CHEMICAL
In	O
the	O
group	O
that	O
received	O
1	O
.	O
0	O
mg	O
doxorubicin	B-CHEMICAL
/	O
kg	O
,	O
the	O
serum	B-CHEMICAL
albumin	I-CHEMICAL
Ascites	B-DISEASE
and	O
hydrothorax	B-DISEASE
The	O
same	O
experiments	O
were	O
performed	O
with	O
non	O
-	O
tumor	B-DISEASE
In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	B-DISEASE
,	O
and	O
nephrotoxicity	B-DISEASE
Albuminuria	B-DISEASE
due	O
to	O
renal	B-DISEASE
damage	I-DISEASE
led	O
to	O
extremely	O
low	O
serum	B-CHEMICAL
albumin	I-CHEMICAL
levels	O
,	O
so	O
ascites	B-DISEASE
and	O
hydrothorax	B-DISEASE
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	B-DISEASE
Intraoperative	O
bradycardia	B-DISEASE
and	O
hypotension	B-DISEASE
associated	O
with	O
timolol	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
A	O
69	O
-	O
yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	B-CHEMICAL
nitrate	O
and	O
timolol	B-CHEMICAL
maleate	O
eye	O
drops	O
,	O
developed	O
a	O
bradycardia	B-DISEASE
and	O
became	O
hypotensive	B-DISEASE
during	O
halothane	B-CHEMICAL
Both	O
timolol	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
were	O
subsequently	O
identified	O
in	O
a	O
24	O
-	O
h	B-CHEMICAL
collection	O
of	O
urine	B-DISEASE
Timolol	B-CHEMICAL
(	O
but	O
not	O
pilocarpine	B-CHEMICAL
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery	O
;	O
the	O
plasma	O
concentration	O
of	O
timolol	B-CHEMICAL
It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	B-CHEMICAL
anaesthesia	O
with	O
resultant	O
bradycardia	B-DISEASE
and	O
hypotension	B-DISEASE
Pilocarpine	B-CHEMICAL
Succinylcholine	B-CHEMICAL
apnoea	B-DISEASE
:	O
attempted	O
reversal	O
with	O
anticholinesterases	B-CHEMICAL
Anticholinesterases	B-CHEMICAL
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	O
blockade	O
following	O
the	O
administration	O
of	O
succinylcholine	B-CHEMICAL
Edrophonium	B-CHEMICAL
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcholine	B-CHEMICAL
Repeated	O
doses	O
of	O
edrophonium	B-CHEMICAL
to	O
70	O
mg	O
and	O
neostigmine	B-CHEMICAL
Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	B-CHEMICAL
It	O
is	O
concluded	O
that	O
anticholinesterases	B-CHEMICAL
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	B-CHEMICAL
apnoea	B-DISEASE
Effect	O
of	O
doxorubicin	B-CHEMICAL
The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	B-CHEMICAL
Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin	B-CHEMICAL
A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	B-DISEASE
a	O
cumulative	O
doxorubicin	B-CHEMICAL
A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1	O
/	O
2	O
of	O
the	O
I	O
-	O
131	O
HA	O
was	O
observed	O
only	O
at	B-DISEASE
No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	B-CHEMICAL
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	B-CHEMICAL
Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I	O
-	O
131	O
HA	O
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	B-CHEMICAL
cardiotoxicity	B-DISEASE
Hemodynamics	O
and	O
myocardial	O
metabolism	B-DISEASE
under	O
deliberate	O
hypotension	B-DISEASE
Coronary	O
blood	O
flow	O
,	O
cardiac	O
work	O
and	O
metabolism	B-DISEASE
were	O
studied	O
in	O
dogs	O
under	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP	B-CHEMICAL
)	O
and	O
trimetaphan	O
(	O
TMP	B-CHEMICAL
)	O
deliberate	O
hypotension	B-DISEASE
Regarding	O
the	O
effects	O
of	O
drug	O
-	O
induced	O
hypotension	B-DISEASE
on	O
coronary	O
blood	O
flow	O
,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusside	B-CHEMICAL
hypotension	B-DISEASE
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control	O
,	O
trimetaphan	O
hypotension	B-DISEASE
Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	B-CHEMICAL
hypotension	B-DISEASE
Careful	O
invasive	O
monitoring	O
of	O
the	O
blood	O
pressure	O
,	O
blood	O
gases	B-CHEMICAL
Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	B-CHEMICAL
Male	O
rats	O
received	O
the	O
noradrenaline	B-CHEMICAL
neurotoxin	O
DSP4	O
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D	O
-	O
amphetamine	B-CHEMICAL
The	O
hyperactivity	B-DISEASE
induced	O
by	O
D	O
-	O
amphetamine	B-CHEMICAL
However	O
,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine	B-CHEMICAL
The	O
reduction	O
of	O
amphetamine	B-CHEMICAL
hyperactivity	B-DISEASE
induced	O
by	O
DSP4	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline	B-CHEMICAL
-	O
uptake	O
blocking	O
agent	O
,	O
desipramine	B-CHEMICAL
,	O
which	O
prevents	O
the	O
neurotoxic	B-DISEASE
The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	B-CHEMICAL
Accelerated	O
junctional	O
rhythms	O
during	O
oral	O
verapamil	B-CHEMICAL
This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	O
junctional	O
rhythms	O
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	B-CHEMICAL
Verapamil	B-CHEMICAL
In	O
patients	O
with	O
various	O
chest	B-DISEASE
pain	I-DISEASE
syndromes	O
,	O
verapamil	B-CHEMICAL
Treatment	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
with	O
a	O
combination	O
of	O
cis	O
-	O
platinum	B-CHEMICAL
,	O
adriamycin	B-CHEMICAL
,	O
cyclophosphamide	B-CHEMICAL
During	O
the	O
last	O
2	O
1	O
/	O
2	O
years	O
,	O
38	O
patients	O
with	O
ovarian	B-DISEASE
cancer	I-DISEASE
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	O
(	O
CPDD	O
),	O
50	O
mg	O
/	O
m2	O
,	O
adriamycin	B-CHEMICAL
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphamide	B-CHEMICAL
2	O
patients	O
had	O
stage	O
II	O
,	O
14	O
stage	O
III	O
and	O
22	O
stage	O
IV	O
disease	B-DISEASE
Hematologic	O
toxicity	B-DISEASE
was	O
moderate	O
and	O
with	O
reversible	O
anemia	B-DISEASE
HMM	O
gastrointestinal	O
toxicity	B-DISEASE
Severe	O
nephrotoxicity	B-DISEASE
There	O
were	O
no	O
drug	O
-	O
related	O
deaths	B-DISEASE
Nontraumatic	O
dissecting	B-DISEASE
aneurysm	I-DISEASE
A	O
case	O
of	O
nontraumatic	O
dissecting	B-DISEASE
aneurysm	I-DISEASE
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	B-DISEASE
,	O
smoke	B-CHEMICAL
,	O
and	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked	B-DISEASE
-	I-DISEASE
in	I-DISEASE
syndrome	I-DISEASE
Propylthiouracil	B-CHEMICAL
-	O
induced	O
hepatic	B-DISEASE
damage	I-DISEASE
Two	O
cases	O
of	O
propylthiouracil	B-CHEMICAL
-	O
induced	O
liver	B-DISEASE
damage	I-DISEASE
The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	O
active	O
hepatitis	B-DISEASE
,	O
with	O
spontaneous	O
remission	B-DISEASE
Studies	O
on	O
the	O
bradycardia	B-DISEASE
induced	O
by	O
bepridil	B-CHEMICAL
Bepridil	B-CHEMICAL
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	O
attacks	O
,	O
induced	O
persistent	O
bradycardia	B-DISEASE
In	O
vitro	O
perfusion	O
of	O
bepridil	B-CHEMICAL
in	O
the	O
life	O
-	O
support	O
medium	O
for	O
isolated	O
sino	O
-	O
atrial	O
tissue	O
from	O
rabbit	O
heart	O
,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(	O
AP	O
)	O
spike	O
frequency	O
(	O
recorded	O
by	O
KCl	O
microelectrodes	O
)	O
starting	O
at	B-DISEASE
Bepridil	B-CHEMICAL
at	B-DISEASE
In	O
vivo	O
injection	O
of	O
bepridil	B-CHEMICAL
at	B-DISEASE
It	O
is	O
concluded	O
that	O
bepridil	B-CHEMICAL
This	O
effect	O
,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
duration	O
,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
),	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	B-CHEMICAL
Hepatitis	B-DISEASE
and	O
renal	B-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
after	O
anesthesia	O
with	O
methoxyflurane	B-CHEMICAL
A	O
69	O
-	O
year	O
-	O
old	O
man	O
operated	O
for	O
acute	O
cholecystitis	B-DISEASE
under	O
methoxyflurane	B-CHEMICAL
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	B-DISEASE
insufficiency	I-DISEASE
syndrome	B-DISEASE
and	O
renal	B-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
Massive	O
bleeding	B-DISEASE
Pituitary	O
response	O
to	O
luteinizing	B-CHEMICAL
hormone	I-CHEMICAL
-	O
releasing	O
hormone	O
during	O
haloperidol	B-CHEMICAL
-	O
induced	O
hyperprolactinemia	B-DISEASE
The	O
effects	O
of	O
a	O
6	O
-	O
hour	O
infusion	O
with	O
haloperidol	B-CHEMICAL
on	O
serum	O
prolactin	B-CHEMICAL
and	O
luteinizing	B-CHEMICAL
hormone	I-CHEMICAL
Control	O
patients	O
received	O
infusions	O
of	O
0	O
.	O
9	O
%	O
NaCl	B-CHEMICAL
During	O
the	O
course	O
of	O
haloperidol	B-CHEMICAL
infusions	O
,	O
significant	O
hyperprolactinemia	B-DISEASE
Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin	O
-	O
associated	O
renal	B-DISEASE
failure	I-DISEASE
5	O
patients	O
with	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
3	O
with	O
thrombopenia	O
and	O
hemolysis	B-DISEASE
The	O
pattern	O
of	O
non	O
-	O
specific	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
Cardiovascular	O
effects	O
of	O
hypotension	B-DISEASE
induced	O
by	O
adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
and	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
Adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
(	O
ATP	B-CHEMICAL
)	O
and	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP	B-CHEMICAL
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	B-DISEASE
SNP	B-CHEMICAL
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	B-CHEMICAL
ATP	B-CHEMICAL
(	O
10	O
dogs	O
)	O
or	O
SNP	B-CHEMICAL
Before	O
,	O
during	O
and	O
after	O
induced	O
hypotension	B-DISEASE
Hypotension	B-DISEASE
induced	O
by	O
ATP	B-CHEMICAL
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
total	O
body	O
oxygen	B-CHEMICAL
consumption	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
),	O
and	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
);	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	B-CHEMICAL
Cardiac	B-DISEASE
output	I-DISEASE
During	O
hypotension	B-DISEASE
produced	O
by	O
SNP	B-CHEMICAL
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
),	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
),	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
),	O
and	O
oxygen	B-CHEMICAL
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
),	O
while	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
cardiac	B-DISEASE
output	I-DISEASE
Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	B-CHEMICAL
Both	O
ATP	B-CHEMICAL
and	O
SNP	B-CHEMICAL
Comparative	O
study	O
:	O
Endografine	O
(	O
diatrizoate	B-CHEMICAL
The	O
Dimer	O
-	O
X	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	B-DISEASE
and	O
dizziness	B-DISEASE
The	O
Endografine	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	B-DISEASE
pain	I-DISEASE
Hexabrix	O
and	O
Vasurix	O
polyvidone	O
are	O
considered	O
the	O
best	O
contrast	B-CHEMICAL
media	I-CHEMICAL
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	B-DISEASE
Post	O
-	O
suxamethonium	B-CHEMICAL
Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon	O
,	O
scoline	O
pain	B-DISEASE
About	O
62	O
%	O
of	O
the	O
out	O
-	O
patients	O
developed	O
scoline	O
pain	B-DISEASE
The	O
abolition	O
of	O
muscle	O
fasciculations	O
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
dose	O
of	O
Fazadinium	B-CHEMICAL
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	O
pain	B-DISEASE
Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	O
or	O
Thiopentone	B-CHEMICAL
)	O
nor	O
the	O
salt	B-CHEMICAL
preparation	O
of	O
suxamethonium	B-CHEMICAL
used	O
(	O
chloride	O
or	O
bromide	O
),	O
affected	O
the	O
incidence	O
of	O
scoline	O
pain	B-DISEASE
Medial	O
changes	O
in	O
arterial	O
spasm	B-DISEASE
induced	O
by	O
L	O
-	O
norepinephrine	B-CHEMICAL
In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch	O
,	O
vasoconstriction	O
induced	O
by	O
L	O
-	O
norepinephrine	B-CHEMICAL
produced	O
many	O
cell	O
-	O
to	O
-	O
cell	O
hernias	B-DISEASE
At	B-DISEASE
The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	B-DISEASE
Abnormalities	B-DISEASE
of	O
the	O
pupil	B-DISEASE
and	O
visual	O
-	O
evoked	O
potential	O
in	O
quinine	B-CHEMICAL
amblyopia	B-DISEASE
Total	O
blindness	B-DISEASE
with	O
a	O
transient	O
tonic	B-DISEASE
pupillary	O
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
developed	O
in	O
a	O
54	O
-	O
year	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-CHEMICAL
sulfate	O
for	O
leg	B-DISEASE
cramps	B-DISEASE
A	O
transient	O
tonic	B-DISEASE
pupillary	O
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
in	O
quinine	B-CHEMICAL
toxicity	B-DISEASE
Suxamethonium	B-CHEMICAL
-	O
induced	O
jaw	B-DISEASE
stiffness	O
and	O
myalgia	B-DISEASE
An	O
11	O
-	O
year	O
-	O
old	O
boy	O
was	O
given	O
halothane	B-CHEMICAL
,	O
nitrous	B-CHEMICAL
oxide	I-CHEMICAL
and	O
oxygen	B-CHEMICAL
,	O
pancuronium	B-CHEMICAL
0	O
.	O
4	O
mg	O
and	O
suxamethonium	B-CHEMICAL
In	O
response	O
to	O
this	O
a	O
marked	O
jaw	B-DISEASE
Four	O
hours	O
of	O
apnoea	B-DISEASE
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	B-DISEASE
He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	B-CHEMICAL
The	O
case	O
shows	O
that	O
prolonged	O
jaw	B-DISEASE
rigidity	B-DISEASE
and	O
myalgia	B-DISEASE
may	O
occur	O
after	O
suxamethonium	B-CHEMICAL
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	B-CHEMICAL
Indomethacin	B-CHEMICAL
-	O
induced	O
hyperkalemia	B-DISEASE
in	O
three	O
patients	O
with	O
gouty	O
arthritis	B-DISEASE
We	O
describe	O
three	O
patients	O
in	O
whom	O
severe	O
,	O
life	O
-	O
threatening	O
hyperkalemia	B-DISEASE
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
developed	O
after	O
treatment	O
of	O
acute	O
gouty	O
arthritis	B-DISEASE
with	O
indomethacin	B-CHEMICAL
Careful	O
attention	O
to	O
renal	B-DISEASE
function	O
and	O
potassium	B-CHEMICAL
balance	O
in	O
patients	O
receiving	O
indomethacin	B-CHEMICAL
or	O
other	O
nonsteroidal	O
anti	B-CHEMICAL
-	I-CHEMICAL
inflammatory	I-CHEMICAL
agents	I-CHEMICAL
,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
or	O
preexisting	O
renal	B-DISEASE
disease	B-DISEASE
Etomidate	B-CHEMICAL
A	O
clinical	O
evaluation	O
of	O
etomidate	B-CHEMICAL
Unpremedicated	O
patients	O
were	O
given	O
fentanyl	B-CHEMICAL
1	O
microgram	O
/	O
kg	O
followed	O
by	O
etomidate	B-CHEMICAL
Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	B-CHEMICAL
Venous	O
pain	B-DISEASE
occurred	O
in	O
68	O
%	O
of	O
patients	O
and	O
50	O
%	O
had	O
redness	O
,	O
pain	B-DISEASE
or	O
swelling	B-DISEASE
Nausea	B-DISEASE
and	O
vomiting	B-DISEASE
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergence	O
psychoses	B-DISEASE
Levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
are	O
improved	O
by	O
fluoxetine	B-CHEMICAL
We	O
evaluated	O
the	O
severity	O
of	O
motor	B-DISEASE
disability	I-DISEASE
and	O
dyskinesias	B-DISEASE
in	O
seven	O
levodopa	B-CHEMICAL
-	O
responsive	O
patients	O
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	B-CHEMICAL
agonist	I-CHEMICAL
,	O
apomorphine	B-CHEMICAL
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	B-CHEMICAL
After	O
fluoxetine	B-CHEMICAL
treatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apomorphine	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
without	O
modification	O
of	O
parkinsonian	B-DISEASE
motor	B-DISEASE
disability	I-DISEASE
The	O
dyskinesias	B-DISEASE
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	O
dyskinesias	B-DISEASE
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dose	O
dyskinesias	B-DISEASE
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	O
mid	O
-	O
dose	O
dyskinesias	B-DISEASE
The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	B-CHEMICAL
may	O
reduce	O
levodopa	B-CHEMICAL
-	O
or	O
dopamine	B-CHEMICAL
agonist	I-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
without	O
aggravating	O
parkinsonian	B-DISEASE
motor	B-DISEASE
disability	I-DISEASE
A	O
large	O
population	O
-	O
based	O
follow	O
-	O
up	O
study	O
of	O
trimethoprim	B-CHEMICAL
-	O
sulfamethoxazole	B-CHEMICAL
,	O
trimethoprim	B-CHEMICAL
,	O
and	O
cephalexin	B-CHEMICAL
for	O
uncommon	O
serious	O
drug	O
toxicity	B-DISEASE
We	O
conducted	O
a	O
population	O
-	O
based	O
45	O
-	O
day	O
follow	O
-	O
up	O
study	O
of	O
232	O
,	O
390	O
people	O
who	O
were	O
prescribed	O
trimethoprim	B-CHEMICAL
-	O
sulfamethoxazole	B-CHEMICAL
(	O
TMP	B-CHEMICAL
-	O
SMZ	O
),	O
266	O
,	O
951	O
prescribed	O
trimethoprim	B-CHEMICAL
alone	O
,	O
and	O
196	O
,	O
397	O
prescribed	O
cephalexin	B-CHEMICAL
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver	B-DISEASE
,	O
blood	O
,	O
skin	B-DISEASE
,	O
and	O
renal	B-DISEASE
The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	B-DISEASE
disease	I-DISEASE
was	O
similar	O
for	O
persons	O
prescribed	O
TMP	B-CHEMICAL
-	O
SMZ	O
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
prescribed	O
trimethoprim	B-CHEMICAL
The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	B-CHEMICAL
Only	O
five	O
patients	O
experienced	O
blood	O
disorders	O
,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP	B-CHEMICAL
-	O
SMZ	O
;	O
of	O
seven	O
with	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
,	O
four	O
were	O
exposed	O
to	O
TMP	B-CHEMICAL
The	O
one	O
case	O
of	O
toxic	B-DISEASE
epidermal	I-DISEASE
necrolysis	I-DISEASE
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	B-CHEMICAL
Finally	O
,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	B-DISEASE
disease	B-DISEASE
We	O
conclude	O
that	O
the	O
risk	O
of	O
the	O
serious	O
diseases	B-DISEASE
Clinical	O
safety	O
of	O
lidocaine	B-CHEMICAL
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
myocardial	B-DISEASE
infarction	I-DISEASE
STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	B-CHEMICAL
in	O
the	O
setting	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
PARTICIPANTS	O
:	O
Patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
MI	O
who	O
received	O
lidocaine	B-CHEMICAL
RESULTS	O
:	O
Of	O
29	O
patients	O
who	O
received	O
lidocaine	B-CHEMICAL
in	O
the	O
setting	O
of	O
cocaine	B-CHEMICAL
-	O
associated	O
MI	O
,	O
no	O
patient	O
died	O
;	O
exhibited	O
bradydysrhythmias	O
,	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
,	O
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
;	O
or	O
experienced	O
seizures	B-DISEASE
after	O
administration	O
of	O
lidocaine	B-CHEMICAL
CONCLUSION	O
:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	B-CHEMICAL
may	O
enhance	O
cocaine	B-CHEMICAL
toxicity	B-DISEASE
,	O
the	O
use	O
of	O
lidocaine	B-CHEMICAL
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
MI	O
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	O
or	O
central	O
nervous	O
system	O
toxicity	B-DISEASE
Paclitaxel	B-CHEMICAL
3	O
-	O
hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	B-CHEMICAL
Paclitaxel	B-CHEMICAL
(	O
Taxol	B-CHEMICAL
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	B-CHEMICAL
in	O
a	O
phase	O
I	O
/	O
II	O
study	O
directed	O
to	O
patients	O
with	O
non	B-DISEASE
-	I-DISEASE
small	I-DISEASE
cell	I-DISEASE
lung	I-DISEASE
cancer	I-DISEASE
Carboplatin	B-CHEMICAL
was	O
given	O
at	B-DISEASE
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
of	O
6	O
.	O
0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	B-CHEMICAL
The	O
225	O
mg	O
/	O
m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	B-DISEASE
(	O
arthralgia	B-DISEASE
and	O
sensory	O
neuropathy	B-DISEASE
Therapeutic	B-CHEMICAL
effects	I-CHEMICAL
were	O
noted	O
at	B-DISEASE
Toxicities	B-DISEASE
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	B-CHEMICAL
alone	O
at	B-DISEASE
Carboplatin	B-CHEMICAL
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	O
toxicities	B-DISEASE
observed	O
,	O
and	O
the	O
paclitaxel	B-CHEMICAL
/	O
carboplatin	B-CHEMICAL
The	O
dose	O
-	O
dependent	O
effect	O
of	O
misoprostol	B-CHEMICAL
on	O
indomethacin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
dysfunction	I-DISEASE
in	O
well	O
compensated	O
cirrhosis	B-DISEASE
Misoprostol	B-CHEMICAL
(	O
200	O
micrograms	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
dysfunction	I-DISEASE
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	B-CHEMICAL
Parameters	O
of	O
renal	B-DISEASE
hemodynamics	O
and	O
tubular	O
sodium	B-CHEMICAL
and	O
water	B-CHEMICAL
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	O
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	B-CHEMICAL
and	O
various	O
doses	O
of	O
misoprostol	B-CHEMICAL
The	O
200	O
-	O
micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	B-DISEASE
effects	O
of	O
indomethacin	B-CHEMICAL
,	O
whereas	O
the	O
800	O
-	O
micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	B-DISEASE
hemodynamics	O
and	O
sodium	B-CHEMICAL
These	O
results	O
suggest	O
that	O
the	O
renal	B-DISEASE
protective	O
effects	O
of	O
misoprostol	B-CHEMICAL
However	O
,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	B-CHEMICAL
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	B-CHEMICAL
on	O
renal	B-DISEASE
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	B-DISEASE
Increased	O
frequency	O
and	O
severity	O
of	O
angio	O
-	O
oedema	O
related	O
to	O
long	O
-	O
term	O
therapy	O
with	O
angiotensin	B-CHEMICAL
Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	B-DISEASE
urticaria	I-DISEASE
Angiotensin	B-CHEMICAL
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
,	O
used	O
to	O
treat	O
hypertension	B-DISEASE
and	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
Myoclonus	B-DISEASE
associated	O
with	O
lorazepam	B-CHEMICAL
Lorazepam	B-CHEMICAL
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant	B-DISEASE
Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	B-CHEMICAL
Three	O
young	O
infants	O
,	O
all	O
of	O
birth	B-DISEASE
weight	I-DISEASE
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
myoclonus	B-DISEASE
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	B-CHEMICAL
The	O
potential	O
neurotoxic	B-DISEASE
Injectable	O
lorazepam	B-CHEMICAL
Transvenous	O
right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	B-DISEASE
Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	B-DISEASE
,	O
one	O
had	O
a	O
carbamazepine	B-CHEMICAL
-	O
induced	O
acute	O
eosinophilic	O
myocarditis	B-DISEASE
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	B-DISEASE
resulting	O
in	O
acute	O
cardiogenic	B-DISEASE
shock	I-DISEASE
An	O
introducer	O
sheath	O
,	O
a	O
pacemaker	O
,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	B-DISEASE
All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	B-DISEASE
and	O
dysrhythmias	B-DISEASE
In	O
four	O
patients	O
,	O
cardiac	O
pacing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
temporary	O
captured	O
rhythm	O
and	O
restoration	O
of	O
their	O
cardiac	B-DISEASE
output	I-DISEASE
These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
,	O
resulting	O
in	O
death	B-DISEASE
Efficacy	O
and	O
safety	O
of	O
granisetron	B-CHEMICAL
,	O
a	O
selective	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
-	O
3	O
receptor	O
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
induced	O
by	O
high	O
-	O
dose	O
cisplatin	B-CHEMICAL
PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	B-CHEMICAL
(	O
Kytril	O
;	O
SmithKline	O
Beecham	O
Pharmaceuticals	O
,	O
Philadelphia	O
,	O
PA	O
)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin	B-CHEMICAL
-	O
induced	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	B-CHEMICAL
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	B-CHEMICAL
Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
signs	O
,	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
RESULTS	O
:	O
After	O
granisetron	B-CHEMICAL
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrograms	O
/	O
kg	O
,	O
a	O
major	O
response	O
(<	O
or	O
=	O
two	O
vomiting	B-DISEASE
or	O
retching	O
episodes	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%,	O
57	O
%,	O
58	O
%,	O
and	O
60	O
%	O
of	O
patients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
response	O
(	O
no	O
vomiting	B-DISEASE
There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	B-DISEASE
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
vomiting	B-DISEASE
As	O
granisetron	B-CHEMICAL
Headache	B-DISEASE
CONCLUSION	O
:	O
A	O
single	O
10	O
-,	O
20	O
-,	O
or	O
40	O
-	O
micrograms	O
/	O
kg	O
dose	O
of	O
granisetron	B-CHEMICAL
was	O
effective	O
in	O
controlling	O
vomiting	B-DISEASE
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patients	O
who	O
received	O
cisplatin	B-CHEMICAL
at	B-DISEASE
doses	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomiting	B-DISEASE
Granisetron	B-CHEMICAL
was	O
well	O
tolerated	O
at	B-DISEASE
Adverse	O
interaction	O
between	O
clonidine	B-CHEMICAL
and	O
verapamil	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	B-CHEMICAL
and	O
verapamil	B-CHEMICAL
resulting	O
in	O
atrioventricular	O
(	O
AV	O
)	O
block	O
in	O
both	O
patients	O
and	O
severe	O
hypotension	B-DISEASE
CASE	O
SUMMARIES	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
hyperaldosteronism	B-DISEASE
was	O
treated	O
with	O
verapamil	B-CHEMICAL
480	O
mg	O
/	O
d	O
and	O
spironolactone	B-CHEMICAL
After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	B-CHEMICAL
(	O
0	O
.	O
15	O
mg	O
bid	O
),	O
she	O
developed	O
complete	O
AV	B-DISEASE
block	I-DISEASE
and	O
severe	O
hypotension	B-DISEASE
A	O
65	O
-	O
year	O
-	O
old	O
woman	O
was	O
treated	O
with	O
extended	O
-	O
release	O
verapamil	B-CHEMICAL
After	O
the	O
addition	O
of	O
clonidine	B-CHEMICAL
0	O
.	O
15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B-DISEASE
block	I-DISEASE
DISCUSSION	O
:	O
An	O
adverse	O
interaction	O
between	O
clonidine	B-CHEMICAL
and	O
verapamil	B-CHEMICAL
Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	B-CHEMICAL
drugs	I-CHEMICAL
CONCLUSIONS	O
:	O
Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	B-CHEMICAL
and	O
verapamil	B-CHEMICAL
Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	O
calcium	B-CHEMICAL
S	O
-	O
312	O
,	O
S	O
-	O
312	O
-	O
d	O
,	O
but	O
not	O
S	O
-	O
312	O
-	O
l	O
,	O
L	O
-	O
type	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
antagonists	I-CHEMICAL
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	O
tonic	B-DISEASE
convulsions	B-DISEASE
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	B-CHEMICAL
Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S	O
-	O
312	O
-	O
d	O
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	B-DISEASE
induced	O
by	O
pentylenetetrazole	B-CHEMICAL
or	O
bemegride	B-CHEMICAL
),	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	B-DISEASE
induced	O
by	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
,	O
picrotoxin	B-CHEMICAL
S	O
-	O
312	O
-	O
d	O
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	B-DISEASE
Transmural	O
myocardial	B-DISEASE
infarction	I-DISEASE
with	O
sumatriptan	B-CHEMICAL
For	O
sumatriptan	B-CHEMICAL
We	O
describe	O
a	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
an	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
after	O
administration	O
of	O
sumatriptan	B-CHEMICAL
6	O
mg	O
subcutaneously	O
for	O
cluster	B-DISEASE
headache	I-DISEASE
The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	O
heart	B-DISEASE
disease	I-DISEASE
or	O
Prinzmetal	O
'	O
s	O
angina	B-DISEASE
Flumazenil	B-CHEMICAL
induces	O
seizures	B-DISEASE
and	O
death	B-DISEASE
in	O
mixed	O
cocaine	B-CHEMICAL
-	O
diazepam	B-CHEMICAL
STUDY	O
HYPOTHESIS	O
:	O
Administration	O
of	O
the	O
benzodiazepine	B-CHEMICAL
antagonist	O
flumazenil	B-CHEMICAL
may	O
unmask	O
seizures	B-DISEASE
in	O
mixed	O
cocaine	B-CHEMICAL
-	O
benzodiazepine	B-CHEMICAL
DESIGN	O
:	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
100	O
mg	O
/	O
kg	O
cocaine	B-CHEMICAL
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazepam	B-CHEMICAL
alone	O
,	O
or	O
a	O
combination	O
of	O
diazepam	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
Three	O
minutes	O
later	O
,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	B-CHEMICAL
Animal	O
behavior	O
,	O
seizures	B-DISEASE
(	O
time	O
to	O
and	O
incidence	O
),	O
death	B-DISEASE
INTERVENTIONS	O
:	O
Administration	O
of	O
flumazenil	B-CHEMICAL
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
RESULTS	O
:	O
In	O
group	O
1	O
,	O
animals	O
received	O
cocaine	B-CHEMICAL
This	O
resulted	O
in	O
100	O
%	O
developing	O
seizures	B-DISEASE
and	O
death	B-DISEASE
Group	O
2	O
received	O
diazepam	B-CHEMICAL
Group	O
3	O
received	O
diazepam	B-CHEMICAL
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	B-CHEMICAL
Animals	O
became	O
somnolent	O
after	O
diazepam	B-CHEMICAL
and	O
then	O
active	O
after	O
flumazenil	B-CHEMICAL
In	O
group	O
4	O
,	O
a	O
combination	O
of	O
cocaine	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectable	O
seizures	B-DISEASE
and	O
a	O
50	O
%	O
incidence	O
of	O
death	B-DISEASE
Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	B-CHEMICAL
This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B-DISEASE
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
),	O
and	O
death	B-DISEASE
Group	O
6	O
received	O
cocaine	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
followed	O
by	O
10	O
mg	O
/	O
kg	O
flumazenil	B-CHEMICAL
This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B-DISEASE
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
),	O
and	O
death	B-DISEASE
CONCLUSION	O
:	O
Flumazenil	B-CHEMICAL
can	O
unmask	O
seizures	B-DISEASE
and	O
increase	O
the	O
incidence	O
of	O
death	B-DISEASE
in	O
a	O
model	O
of	O
combined	O
cocaine	B-CHEMICAL
-	O
diazepam	B-CHEMICAL
Mechanisms	O
for	O
protective	O
effects	O
of	O
free	B-CHEMICAL
radical	I-CHEMICAL
scavengers	I-CHEMICAL
on	O
gentamicin	B-CHEMICAL
-	O
mediated	O
nephropathy	B-DISEASE
Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	B-CHEMICAL
radical	I-CHEMICAL
scavengers	I-CHEMICAL
on	O
gentamicin	B-CHEMICAL
(	O
GM	B-CHEMICAL
)-	O
mediated	O
nephropathy	B-DISEASE
Administration	O
of	O
GM	B-CHEMICAL
at	B-DISEASE
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	B-DISEASE
blood	O
flow	O
(	O
RBF	O
)	O
and	O
inulin	B-CHEMICAL
A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	B-CHEMICAL
3	O
',	O
5	O
'-	O
cyclic	O
monophosphate	O
(	O
cGMP	O
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	B-DISEASE
cortical	O
renin	O
and	O
endothelin	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
contents	O
were	O
also	O
observed	O
in	O
GM	B-CHEMICAL
-	O
mediated	O
nephropathy	B-DISEASE
Superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
(	O
SOD	O
)	O
or	O
dimethylthiourea	O
(	O
DMTU	O
)	O
significantly	O
lessened	O
the	O
GM	B-CHEMICAL
The	O
SOD	O
-	O
induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF	O
,	O
an	O
increase	O
in	O
urinary	O
cGMP	O
excretion	O
,	O
and	O
a	O
decrease	O
in	O
renal	B-DISEASE
renin	O
and	O
endothelin	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
In	O
contrast	O
,	O
DMTU	O
significantly	O
reduced	O
the	O
tubular	O
damage	O
and	O
lipid	O
peroxidation	O
,	O
but	O
it	O
did	O
not	O
affect	O
renal	B-DISEASE
Neither	O
SOD	O
nor	O
DMTU	O
affected	O
the	O
renal	B-DISEASE
cortical	O
GM	B-CHEMICAL
content	O
in	O
GM	B-CHEMICAL
These	O
results	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	O
have	O
protective	O
effects	O
on	O
GM	B-CHEMICAL
-	O
mediated	O
nephropathy	B-DISEASE
,	O
2	O
)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	O
,	O
and	O
3	O
)	O
superoxide	B-CHEMICAL
anions	B-CHEMICAL
play	O
a	O
critical	O
role	O
in	O
GM	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	B-DISEASE
The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
Isoproterenol	B-CHEMICAL
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb	O
/	O
FeJ	O
mice	O
resulted	O
in	O
a	O
46	O
%	O
increase	O
in	O
heart	O
weight	O
and	O
a	B-CHEMICAL
19	I-CHEMICAL
To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
Central	O
cardiovascular	O
effects	O
of	O
AVP	B-CHEMICAL
and	O
ANP	B-CHEMICAL
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	B-DISEASE
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
(	O
AVP	B-CHEMICAL
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	B-CHEMICAL
)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
in	O
normotensive	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	B-DISEASE
injections	O
of	O
either	O
vehicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-CHEMICAL
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	B-CHEMICAL
Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(	O
CCB	O
),	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
period	O
(	O
HRp	O
)	O
during	O
phenylephrine	B-CHEMICAL
(	O
Phe	O
)-	O
induced	O
hypertension	B-DISEASE
and	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SN	O
)-	O
induced	O
hypotension	B-DISEASE
CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle	O
,	O
AVP	B-CHEMICAL
,	O
ANP	B-CHEMICAL
,	O
or	O
both	O
peptides	B-CHEMICAL
Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-CHEMICAL
ANP	B-CHEMICAL
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle	O
,	O
but	O
it	O
abolished	O
AVP	B-CHEMICAL
CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	B-CHEMICAL
during	O
SN	O
-	O
induced	O
hypotension	B-DISEASE
In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP	B-CHEMICAL
,	O
AVP	B-CHEMICAL
and	O
ANP	B-CHEMICAL
+	O
AVP	B-CHEMICAL
The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	B-CHEMICAL
and	O
ANP	B-CHEMICAL
exert	O
differential	O
effects	O
on	O
blood	O
pressure	O
and	O
baroreflex	O
control	O
of	O
heart	O
rate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interaction	O
of	O
these	O
two	O
peptides	B-CHEMICAL
in	O
blood	O
pressure	O
regulation	O
at	B-DISEASE
Cutaneous	O
exposure	O
to	O
warfarin	B-CHEMICAL
-	O
like	O
anticoagulant	O
causing	O
an	O
intracerebral	B-DISEASE
hemorrhage	I-DISEASE
A	O
case	O
of	O
intercerebral	O
hematoma	B-DISEASE
due	O
to	O
warfarin	B-CHEMICAL
-	O
induced	O
coagulopathy	B-DISEASE
The	O
39	O
-	O
year	O
-	O
old	O
woman	O
had	O
spread	O
a	O
warfarin	B-CHEMICAL
Percutaneous	O
absorption	O
of	O
warfarin	B-CHEMICAL
causing	O
coagulopathy	B-DISEASE
An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	B-CHEMICAL
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	B-DISEASE
Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	B-CHEMICAL
Indications	O
for	O
transplantation	O
were	O
idiopathic	O
cardiomyopathy	B-DISEASE
(	O
52	O
%),	O
congenital	B-DISEASE
heart	B-DISEASE
disease	I-DISEASE
(	O
35	O
%)	O
with	O
and	O
without	O
prior	O
repair	O
(	O
71	O
%	O
and	O
29	O
%,	O
respectively	O
),	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
(	O
5	O
%),	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
(	O
3	O
%),	O
and	O
doxorubicin	B-CHEMICAL
cardiomyopathy	B-DISEASE
Patients	O
were	O
managed	O
with	O
cyclosporine	B-CHEMICAL
and	O
azathioprine	B-CHEMICAL
Steroids	B-CHEMICAL
Five	O
patients	O
(	O
14	O
%)	O
received	O
maintenance	O
steroids	B-CHEMICAL
There	O
have	O
been	O
no	O
deaths	B-DISEASE
related	O
to	O
rejection	O
or	O
infection	B-DISEASE
Cumulative	O
survival	O
is	O
88	O
%	O
at	B-DISEASE
Freedom	O
from	O
serious	O
infections	B-DISEASE
was	O
83	O
%	O
at	B-DISEASE
1	O
month	O
and	O
65	O
%	O
at	B-DISEASE
Cytomegalovirus	B-DISEASE
infections	I-DISEASE
were	O
treated	O
successfully	O
with	O
ganciclovir	B-CHEMICAL
Twenty	O
-	O
one	O
patients	O
(	O
60	O
%)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	B-DISEASE
Seizures	B-DISEASE
occurred	O
in	O
five	O
patients	O
(	O
14	O
%)	O
and	O
hypertension	B-DISEASE
(	O
ABSTRACT	O
TRUNCATED	O
AT	B-DISEASE
Delirium	B-DISEASE
during	O
fluoxetine	B-CHEMICAL
The	O
correlation	O
between	O
high	O
serum	O
tricyclic	O
antidepressant	B-CHEMICAL
Only	O
a	O
few	O
reports	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	B-CHEMICAL
In	O
some	O
cases	O
,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	B-CHEMICAL
(>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	B-DISEASE
Widespread	O
cognitive	O
disorders	O
,	O
such	O
as	O
delirium	B-DISEASE
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	O
delirium	B-DISEASE
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	B-CHEMICAL
(	O
fluoxetine	B-CHEMICAL
Pulmonary	B-DISEASE
edema	I-DISEASE
and	O
shock	B-DISEASE
after	O
high	O
-	O
dose	O
aracytine	O
-	O
C	O
for	O
lymphoma	B-DISEASE
Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
Ara	O
-	O
C	O
for	O
lymphomas	O
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	B-DISEASE
It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	B-DISEASE
,	O
diarrhea	B-DISEASE
,	O
shock	B-DISEASE
,	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
weight	B-DISEASE
gain	I-DISEASE
and	O
leukocytosis	B-DISEASE
Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	B-DISEASE
Sequential	O
biological	O
assays	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	O
-	O
C	O
infusion	O
to	O
ten	B-DISEASE
patients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome	B-DISEASE
As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	B-DISEASE
and	O
adult	O
respiratory	B-DISEASE
distress	I-DISEASE
syndrome	I-DISEASE
Protective	O
effect	O
of	O
clentiazem	B-CHEMICAL
against	O
epinephrine	B-CHEMICAL
We	O
investigated	O
the	O
effects	O
of	O
clentiazem	B-CHEMICAL
,	O
a	O
1	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
benzothiazepine	I-CHEMICAL
calcium	B-CHEMICAL
antagonist	O
,	O
on	O
epinephrine	B-CHEMICAL
-	O
induced	O
cardiomyopathy	B-DISEASE
With	O
2	O
-	O
week	O
chronic	O
epinephrine	B-CHEMICAL
infusion	O
,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days	O
,	O
and	O
severe	O
ischemic	O
lesions	O
and	O
fibrosis	B-DISEASE
In	O
epinephrine	B-CHEMICAL
-	O
treated	O
rats	O
,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B-CHEMICAL
were	O
reduced	O
,	O
but	O
responses	O
to	O
calcium	B-CHEMICAL
Treatment	O
with	O
clentiazem	B-CHEMICAL
prevented	O
epinephrine	B-CHEMICAL
-	O
induced	O
death	B-DISEASE
(	O
P	O
<	O
.	O
05	O
),	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	O
lesions	O
and	O
fibrosis	B-DISEASE
Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B-CHEMICAL
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	B-CHEMICAL
alone	O
,	O
but	O
combined	O
with	O
epinephrine	B-CHEMICAL
,	O
clentiazem	B-CHEMICAL
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	B-CHEMICAL
On	O
the	O
other	O
hand	B-DISEASE
clentiazem	B-CHEMICAL
did	O
not	O
prevent	O
epinephrine	B-CHEMICAL
Interestingly	O
,	O
clentiazem	B-CHEMICAL
Clentiazem	B-CHEMICAL
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	B-CHEMICAL
seen	O
in	O
the	O
epinephrine	B-CHEMICAL
-	O
treated	O
animals	O
,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	B-CHEMICAL
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	B-CHEMICAL
compared	O
to	O
epinephrine	B-CHEMICAL
In	O
conclusion	O
,	O
clentiazem	B-CHEMICAL
attenuated	O
epinephrine	B-CHEMICAL
Cocaine	B-CHEMICAL
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
We	O
report	O
a	O
case	O
of	O
myocardial	B-DISEASE
ischemia	I-DISEASE
induced	O
by	O
cocaine	B-CHEMICAL
The	O
ischemia	B-DISEASE
probably	O
induced	O
by	O
coronary	O
artery	O
spasm	B-DISEASE
was	O
reversed	O
by	O
nitroglycerin	B-CHEMICAL
and	O
calcium	B-CHEMICAL
Doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
In	O
laboratory	O
animals	O
,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	B-CHEMICAL
The	O
ST	O
interval	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+/-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+/-	O
11	O
.	O
8	O
ms	B-DISEASE
in	O
week	O
10	O
(	O
7	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-CHEMICAL
After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin	B-CHEMICAL
As	O
this	O
schedule	O
exerted	O
more	O
toxicity	B-DISEASE
than	O
needed	O
to	O
investigate	O
protective	B-CHEMICAL
agents	I-CHEMICAL
,	O
the	O
protection	O
of	O
ICRF	O
-	O
187	O
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	B-DISEASE
(	O
6	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-CHEMICAL
1	O
h	B-CHEMICAL
before	O
doxorubicin	B-CHEMICAL
The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	B-DISEASE
These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
Epinephrine	B-CHEMICAL
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	B-CHEMICAL
Since	O
bupivacaine	B-CHEMICAL
and	O
epinephrine	B-CHEMICAL
may	O
both	O
precipitate	O
dysrhythmias	B-DISEASE
,	O
circulating	O
bupivacaine	B-CHEMICAL
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	B-CHEMICAL
We	O
therefore	O
examined	O
whether	O
bupivacaine	B-CHEMICAL
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	B-CHEMICAL
in	O
conscious	O
,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	B-DISEASE
infarction	I-DISEASE
Forty	O
-	O
one	O
conscious	O
dogs	O
received	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-CHEMICAL
Seventeen	O
animals	O
responded	O
with	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
After	O
3	O
h	B-CHEMICAL
,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupivacaine	B-CHEMICAL
or	O
saline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-CHEMICAL
In	O
the	O
bupivacaine	B-CHEMICAL
groups	O
,	O
epinephrine	B-CHEMICAL
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	B-CHEMICAL
VT	O
appeared	O
in	O
fewer	O
dogs	O
and	O
at	B-DISEASE
Epinephrine	B-CHEMICAL
shortened	O
QT	O
less	O
after	O
bupivacaine	B-CHEMICAL
One	O
day	O
after	O
experimental	O
myocardial	B-DISEASE
infarction	I-DISEASE
,	O
six	O
additional	O
halothane	B-CHEMICAL
-	O
anesthetized	O
dogs	O
received	O
4	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-CHEMICAL
After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivacaine	B-CHEMICAL
was	O
injected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-CHEMICAL
In	O
these	O
dogs	O
,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	B-CHEMICAL
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	B-CHEMICAL
Bupivacaine	B-CHEMICAL
antagonizes	O
epinephrine	B-CHEMICAL
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	O
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	B-DISEASE
There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	B-CHEMICAL
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	B-CHEMICAL
Milk	O
-	O
alkali	O
syndrome	B-DISEASE
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
in	O
a	O
patient	O
with	O
hypoparathyroidism	B-DISEASE
Milk	O
-	O
alkali	O
syndrome	B-DISEASE
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	B-DISEASE
ulcer	I-DISEASE
disease	B-DISEASE
with	O
large	O
amounts	O
of	O
calcium	B-CHEMICAL
Although	O
with	O
current	O
ulcer	B-DISEASE
therapy	O
(	O
H	B-CHEMICAL
-	O
2	O
blockers	O
,	O
omeprazole	B-CHEMICAL
,	O
and	O
sucralfate	B-CHEMICAL
),	O
the	O
frequency	O
of	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
has	O
decreased	O
significantly	O
,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	B-DISEASE
,	O
alkalosis	B-DISEASE
,	O
and	O
renal	B-DISEASE
impairment	O
remains	O
the	O
hallmark	O
of	O
the	O
syndrome	B-DISEASE
Milk	O
-	O
alkali	O
syndrome	B-DISEASE
This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	B-DISEASE
who	O
was	O
treated	O
with	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
and	O
calcitriol	B-CHEMICAL
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	B-CHEMICAL
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	B-CHEMICAL
This	O
illustrates	O
intravenous	O
pamidronate	B-CHEMICAL
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
Encephalopathy	B-DISEASE
during	O
amitriptyline	B-CHEMICAL
therapy	O
:	O
are	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
and	O
serotonin	B-DISEASE
syndrome	I-DISEASE
This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	B-DISEASE
developed	O
in	O
the	O
course	O
of	O
amitriptyline	B-CHEMICAL
therapy	O
,	O
during	O
a	O
remission	B-DISEASE
of	O
unipolar	B-DISEASE
depression	I-DISEASE
This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
(	O
NMS	O
)	O
or	O
serotonin	B-DISEASE
syndrome	I-DISEASE
The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine	B-CHEMICAL
/	O
serotonin	B-CHEMICAL
The	O
NMS	O
-	O
like	O
encephalopathy	B-DISEASE
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	B-CHEMICAL
Genetic	O
separation	O
of	O
tumor	B-DISEASE
growth	O
and	O
hemorrhagic	B-DISEASE
phenotypes	O
in	O
an	O
estrogen	B-CHEMICAL
-	O
induced	O
tumor	B-DISEASE
Chronic	O
administration	O
of	O
estrogen	B-CHEMICAL
to	O
the	O
Fischer	O
344	O
(	O
F344	O
)	O
rat	O
induces	O
growth	O
of	O
large	O
,	O
hemorrhagic	B-DISEASE
pituitary	B-DISEASE
tumors	I-DISEASE
Ten	B-DISEASE
weeks	O
of	O
diethylstilbestrol	B-CHEMICAL
(	O
DES	B-CHEMICAL
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109	O
.	O
2	O
+/-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+/-	O
SE	B-DISEASE
)	O
versus	O
11	O
.	O
3	O
+/-	O
1	O
.	O
4	O
mg	O
for	O
untreated	O
rats	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagic	B-DISEASE
The	O
same	O
DES	B-CHEMICAL
An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	B-CHEMICAL
Surprisingly	O
,	O
the	O
F1	O
hybrid	O
tumors	B-DISEASE
were	O
not	O
hemorrhagic	B-DISEASE
However	O
,	O
while	O
DES	B-CHEMICAL
-	O
induced	O
pituitary	O
growth	O
exhibited	O
quantitative	O
,	O
additive	O
inheritance	O
,	O
the	O
hemorrhagic	B-DISEASE
Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	B-DISEASE
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	B-DISEASE
,	O
indicating	O
that	O
the	O
hemorrhagic	B-DISEASE
The	O
hemorrhagic	B-DISEASE
Increased	O
expression	O
of	O
neuronal	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthase	I-CHEMICAL
Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthase	I-CHEMICAL
Chemical	O
cystitis	B-DISEASE
was	O
induced	O
by	O
cyclophosphamide	B-CHEMICAL
(	O
CYP	O
)	O
which	O
is	O
metabolized	O
to	O
acrolein	B-CHEMICAL
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine	B-DISEASE
2	O
hours	O
prior	O
to	O
perfusion	O
(	O
acute	O
treatment	O
)	O
of	O
the	O
animals	O
increased	O
Fos	O
-	O
immunoreactivity	O
(	O
IR	O
)	O
in	O
neurons	O
in	O
the	O
dorsal	O
commissure	O
,	O
dorsal	O
horn	O
,	O
and	O
autonomic	O
regions	O
of	O
spinal	O
segments	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
afferent	O
inputs	O
from	O
the	O
bladder	O
,	O
urethra	O
,	O
and	O
ureter	B-DISEASE
Effects	O
of	O
a	O
new	O
calcium	B-CHEMICAL
antagonist	O
,	O
CD	O
-	O
832	O
,	O
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
in	O
dogs	O
with	O
partial	O
coronary	B-DISEASE
stenosis	I-DISEASE
Effects	O
of	O
CD	O
-	O
832	O
on	O
isoproterenol	B-CHEMICAL
(	O
ISO	B-CHEMICAL
)-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	B-DISEASE
stenosis	I-DISEASE
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	B-CHEMICAL
or	O
diltiazem	B-CHEMICAL
In	O
the	O
presence	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
stenosis	I-DISEASE
,	O
3	O
-	O
min	O
periods	O
of	O
intracoronary	O
ISO	B-CHEMICAL
After	O
the	O
control	O
ISO	B-CHEMICAL
infusion	O
with	O
stenosis	B-DISEASE
was	O
performed	O
,	O
equihypotensive	O
doses	O
of	O
CD	O
-	O
832	O
(	O
3	O
and	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
),	O
nifedipine	B-CHEMICAL
(	O
1	O
and	O
3	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiazem	B-CHEMICAL
(	O
10	O
and	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	B-CHEMICAL
Both	O
CD	O
-	O
832	O
and	O
diltiazem	B-CHEMICAL
,	O
but	O
not	O
nifedipine	B-CHEMICAL
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	B-CHEMICAL
In	O
contrast	O
to	O
nifedipine	B-CHEMICAL
,	O
CD	O
-	O
832	O
(	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
32	O
+/-	O
12	O
%	O
to	O
115	O
+/-	O
26	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
5	O
.	O
6	O
+/-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+/-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	B-DISEASE
3	O
min	O
after	O
ISO	B-CHEMICAL
infusion	O
with	O
stenosis	B-DISEASE
Diltiazem	B-CHEMICAL
(	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+/-	O
14	O
%	O
to	O
63	O
+/-	O
18	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
4	O
.	O
7	O
+/-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+/-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	B-DISEASE
3	O
min	O
after	O
ISO	B-CHEMICAL
infusion	O
with	O
stenosis	B-DISEASE
These	O
data	O
show	O
that	O
CD	O
-	O
832	O
improves	O
myocardial	B-DISEASE
ischemia	I-DISEASE
during	O
ISO	B-CHEMICAL
infusion	O
with	O
stenosis	B-DISEASE
The	O
effect	O
of	O
recombinant	O
human	O
insulin	B-CHEMICAL
-	O
like	O
growth	O
factor	O
-	O
I	O
on	O
chronic	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
nephropathy	B-DISEASE
We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	B-DISEASE
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
PAN	B-CHEMICAL
)	O
nephropathy	B-DISEASE
,	O
an	O
experimental	O
model	O
of	O
glomerular	O
disease	B-DISEASE
Therefore	O
,	O
we	O
examined	O
whether	O
recombinant	O
human	O
(	O
rh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	B-DISEASE
failure	I-DISEASE
in	O
rats	O
with	O
chronic	O
PAN	B-CHEMICAL
nephropathy	B-DISEASE
The	O
glomerulopathy	O
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	B-CHEMICAL
rhIGF	O
-	O
I	O
improved	O
weight	B-DISEASE
gain	I-DISEASE
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	B-DISEASE
disease	B-DISEASE
Urinary	O
protein	O
excretion	O
was	O
unaltered	O
by	O
rhIGF	O
-	O
I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	B-CHEMICAL
nephropathy	B-DISEASE
After	O
12	O
wk	O
,	O
the	O
inulin	B-CHEMICAL
clearance	O
was	O
higher	O
in	O
rhIGF	O
-	O
I	O
-	O
treated	O
rats	O
,	O
0	O
.	O
48	O
+/-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+/-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
body	B-DISEASE
weight	I-DISEASE
in	O
untreated	O
PAN	B-CHEMICAL
nephropathy	B-DISEASE
The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	O
hypertrophy	B-DISEASE
or	O
increased	O
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
,	O
tubulointerstitial	O
injury	O
,	O
or	O
renal	B-DISEASE
cortical	O
malondialdehyde	B-CHEMICAL
In	O
rats	O
with	O
PAN	B-CHEMICAL
nephropathy	B-DISEASE
In	O
normal	O
rats	O
with	O
intact	O
kidneys	O
,	O
rhIGF	O
-	O
I	O
administration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
weight	B-DISEASE
gain	I-DISEASE
,	O
blood	O
pressure	O
,	O
proteinuria	B-DISEASE
,	O
GFR	O
,	O
glomerular	O
planar	O
area	O
,	O
renal	B-DISEASE
cortical	O
malondialdehyde	B-CHEMICAL
rhIGF	O
-	O
I	O
treatment	O
reduced	O
the	O
steady	O
state	O
renal	B-DISEASE
We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF	O
-	O
I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	B-CHEMICAL
nephropathy	B-DISEASE
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worsen	O
renal	B-DISEASE
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	B-DISEASE
Nefiracetam	B-CHEMICAL
(	O
DM	B-DISEASE
-	O
9384	O
)	O
reverses	O
apomorphine	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
Nefiracetam	B-CHEMICAL
is	O
a	O
novel	O
pyrrolidone	O
derivative	O
which	O
attenuates	O
scopolamine	B-CHEMICAL
Given	O
that	O
apomorphine	B-CHEMICAL
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	B-CHEMICAL
to	O
attenuate	O
amnesia	B-DISEASE
A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	B-CHEMICAL
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	B-CHEMICAL
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	B-DISEASE
Co	B-CHEMICAL
-	O
administration	O
of	O
nefiracetam	B-CHEMICAL
and	O
apomorphine	B-CHEMICAL
However	O
,	O
administration	O
of	O
nefiracetam	B-CHEMICAL
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B-DISEASE
induced	O
by	O
apomorphine	B-CHEMICAL
at	B-DISEASE
These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	B-CHEMICAL
,	O
at	B-DISEASE
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	B-CHEMICAL
23390	I-CHEMICAL
or	O
[	O
3H	O
]	O
spiperone	B-CHEMICAL
binding	O
from	O
D1	O
or	O
D2	O
dopamine	B-CHEMICAL
It	O
is	O
suggested	O
that	O
nefiracetam	B-CHEMICAL
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	B-CHEMICAL
Human	O
corticotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
and	O
thyrotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
Human	O
corticotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
(	O
hCRH	O
)	O
and	O
thyrotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blind	O
study	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptides	B-CHEMICAL
Two	O
subsequent	O
CO2	B-CHEMICAL
During	O
the	O
first	O
test	O
0	O
.	O
9	O
%	O
NaCl	B-CHEMICAL
Nine	O
subjects	O
received	O
0	O
.	O
9	O
%	O
NaCl	B-CHEMICAL
The	O
CO2	B-CHEMICAL
In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	B-CHEMICAL
hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	B-CHEMICAL
The	O
CO2	B-CHEMICAL
The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	B-CHEMICAL
Lamivudine	B-CHEMICAL
is	O
effective	O
in	O
suppressing	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
DNA	O
in	O
Chinese	O
hepatitis	B-DISEASE
B	I-DISEASE
Lamivudine	B-CHEMICAL
is	O
a	O
novel	O
2	O
',	O
3	O
'-	O
dideoxy	O
cytosine	B-CHEMICAL
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	B-DISEASE
B	I-DISEASE
We	O
performed	O
a	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	B-DISEASE
B	I-DISEASE
surface	O
antigen	O
(	O
HBsAg	B-CHEMICAL
Forty	O
-	O
two	O
Chinese	O
HBsAg	B-CHEMICAL
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
6	O
patients	O
)	O
or	O
lamivudine	B-CHEMICAL
All	O
36	O
patients	O
receiving	O
lamivudine	B-CHEMICAL
had	O
a	O
decrease	O
in	O
hepatitis	B-DISEASE
B	I-DISEASE
Although	O
25	O
mg	O
of	O
lamivudine	B-CHEMICAL
There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	B-DISEASE
B	I-DISEASE
In	O
conclusion	O
,	O
a	O
4	O
-	O
week	O
course	O
of	O
lamivudine	B-CHEMICAL
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	B-CHEMICAL
Studies	O
with	O
long	O
-	O
term	O
lamivudine	B-CHEMICAL
Population	O
-	O
based	O
study	O
of	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
associated	O
with	O
various	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
BACKGROUND	O
:	O
Four	O
studies	O
published	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	B-DISEASE
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
(	O
OCs	O
)	O
containing	O
the	O
third	O
-	O
generation	O
progestagens	O
gestodene	B-CHEMICAL
or	O
desogestrel	B-CHEMICAL
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re	O
-	O
examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	B-DISEASE
and	O
OC	B-CHEMICAL
All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep	O
-	O
vein	O
thrombosis	B-DISEASE
,	O
venous	B-DISEASE
thrombosis	I-DISEASE
not	O
otherwise	O
specified	O
,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period	O
,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	B-DISEASE
We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	B-DISEASE
in	O
users	O
of	O
the	O
main	O
OC	B-CHEMICAL
preparations	O
,	O
and	O
a	O
nested	O
case	O
-	O
control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	B-DISEASE
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	B-CHEMICAL
We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body	O
-	O
mass	O
index	O
,	O
number	O
of	O
cycles	O
,	O
change	O
in	O
type	O
of	O
OC	B-CHEMICAL
prescribed	O
within	O
3	O
months	O
of	O
the	O
event	O
,	O
previous	O
pregnancy	B-DISEASE
,	O
and	O
concurrent	O
disease	B-DISEASE
FINDINGS	O
:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	B-DISEASE
Of	O
the	O
83	O
cases	O
of	O
VTE	B-DISEASE
associated	O
with	O
use	O
of	O
combined	O
OCs	O
,	O
43	O
were	O
recorded	O
as	O
deep	O
-	O
vein	O
thrombosis	B-DISEASE
,	O
35	O
as	O
pulmonary	O
thrombosis	B-DISEASE
,	O
and	O
five	O
as	O
venous	B-DISEASE
thrombosis	I-DISEASE
The	O
crude	O
rate	O
of	O
VTE	B-DISEASE
per	O
10	O
,	O
000	O
woman	O
-	O
years	O
was	O
4	O
.	O
10	O
in	O
current	O
users	O
of	O
any	O
OC	B-CHEMICAL
After	O
adjustment	O
for	O
age	O
,	O
the	O
rate	O
ratio	O
of	O
VTE	B-DISEASE
Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	B-DISEASE
Among	O
users	O
of	O
third	O
-	O
generation	O
progestagens	O
,	O
the	O
risk	O
of	O
VTE	B-DISEASE
was	O
higher	O
in	O
users	O
of	O
desogestrel	B-CHEMICAL
with	O
20	O
g	O
ethinyloestradiol	B-CHEMICAL
than	O
in	O
users	O
of	O
gestodene	B-CHEMICAL
or	O
desogestrel	B-CHEMICAL
with	O
30	O
g	O
ethinyloestradiol	B-CHEMICAL
With	O
all	O
second	O
-	O
generation	O
OCs	O
as	O
the	O
reference	O
,	O
the	O
odds	O
ratios	O
for	O
VTE	B-DISEASE
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
desogestrel	B-CHEMICAL
plus	O
20	O
g	O
ethinyloestradiol	B-CHEMICAL
The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	B-CHEMICAL
and	O
desogestrel	B-CHEMICAL
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
augments	O
pilocarpine	B-CHEMICAL
-	O
induced	O
electrographic	O
seizure	B-DISEASE
but	O
protects	O
against	O
brain	B-DISEASE
damage	I-DISEASE
The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
on	O
the	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
Intraperitoneal	O
injection	O
of	O
pilocarpine	B-CHEMICAL
(	O
400	O
mg	O
/	O
kg	O
)	O
induced	O
tonic	B-DISEASE
and	O
clonic	O
seizure	B-DISEASE
Scopolamine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pentobarbital	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
development	O
of	O
pilocarpine	B-CHEMICAL
-	O
induced	O
behavioral	O
seizure	B-DISEASE
but	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
An	O
electrical	O
seizure	B-DISEASE
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine	B-CHEMICAL
Scopolamine	B-CHEMICAL
and	O
pentobarbital	B-CHEMICAL
blocked	O
the	O
pilocarpine	B-CHEMICAL
-	O
induced	O
electrographic	O
seizure	B-DISEASE
,	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
treatment	O
augmented	O
the	O
electrographic	O
seizure	B-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
Brain	B-DISEASE
damage	I-DISEASE
Pilocarpine	B-CHEMICAL
produced	O
neuronal	O
death	B-DISEASE
Pentobarbital	B-CHEMICAL
,	O
scopolamine	B-CHEMICAL
and	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
protected	O
the	O
brain	B-DISEASE
damage	I-DISEASE
by	O
pilocarpine	B-CHEMICAL
,	O
though	O
in	O
the	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
These	O
results	O
indicate	O
that	O
status	B-DISEASE
epilepticus	I-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission	O
,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	B-DISEASE
damage	I-DISEASE
through	O
an	O
excitatory	O
NMDA	B-CHEMICAL
Paclitaxel	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
,	O
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
in	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
5	B-CHEMICAL
-	I-CHEMICAL
Fluorouracil	I-CHEMICAL
plus	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
(	O
Taxol	B-CHEMICAL
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
Paclitaxel	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-CHEMICAL
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
300	O
mg	O
over	O
1	O
hour	O
before	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
350	O
mg	O
/	O
m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(	O
TFL	O
)	O
in	O
women	O
with	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL	O
:	O
nine	O
cycles	O
(	O
5	O
%)	O
were	O
associated	O
with	O
grade	O
3	O
/	O
4	O
neutropenia	B-DISEASE
requiring	O
hospitalization	O
;	O
seven	O
(	O
4	O
%)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	B-CHEMICAL
colony	I-CHEMICAL
-	I-CHEMICAL
stimulating	I-CHEMICAL
factor	I-CHEMICAL
due	O
to	O
neutropenia	B-DISEASE
Grade	O
3	O
/	O
4	O
nonhematologic	O
toxicities	B-DISEASE
Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	B-CHEMICAL
exposure	O
,	O
11	O
(	O
58	O
%)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(	O
60	O
%)	O
without	O
prior	O
doxorubicin	B-CHEMICAL
Plasma	O
paclitaxel	B-CHEMICAL
concentrations	O
were	O
measured	O
at	B-DISEASE
the	O
completion	O
of	O
paclitaxel	B-CHEMICAL
infusion	O
and	O
at	B-DISEASE
TFL	O
is	O
an	O
active	O
,	O
well	O
-	O
tolerated	O
regimen	O
in	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
Efficacy	O
and	O
proarrhythmia	O
with	O
the	O
use	O
of	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy	O
,	O
the	O
incidence	O
of	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
in	O
patients	O
treated	O
with	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Eighty	O
-	O
one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
and	O
20	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
)	O
with	O
inducible	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
received	O
oral	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
During	O
oral	O
loading	O
with	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Those	O
patients	O
in	O
whom	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
prevented	O
induction	O
of	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
Induction	O
of	O
the	O
ventricular	O
tachyarrhythmia	O
was	O
prevented	O
by	O
oral	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
in	O
35	O
(	O
43	O
%)	O
patients	O
;	O
the	O
ventricular	O
tachyarrhythmia	O
remained	O
inducible	O
in	O
40	O
(	O
49	O
%)	O
patients	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%)	O
patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Four	O
(	O
5	O
%)	O
patients	O
had	O
from	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Neither	O
ECG	O
[	O
sinus	O
-	O
cycle	O
length	O
(	O
SCL	O
),	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	B-DISEASE
risk	O
for	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
However	O
,	O
the	O
oral	O
dose	O
of	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(	O
p	O
=	O
0	O
.	O
049	O
),	O
female	O
gender	O
(	O
p	O
=	O
0	O
.	O
015	O
),	O
and	O
significant	O
dose	O
-	O
corrected	O
changes	O
of	O
SCL	O
,	O
QT	B-DISEASE
interval	I-DISEASE
During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
recurrence	B-DISEASE
One	O
female	O
patient	O
with	O
stable	O
cardiac	B-DISEASE
disease	I-DISEASE
had	O
recurrent	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(	O
cycle	O
length	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
did	O
not	O
identify	O
patients	O
at	B-DISEASE
increased	O
risk	O
for	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
Recurrence	B-DISEASE
rates	O
of	O
ventricular	O
tachyarrhythmias	O
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	B-DISEASE
Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d	O
,	O
l	O
-	O
sotalol	B-CHEMICAL
Chronic	O
hyperprolactinemia	B-DISEASE
and	O
changes	O
in	O
dopamine	B-CHEMICAL
The	O
tuberoinfundibular	O
dopaminergic	O
(	O
TIDA	O
)	O
system	O
is	O
known	O
to	O
inhibit	O
prolactin	B-CHEMICAL
However	O
,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	B-DISEASE
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	B-DISEASE
Hyperprolactinemia	B-DISEASE
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	B-CHEMICAL
,	O
a	O
dopamine	B-CHEMICAL
After	O
6	O
months	O
of	O
hyperprolactinemia	B-DISEASE
,	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
Nine	O
months	O
of	O
hyperprolactinemia	B-DISEASE
produced	O
a	O
50	O
%	O
increase	O
in	O
DA	B-CHEMICAL
However	O
,	O
DA	B-CHEMICAL
response	O
was	O
lost	O
if	O
a	O
9	O
-	O
month	O
long	O
haloperidol	B-CHEMICAL
-	O
induced	O
hyperprolactinemia	B-DISEASE
There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	B-CHEMICAL
,	O
norepinephrine	B-CHEMICAL
(	O
NE	O
),	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
),	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(	O
AN	O
),	O
medial	O
preoptic	O
area	O
(	O
MPA	O
),	O
caudate	O
putamen	O
(	O
CP	O
),	O
substantia	O
nigra	O
(	O
SN	O
),	O
and	O
zona	O
incerta	O
(	O
ZI	O
),	O
except	O
for	O
a	O
decrease	O
in	O
5	O
-	O
hydroxyindoleacetic	B-CHEMICAL
acid	I-CHEMICAL
(	O
5	O
-	O
HIAA	O
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
months	O
of	O
hyperprolactinemia	B-DISEASE
and	O
an	O
increase	O
in	O
DA	B-CHEMICAL
concentrations	O
in	O
the	O
AN	O
after	O
9	O
-	O
months	O
of	O
hyperprolactinemia	B-DISEASE
These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	B-DISEASE
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary	O
,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	B-DISEASE
The	O
age	O
-	O
related	O
decrease	O
in	O
hypothalamic	O
dopamine	B-CHEMICAL
Treatment	O
-	O
related	O
disseminated	O
necrotizing	O
leukoencephalopathy	B-DISEASE
This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	B-DISEASE
,	O
which	O
developed	O
from	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
treated	O
with	O
high	O
-	O
dose	O
methotrexate	B-CHEMICAL
In	O
both	O
patients	O
,	O
the	O
enhancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
brain	O
than	O
at	B-DISEASE
Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	O
of	O
myelination	O
and	O
necrosis	B-DISEASE
Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	B-DISEASE
Thrombotic	B-DISEASE
complications	O
in	O
acute	O
promyelocytic	O
leukemia	B-DISEASE
A	O
case	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
due	O
to	O
occlusion	O
of	O
renal	B-DISEASE
vessels	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	B-DISEASE
(	O
APL	O
)	O
treated	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
We	O
report	O
a	O
case	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	B-DISEASE
The	O
patients	O
,	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
After	O
10	O
days	O
of	O
treatment	O
,	O
he	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	B-DISEASE
Thrombotic	B-DISEASE
events	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dose	O
heparin	B-CHEMICAL
Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant	O
-	O
induced	O
mania	B-DISEASE
A	O
30	O
-	O
year	O
-	O
old	O
cocaine	B-CHEMICAL
-	O
dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	B-CHEMICAL
(	O
DEP	O
)	O
became	O
manic	B-DISEASE
Pupillometric	O
changes	O
while	O
on	O
DEP	O
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	O
oscillation	O
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	B-DISEASE
The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	O
oscillation	O
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	B-DISEASE
Such	O
medication	O
-	O
associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	O
oscillation	O
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	B-DISEASE
risk	O
for	O
manic	B-DISEASE
OBJECTIVE	O
:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain	B-DISEASE
For	O
this	O
purpose	O
,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	B-DISEASE
pain	B-DISEASE
METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
controlled	O
,	O
threefold	O
cross	O
-	O
over	O
design	O
,	O
18	O
healthy	O
subjects	O
(	O
11	O
males	O
,	O
7	O
females	O
;	O
mean	O
age	O
26	O
years	O
)	O
received	O
either	O
placebo	O
,	O
400	O
mg	O
ibuprofen	B-CHEMICAL
,	O
or	O
800	O
mg	O
ibuprofen	B-CHEMICAL
Phasic	O
pain	B-DISEASE
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	B-CHEMICAL
to	O
the	O
nasal	O
mucosa	O
(	O
stimulus	O
duration	O
500	O
ms	B-DISEASE
,	O
interval	O
approximately	O
60	O
s	O
),	O
and	O
tonic	B-DISEASE
pain	B-DISEASE
Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	B-DISEASE
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	B-CHEMICAL
Additionally	O
,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	B-DISEASE
pain	B-DISEASE
RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
administration	O
of	O
ibuprofen	B-CHEMICAL
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	B-DISEASE
pain	B-DISEASE
but	O
-	O
relative	O
to	O
placebo	O
-	O
an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	B-DISEASE
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	B-CHEMICAL
on	O
the	O
interaction	O
between	O
the	O
pain	B-DISEASE
The	O
major	O
advantage	O
of	O
this	O
pain	B-DISEASE
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain	B-DISEASE
Acute	O
severe	O
depression	B-DISEASE
following	O
peri	O
-	O
operative	O
ondansetron	B-CHEMICAL
A	O
41	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	B-CHEMICAL
She	O
had	O
developed	O
a	O
severe	O
acute	O
major	B-DISEASE
depression	I-DISEASE
disorder	O
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	B-CHEMICAL
Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self	O
-	O
limited	O
puerperal	O
depressive	B-DISEASE
Anaesthesia	O
with	O
a	O
propofol	B-CHEMICAL
infusion	O
and	O
avoidance	O
of	O
serotonin	B-CHEMICAL
antagonists	I-CHEMICAL
provided	O
a	O
nausea	B-DISEASE
-	O
free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	B-DISEASE
Hypertensive	B-DISEASE
response	O
during	O
dobutamine	B-CHEMICAL
Among	O
3	O
,	O
129	O
dobutamine	B-CHEMICAL
stress	O
echocardiographic	O
studies	O
,	O
a	O
hypertensive	B-DISEASE
Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	B-DISEASE
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O
BP	O
before	O
dobutamine	B-CHEMICAL
Continuously	O
nebulized	O
albuterol	B-CHEMICAL
in	O
severe	O
exacerbations	O
of	O
asthma	B-DISEASE
A	O
retrospective	O
,	O
case	O
-	O
controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	B-DISEASE
who	O
received	O
continuously	O
nebulized	O
albuterol	B-CHEMICAL
(	O
CNA	O
)	O
versus	O
intermittent	O
albuterol	B-CHEMICAL
Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	B-DISEASE
The	O
incidence	O
of	O
cardiac	O
dysrhythmias	B-DISEASE
Symptomatic	O
hypokalemia	B-DISEASE
Hyperosmolar	O
nonketotic	O
coma	B-DISEASE
precipitated	O
by	O
lithium	B-CHEMICAL
-	O
induced	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
with	O
a	O
10	O
-	O
year	O
history	O
of	O
manic	B-DISEASE
depression	B-DISEASE
treated	O
with	O
lithium	B-CHEMICAL
,	O
was	O
admitted	O
with	O
hyperosmolar	O
,	O
nonketotic	O
coma	B-DISEASE
He	O
gave	O
a	O
five	O
-	O
year	O
history	O
of	O
polyuria	B-DISEASE
and	O
polydipsia	B-DISEASE
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	B-CHEMICAL
After	O
recovery	O
from	O
hyperglycaemia	O
,	O
he	O
remained	O
polyuric	O
despite	O
normal	O
blood	B-CHEMICAL
glucose	I-CHEMICAL
concentrations	O
;	O
water	B-CHEMICAL
deprivation	O
testing	O
indicated	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
likely	O
to	O
be	O
lithium	B-CHEMICAL
We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
,	O
chronic	O
polyuria	B-DISEASE
due	O
to	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	B-DISEASE
Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	B-CHEMICAL
BACKGROUND	O
:	O
In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	B-CHEMICAL
This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	B-CHEMICAL
METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patients	O
(	O
14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years	O
)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	B-DISEASE
pain	I-DISEASE
,	O
we	O
measured	O
heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(	O
dP	O
/	O
dt	O
),	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15	O
-	O
minute	O
intracoronary	O
infusion	O
of	O
saline	O
(	O
n	O
=	O
10	O
,	O
control	O
subjects	O
)	O
or	O
cocaine	B-CHEMICAL
With	O
cocaine	B-CHEMICAL
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3	O
.	O
0	O
+/-	O
0	O
.	O
4	O
(	O
mean	O
+/-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	B-CHEMICAL
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	B-CHEMICAL
Cocaine	B-CHEMICAL
CONCLUSIONS	O
:	O
In	O
humans	O
,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	B-CHEMICAL
Heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
,	O
paradoxical	O
thromboembolism	B-DISEASE
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	B-CHEMICAL
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B-CHEMICAL
The	O
clinical	O
effects	O
of	O
heparin	B-CHEMICAL
Important	O
untoward	O
effects	O
of	O
heparin	B-CHEMICAL
therapy	O
including	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
,	O
heparin	B-CHEMICAL
-	O
associated	O
osteoporosis	B-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
skin	B-DISEASE
reactions	O
,	O
allergic	B-DISEASE
reactions	I-DISEASE
other	O
than	O
thrombocytopenia	B-DISEASE
and	O
alopecia	B-DISEASE
Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	O
obstruction	O
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	B-CHEMICAL
OBJECTIVE	O
:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	O
calculi	B-DISEASE
in	O
six	O
HIV	B-DISEASE
-	I-DISEASE
infected	I-DISEASE
patients	O
receiving	O
indinavir	B-CHEMICAL
,	O
the	O
most	O
commonly	O
used	O
HIV	B-CHEMICAL
protease	I-CHEMICAL
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	B-DISEASE
CONCLUSION	O
:	O
Ureteric	O
obstruction	O
caused	O
by	O
precipitated	O
indinavir	B-CHEMICAL
The	O
calculi	B-DISEASE
contrast	B-CHEMICAL
material	I-CHEMICAL
to	O
enable	O
diagnosis	O
of	O
ureteric	O
stones	O
or	O
obstruction	O
in	O
patients	O
with	O
HIV	O
infection	B-DISEASE
who	O
receive	O
indinavir	B-CHEMICAL
Ischemic	B-DISEASE
colitis	I-DISEASE
and	O
sumatriptan	B-CHEMICAL
Sumatriptan	B-CHEMICAL
succinate	O
,	O
a	O
serotonin	B-CHEMICAL
-	O
1	O
(	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
Cases	O
have	O
been	O
published	O
of	O
coronary	B-DISEASE
vasospasm	I-DISEASE
,	O
myocardial	B-DISEASE
ischemia	I-DISEASE
,	O
and	O
myocardial	B-DISEASE
infarction	I-DISEASE
occurring	O
after	O
sumatriptan	B-CHEMICAL
We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	B-DISEASE
colitis	I-DISEASE
in	O
patients	O
with	O
migraine	B-DISEASE
treated	O
with	O
sumatriptan	B-CHEMICAL
51	O
patients	O
with	O
medically	O
refractory	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	O
,	O
rigidity	B-DISEASE
,	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
Disease	I-DISEASE
85	O
percent	O
of	O
patients	O
with	O
dyskinesias	B-DISEASE
About	O
2	O
/	O
3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	O
and	O
rigidity	B-DISEASE
One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(	O
3	O
.	O
4	O
%)	O
developed	O
a	O
homonymous	O
hemianopsia	B-DISEASE
Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants	B-CHEMICAL
,	O
have	O
bleeding	B-DISEASE
Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
and	O
methylphenidate	B-CHEMICAL
A	O
1	O
-	O
year	O
-	O
old	O
female	O
presented	O
with	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
probably	O
caused	O
by	O
methylphenidate	B-CHEMICAL
She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	O
encephalomalacia	B-DISEASE
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic	O
-	O
ischemic	O
encephalopathy	B-DISEASE
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
A	O
dopaminergic	O
blockade	O
mechanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesis	O
of	O
this	O
syndrome	B-DISEASE
However	O
,	O
methylphenidate	B-CHEMICAL
is	O
a	O
dopamine	B-CHEMICAL
agonist	I-CHEMICAL
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	B-CHEMICAL
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(	O
mainly	O
the	O
midbrain	O
)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome	B-DISEASE
A	O
relative	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
-	O
ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	B-CHEMICAL
,	O
a	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
probably	O
caused	O
by	O
methylphenidate	B-CHEMICAL
Differential	O
effects	O
of	O
17alpha	O
-	O
ethinylestradiol	O
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	O
salt	B-CHEMICAL
Effects	O
of	O
17alpha	O
-	O
ethinylestradiol	O
(	O
EE	B-CHEMICAL
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	O
salt	B-CHEMICAL
For	O
this	O
purpose	O
,	O
bile	O
salt	B-CHEMICAL
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	O
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	B-CHEMICAL
7alpha	O
-	O
hydroxylase	O
(	O
CYP7A	O
),	O
and	O
sterol	O
27	O
-	O
hydroxylase	O
(	O
CYP27	O
),	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	O
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	B-CHEMICAL
BS	O
pool	O
size	O
was	O
decreased	O
by	O
27	O
%	O
but	O
total	O
BS	O
synthesis	O
was	O
not	O
affected	O
by	O
EE	B-CHEMICAL
Synthesis	O
of	O
cholate	O
was	O
reduced	O
by	O
68	O
%	O
in	O
EE	B-CHEMICAL
The	O
recently	O
identified	O
Delta22	O
-	O
isomer	O
of	O
beta	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE	B-CHEMICAL
A	O
clear	O
reduction	O
of	O
BS	O
synthesis	O
was	O
found	O
in	O
bile	O
-	O
diverted	O
rats	O
treated	O
with	O
EE	B-CHEMICAL
Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	B-CHEMICAL
Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	B-CHEMICAL
in	O
bile	O
-	O
diverted	O
rats	O
only	O
;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	B-CHEMICAL
In	O
addition	O
,	O
mRNA	O
levels	O
of	O
sterol	O
12alpha	O
-	O
hydroxylase	O
and	O
lithocholate	O
6beta	O
-	O
hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	B-CHEMICAL
This	O
study	O
shows	O
that	O
17alpha	O
-	O
ethinylestradiol	O
(	O
EE	B-CHEMICAL
)-	O
induced	O
intrahepatic	O
cholestasis	B-DISEASE
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	O
salt	B-CHEMICAL
Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	O
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	B-CHEMICAL
Glibenclamide	O
-	O
sensitive	O
hypotension	B-DISEASE
The	O
effects	O
of	O
helodermin	O
,	O
a	O
basic	O
35	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland	O
,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	B-CHEMICAL
sensitive	O
K	B-CHEMICAL
+	O
(	O
K	B-CHEMICAL
(	O
ATP	B-CHEMICAL
Helodermin	O
produced	O
hypotension	B-DISEASE
Hypotension	B-DISEASE
induced	O
by	O
both	O
peptides	B-CHEMICAL
Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin	O
-	O
induced	O
hypotension	B-DISEASE
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	B-CHEMICAL
(	O
ACh	B-CHEMICAL
)-	O
produced	O
hypotension	B-DISEASE
These	O
findings	O
suggest	O
that	O
helodermin	O
-	O
produced	O
hypotension	B-DISEASE
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide	O
-	O
sensitive	O
K	B-CHEMICAL
+	O
channels	O
(	O
K	B-CHEMICAL
(	O
ATP	B-CHEMICAL
EDRF	O
(	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
)/	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide	O
-	O
produced	O
hypotension	B-DISEASE
Long	O
-	O
term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	B-CHEMICAL
sustained	O
-	O
release	O
tablets	O
for	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
in	O
patients	O
with	O
psoriasis	B-DISEASE
Thirteen	O
psoriatic	O
patients	O
with	O
hypertension	B-DISEASE
during	O
the	O
course	O
of	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	B-CHEMICAL
channel	O
blocker	O
,	O
sustained	O
-	O
release	O
nifedipine	B-CHEMICAL
Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	B-DISEASE
state	O
before	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	B-CHEMICAL
The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
and	O
nifedipine	B-CHEMICAL
included	O
an	O
increase	O
in	O
blood	B-CHEMICAL
urea	I-CHEMICAL
nitrogen	I-CHEMICAL
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	B-DISEASE
hyperplasia	I-DISEASE
Our	O
findings	O
indicate	O
that	O
sustained	O
-	O
release	O
nifedipine	B-CHEMICAL
is	O
useful	O
for	O
hypertensive	B-DISEASE
psoriatic	O
patients	O
under	O
long	O
-	O
term	O
treatment	O
with	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	B-DISEASE
hyperplasia	I-DISEASE
Torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
ventricular	B-DISEASE
tachycardia	I-DISEASE
during	O
low	O
dose	O
intermittent	O
dobutamine	B-CHEMICAL
treatment	O
in	O
a	O
patient	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
and	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	O
,	O
severe	O
heart	B-DISEASE
failure	I-DISEASE
secondary	O
to	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
and	O
absence	O
of	O
significant	O
ventricular	B-DISEASE
arrhythmias	I-DISEASE
who	O
developed	O
QT	O
prolongation	O
and	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
ventricular	B-DISEASE
tachycardia	I-DISEASE
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(	O
2	O
.	O
5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O
dobutamine	B-CHEMICAL
This	O
report	O
of	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
ventricular	B-DISEASE
tachycardia	I-DISEASE
during	O
intermittent	O
dobutamine	B-CHEMICAL
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	B-DISEASE
Positive	O
skin	B-DISEASE
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	B-CHEMICAL
media	I-CHEMICAL
In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	B-CHEMICAL
materials	I-CHEMICAL
After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	B-DISEASE
,	O
loss	O
of	O
consciousness	O
)	O
and	O
delayed	O
macro	O
-	O
papular	O
rash	B-DISEASE
appeared	O
,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat	O
,	O
persistent	O
pain	B-DISEASE
at	B-DISEASE
The	O
skin	B-DISEASE
The	O
positive	O
skin	B-DISEASE
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	B-DISEASE
Risk	O
of	O
transient	O
hyperammonemic	O
encephalopathy	B-DISEASE
in	O
cancer	B-DISEASE
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
with	O
the	O
complication	O
of	O
dehydration	B-DISEASE
and	O
infection	B-DISEASE
From	O
1986	O
to	O
1998	O
,	O
29	O
cancer	B-DISEASE
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	O
encephalopathy	B-DISEASE
related	O
to	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	B-DISEASE
disease	I-DISEASE
Onset	O
of	O
hyperammonemic	O
encephalopathy	B-DISEASE
Among	O
the	O
32	O
episodes	O
,	O
26	O
(	O
81	O
%)	O
had	O
various	O
degrees	O
of	O
azotemia	B-DISEASE
,	O
18	O
(	O
56	O
%)	O
occurred	O
during	O
bacterial	B-DISEASE
infections	I-DISEASE
and	O
14	O
(	O
44	O
%)	O
without	O
infection	B-DISEASE
occurred	O
during	O
periods	O
of	O
dehydration	B-DISEASE
Higher	O
plasma	O
ammonium	O
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	B-DISEASE
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	B-DISEASE
infections	I-DISEASE
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
In	O
conclusion	O
,	O
hyperammonemic	O
encephalopathy	B-DISEASE
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
Azotemia	B-DISEASE
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	B-DISEASE
infections	I-DISEASE
It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
The	O
effects	O
of	O
quinine	B-CHEMICAL
and	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B-CHEMICAL
The	O
effects	O
of	O
two	O
unselective	O
potassium	B-CHEMICAL
(	O
K	B-CHEMICAL
(+)-)	O
channel	O
blockers	O
,	O
quinine	B-CHEMICAL
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
),	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B-CHEMICAL
Quinine	B-CHEMICAL
is	O
known	O
to	O
block	O
voltage	O
-,	O
calcium	B-CHEMICAL
-	O
and	O
ATP	B-CHEMICAL
-	O
sensitive	O
K	B-CHEMICAL
(+)-	O
channels	O
while	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
is	O
known	O
to	O
block	O
voltage	O
-	O
sensitive	O
K	B-CHEMICAL
In	O
the	O
counterbalanced	O
method	O
,	O
quinine	B-CHEMICAL
attenuated	O
morphine	B-CHEMICAL
-	O
induced	O
place	O
preference	O
,	O
whereas	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex	O
-	O
activity	O
meter	O
neither	O
of	O
the	O
K	B-CHEMICAL
(+)-	O
channel	O
blockers	O
affected	O
morphine	B-CHEMICAL
-	O
induced	O
hypoactivity	O
,	O
but	O
both	O
K	B-CHEMICAL
(+)-	O
channel	O
blockers	O
prevented	O
morphine	B-CHEMICAL
-	O
induced	O
secondary	O
hyperactivity	B-DISEASE
These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine	B-CHEMICAL
-	O
sensitive	O
but	O
not	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
-	O
sensitive	O
K	B-CHEMICAL
(+)-	O
channels	O
in	O
morphine	B-CHEMICAL
It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K	B-CHEMICAL
(+)-	O
channels	O
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine	B-CHEMICAL
-	O
induced	O
hypoactivity	O
whereas	O
morphine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine	B-CHEMICAL
-	O
and	O
4	B-CHEMICAL
-	I-CHEMICAL
aminopyridine	I-CHEMICAL
-	O
sensitive	O
K	B-CHEMICAL
Nociceptin	B-CHEMICAL
/	O
orphanin	O
FQ	O
and	O
nocistatin	B-CHEMICAL
on	O
learning	O
and	O
memory	B-DISEASE
impairment	I-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
Nociceptin	B-CHEMICAL
On	O
the	O
other	O
hand	B-DISEASE
,	O
nocistatin	B-CHEMICAL
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	B-CHEMICAL
and	O
blocks	O
nociceptin	B-CHEMICAL
-	O
induced	O
allodynia	O
and	O
hyperalgesia	B-DISEASE
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin	B-CHEMICAL
/	O
orphanin	O
FQ	O
and	O
nocistatin	B-CHEMICAL
could	O
modulate	O
impairment	O
of	O
learning	O
and	O
memory	O
induced	O
by	O
scopolamine	B-CHEMICAL
While	O
nocistatin	B-CHEMICAL
administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours	O
,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step	O
-	O
down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	B-CHEMICAL
Administration	O
of	O
nocistatin	B-CHEMICAL
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
attenuated	O
the	O
scopolamine	B-CHEMICAL
These	O
results	O
indicated	O
that	O
nocistatin	B-CHEMICAL
,	O
a	O
new	O
biologically	O
active	O
peptide	O
,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	B-CHEMICAL
,	O
and	O
suggested	O
that	O
these	O
peptides	B-CHEMICAL
Meloxicam	B-CHEMICAL
-	O
induced	O
liver	B-DISEASE
toxicity	B-DISEASE
We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
who	O
developed	O
acute	O
cytolytic	O
hepatitis	B-DISEASE
due	O
to	O
meloxicam	B-CHEMICAL
Recently	O
introduced	O
in	O
Belgium	O
,	O
meloxicam	B-CHEMICAL
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	B-CHEMICAL
2	I-CHEMICAL
The	O
acute	O
cytolytic	O
hepatitis	B-DISEASE
occurred	O
rapidly	O
after	O
meloxicam	B-CHEMICAL
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	B-DISEASE
This	O
first	O
case	O
of	O
meloxicam	B-CHEMICAL
related	O
liver	B-DISEASE
toxicity	B-DISEASE
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	B-DISEASE
damage	I-DISEASE
Induction	O
of	O
apoptosis	O
by	O
remoxipride	B-CHEMICAL
metabolites	O
in	O
HL60	O
and	O
CD34	O
+/	O
CD19	O
-	O
human	O
bone	O
marrow	O
progenitor	O
cells	O
:	O
potential	O
relevance	O
to	O
remoxipride	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
The	O
antipsychotic	O
agent	O
,	O
remoxipride	B-CHEMICAL
[(	O
S	O
)-(-)-	O
3	O
-	O
bromo	O
-	O
N	O
-[(	O
1	O
-	O
ethyl	O
-	O
2	O
-	O
pyrrolidinyl	O
)	O
methyl	O
]-	O
2	O
,	O
6	O
-	O
dimethoxybenz	O
amide	O
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	B-DISEASE
anemia	I-DISEASE
We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	B-CHEMICAL
,	O
three	O
pyrrolidine	B-CHEMICAL
Cells	O
were	O
treated	O
for	O
0	O
-	O
24	O
h	B-CHEMICAL
Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	O
33342	O
-	O
and	O
propidium	B-CHEMICAL
The	O
catechol	B-CHEMICAL
and	O
hydroquinone	B-CHEMICAL
metabolites	O
,	O
NCQ436	O
and	O
NCQ344	O
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time	O
-	O
and	O
concentration	O
dependent	O
manner	O
,	O
while	O
the	O
phenols	B-CHEMICAL
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	O
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	B-CHEMICAL
No	O
necrosis	B-DISEASE
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	O
but	O
NCQ344	O
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types	O
,	O
inducing	O
apoptosis	O
at	B-DISEASE
lower	O
concentrations	O
and	O
necrosis	B-DISEASE
at	B-DISEASE
These	O
data	O
show	O
that	O
the	O
catechol	B-CHEMICAL
and	O
hydroquinone	B-CHEMICAL
metabolites	O
of	O
remoxipride	B-CHEMICAL
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells	O
,	O
leading	O
to	O
apoptosis	O
,	O
while	O
the	O
phenol	B-CHEMICAL
Similarly	O
,	O
benzene	B-CHEMICAL
-	O
derived	O
catechol	B-CHEMICAL
and	O
hydroquinone	B-CHEMICAL
,	O
but	O
not	O
phenol	B-CHEMICAL
We	O
propose	O
that	O
remoxipride	B-CHEMICAL
and	O
benzene	B-CHEMICAL
may	O
induce	O
aplastic	B-DISEASE
anemia	I-DISEASE
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	O
and	O
NCQ344	O
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B-DISEASE
anemia	I-DISEASE
that	O
has	O
been	O
associated	O
with	O
remoxipride	B-CHEMICAL
Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1	O
-(	O
1	O
,	O
2	O
-	O
dihydro	O
-	O
2	O
-	O
acenaphthylenyl	O
)	O
piperazine	B-CHEMICAL
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	B-CHEMICAL
agents	I-CHEMICAL
In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	O
antipsychotic	B-CHEMICAL
agents	I-CHEMICAL
The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	B-CHEMICAL
agents	I-CHEMICAL
based	O
on	O
the	O
structure	O
of	O
1	O
-(	O
1	O
,	O
2	O
-	O
dihydro	O
-	O
2	O
-	O
acenaphthylenyl	O
)	O
piperazine	B-CHEMICAL
Compound	O
7e	O
,	O
5	O
-{	O
2	O
-[	O
4	O
-(	O
1	O
,	O
2	O
-	O
dihydro	O
-	O
2	O
-	O
acenaphthylenyl	O
)	O
piperazinyl	O
]	O
ethyl	O
}-	O
2	O
,	O
3	O
-	O
dihy	O
dro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	B-DISEASE
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	B-DISEASE
7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	B-DISEASE
induced	O
by	O
haloperidol	B-CHEMICAL
Sub	O
-	O
chronic	O
inhibition	O
of	O
nitric	O
-	O
oxide	O
synthesis	O
modifies	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
RATIONALE	O
:	O
NG	O
-	O
nitro	O
-	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
(	O
L	O
-	O
NOARG	O
),	O
an	O
inhibitor	O
of	O
nitric	O
-	O
oxide	O
synthase	O
(	O
NOS	O
),	O
induces	O
catalepsy	B-DISEASE
Nitric	B-CHEMICAL
oxide	I-CHEMICAL
Neuroleptic	B-CHEMICAL
drugs	I-CHEMICAL
such	O
as	O
haloperidol	B-CHEMICAL
,	O
which	O
block	O
dopamine	B-CHEMICAL
receptors	O
,	O
also	O
cause	O
catalepsy	B-DISEASE
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L	O
-	O
NOARG	O
treatment	O
in	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
or	O
haloperidol	B-CHEMICAL
Catalepsy	B-DISEASE
was	O
evaluated	O
at	B-DISEASE
Reduced	O
nicotinamide	O
adenine	B-CHEMICAL
dinucleotide	O
phosphate	B-CHEMICAL
RESULTS	O
:	O
L	O
-	O
NOARG	O
sub	O
-	O
chronic	O
administration	O
produced	O
tolerance	O
of	O
L	O
-	O
NOARG	O
and	O
of	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH	O
-	O
d	O
-	O
positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	B-CHEMICAL
In	O
contrast	O
,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH	O
-	O
d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra	O
,	O
pars	O
compacta	O
in	O
both	O
haloperidol	B-CHEMICAL
Prolonged	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
occurs	O
in	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
after	O
both	O
dobutamine	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
in	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
DESIGN	O
:	O
A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	B-CHEMICAL
SUBJECTS	O
:	O
10	O
patients	O
with	O
stable	O
angina	B-DISEASE
,	O
angiographically	O
proven	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
INTERVENTIONS	O
:	O
Treadmill	O
exercise	O
and	O
dobutamine	B-CHEMICAL
Quantitative	O
assessment	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
was	O
performed	O
using	O
transthoracic	O
echocardiography	O
at	B-DISEASE
baseline	O
and	O
at	B-DISEASE
There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
depression	B-DISEASE
After	O
exercise	O
,	O
ejection	O
fraction	O
was	O
reduced	O
at	B-DISEASE
01	O
),	O
and	O
at	B-DISEASE
30	O
and	O
45	O
minutes	O
after	O
dobutamine	B-CHEMICAL
Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)%,	O
both	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
at	B-DISEASE
30	O
minutes	O
after	O
dobutamine	B-CHEMICAL
CONCLUSIONS	O
:	O
In	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
dobutamine	B-CHEMICAL
induced	O
ischaemia	O
results	O
in	O
prolonged	O
reversible	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
,	O
presumed	O
to	O
be	O
myocardial	B-DISEASE
stunning	I-DISEASE
Dobutamine	B-CHEMICAL
induced	O
ischaemia	O
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
Anorexigens	O
and	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
in	O
the	O
United	O
States	O
:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
BACKGROUND	O
:	O
The	O
use	O
of	O
appetite	B-CHEMICAL
suppressants	I-CHEMICAL
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
Recently	O
,	O
fenfluramine	B-CHEMICAL
appetite	B-CHEMICAL
suppressants	I-CHEMICAL
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
at	B-DISEASE
Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants	B-CHEMICAL
,	O
anorexigens	O
,	O
and	O
amphetamines	B-CHEMICAL
RESULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
patients	O
were	O
studied	O
,	O
205	O
with	O
PPH	O
and	O
374	O
with	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
from	O
other	O
causes	O
(	O
secondary	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
Clinical	O
aspects	O
of	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
and	O
thrombosis	B-DISEASE
and	O
other	O
side	O
effects	O
of	O
heparin	B-CHEMICAL
Heparin	B-CHEMICAL
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	B-DISEASE
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B-CHEMICAL
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	B-DISEASE
The	O
clinical	O
effects	O
of	O
heparin	B-CHEMICAL
Bleeding	B-DISEASE
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	B-CHEMICAL
Major	O
bleeding	B-DISEASE
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	B-CHEMICAL
However	O
,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	B-CHEMICAL
therapy	O
include	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
,	O
heparin	B-CHEMICAL
-	O
associated	O
osteoporosis	B-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
skin	B-DISEASE
reactions	O
,	O
allergic	B-DISEASE
reactions	I-DISEASE
other	O
than	O
thrombocytopenia	B-DISEASE
,	O
alopecia	B-DISEASE
,	O
transaminasemia	O
,	O
hyperkalemia	B-DISEASE
,	O
hypoaldosteronism	B-DISEASE
,	O
and	O
priapism	B-DISEASE
These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	B-CHEMICAL
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	B-DISEASE
and	O
osteoporosis	B-DISEASE
Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
"	O
softly	O
"	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	B-CHEMICAL
,	O
at	B-DISEASE
A	O
case	O
of	O
bilateral	O
optic	B-DISEASE
neuropathy	I-DISEASE
in	O
a	O
patient	O
on	O
tacrolimus	B-CHEMICAL
(	O
FK506	B-CHEMICAL
)	O
therapy	O
after	O
liver	B-DISEASE
PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B-DISEASE
neuropathy	I-DISEASE
in	O
a	O
patient	O
receiving	O
tacrolimus	B-CHEMICAL
(	O
FK	B-CHEMICAL
506	I-CHEMICAL
,	O
Prograf	O
;	O
Fujisawa	O
USA	O
,	O
Inc	O
,	O
Deerfield	O
,	O
Illinois	O
)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	B-DISEASE
In	O
a	O
58	O
-	O
year	O
-	O
old	O
man	O
receiving	O
tacrolimus	B-CHEMICAL
after	O
orthotropic	O
liver	B-DISEASE
RESULTS	O
:	O
The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	B-DISEASE
Deterioration	O
of	O
vision	B-DISEASE
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	B-CHEMICAL
CONCLUSION	O
:	O
Tacrolimus	B-CHEMICAL
and	O
other	O
immunosuppressive	B-CHEMICAL
agents	I-CHEMICAL
may	O
be	O
associated	O
with	O
optic	O
nerve	O
toxicity	B-DISEASE
Hypercalcemia	B-DISEASE
,	O
arrhythmia	B-DISEASE
Recent	O
findings	O
in	O
a	O
bipolar	B-DISEASE
patient	O
receiving	O
maintenance	O
lithium	B-CHEMICAL
therapy	O
who	O
developed	O
hypercalcemia	B-DISEASE
and	O
severe	O
bradyarrhythmia	O
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	B-DISEASE
patients	O
with	O
lithium	B-CHEMICAL
-	O
associated	O
hypercalcemia	B-DISEASE
A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	B-DISEASE
After	O
eliminating	O
spurious	O
hypercalcemias	O
or	O
those	O
associated	O
with	O
intravenous	O
fluids	O
,	O
the	O
authors	O
identified	O
18	O
non	O
-	O
lithium	B-CHEMICAL
-	O
treated	O
patients	O
with	O
hypercalcemias	O
related	O
to	O
malignancies	B-DISEASE
and	O
other	O
medical	O
conditions	O
(	O
group	O
A	O
)	O
and	O
12	O
patients	O
with	O
lithium	B-CHEMICAL
-	O
associated	O
hypercalcemia	B-DISEASE
Thus	O
,	O
two	O
control	O
groups	O
were	O
generated	O
:	O
group	O
C1	O
,	O
which	O
included	O
age	O
-	O
and	O
sex	O
-	O
comparable	O
lithium	B-CHEMICAL
-	O
treated	O
bipolar	B-DISEASE
normocalcemic	O
patients	O
,	O
and	O
group	O
C2	O
,	O
which	O
included	O
bipolar	B-DISEASE
It	O
was	O
found	O
that	O
these	O
groups	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequency	O
of	O
ECG	O
abnormalities	B-DISEASE
Patients	O
with	O
hypercalcemia	B-DISEASE
resulting	O
from	O
medical	O
diseases	B-DISEASE
and	O
bipolar	B-DISEASE
patients	O
with	O
lithium	B-CHEMICAL
-	O
associated	O
hypercalcemia	B-DISEASE
Patients	O
in	O
group	O
A	O
had	O
significant	O
mortality	O
at	B-DISEASE
Attenuation	O
of	O
nephrotoxicity	B-DISEASE
by	O
a	O
novel	O
lipid	O
nanosphere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
NS	O
-	O
718	O
,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	B-DISEASE
We	O
compared	O
the	O
toxicity	B-DISEASE
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fungizone	B-CHEMICAL
(	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
-	O
sodium	B-CHEMICAL
deoxycholate	I-CHEMICAL
;	O
D	O
-	O
AmB	B-CHEMICAL
)	O
in	O
vitro	O
using	O
renal	B-DISEASE
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis	O
,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
Incubation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	B-DISEASE
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D	O
-	O
AmB	B-CHEMICAL
Serum	O
blood	O
urea	B-CHEMICAL
and	O
creatinine	B-CHEMICAL
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D	O
-	O
AmB	B-CHEMICAL
Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	B-DISEASE
necrosis	I-DISEASE
in	O
D	O
-	O
AmB	B-CHEMICAL
Amphotericin	B-CHEMICAL
B	I-CHEMICAL
concentrations	O
in	O
the	O
kidney	O
in	O
NS	O
-	O
718	O
-	O
treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D	O
-	O
AmB	B-CHEMICAL
Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
into	O
lipid	O
nanospheres	O
of	O
NS	O
-	O
718	O
attenuates	O
the	O
nephrotoxicity	B-DISEASE
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
Patterns	O
of	O
sulfadiazine	B-CHEMICAL
acute	O
nephrotoxicity	B-DISEASE
Sulfadiazine	B-CHEMICAL
acute	O
nephrotoxicity	B-DISEASE
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	B-DISEASE
Under	O
treatment	O
with	O
sulfadiazine	B-CHEMICAL
they	O
developed	O
oliguria	B-DISEASE
,	O
abdominal	B-DISEASE
pain	I-DISEASE
,	O
renal	B-DISEASE
failure	I-DISEASE
and	O
showed	O
multiple	O
radiolucent	O
renal	B-DISEASE
calculi	B-DISEASE
All	O
patients	O
recovered	O
their	O
previous	O
normal	O
renal	B-DISEASE
A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	O
lithiasis	B-DISEASE
None	O
of	O
them	O
needed	O
dialysis	O
or	O
a	O
renal	B-DISEASE
Treatment	O
with	O
sulfadiazine	B-CHEMICAL
requires	O
exquisite	O
control	O
of	O
renal	B-DISEASE
function	O
,	O
an	O
increase	O
in	O
water	B-CHEMICAL
ingestion	O
and	O
possibly	O
the	O
alcalinization	O
of	O
the	O
urine	B-DISEASE
Downbeat	O
nystagmus	B-DISEASE
associated	O
with	O
intravenous	O
patient	O
-	O
controlled	O
administration	O
of	O
morphine	B-CHEMICAL
IMPLICATIONS	O
:	O
This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	B-DISEASE
with	O
downbeating	O
nystagmus	B-DISEASE
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient	O
-	O
controlled	O
analgesia	O
morphine	B-CHEMICAL
Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	B-CHEMICAL
with	O
these	O
symptoms	B-DISEASE
and	I-DISEASE
signs	I-DISEASE
,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient	O
-	O
controlled	O
analgesia	O
morphine	B-CHEMICAL
Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B-CHEMICAL
and	O
amiodarone	B-CHEMICAL
in	O
animals	O
with	O
a	O
healed	O
myocardial	B-DISEASE
infarction	I-DISEASE
The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B-CHEMICAL
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	B-CHEMICAL
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	B-CHEMICAL
after	O
prolonged	O
oral	O
administration	O
,	O
both	O
at	B-DISEASE
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	B-DISEASE
infarction	I-DISEASE
All	O
dogs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
dronedarone	B-CHEMICAL
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
),	O
amiodarone	B-CHEMICAL
Heart	O
rate	O
(	O
HR	O
),	O
mean	O
arterial	O
pressure	O
(	O
MBP	O
),	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(+	O
LVdP	O
/	O
dt	O
),	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
),	O
and	O
fractional	O
shortening	O
(	O
FS	O
),	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	B-CHEMICAL
Resting	O
values	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen	O
,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose	O
-	O
dependently	O
lowered	O
after	O
dronedarone	B-CHEMICAL
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	B-CHEMICAL
Both	O
dronedarone	B-CHEMICAL
and	O
amiodarone	B-CHEMICAL
significantly	O
reduced	O
the	O
exercise	O
-	O
induced	O
tachycardia	B-DISEASE
and	O
,	O
at	B-DISEASE
the	O
highest	O
dose	O
,	O
decreased	O
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
tachycardia	B-DISEASE
Thus	O
,	O
dronedarone	B-CHEMICAL
and	O
amiodarone	B-CHEMICAL
Consequently	O
,	O
dronedarone	B-CHEMICAL
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	B-DISEASE
Phase	O
2	O
trial	O
of	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
))	O
in	O
platinum	B-CHEMICAL
/	O
paclitaxel	B-CHEMICAL
-	O
refractory	O
ovarian	O
and	O
fallopian	O
tube	O
cancers	B-DISEASE
and	O
primary	O
carcinoma	B-DISEASE
BACKGROUND	O
:	O
Several	O
studies	O
have	O
demonstrated	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
(	O
Doxil	B-CHEMICAL
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum	B-CHEMICAL
-	O
resistant	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
with	O
dose	O
limiting	O
toxicity	B-DISEASE
of	O
the	O
standard	O
dosing	O
regimen	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
)	O
being	O
severe	O
erythrodysesthesia	O
("	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
")	O
and	O
stomatitis	B-DISEASE
We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well	O
-	O
defined	O
patient	O
population	O
with	O
platinum	B-CHEMICAL
/	O
paclitaxel	B-CHEMICAL
-	O
refractory	O
disease	B-DISEASE
METHODS	O
AND	O
MATERIALS	O
:	O
Patients	O
with	O
ovarian	O
or	O
fallopian	O
tube	O
cancers	B-DISEASE
or	O
primary	O
peritoneal	O
carcinoma	B-DISEASE
with	O
platinum	B-CHEMICAL
/	O
paclitaxel	B-CHEMICAL
-	O
refractory	O
disease	B-DISEASE
(	O
stable	O
or	O
progressive	O
disease	B-DISEASE
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<	O
3	O
months	O
in	O
duration	O
)	O
were	O
treated	O
with	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
at	B-DISEASE
Six	O
(	O
12	O
%)	O
and	O
4	O
(	O
8	O
%)	O
patients	O
experienced	O
grade	O
2	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
and	O
stomatitis	B-DISEASE
One	O
patient	O
developed	O
grade	O
3	O
diarrhea	B-DISEASE
The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
CONCLUSION	O
:	O
This	O
modified	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
regimen	O
results	O
in	O
less	O
toxicity	B-DISEASE
(	O
stomatitis	B-DISEASE
,	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
Definite	O
,	O
although	O
limited	O
,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well	O
-	O
defined	O
platinum	B-CHEMICAL
-	O
and	O
paclitaxel	B-CHEMICAL
-	O
refractory	O
ovarian	B-DISEASE
cancer	I-DISEASE
Efficacy	O
of	O
olanzapine	B-CHEMICAL
in	O
acute	O
bipolar	B-DISEASE
mania	B-DISEASE
BACKGROUND	O
:	O
We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	B-CHEMICAL
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	B-DISEASE
mania	B-DISEASE
A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
bipolar	B-DISEASE
disorder	I-DISEASE
,	O
manic	B-DISEASE
or	O
mixed	O
,	O
were	O
randomized	O
to	O
olanzapine	B-CHEMICAL
The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young	O
-	O
Mania	B-DISEASE
Response	O
and	O
euthymia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	B-DISEASE
least	O
a	O
50	O
%	O
improvement	O
from	O
baseline	O
to	O
end	O
point	O
and	O
as	O
a	O
score	O
of	O
no	O
less	O
than	O
12	O
at	B-DISEASE
Safety	O
was	O
assessed	O
using	O
adverse	O
events	O
,	O
Extrapyramidal	O
Symptom	O
(	O
EPS	B-DISEASE
RESULTS	O
:	O
Olanzapine	B-CHEMICAL
-	O
treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(+/-	O
SD	O
)	O
improvement	O
in	O
Y	O
-	O
MRS	O
total	O
score	O
than	O
placebo	O
-	O
treated	O
patients	O
(-	O
14	O
.	O
8	O
+/-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+/-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<.	O
001	O
),	O
which	O
was	O
evident	O
at	B-DISEASE
Olanzapine	B-CHEMICAL
However	O
,	O
olanzapine	B-CHEMICAL
-	O
treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(+/-	O
SD	O
)	O
weight	B-DISEASE
gain	I-DISEASE
than	O
placebo	O
-	O
treated	O
patients	O
(	O
2	O
.	O
1	O
+/-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+/-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatment	O
-	O
emergent	O
somnolence	B-DISEASE
CONCLUSION	O
:	O
Olanzapine	B-CHEMICAL
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	B-DISEASE
mania	B-DISEASE
The	O
effect	O
of	O
pupil	B-DISEASE
dilation	O
with	O
tropicamide	B-CHEMICAL
on	O
vision	B-DISEASE
PURPOSE	O
:	O
To	O
assess	O
the	O
effect	O
of	O
pupil	B-DISEASE
dilation	O
on	O
vision	B-DISEASE
METHODS	O
:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers	O
,	O
before	O
and	O
after	O
pupil	B-DISEASE
dilation	O
using	O
guttae	O
tropicamide	B-CHEMICAL
The	O
mean	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
dilatation	B-DISEASE
measurements	O
were	O
tested	O
for	O
statistical	O
significance	O
at	B-DISEASE
CONCLUSIONS	O
:	O
Pupillary	O
dilation	O
may	O
lead	B-CHEMICAL
to	O
a	O
decrease	O
in	O
vision	B-DISEASE
A	O
case	O
of	O
isotretinoin	B-CHEMICAL
We	O
report	O
a	O
newborn	O
infant	B-DISEASE
with	O
multiple	O
congenital	B-DISEASE
anomalies	O
(	O
anotia	O
and	O
Taussig	O
-	O
Bing	O
malformation	O
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	B-CHEMICAL
In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
Effect	O
of	O
methoxamine	B-CHEMICAL
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	B-DISEASE
incontinence	I-DISEASE
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1	O
-	O
adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	O
stress	B-DISEASE
incontinence	I-DISEASE
Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	B-CHEMICAL
or	O
placebo	O
(	O
saline	O
)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	B-DISEASE
incontinence	I-DISEASE
Methoxamine	B-CHEMICAL
evoked	O
non	O
-	O
significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	O
significant	O
rise	O
in	O
systolic	O
blood	O
pressure	O
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	B-DISEASE
Systemic	O
side	O
effects	O
including	O
piloerection	O
,	O
headache	B-DISEASE
,	O
and	O
cold	B-DISEASE
The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub	O
-	O
type	O
-	O
selective	O
alpha1	O
-	O
adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	B-DISEASE
incontinence	I-DISEASE
Toleration	O
of	O
high	O
doses	O
of	O
angiotensin	B-CHEMICAL
-	I-CHEMICAL
converting	I-CHEMICAL
enzyme	I-CHEMICAL
inhibitors	I-CHEMICAL
in	O
patients	O
with	O
chronic	O
heart	B-DISEASE
failure	I-DISEASE
The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	B-CHEMICAL
BACKGROUND	O
:	O
Treatment	O
with	O
angiotensin	B-CHEMICAL
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	B-DISEASE
failure	I-DISEASE
(	O
CHF	B-DISEASE
),	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials	O
,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents	O
,	O
especially	O
at	B-DISEASE
The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high	O
-	O
compared	O
with	O
low	O
-	O
dose	O
lisinopril	B-CHEMICAL
in	O
CHF	B-DISEASE
METHODS	O
:	O
The	O
Assessment	O
of	O
Lisinopril	B-CHEMICAL
and	O
Survival	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
treatment	O
were	O
stabilized	O
receiving	O
medium	O
-	O
dose	O
lisinopril	B-CHEMICAL
Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	B-DISEASE
We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment	O
,	O
with	O
a	O
focus	O
on	O
hypotension	B-DISEASE
and	O
renal	B-DISEASE
dysfunction	I-DISEASE
RESULTS	O
:	O
Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
,	O
doses	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	B-DISEASE
(	O
2	O
.	O
0	O
%)	O
or	O
because	O
of	O
renal	B-DISEASE
dysfunction	I-DISEASE
or	O
hyperkalemia	B-DISEASE
Subgroups	O
presumed	O
to	O
be	O
at	B-DISEASE
higher	O
risk	O
for	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
intolerance	O
(	O
blood	O
pressure	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatinine	B-CHEMICAL
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
];	O
age	O
,	O
>	O
or	O
=	O
70	O
years	O
;	O
and	O
patients	O
with	O
diabetes	B-DISEASE
CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
therapy	O
in	O
most	O
patients	O
with	O
CHF	B-DISEASE
can	O
be	O
successfully	O
titrated	O
to	O
and	O
maintained	O
at	B-DISEASE
Cocaine	B-CHEMICAL
,	O
ethanol	B-CHEMICAL
,	O
and	O
cocaethylene	B-CHEMICAL
cardiotoxity	O
in	O
an	O
animal	O
model	O
of	O
cocaine	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
OBJECTIVES	O
:	O
Simultaneous	O
abuse	O
of	O
cocaine	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
Their	O
combined	O
cardiac	B-DISEASE
toxicity	I-DISEASE
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	B-CHEMICAL
(	O
CE	O
),	O
a	O
cocaine	B-CHEMICAL
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	B-CHEMICAL
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	O
in	O
the	O
combined	O
cardiotoxicity	B-DISEASE
of	O
cocaine	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
METHODS	O
:	O
Twenty	O
-	O
three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	B-CHEMICAL
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
ethanol	B-CHEMICAL
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
),	O
2	O
)	O
three	O
cocaine	B-CHEMICAL
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
),	O
3	O
)	O
ethanol	B-CHEMICAL
Hemodynamic	O
measurements	O
,	O
electrocardiograms	O
,	O
and	O
serum	O
drug	O
concentrations	O
were	O
obtained	O
at	B-DISEASE
baseline	O
,	O
and	O
then	O
at	B-DISEASE
The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	B-CHEMICAL
Peak	O
CE	O
levels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+/-	O
22	O
%,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%)	O
decrease	O
in	O
cardiac	B-DISEASE
output	I-DISEASE
Ventricular	B-DISEASE
arrhythmias	I-DISEASE
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
group	O
,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
CONCLUSIONS	O
:	O
Cocaine	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
Co	B-CHEMICAL
-	O
administration	O
resulted	O
in	O
prolonged	O
cardiac	B-DISEASE
toxicity	I-DISEASE
Peak	O
serum	O
cocaethylene	B-CHEMICAL
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	O
depression	B-DISEASE
Worsening	O
of	O
Parkinsonism	B-DISEASE
after	O
the	O
use	O
of	O
veralipride	B-CHEMICAL
for	O
treatment	O
of	O
menopause	B-DISEASE
We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	B-DISEASE
related	O
symptoms	O
with	O
veralipride	B-CHEMICAL
We	O
emphasize	O
the	O
anti	O
-	O
dopaminergic	O
effect	O
of	O
veralipride	B-CHEMICAL
A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	B-CHEMICAL
inhibitor	I-CHEMICAL
Viracept	O
may	O
cause	O
an	O
irregular	O
heart	O
beat	O
,	O
known	O
as	O
bradycardia	B-DISEASE
Bradycardia	B-DISEASE
Frequency	O
of	O
appearance	O
of	O
myeloperoxidase	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
patients	O
treated	O
with	O
propylthiouracil	B-CHEMICAL
OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)-	O
positive	O
vasculitis	B-DISEASE
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
who	O
were	O
treated	O
with	O
propylthiouracil	B-CHEMICAL
Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasculitis	B-DISEASE
during	O
PTU	O
therapy	O
,	O
or	O
on	O
the	O
incidence	O
of	O
MPO	O
-	O
ANCA	O
in	O
untreated	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
PATIENTS	O
:	O
We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	B-DISEASE
due	O
to	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
for	O
the	O
presence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
development	O
vasculitis	B-DISEASE
MEASUREMENTS	O
:	O
MPO	O
-	O
ANCA	O
was	O
measured	O
at	B-DISEASE
RESULTS	O
:	O
Before	O
treatment	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
Three	O
(	O
4	O
.	O
1	O
%)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO	O
-	O
ANCA	O
at	B-DISEASE
In	O
the	O
third	O
patient	O
,	O
the	O
MPO	O
-	O
ANCA	O
titre	O
increased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	B-DISEASE
CONCLUSIONS	O
:	O
PTU	O
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	B-DISEASE
Prevalence	O
of	O
heart	B-DISEASE
disease	I-DISEASE
in	O
asymptomatic	O
chronic	O
cocaine	B-CHEMICAL
To	O
determine	O
the	O
prevalence	O
of	O
heart	B-DISEASE
disease	I-DISEASE
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	B-CHEMICAL
users	O
,	O
35	O
cocaine	B-CHEMICAL
Findings	O
consistent	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
We	O
conclude	O
that	O
coronary	O
artery	O
or	O
myocardial	O
disease	B-DISEASE
is	O
common	O
(	O
38	O
%)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	B-CHEMICAL
Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	B-CHEMICAL
The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	B-CHEMICAL
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
with	O
respect	O
to	O
lipid	B-DISEASE
metabolism	I-DISEASE
Oral	O
pre	O
-	O
treatment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(-	O
1	O
)	O
day	O
(-	O
1	O
)	O
for	O
15	O
days	O
)	O
significantly	O
prevented	O
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
and	O
maintained	O
the	O
rats	O
at	B-DISEASE
Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
in	O
acquired	O
long	O
-	O
QT	O
syndrome	B-DISEASE
BACKGROUND	O
:	O
This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
(	O
TdP	B-DISEASE
)	O
with	O
QT	O
prolongation	O
induced	O
by	O
dl	O
-	O
sotalol	B-CHEMICAL
and	O
azimilide	B-CHEMICAL
The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	B-DISEASE
dl	O
-	O
Sotalol	B-CHEMICAL
Azimilide	B-CHEMICAL
,	O
however	O
,	O
significantly	O
prolonged	O
APD	O
and	O
QT	B-DISEASE
interval	I-DISEASE
at	B-DISEASE
concentrations	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shortened	O
them	O
at	B-DISEASE
Unlike	O
dl	O
-	O
sotalol	B-CHEMICAL
,	O
azimilide	B-CHEMICAL
Although	O
both	O
dl	O
-	O
sotalol	B-CHEMICAL
and	O
azimilide	B-CHEMICAL
An	O
increase	O
in	O
TDR	O
by	O
dl	O
-	O
sotalol	B-CHEMICAL
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	B-DISEASE
Of	O
note	O
,	O
although	O
azimilide	B-CHEMICAL
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
increased	O
APD	O
more	O
than	O
dl	O
-	O
sotalol	B-CHEMICAL
CONCLUSIONS	O
:	O
This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	B-DISEASE
Prenatal	O
cocaine	B-CHEMICAL
PURPOSE	O
:	O
Prenatal	O
cocaine	B-CHEMICAL
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	B-DISEASE
and	O
the	O
formation	O
of	O
cysts	B-DISEASE
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	B-DISEASE
We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	B-CHEMICAL
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	O
cysts	B-DISEASE
Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups	O
:	O
those	O
exposed	O
to	O
cocaine	B-CHEMICAL
and	O
those	O
not	O
exposed	O
to	O
cocaine	B-CHEMICAL
Infants	O
were	O
assigned	O
to	O
the	O
cocaine	B-CHEMICAL
-	O
exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	B-DISEASE
abuse	I-DISEASE
during	O
pregnancy	B-DISEASE
or	O
if	O
maternal	O
or	O
neonatal	O
urine	B-DISEASE
toxicology	O
results	O
were	O
positive	O
at	B-DISEASE
The	O
incidence	O
of	O
subependymal	O
cysts	B-DISEASE
The	O
incidence	O
of	O
subependymal	O
cysts	B-DISEASE
in	O
infants	O
exposed	O
to	O
cocaine	B-CHEMICAL
CONCLUSIONS	O
:	O
We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	O
cyst	B-DISEASE
formation	O
in	O
preterm	O
infants	O
who	O
were	O
exposed	O
to	O
cocaine	B-CHEMICAL
Thalidomide	B-CHEMICAL
neuropathy	B-DISEASE
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	B-DISEASE
cancer	I-DISEASE
We	O
prospectively	O
evaluated	O
thalidomide	B-CHEMICAL
-	O
induced	O
neuropathy	B-DISEASE
Sixty	O
-	O
seven	O
men	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
in	O
an	O
open	O
-	O
label	O
trial	O
of	O
oral	O
thalidomide	B-CHEMICAL
underwent	O
neurologic	B-DISEASE
examinations	O
and	O
nerve	O
conduction	O
studies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	B-DISEASE
Thalidomide	B-CHEMICAL
Of	O
67	O
patients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidomide	B-CHEMICAL
for	O
3	O
months	O
,	O
8	O
remained	O
at	B-DISEASE
6	O
months	O
,	O
and	O
3	O
remained	O
at	B-DISEASE
Six	O
patients	O
developed	O
neuropathy	B-DISEASE
Neuropathy	B-DISEASE
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	B-CHEMICAL
The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Overexpression	O
of	O
copper	B-CHEMICAL
/	O
zinc	B-CHEMICAL
-	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
protects	O
from	O
kanamycin	B-CHEMICAL
-	O
induced	O
hearing	B-DISEASE
loss	I-DISEASE
The	O
participation	O
of	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
in	O
aminoglycoside	B-CHEMICAL
-	O
induced	O
ototoxicity	B-DISEASE
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside	B-CHEMICAL
-	O
iron	B-CHEMICAL
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	B-CHEMICAL
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	B-CHEMICAL
attenuate	O
ototoxicity	B-DISEASE
We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu	O
/	O
Zn	O
-	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
(	O
h	B-CHEMICAL
-	O
SOD1	O
)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	B-DISEASE
Immunocytochemistry	O
confirmed	O
expression	O
of	O
h	B-CHEMICAL
Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	B-CHEMICAL
(	O
400	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
Auditory	O
thresholds	O
were	O
tested	O
by	O
evoked	O
auditory	O
brain	O
stem	O
responses	O
at	B-DISEASE
In	O
nontransgenic	O
animals	O
,	O
the	O
threshold	O
in	O
the	O
kanamycin	B-CHEMICAL
In	O
the	O
transgenic	O
group	O
,	O
kanamycin	B-CHEMICAL
The	O
effects	O
were	O
similar	O
at	B-DISEASE
The	O
protection	O
by	O
overexpression	O
of	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	B-CHEMICAL
-	O
induced	O
ototoxicity	B-DISEASE
Prednisone	B-CHEMICAL
induces	O
anxiety	B-DISEASE
OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisone	B-CHEMICAL
(	O
PDN	O
)	O
produces	O
anxiety	B-DISEASE
Anxiety	B-DISEASE
RESULTS	O
:	O
Anxiety	B-DISEASE
CONCLUSION	O
:	O
Subacute	O
exposure	O
to	O
PDN	O
induced	O
anxiety	B-DISEASE
Phase	O
II	O
study	O
of	O
carboplatin	B-CHEMICAL
and	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
in	O
patients	O
with	O
recurrent	O
squamous	O
cell	O
carcinoma	B-DISEASE
BACKGROUND	O
:	O
The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	B-CHEMICAL
and	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	O
carcinoma	B-DISEASE
METHODS	O
:	O
The	O
combination	O
of	O
carboplatin	B-CHEMICAL
(	O
area	O
under	O
the	O
concentration	O
curve	O
[	O
AUC	O
],	O
5	O
)	O
and	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
(	O
Doxil	B-CHEMICAL
;	O
starting	O
dose	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
))	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	O
cell	O
cervical	O
carcinoma	B-DISEASE
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	B-DISEASE
RESULTS	O
:	O
Twenty	O
-	O
nine	O
patients	O
were	O
assessable	O
for	O
response	O
,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	B-DISEASE
The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	B-DISEASE
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	B-DISEASE
in	O
16	O
patients	O
,	O
anemia	B-DISEASE
in	O
12	O
patients	O
,	O
thrombocytopenia	B-DISEASE
in	O
11	O
patients	O
,	O
and	O
neutropenic	O
fever	B-DISEASE
Four	O
patients	O
had	O
five	O
infusion	O
-	O
related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	B-DISEASE
included	O
nausea	B-DISEASE
in	O
17	O
patients	O
,	O
emesis	O
in	O
14	O
patients	O
,	O
fatigue	B-DISEASE
in	O
9	O
patients	O
,	O
mucositis	B-DISEASE
and	O
/	O
or	O
stomatitis	B-DISEASE
in	O
8	O
patients	O
,	O
constipation	B-DISEASE
in	O
6	O
patients	O
,	O
weight	B-DISEASE
loss	I-DISEASE
in	O
5	O
patients	O
,	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
in	O
2	O
patients	O
,	O
and	O
skin	B-DISEASE
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
carboplatin	B-CHEMICAL
and	O
liposomal	B-CHEMICAL
doxorubicin	I-CHEMICAL
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	O
carcinoma	B-DISEASE
Antimicrobial	O
-	O
induced	O
mania	B-DISEASE
The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic	O
-	O
induced	O
manic	B-DISEASE
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic	O
-	O
induced	O
mania	B-DISEASE
Twenty	O
-	O
one	O
reports	O
of	O
antimicrobial	O
-	O
induced	O
mania	B-DISEASE
There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	B-CHEMICAL
,	O
13	O
implicating	O
isoniazid	B-CHEMICAL
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	B-CHEMICAL
and	O
amoxicillin	B-CHEMICAL
Of	O
these	O
,	O
clarithromycin	B-CHEMICAL
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%)	O
cases	O
,	O
ciprofloxacin	B-CHEMICAL
in	O
12	O
(	O
14	O
.	O
4	O
%)	O
cases	O
,	O
and	O
ofloxacin	B-CHEMICAL
Cotrimoxazole	O
,	O
metronidazole	B-CHEMICAL
,	O
and	O
erythromycin	B-CHEMICAL
were	O
involved	O
in	O
15	O
reported	O
manic	B-DISEASE
Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	B-CHEMICAL
and	O
ciprofloxacin	B-CHEMICAL
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	B-DISEASE
Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	B-DISEASE
Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial	O
-	O
induced	O
mania	B-DISEASE
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial	O
-	O
induced	O
manic	B-DISEASE
episode	O
among	O
various	O
demographic	O
populations	O
,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	B-DISEASE
disorders	I-DISEASE
The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	B-DISEASE
Levodopa	B-CHEMICAL
-	O
induced	O
ocular	O
dyskinesias	B-DISEASE
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
Levodopa	B-CHEMICAL
-	O
induced	O
ocular	O
dyskinesias	B-DISEASE
Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak	O
-	O
dose	O
choreatic	O
dyskinesias	B-DISEASE
We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	B-CHEMICAL
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa	B-CHEMICAL
-	O
induce	O
ocular	O
dyskinesias	B-DISEASE
A	O
comparison	O
of	O
glyceryl	O
trinitrate	O
with	O
diclofenac	B-CHEMICAL
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B-DISEASE
Primary	O
dysmenorrhea	B-DISEASE
is	O
a	O
syndrome	B-DISEASE
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	B-CHEMICAL
However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	O
trinitrate	O
(	O
GTN	O
),	O
an	O
NO	O
donor	O
,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	B-DISEASE
in	O
comparison	O
with	O
diclofenac	B-CHEMICAL
A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	B-DISEASE
In	O
an	O
open	O
,	O
cross	O
-	O
over	O
,	O
controlled	O
design	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	O
per	O
os	O
or	O
GTN	O
patches	O
the	O
first	O
days	O
of	O
menses	O
,	O
when	O
menstrual	B-DISEASE
cramps	I-DISEASE
Patients	O
received	O
up	O
to	O
3	O
doses	O
/	O
day	O
of	O
50	O
mg	O
DCF	O
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	B-CHEMICAL
The	O
participants	O
recorded	O
menstrual	O
symptoms	O
and	O
possible	O
side	O
-	O
effects	O
at	B-DISEASE
The	O
difference	O
in	O
pain	B-DISEASE
However	O
,	O
DCF	O
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	B-DISEASE
pain	I-DISEASE
Low	B-DISEASE
back	I-DISEASE
pain	I-DISEASE
Headache	B-DISEASE
Eight	O
patients	O
stopped	O
using	O
GTN	O
because	O
headache	B-DISEASE
These	O
findings	O
indicate	O
that	O
GTN	O
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	O
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B-DISEASE
Temocapril	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	B-CHEMICAL
converting	O
enzyme	O
inhibitor	O
,	O
modulates	O
glomerular	O
injury	O
in	O
chronic	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
nephrosis	B-DISEASE
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	B-CHEMICAL
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
reduced	O
proteinuria	B-DISEASE
,	O
inhibited	O
glomerular	O
hypertrophy	B-DISEASE
and	O
prevented	O
glomerulosclerosis	B-DISEASE
in	O
chronic	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
PAN	B-CHEMICAL
)	O
-	O
induced	O
nephrotic	B-DISEASE
Nephrosis	B-DISEASE
was	O
induced	O
by	O
injection	O
of	O
PAN	B-CHEMICAL
(	O
15mg	O
/	O
100g	O
body	B-DISEASE
weight	I-DISEASE
Four	O
groups	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	B-CHEMICAL
group	O
(	O
14	O
),	O
ii	O
)	O
PAN	B-CHEMICAL
Temocapril	O
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	B-DISEASE
At	B-DISEASE
each	O
time	O
point	O
,	O
systolic	O
blood	O
pressure	O
(	O
BP	O
),	O
urinary	O
protein	O
excretion	O
and	O
renal	B-DISEASE
Systolic	O
BP	O
in	O
the	O
PAN	B-CHEMICAL
group	O
was	O
significantly	O
high	O
at	B-DISEASE
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN	B-CHEMICAL
Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	B-CHEMICAL
group	O
increased	O
significantly	O
,	O
peaking	O
at	B-DISEASE
8	O
days	O
,	O
then	O
decreased	O
at	B-DISEASE
4	O
weeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	B-DISEASE
Temocapril	O
did	O
not	O
attenuate	O
proteinuria	B-DISEASE
at	B-DISEASE
The	O
glomerulosclerosis	B-DISEASE
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	B-DISEASE
4	O
weeks	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	B-DISEASE
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	B-CHEMICAL
The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
'	O
s	O
capsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	B-CHEMICAL
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	B-CHEMICAL
It	O
appears	O
that	O
temocapril	O
was	O
effective	O
in	O
retarding	O
renal	B-DISEASE
progression	O
and	O
protected	O
renal	B-DISEASE
function	O
in	O
PAN	B-CHEMICAL
Pulmonary	B-DISEASE
hypertension	I-DISEASE
after	O
ibuprofen	B-CHEMICAL
We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	O
after	O
ibuprofen	B-CHEMICAL
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	B-DISEASE
ductus	I-DISEASE
arteriosus	I-DISEASE
with	O
ibuprofen	B-CHEMICAL
in	O
premature	O
infants	O
born	O
at	B-DISEASE
Hypoxaemia	O
resolved	O
quickly	O
on	O
inhaled	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	O
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	B-CHEMICAL
Hyponatremia	B-DISEASE
and	O
syndrome	B-DISEASE
of	O
inappropriate	O
anti	O
-	O
diuretic	O
hormone	O
reported	O
with	O
the	O
use	O
of	O
Vincristine	B-CHEMICAL
PURPOSE	O
:	O
This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company	O
'	O
s	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	B-DISEASE
and	O
/	O
or	O
syndrome	B-DISEASE
of	O
inappropriate	O
secretion	O
of	O
anti	O
-	O
diuretic	O
hormone	O
(	O
SIADH	O
)	O
among	O
vincristine	B-CHEMICAL
-	O
treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	B-DISEASE
METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
'	O
s	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	B-DISEASE
and	O
/	O
or	O
SIADH	O
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	B-CHEMICAL
RESULTS	O
:	O
A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	B-DISEASE
and	O
/	O
or	O
SIADH	O
associated	O
with	O
vincristine	B-CHEMICAL
Approximately	O
75	O
%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	B-DISEASE
or	O
lymphoma	B-DISEASE
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	B-DISEASE
increased	O
risk	O
of	O
hyponatremia	B-DISEASE
and	O
/	O
or	O
SIADH	O
associated	O
with	O
vincristine	B-CHEMICAL
Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	O
associated	O
with	O
vincristine	B-CHEMICAL
Delayed	O
toxicity	B-DISEASE
of	O
cyclophosphamide	B-CHEMICAL
The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dose	O
of	O
cyclophosphamide	B-CHEMICAL
(	O
CY	B-CHEMICAL
Inbred	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
female	O
mice	O
were	O
injected	O
with	O
CY	B-CHEMICAL
Early	O
CY	B-CHEMICAL
toxicity	B-DISEASE
caused	O
a	O
typical	O
haemorrhagic	O
cystitis	B-DISEASE
After	O
30	O
days	O
of	O
CY	B-CHEMICAL
injection	O
ulcerous	O
and	O
non	O
-	O
ulcerous	O
forms	O
of	O
chronic	O
cystitis	B-DISEASE
Delayed	O
cystitis	B-DISEASE
Mast	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
muscular	O
layers	O
of	O
the	O
bladder	O
at	B-DISEASE
Delayed	O
cystitis	B-DISEASE
These	O
results	O
indicate	O
that	O
delayed	O
toxicity	B-DISEASE
of	O
CY	B-CHEMICAL
This	O
pathology	O
resembles	O
interstitial	B-DISEASE
cystitis	I-DISEASE
in	O
humans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animal	O
model	O
for	O
studies	O
on	O
the	O
disease	B-DISEASE
High	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
/	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
in	O
combination	O
with	O
three	O
-	O
weekly	O
mitomycin	B-CHEMICAL
C	O
in	O
the	O
treatment	O
of	O
advanced	O
gastric	B-DISEASE
cancer	I-DISEASE
BACKGROUND	O
:	O
The	O
24	O
-	O
hour	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
FA	O
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	B-DISEASE
cancer	I-DISEASE
(	O
AGC	O
)	O
has	O
shown	O
to	O
be	O
effective	O
,	O
with	O
low	O
toxicity	B-DISEASE
In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3	O
-	O
weekly	O
bolus	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
,	O
FA	O
and	O
mitomycin	B-CHEMICAL
C	O
(	O
MMC	O
)	O
we	O
found	O
a	O
low	O
toxicity	B-DISEASE
In	O
order	O
to	O
improve	O
this	O
MMC	O
-	O
dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
PATIENTS	O
AND	O
METHODS	O
:	O
From	O
February	O
,	O
1998	O
to	O
September	O
,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	O
to	O
receive	O
weekly	O
24	O
-	O
hour	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
RESULTS	O
:	O
32	O
patients	O
were	O
evaluable	O
for	O
response	O
-	O
complete	O
remission	B-DISEASE
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
),	O
partial	O
remission	B-DISEASE
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
),	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
),	O
progressive	O
disease	B-DISEASE
The	O
worst	O
toxicities	B-DISEASE
(%)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
):	O
leukopenia	B-DISEASE
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrombocytopenia	B-DISEASE
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vomitus	O
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarrhea	B-DISEASE
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomatitis	B-DISEASE
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
Two	O
patients	O
developed	O
hemolytic	B-DISEASE
-	I-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
(	O
HUS	B-DISEASE
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	B-CHEMICAL
-	O
containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B-DISEASE
Persistent	O
sterile	O
leukocyturia	O
is	O
associated	O
with	O
impaired	O
renal	B-DISEASE
function	O
in	O
human	B-DISEASE
immunodeficiency	I-DISEASE
virus	I-DISEASE
type	O
1	O
-	O
infected	O
children	O
treated	O
with	O
indinavir	B-CHEMICAL
BACKGROUND	O
:	O
Prolonged	O
administration	O
of	O
indinavir	B-CHEMICAL
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	B-DISEASE
These	O
well	O
-	O
documented	O
side	O
effects	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
protease	B-CHEMICAL
inhibitor	I-CHEMICAL
DESIGN	O
:	O
A	O
prospective	O
study	O
to	O
monitor	O
indinavir	B-CHEMICAL
-	O
related	O
nephrotoxicity	B-DISEASE
in	O
a	O
cohort	O
of	O
30	O
human	B-DISEASE
immunodeficiency	I-DISEASE
virus	I-DISEASE
type	O
1	O
-	O
infected	O
children	O
treated	O
with	O
indinavir	B-CHEMICAL
METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	B-CHEMICAL
Serum	O
creatinine	B-CHEMICAL
levels	O
were	O
routinely	O
determined	O
at	B-DISEASE
Steady	O
-	O
state	O
pharmacokinetics	O
of	O
indinavir	B-CHEMICAL
were	O
done	O
at	B-DISEASE
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	B-CHEMICAL
RESULTS	O
:	O
The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	O
(>	O
or	O
=	O
75	O
cells	O
/	O
micro	O
L	O
in	O
at	B-DISEASE
Persistent	O
sterile	O
leukocyturia	O
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	B-DISEASE
albumin	O
/	O
creatinine	B-CHEMICAL
ratio	O
and	O
by	O
microscopic	B-DISEASE
hematuria	I-DISEASE
The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	B-CHEMICAL
Children	O
with	O
persistent	O
sterile	O
leukocyturia	O
more	O
frequently	O
had	O
serum	O
creatinine	B-CHEMICAL
A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	O
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	B-CHEMICAL
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	B-CHEMICAL
In	O
4	O
children	O
,	O
indinavir	B-CHEMICAL
was	O
discontinued	O
because	O
of	O
nephrotoxicity	B-DISEASE
Subsequently	O
,	O
the	O
serum	O
creatinine	B-CHEMICAL
levels	O
decreased	O
,	O
the	O
urine	B-DISEASE
albumin	O
/	O
creatinine	B-CHEMICAL
CONCLUSIONS	O
:	O
Children	O
treated	O
with	O
indinavir	B-CHEMICAL
Children	O
with	O
persistent	O
sterile	O
leukocyturia	O
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	B-CHEMICAL
Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	B-DISEASE
The	O
impairment	O
of	O
the	O
renal	B-DISEASE
function	O
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	B-DISEASE
Indinavir	B-CHEMICAL
-	O
associated	O
nephrotoxicity	B-DISEASE
must	O
be	O
monitored	O
closely	O
,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	O
,	O
age	O
<	O
5	O
.	O
6	O
years	O
,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	B-CHEMICAL
>	O
19	O
mg	O
/	O
L	O
x	O
h	B-CHEMICAL
Utility	O
of	O
troponin	B-CHEMICAL
I	I-CHEMICAL
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
Baseline	O
electrocardiogram	O
abnormalities	B-DISEASE
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	O
necrosis	B-DISEASE
make	O
accurate	O
diagnosis	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
MI	O
)	O
difficult	O
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
OBJECTIVE	O
:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	B-CHEMICAL
chest	B-DISEASE
pain	I-DISEASE
METHODS	O
:	O
Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	O
after	O
cocaine	B-CHEMICAL
All	O
patients	O
underwent	O
a	O
rapid	O
rule	O
-	O
in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	B-CHEMICAL
kinase	I-CHEMICAL
(	O
CK	O
),	O
CK	O
-	O
MB	O
,	O
and	O
cardiac	O
troponin	B-CHEMICAL
I	I-CHEMICAL
Outcomes	O
included	O
CK	O
-	O
MB	O
MI	O
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[(	O
CK	O
-	O
MB	O
x	O
100	O
)/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
cardiac	O
death	B-DISEASE
,	O
and	O
significant	O
coronary	B-DISEASE
disease	I-DISEASE
Angiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patients	O
who	O
were	O
cTnI	O
-	O
positive	O
,	O
with	O
significant	O
disease	B-DISEASE
Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	B-DISEASE
Sensitivities	O
,	O
specificities	O
,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	O
death	B-DISEASE
or	O
significant	O
disease	B-DISEASE
CONCLUSIONS	O
:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	O
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease	B-DISEASE
Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK	O
-	O
MB	O
for	O
diagnosing	O
necrosis	B-DISEASE
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
Acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
due	O
to	O
nicergoline	B-CHEMICAL
We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
(	O
AIN	O
)	O
due	O
to	O
nicergoline	B-CHEMICAL
A	O
50	O
-	O
year	O
-	O
old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	B-CHEMICAL
and	O
bendazac	B-CHEMICAL
lysine	I-CHEMICAL
due	O
to	O
retinal	B-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
at	B-DISEASE
Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fever	B-DISEASE
and	O
skin	B-DISEASE
rash	B-DISEASE
arthralgia	B-DISEASE
and	O
fever	B-DISEASE
eosinophilia	B-DISEASE
and	O
renal	B-DISEASE
failure	I-DISEASE
)	O
suggested	O
AIN	O
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	B-DISEASE
A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	B-CHEMICAL
Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	B-CHEMICAL
and	O
intravenous	O
methylprednisolone	B-CHEMICAL
,	O
and	O
his	O
renal	B-DISEASE
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline	B-CHEMICAL
Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
complicated	O
by	O
massive	O
intestinal	O
bleeding	B-DISEASE
in	O
a	O
patient	O
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
A	O
patient	O
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
CRF	B-DISEASE
)	O
developed	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
(	O
NMS	O
)	O
after	O
administration	O
of	O
risperidone	B-CHEMICAL
In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	O
,	O
massive	O
intestinal	O
bleeding	B-DISEASE
This	O
report	O
suggests	O
that	O
NMS	O
in	O
a	O
patient	O
with	O
CRF	B-DISEASE
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	B-DISEASE
Adrenaline	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	B-CHEMICAL
(	O
TTC	O
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	B-CHEMICAL
After	O
adrenaline	B-CHEMICAL
Similar	O
results	O
were	O
obtained	O
in	O
seizure	B-DISEASE
Carvedilol	B-CHEMICAL
protects	O
against	O
doxorubicin	B-CHEMICAL
-	O
induced	O
mitochondrial	O
cardiomyopathy	B-DISEASE
Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose	O
-	O
limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	B-DISEASE
caused	O
by	O
doxorubicin	B-CHEMICAL
Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	B-CHEMICAL
,	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties	O
,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	B-CHEMICAL
toxicity	B-DISEASE
Heart	O
and	O
liver	B-DISEASE
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	B-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
),	O
carvedilol	B-CHEMICAL
Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin	B-CHEMICAL
-	O
treated	O
rats	O
exhibited	O
depressed	B-DISEASE
Mitochondrial	O
calcium	B-CHEMICAL
-	O
loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH	O
-	O
dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin	B-CHEMICAL
Doxorubicin	B-CHEMICAL
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	B-DISEASE
Coadministration	O
of	O
carvedilol	B-CHEMICAL
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	B-CHEMICAL
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver	B-DISEASE
Carvedilol	B-CHEMICAL
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca	B-CHEMICAL
(	O
2	O
+)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	B-CHEMICAL
Carvedilol	B-CHEMICAL
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	B-DISEASE
It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	B-CHEMICAL
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose	O
-	O
limiting	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
and	O
cardiomyopathy	B-DISEASE
that	O
accompanies	O
long	O
-	O
term	O
doxorubicin	B-CHEMICAL
therapy	O
in	O
cancer	B-DISEASE
Cocaine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
is	O
more	O
influenced	O
by	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
than	O
amphetamine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
The	O
influence	O
of	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine	B-CHEMICAL
-	O
and	O
amphetamine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
All	O
adenosine	B-CHEMICAL
It	O
seems	O
that	O
adenosine	B-CHEMICAL
Moreover	O
,	O
all	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
:	O
2	O
-	O
p	O
-(	O
2	O
-	O
carboxyethyl	O
)	O
phenethylamino	O
-	O
5	O
'-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
CGS	O
21680	O
),	O
A2A	O
receptor	O
agonist	O
,	O
N6	O
-	O
cyclopentyladenosine	O
(	O
CPA	B-CHEMICAL
),	O
A1	O
receptor	O
agonist	O
,	O
and	O
5	O
'-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
NECA	O
),	O
A2	O
/	O
A1	O
receptor	O
agonist	O
significantly	O
and	O
dose	O
-	O
dependently	O
decreased	O
cocaine	B-CHEMICAL
CPA	B-CHEMICAL
reduced	O
cocaine	B-CHEMICAL
action	O
at	B-DISEASE
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	O
21680	O
and	O
NECA	O
decreased	O
the	O
action	O
of	O
cocaine	B-CHEMICAL
at	B-DISEASE
These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	B-CHEMICAL
receptors	O
in	O
the	O
action	O
of	O
cocaine	B-CHEMICAL
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B-CHEMICAL
receptor	O
by	O
DMPX	O
(	O
3	B-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
propargylxanthine	I-CHEMICAL
)	O
significantly	O
enhanced	O
cocaine	B-CHEMICAL
Caffeine	B-CHEMICAL
Similarly	O
,	O
all	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
decreased	O
amphetamine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
,	O
but	O
at	B-DISEASE
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B-CHEMICAL
receptors	O
(	O
DMPX	O
)	O
and	O
non	O
-	O
selective	O
blockade	O
of	O
adenosine	B-CHEMICAL
receptors	O
(	O
caffeine	B-CHEMICAL
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	B-CHEMICAL
Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
(	O
A1	O
and	O
A2	O
)	O
reduce	O
cocaine	B-CHEMICAL
-	O
and	O
amphetamine	B-CHEMICAL
-	O
induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
is	O
more	O
influenced	O
by	O
adenosine	B-CHEMICAL
receptor	O
agonists	O
(	O
particularly	O
A1	O
receptors	O
)	O
than	O
amphetamine	B-CHEMICAL
-	O
induced	O
hyperactivity	B-DISEASE
Amiodarone	B-CHEMICAL
and	O
the	O
risk	O
of	O
bradyarrhythmia	O
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
and	O
prior	O
myocardial	B-DISEASE
infarction	I-DISEASE
OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	B-CHEMICAL
in	O
patients	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
BACKGROUND	O
:	O
Reports	O
of	O
severe	O
bradyarrhythmia	O
during	O
amiodarone	B-CHEMICAL
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy	O
'	O
s	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	B-DISEASE
arrhythmias	I-DISEASE
METHODS	O
:	O
A	O
study	O
cohort	O
of	O
8	O
,	O
770	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	O
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	B-CHEMICAL
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	B-CHEMICAL
,	O
Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
,	O
and	O
digoxin	B-CHEMICAL
RESULTS	O
:	O
amiodarone	B-CHEMICAL
Digoxin	B-CHEMICAL
CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	B-CHEMICAL
The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	B-CHEMICAL
Indomethacin	B-CHEMICAL
-	O
induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	B-DISEASE
bladder	I-DISEASE
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	B-CHEMICAL
Nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B-DISEASE
In	O
addition	O
to	O
tiaprofenic	B-CHEMICAL
acid	I-CHEMICAL
,	O
indomethacin	B-CHEMICAL
METHODS	O
:	O
Three	O
groups	O
were	O
established	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
10	O
),	O
a	O
high	O
-	O
dose	O
group	O
(	O
n	O
=	O
10	O
),	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	B-CHEMICAL
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oral	O
indomethacin	B-CHEMICAL
was	O
administered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
When	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
indomethacin	B-CHEMICAL
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
penetration	O
of	O
lanthanum	B-CHEMICAL
CONCLUSIONS	O
:	O
Indomethacin	B-CHEMICAL
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	B-DISEASE
cystitis	I-DISEASE
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	B-DISEASE
The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B-DISEASE
An	O
open	O
-	O
label	O
phase	O
II	O
study	O
of	O
low	O
-	O
dose	O
thalidomide	B-CHEMICAL
in	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
The	O
antiangiogenic	O
effects	O
of	O
thalidomide	B-CHEMICAL
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	O
malignancies	B-DISEASE
Thalidomide	B-CHEMICAL
We	O
undertook	O
an	O
open	O
-	O
label	O
study	O
using	O
thalidomide	B-CHEMICAL
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate	B-CHEMICAL
-	I-CHEMICAL
specific	I-CHEMICAL
antigen	I-CHEMICAL
(	O
PSA	O
),	O
urea	B-CHEMICAL
and	O
electrolytes	B-CHEMICAL
Three	O
men	O
(	O
15	O
%)	O
showed	O
a	O
decline	O
in	O
serum	O
PSA	O
of	O
at	B-DISEASE
Of	O
16	O
men	O
treated	O
for	O
at	B-DISEASE
Increasing	O
levels	O
of	O
serum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressive	O
disease	B-DISEASE
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decline	O
in	O
bFGF	O
and	O
VEGF	O
levels	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increase	O
in	O
both	O
growth	B-DISEASE
factors	I-DISEASE
Adverse	O
effects	O
included	O
constipation	B-DISEASE
,	O
morning	O
drowsiness	O
,	O
dizziness	B-DISEASE
and	O
rash	B-DISEASE
Evidence	O
of	O
peripheral	O
sensory	O
neuropathy	B-DISEASE
In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	B-CHEMICAL
,	O
subclinical	O
evidence	O
of	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	B-DISEASE
The	O
findings	O
indicate	O
that	O
thalidomide	B-CHEMICAL
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Central	O
nervous	O
system	O
toxicity	B-DISEASE
following	O
the	O
administration	O
of	O
levobupivacaine	B-CHEMICAL
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Central	O
nervous	O
system	O
and	O
cardiac	B-DISEASE
toxicity	I-DISEASE
following	O
the	O
administration	O
of	O
local	O
anesthetics	B-CHEMICAL
Levobupivacaine	B-CHEMICAL
,	O
the	O
pure	O
S	O
(-)	O
enantiomer	O
of	O
bupivacaine	B-CHEMICAL
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	B-CHEMICAL
We	O
describe	O
2	O
cases	O
of	O
grand	O
mal	O
seizures	B-DISEASE
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	B-CHEMICAL
Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	B-CHEMICAL
0	O
.	O
5	O
%	O
with	O
epinephrine	B-CHEMICAL
2	O
.	O
5	O
microgram	O
/	O
mL	O
,	O
the	O
patients	O
developed	O
grand	O
mal	O
seizures	B-DISEASE
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	B-CHEMICAL
The	O
seizures	B-DISEASE
were	O
successfully	O
treated	O
with	O
sodium	B-CHEMICAL
thiopental	B-CHEMICAL
in	O
addition	O
to	O
succinylcholine	B-CHEMICAL
Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	O
toxicity	B-DISEASE
Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta	O
-	O
adrenergic	B-CHEMICAL
antagonist	I-CHEMICAL
medications	O
,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	B-CHEMICAL
with	O
epinephrine	B-CHEMICAL
CONCLUSIONS	O
:	O
Although	O
levobupivacaine	B-CHEMICAL
may	O
have	O
a	O
safer	O
cardiac	B-DISEASE
toxicity	I-DISEASE
profile	O
than	O
racemic	O
bupivacaine	B-CHEMICAL
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	B-CHEMICAL
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	B-DISEASE
Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	O
nervous	O
system	O
toxicity	B-DISEASE
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	B-DISEASE
toxicity	I-DISEASE
Anaesthetic	O
complications	O
associated	O
with	O
myotonia	B-DISEASE
congenita	I-DISEASE
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	B-DISEASE
disorders	I-DISEASE
Myotonia	B-DISEASE
congenita	I-DISEASE
We	O
describe	O
a	O
previously	O
healthy	O
32	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
life	O
-	O
threatening	O
muscle	O
spasm	B-DISEASE
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	B-CHEMICAL
The	O
muscle	O
spasms	B-DISEASE
Myotonia	B-DISEASE
We	O
give	O
a	O
brief	B-DISEASE
overview	O
of	O
ion	O
channel	O
disorders	O
including	O
malignant	B-DISEASE
hyperthermia	I-DISEASE
Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	B-DISEASE
PURPOSE	O
:	O
Apnea	B-DISEASE
is	O
known	O
to	O
occur	O
during	O
seizures	B-DISEASE
Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine	B-CHEMICAL
-	O
induced	O
epilepsy	B-DISEASE
METHODS	O
:	O
Twelve	O
rats	O
(	O
six	O
chronically	O
epileptic	B-DISEASE
animals	O
and	O
six	O
controls	O
)	O
were	O
anesthetized	O
,	O
given	O
tracheotomies	O
,	O
and	O
subjected	O
to	O
hyperventilation	B-DISEASE
or	O
hypoventilation	B-DISEASE
RESULTS	O
:	O
The	O
hyperventilation	B-DISEASE
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine	B-CHEMICAL
Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups	O
,	O
in	O
the	O
epileptic	B-DISEASE
The	O
hypoventilation	B-DISEASE
In	O
the	O
epileptic	B-DISEASE
CONCLUSIONS	O
:	O
The	O
data	O
indicate	O
that	O
pilocarpine	B-CHEMICAL
We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy	B-DISEASE
Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
due	O
to	O
paracetamol	B-CHEMICAL
overdose	B-DISEASE
BACKGROUND	O
/	O
AIMS	O
:	O
Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas	O
/	O
Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
METHODOLOGY	O
:	O
Serum	O
levels	O
of	O
sFas	O
(	O
soluble	O
Fas	O
)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
Serum	O
levels	O
of	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
and	O
interferon	B-CHEMICAL
-	I-CHEMICAL
gamma	I-CHEMICAL
RESULTS	O
:	O
Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
due	O
to	O
paracetamol	B-CHEMICAL
overdose	B-DISEASE
(	O
median	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepatitis	B-DISEASE
A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	B-CHEMICAL
CONCLUSIONS	O
:	O
The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
may	O
reflect	O
activation	O
of	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
liver	B-DISEASE
and	O
this	O
together	O
with	O
increased	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
may	O
be	O
an	O
important	O
factor	O
in	O
liver	B-DISEASE
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
advanced	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
METHOD	O
:	O
Twenty	O
-	O
three	O
patients	O
suffering	O
from	O
severe	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
Stages	O
III	O
-	O
V	O
on	O
Hoehn	O
and	O
Yahr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinesia	O
,	O
rigidity	B-DISEASE
,	O
and	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	B-DISEASE
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
follow	O
-	O
up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
drug	O
conditions	O
,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
Disease	I-DISEASE
RESULTS	O
:	O
After	O
one	O
year	O
of	O
electrical	O
stimulation	O
of	O
the	O
STN	O
,	O
the	O
patients	O
'	O
scores	O
for	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
examination	O
scores	O
(	O
Unified	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
Disease	I-DISEASE
The	O
subscores	O
for	O
the	O
akinesia	O
,	O
rigidity	B-DISEASE
,	O
tremor	B-DISEASE
The	O
average	O
levodopa	B-CHEMICAL
Two	O
patients	O
developed	O
device	O
-	O
related	O
complications	O
and	O
two	O
patients	O
experienced	O
abnormal	O
weight	B-DISEASE
gain	I-DISEASE
CONCLUSION	O
:	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
It	O
reduces	O
the	O
severity	O
of	O
"	O
off	O
"	O
phase	O
symptoms	O
,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	B-CHEMICAL
The	O
reduction	O
in	O
the	O
levodopa	B-CHEMICAL
dose	O
is	O
useful	O
in	O
controlling	O
drug	O
-	O
induced	O
dyskinesias	B-DISEASE
Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	B-CHEMICAL
chemotherapy	O
for	O
retinoblastoma	B-DISEASE
BACKGROUND	O
:	O
Focal	O
subtenon	O
carboplatin	B-CHEMICAL
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity	B-DISEASE
-	O
free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	B-DISEASE
OBJECTIVE	O
:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	O
ocular	O
motility	O
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	B-CHEMICAL
METHODS	O
:	O
We	O
noted	O
abnormal	O
ocular	O
motility	O
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	B-DISEASE
who	O
had	O
received	O
subtenon	O
carboplatin	B-CHEMICAL
During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia	O
,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing	O
,	O
comparing	O
ocular	O
motility	O
after	O
tumor	B-DISEASE
control	O
with	O
ocular	O
motility	O
at	B-DISEASE
RESULTS	O
:	O
Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	B-DISEASE
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	B-CHEMICAL
Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye	O
,	O
indicative	O
of	O
phagocytosis	B-DISEASE
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	B-DISEASE
necrosis	I-DISEASE
The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	B-DISEASE
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	B-DISEASE
adhesions	I-DISEASE
CONCLUSIONS	O
:	O
Subtenon	O
carboplatin	B-CHEMICAL
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	B-DISEASE
Subtenon	O
carboplatin	B-CHEMICAL
is	O
not	O
free	O
of	O
toxicity	B-DISEASE
Ethambutol	B-CHEMICAL
and	O
optic	B-DISEASE
neuropathy	I-DISEASE
PURPOSE	O
:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	B-CHEMICAL
and	O
optic	B-DISEASE
neuropathy	I-DISEASE
METHOD	O
:	O
Thirteen	O
patients	O
who	O
developed	O
optic	B-DISEASE
neuropathy	I-DISEASE
after	O
being	O
treated	O
with	O
ethambutol	B-CHEMICAL
for	O
tuberculosis	B-DISEASE
of	O
the	O
lung	B-DISEASE
or	O
lymph	O
node	O
at	B-DISEASE
RESULTS	O
:	O
All	O
patients	O
had	O
optic	B-DISEASE
neuropathy	I-DISEASE
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2	O
.	O
9	O
months	O
)	O
after	O
starting	O
ethambutol	B-CHEMICAL
therapy	O
at	B-DISEASE
Of	O
6	O
patients	O
with	O
irreversible	O
visual	O
impairment	O
,	O
4	O
patients	O
had	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
glaucoma	B-DISEASE
and	O
a	O
history	O
of	O
heavy	O
smoking	B-CHEMICAL
CONCLUSION	O
:	O
Early	O
recognition	O
of	O
optic	B-DISEASE
neuropathy	I-DISEASE
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	B-CHEMICAL
A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
glaucoma	B-DISEASE
Treatment	O
of	O
compensatory	O
gustatory	O
hyperhidrosis	B-DISEASE
with	O
topical	O
glycopyrrolate	B-CHEMICAL
Gustatory	O
hyperhidrosis	B-DISEASE
is	O
facial	O
sweating	B-DISEASE
Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	B-CHEMICAL
chloride	I-CHEMICAL
Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
topical	O
glycopyrrolate	B-CHEMICAL
All	O
patients	O
had	O
gustatory	O
hyperhidrosis	B-DISEASE
,	O
which	O
interfered	O
with	O
their	O
social	O
activities	O
,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	B-DISEASE
After	O
applying	O
topical	O
glycopyrrolate	B-CHEMICAL
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	B-DISEASE
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77	O
%),	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	B-DISEASE
Adverse	O
effects	O
included	O
a	O
mildly	O
dry	B-DISEASE
mouth	I-DISEASE
and	O
a	O
sore	B-DISEASE
throat	I-DISEASE
in	O
2	O
patients	O
(	O
2	O
%	O
glycopyrrolate	B-CHEMICAL
),	O
a	O
light	O
headache	B-DISEASE
in	O
1	O
patient	O
(	O
1	O
.	O
5	O
%	O
glycopyrrolate	B-CHEMICAL
The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	B-CHEMICAL
pad	B-DISEASE
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
well	O
tolerated	O
,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	O
hyperhidrosis	B-DISEASE
Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	B-CHEMICAL
We	O
compared	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	B-CHEMICAL
(	O
AM149	O
1	O
%),	O
which	O
does	O
not	O
contain	O
soyabean	O
oil	O
,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	B-CHEMICAL
In	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
propofol	B-CHEMICAL
Plasma	O
propofol	B-CHEMICAL
levels	O
were	O
measured	O
for	O
48	O
h	B-CHEMICAL
The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
effects	O
,	O
and	O
pain	B-DISEASE
Patients	O
were	O
monitored	O
for	O
side	O
effects	O
over	O
48	O
h	B-CHEMICAL
.	O
Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	B-DISEASE
Pain	B-DISEASE
20	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thrombophlebitis	B-DISEASE
Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	B-DISEASE
Vinorelbine	B-CHEMICAL
Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	B-CHEMICAL
In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	B-DISEASE
Randomized	O
clinical	O
trials	O
comparing	O
VNR	O
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	B-DISEASE
Outcomes	O
of	O
interest	O
were	O
severe	O
cardiac	O
events	O
,	O
toxic	O
deaths	B-DISEASE
and	O
cardiac	O
event	O
-	O
related	O
deaths	B-DISEASE
The	O
risk	O
of	O
VNR	O
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	B-CHEMICAL
(	O
VDS	O
)	O
and	O
other	O
cardiotoxic	B-DISEASE
drugs	O
[	O
fluorouracil	B-CHEMICAL
,	O
anthracyclines	B-CHEMICAL
,	O
gemcitabine	B-CHEMICAL
(	O
GEM	B-CHEMICAL
Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases	O
,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history	O
,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre	O
-	O
existing	O
cardiac	B-DISEASE
diseases	I-DISEASE
Vinorelbine	B-CHEMICAL
MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	B-DISEASE
in	O
a	O
child	O
with	O
hemolytic	B-DISEASE
anemia	I-DISEASE
We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	B-DISEASE
anemia	I-DISEASE
crisis	O
induced	O
by	O
trimethoprim	B-CHEMICAL
Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	B-DISEASE
Although	O
cortical	O
laminar	O
necrosis	B-DISEASE
The	O
natural	O
history	O
of	O
Vigabatrin	B-CHEMICAL
associated	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
PURPOSE	O
:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin	B-CHEMICAL
-	O
associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	B-DISEASE
METHODS	O
:	O
All	O
patients	O
taking	O
Vigabatrin	B-CHEMICAL
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	B-DISEASE
Patients	O
were	O
followed	O
up	O
at	B-DISEASE
Following	O
already	O
published	O
methodology	O
(	O
Eye	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
monocular	O
mean	O
radial	O
degrees	O
(	O
MRDs	O
)	O
to	O
the	O
I	O
/	O
4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	B-DISEASE
RESULTS	O
:	O
Mean	O
right	O
eye	O
MRD	O
at	B-DISEASE
CONCLUSION	O
:	O
Established	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	B-CHEMICAL
These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin	B-CHEMICAL
-	O
associated	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose	O
-	O
dependent	O
toxicity	B-DISEASE
Induction	O
of	O
rosaceiform	O
dermatitis	B-DISEASE
during	O
treatment	O
of	O
facial	O
inflammatory	O
dermatoses	B-DISEASE
with	O
tacrolimus	B-CHEMICAL
BACKGROUND	O
:	O
Tacrolimus	B-CHEMICAL
ointment	O
is	O
increasingly	O
used	O
for	O
anti	O
-	O
inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face	O
,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid	B-CHEMICAL
-	O
aggravated	O
rosacea	B-DISEASE
and	O
perioral	O
dermatitis	B-DISEASE
We	O
report	O
on	O
rosaceiform	O
dermatitis	B-DISEASE
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B-CHEMICAL
OBSERVATIONS	O
:	O
Six	O
adult	O
patients	O
with	O
inflammatory	O
facial	B-DISEASE
dermatoses	I-DISEASE
were	O
treated	O
with	O
tacrolimus	B-CHEMICAL
Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well	O
-	O
tolerated	O
treatment	O
,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	B-DISEASE
and	O
1	O
with	O
a	O
history	O
of	O
acne	B-DISEASE
In	O
1	O
patient	O
with	O
eyelid	O
eczema	B-DISEASE
,	O
rosaceiform	O
periocular	O
dermatitis	B-DISEASE
In	O
1	O
patient	O
with	O
atopic	B-DISEASE
dermatitis	I-DISEASE
,	O
telangiectatic	O
and	O
papular	O
rosacea	B-DISEASE
CONCLUSIONS	O
:	O
Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	B-DISEASE
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B-CHEMICAL
A	O
variety	O
of	O
factors	O
,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	B-CHEMICAL
Structural	O
abnormalities	B-DISEASE
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	B-CHEMICAL
We	O
visualize	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
profile	O
of	O
structural	O
deficits	O
in	O
the	O
human	O
brain	O
associated	O
with	O
chronic	O
methamphetamine	B-CHEMICAL
Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	O
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	O
abnormalities	B-DISEASE
Using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
new	O
computational	O
brain	O
-	O
mapping	O
techniques	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	O
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	B-DISEASE
impairment	I-DISEASE
We	O
used	O
high	O
-	O
resolution	O
MRI	O
and	O
surface	O
-	O
based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	B-DISEASE
On	O
average	O
,	O
MA	O
abusers	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
left	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
right	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
white	O
-	O
matter	O
hypertrophy	B-DISEASE
MRI	O
-	O
based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	B-CHEMICAL
MA	O
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and	O
,	O
consistent	O
with	O
metabolic	O
studies	O
,	O
the	O
cingulate	O
-	O
limbic	O
cortex	O
,	O
inducing	O
neuroadaptation	O
,	O
neuropil	O
reduction	O
,	O
or	O
cell	O
death	B-DISEASE
Prominent	O
white	O
-	O
matter	O
hypertrophy	B-DISEASE
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes	O
,	O
including	O
gliosis	B-DISEASE
secondary	O
to	O
neuronal	B-DISEASE
damage	I-DISEASE
These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	O
abuse	O
,	O
providing	O
therapeutic	O
targets	O
for	O
drug	O
-	O
induced	O
brain	B-DISEASE
injury	I-DISEASE
Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	B-CHEMICAL
Amiodarone	B-CHEMICAL
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	B-DISEASE
To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	B-CHEMICAL
Amiodarone	B-CHEMICAL
induced	O
hepatomegaly	B-DISEASE
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	B-CHEMICAL
and	O
glucose	B-CHEMICAL
The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	B-DISEASE
in	O
PPARalpha	O
knockout	O
[	O
PPARalpha	O
-/-]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	B-CHEMICAL
Compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
treatment	O
of	O
PPARalpha	O
-/-	O
mice	O
with	O
amiodarone	B-CHEMICAL
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	B-DISEASE
weight	I-DISEASE
The	O
inability	O
of	O
amiodarone	B-CHEMICAL
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	O
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	B-CHEMICAL
Based	O
upon	O
these	O
results	O
,	O
we	O
conclude	O
that	O
amiodarone	B-CHEMICAL
These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	B-DISEASE
effects	O
of	O
amiodarone	B-CHEMICAL
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone	B-CHEMICAL
-	O
induced	O
hepatotoxicity	B-DISEASE
Safety	O
and	O
compliance	O
with	O
once	O
-	O
daily	O
niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
Niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	B-DISEASE
This	O
open	O
-	O
labeled	O
,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
A	O
total	O
of	O
4	O
,	O
499	O
patients	O
with	O
dyslipidemia	O
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	B-DISEASE
Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(	O
500	O
mg	O
of	O
niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
20	O
mg	O
of	O
lovastatin	B-CHEMICAL
Patients	O
also	O
received	O
dietary	O
counseling	O
,	O
educational	O
materials	O
,	O
and	O
reminders	O
to	O
call	O
a	O
toll	O
-	O
free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	O
and	O
niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
Primary	O
end	O
points	O
were	O
study	O
compliance	O
,	O
increases	O
in	O
liver	B-DISEASE
transaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
clinical	O
myopathy	B-DISEASE
Compliance	O
to	O
niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
Flushing	B-DISEASE
Incidence	O
of	O
increased	O
aspartate	B-CHEMICAL
aminotransferase	O
and	O
/	O
or	O
alanine	B-CHEMICAL
An	O
increase	O
of	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
to	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
patients	O
,	O
and	O
no	O
cases	O
of	O
drug	O
-	O
induced	O
myopathy	B-DISEASE
Niacin	B-CHEMICAL
extended	O
-	O
release	O
/	O
lovastatin	B-CHEMICAL
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	B-DISEASE
Protective	O
effect	O
of	O
Terminalia	O
chebula	O
against	O
experimental	O
myocardial	B-DISEASE
injury	I-DISEASE
induced	O
by	O
isoproterenol	B-CHEMICAL
Cardioprotective	O
effect	O
of	O
ethanolic	O
extract	O
of	O
Terminalia	O
chebula	O
fruits	O
(	O
500	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
was	O
examined	O
in	O
isoproterenol	B-CHEMICAL
(	O
200	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
induced	O
myocardial	B-DISEASE
damage	I-DISEASE
In	O
isoproterenol	B-CHEMICAL
administered	O
rats	O
,	O
the	O
level	O
of	O
lipid	B-CHEMICAL
peroxides	I-CHEMICAL
Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	B-DISEASE
T	O
.	O
chebula	O
extract	O
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	B-CHEMICAL
A	O
case	O
of	O
postoperative	O
anxiety	B-DISEASE
due	O
to	O
low	O
dose	O
droperidol	B-CHEMICAL
Postoperatively	O
,	O
she	O
was	O
given	O
a	O
patient	O
-	O
controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	O
0	O
.	O
5	O
mg	O
and	O
droperidol	B-CHEMICAL
The	O
diagnosis	O
of	O
droperidol	B-CHEMICAL
After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
droperidol	B-CHEMICAL
We	O
feel	O
that	O
,	O
although	O
the	O
dramatic	O
extrapyramidal	O
side	O
effects	O
of	O
dopaminergic	O
antiemetics	B-CHEMICAL
Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	B-DISEASE
insipidus	I-DISEASE
The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
(	O
DI	O
)	O
secondary	O
to	O
a	O
traumatic	B-DISEASE
brain	I-DISEASE
injury	I-DISEASE
The	O
nursing	O
staff	O
,	O
by	O
reviewing	O
the	O
patient	O
'	O
s	O
health	O
history	O
with	O
his	O
family	O
,	O
discovered	O
a	O
history	O
of	O
polydipsia	B-DISEASE
and	O
long	O
-	O
standing	O
lithium	B-CHEMICAL
Lithium	B-CHEMICAL
is	O
implicated	O
in	O
drug	O
-	O
induced	O
nephrogenic	O
DI	O
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	B-CHEMICAL
By	O
combining	O
information	O
from	O
the	O
patient	O
history	O
,	O
the	O
physical	O
examination	O
,	O
and	O
radiologic	O
and	O
laboratory	O
studies	O
,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self	O
-	O
treating	O
his	O
lithium	B-CHEMICAL
-	O
induced	O
nephrogenic	O
DI	O
and	O
developed	O
neurogenic	O
DI	O
secondary	O
to	O
brain	O
trauma	B-DISEASE
Factors	O
contributing	O
to	O
ribavirin	B-CHEMICAL
-	O
induced	O
anemia	B-DISEASE
BACKGROUND	O
AND	O
AIM	O
:	O
Interferon	O
and	O
ribavirin	B-CHEMICAL
combination	O
therapy	O
for	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
produces	O
hemolytic	B-DISEASE
anemia	I-DISEASE
This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin	B-CHEMICAL
-	O
induced	O
anemia	B-DISEASE
METHODS	O
:	O
Eighty	O
-	O
eight	O
patients	O
with	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
who	O
received	O
interferon	B-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	O
2b	O
at	B-DISEASE
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	B-CHEMICAL
administered	O
orally	O
at	B-DISEASE
A	O
hemoglobin	O
concentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribavirin	B-CHEMICAL
-	O
induced	O
anemia	B-DISEASE
RESULTS	O
:	O
Ribavirin	B-CHEMICAL
-	O
induced	O
anemia	B-DISEASE
A	O
2	O
g	O
/	O
dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	B-DISEASE
was	O
observed	O
at	B-DISEASE
The	O
hemoglobin	O
concentration	O
in	O
patients	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decrease	O
at	B-DISEASE
A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	B-DISEASE
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	B-DISEASE
Such	O
factors	O
as	O
sex	O
(	O
female	O
),	O
age	O
(>	O
or	O
=	O
60	O
years	O
old	O
),	O
and	O
the	O
ribavirin	B-CHEMICAL
dose	O
by	O
body	B-DISEASE
weight	I-DISEASE
CONCLUSIONS	O
:	O
Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=	O
60	O
years	O
old	O
,	O
in	O
female	O
patients	O
,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	B-CHEMICAL
Patients	O
who	O
experience	O
a	O
fall	O
in	O
hemoglobin	O
concentrations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	B-DISEASE
Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin	B-CHEMICAL
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	B-CHEMICAL
(	O
ROS	O
)/	O
nitrogen	B-CHEMICAL
species	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	B-CHEMICAL
(	O
ADR	B-CHEMICAL
)-	O
induced	O
cardiotoxicity	B-DISEASE
B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg	O
/	O
kg	O
ADR	B-CHEMICAL
Ultrastructural	O
damage	O
and	O
levels	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
nonenal	I-CHEMICAL
(	O
4HNE	O
)-	O
protein	O
adducts	O
and	O
3	B-CHEMICAL
-	I-CHEMICAL
nitrotyrosine	I-CHEMICAL
Analysis	O
of	O
4HNE	O
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	O
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	B-DISEASE
6	O
hours	O
and	O
subsequent	O
decline	O
at	B-DISEASE
3NT	O
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	B-DISEASE
6	O
hours	O
and	O
subsequently	O
declined	O
at	B-DISEASE
Our	O
data	O
showed	O
ADR	B-CHEMICAL
induced	O
4HNE	O
-	O
protein	O
adducts	O
in	O
mitochondria	O
at	B-DISEASE
Sotalol	B-CHEMICAL
-	O
induced	O
coronary	B-DISEASE
spasm	I-DISEASE
in	O
a	O
patient	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
associated	O
with	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
A	O
54	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
due	O
to	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
After	O
the	O
administration	O
of	O
nifekalant	B-CHEMICAL
An	O
alternate	O
class	O
III	O
agent	O
,	O
sotalol	B-CHEMICAL
However	O
,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	B-CHEMICAL
to	O
sotalol	B-CHEMICAL
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	B-DISEASE
ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiazem	B-CHEMICAL
Coronary	B-DISEASE
vasospasm	I-DISEASE
may	O
be	O
induced	O
by	O
the	O
non	O
-	O
selective	O
beta	O
-	O
blocking	O
properties	O
of	O
sotalol	B-CHEMICAL
Effects	O
of	O
the	O
antidepressant	B-CHEMICAL
trazodone	B-CHEMICAL
,	O
a	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
2A	O
/	O
2C	O
receptor	O
antagonist	O
,	O
on	O
dopamine	B-CHEMICAL
RATIONALE	O
:	O
5	B-CHEMICAL
-	I-CHEMICAL
Hydroxytryptamine	I-CHEMICAL
,	O
via	O
stimulation	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
2C	O
receptors	O
,	O
exerts	O
a	O
tonic	B-DISEASE
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
The	O
antidepressant	B-CHEMICAL
trazodone	B-CHEMICAL
is	O
a	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	B-CHEMICAL
METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	B-CHEMICAL
on	O
dexamphetamine	O
-	O
and	O
apomorphine	B-CHEMICAL
-	O
induced	O
oral	O
stereotypies	O
,	O
on	O
catalepsy	B-DISEASE
induced	O
by	O
haloperidol	B-CHEMICAL
and	O
apomorphine	B-CHEMICAL
),	O
on	O
ergometrine	O
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	B-CHEMICAL
We	O
also	O
investigated	O
whether	O
trazodone	B-CHEMICAL
induces	O
catalepsy	B-DISEASE
RESULTS	O
:	O
Trazodone	B-CHEMICAL
at	B-DISEASE
did	O
not	O
induce	O
catalepsy	B-DISEASE
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	B-CHEMICAL
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotypy	O
and	O
apomorphine	B-CHEMICAL
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)-	O
induced	O
catalepsy	B-DISEASE
trazodone	B-CHEMICAL
enhanced	O
dexamphetamine	O
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	B-CHEMICAL
catalepsy	B-DISEASE
,	O
ergometrine	O
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	B-CHEMICAL
Trazodone	B-CHEMICAL
at	B-DISEASE
induced	O
catalepsy	B-DISEASE
and	O
antagonized	O
apomorphine	B-CHEMICAL
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	B-CHEMICAL
at	B-DISEASE
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre	O
-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	B-CHEMICAL
receptors	O
,	O
while	O
at	B-DISEASE
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	B-CHEMICAL
Furthermore	O
,	O
at	B-DISEASE
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodone	B-CHEMICAL
blocks	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
2A	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
We	O
suggest	O
that	O
trazodone	B-CHEMICAL
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
),	O
by	O
blocking	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
2C	O
receptors	O
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	B-DISEASE
inhibition	O
caused	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	O
stereotypy	O
and	O
antagonizes	O
haloperidol	B-CHEMICAL
catalepsy	B-DISEASE
Swallowing	O
abnormalities	B-DISEASE
and	O
dyskinesia	B-DISEASE
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
Gastrointestinal	O
abnormalities	B-DISEASE
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
PD	B-DISEASE
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	B-DISEASE
patients	O
with	O
and	O
without	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesia	B-DISEASE
Patients	O
were	O
asked	O
about	O
dysphagia	B-DISEASE
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
Disease	I-DISEASE
Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	B-CHEMICAL
Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	B-CHEMICAL
Neither	O
the	O
report	O
of	O
dysphagia	B-DISEASE
nor	O
any	O
of	O
the	O
PD	B-DISEASE
In	O
the	O
current	O
study	O
,	O
dyskinetic	O
patients	O
performed	O
better	O
in	O
swallowing	O
function	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	B-CHEMICAL
Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	B-CHEMICAL
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	B-DISEASE
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	B-DISEASE
Inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	O
nephritis	B-DISEASE
induced	O
by	O
gentamicin	B-CHEMICAL
BACKGROUND	O
:	O
Animals	O
treated	O
with	O
gentamicin	B-CHEMICAL
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	B-DISEASE
in	O
the	O
renal	B-DISEASE
This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	B-DISEASE
cortex	O
and	O
structural	O
and	O
functional	O
renal	B-DISEASE
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	B-CHEMICAL
or	O
gentamicin	B-CHEMICAL
+	O
pyrrolidine	B-CHEMICAL
dithiocarbamate	O
(	O
PDTC	B-CHEMICAL
METHODS	O
:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	B-CHEMICAL
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
days	O
,	O
38	O
with	O
gentamicin	B-CHEMICAL
+	O
PDTC	B-CHEMICAL
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NaCl	B-CHEMICAL
RESULTS	O
:	O
Gentamicin	B-CHEMICAL
-	O
treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	B-CHEMICAL
Increased	O
ED	B-DISEASE
-	O
1	O
,	O
MAP	O
kinases	O
and	O
NF	O
-	O
kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	B-DISEASE
cortex	O
from	O
all	O
gentamicin	B-CHEMICAL
The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	B-DISEASE
in	O
the	O
renal	B-DISEASE
cortex	O
despite	O
the	O
recovery	O
of	O
renal	B-DISEASE
Treatment	O
with	O
PDTC	B-CHEMICAL
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	B-CHEMICAL
CONCLUSIONS	O
:	O
These	O
data	O
show	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	O
nephritis	B-DISEASE
induced	O
by	O
gentamicin	B-CHEMICAL
Glucose	B-CHEMICAL
metabolism	B-DISEASE
in	O
patients	O
with	O
schizophrenia	B-DISEASE
treated	O
with	O
atypical	O
antipsychotic	B-CHEMICAL
agents	I-CHEMICAL
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-CHEMICAL
BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-DISEASE
mellitus	I-DISEASE
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B-DISEASE
treated	O
with	O
certain	O
atypical	O
antipsychotic	B-CHEMICAL
agents	I-CHEMICAL
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B-CHEMICAL
metabolism	B-DISEASE
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B-DISEASE
OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-CHEMICAL
and	O
olanzapine	B-CHEMICAL
)	O
and	O
risperidone	B-CHEMICAL
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-CHEMICAL
DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B-DISEASE
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-CHEMICAL
SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	B-DISEASE
Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B-CHEMICAL
Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B-DISEASE
or	O
schizoaffective	B-DISEASE
disorder	I-DISEASE
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
,	O
or	O
risperidone	B-CHEMICAL
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B-CHEMICAL
and	O
fasting	O
serum	O
insulin	B-CHEMICAL
levels	O
,	O
insulin	B-DISEASE
sensitivity	I-DISEASE
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-DISEASE
resistance	I-DISEASE
,	O
and	O
glucose	B-CHEMICAL
RESULTS	O
:	O
The	O
mean	O
+/-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	O
agent	O
was	O
68	O
.	O
3	O
+/-	O
28	O
.	O
9	O
months	O
(	O
clozapine	B-CHEMICAL
),	O
29	O
.	O
5	O
+/-	O
17	O
.	O
5	O
months	O
(	O
olanzapine	B-CHEMICAL
),	O
and	O
40	O
.	O
9	O
+/-	O
33	O
.	O
7	O
(	O
risperidone	B-CHEMICAL
Fasting	O
serum	O
insulin	B-CHEMICAL
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozapine	B-CHEMICAL
>	O
olanzapine	B-CHEMICAL
>	O
risperidone	B-CHEMICAL
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-CHEMICAL
and	O
risperidone	B-CHEMICAL
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzapine	B-CHEMICAL
and	O
risperidone	B-CHEMICAL
There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	B-DISEASE
sensitivity	I-DISEASE
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<.	O
001	O
)	O
(	O
clozapine	B-CHEMICAL
<	O
olanzapine	B-CHEMICAL
<	O
risperidone	B-CHEMICAL
),	O
with	O
subjects	O
who	O
received	O
clozapine	B-CHEMICAL
and	O
olanzapine	B-CHEMICAL
exhibiting	O
significant	O
insulin	B-DISEASE
resistance	I-DISEASE
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B-CHEMICAL
(	O
clozapine	B-CHEMICAL
vs	O
risperidone	B-CHEMICAL
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<.	O
001	O
;	O
olanzapine	B-CHEMICAL
vs	O
risperidone	B-CHEMICAL
The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-DISEASE
resistance	I-DISEASE
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clozapine	B-CHEMICAL
>	O
olanzapine	B-CHEMICAL
>	O
risperidone	B-CHEMICAL
)	O
(	O
clozapine	B-CHEMICAL
vs	O
risperidone	B-CHEMICAL
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanzapine	B-CHEMICAL
vs	O
risperidone	B-CHEMICAL
There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B-CHEMICAL
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clozapine	B-CHEMICAL
<	O
olanzapine	B-CHEMICAL
<	O
risperidone	B-CHEMICAL
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-CHEMICAL
and	O
risperidone	B-CHEMICAL
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzapine	B-CHEMICAL
and	O
risperidone	B-CHEMICAL
CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	B-CHEMICAL
-	O
and	O
olanzapine	B-CHEMICAL
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-DISEASE
resistance	I-DISEASE
and	O
impairment	O
of	O
glucose	B-CHEMICAL
effectiveness	O
compared	O
with	O
risperidone	B-CHEMICAL
Patients	O
taking	O
clozapine	B-CHEMICAL
and	O
olanzapine	B-CHEMICAL
must	O
be	O
examined	O
for	O
insulin	B-DISEASE
resistance	I-DISEASE
Focal	O
cerebral	O
ischemia	B-DISEASE
in	O
rats	O
:	O
effect	O
of	O
phenylephrine	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
After	O
180	O
min	O
of	O
temporary	O
middle	O
cerebral	O
artery	O
occlusion	O
in	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
,	O
the	O
effect	O
of	O
phenylephrine	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
on	O
ischemic	O
brain	B-DISEASE
injury	I-DISEASE
Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion	O
:	O
Control	O
,	O
normotensive	O
reperfusion	O
;	O
90	O
/	O
hypertension	B-DISEASE
(	O
90	O
/	O
HTN	O
),	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only	O
;	O
15	O
/	O
hypertension	B-DISEASE
(	O
15	O
/	O
HTN	O
),	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	B-DISEASE
Part	O
A	O
,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	B-DISEASE
injury	I-DISEASE
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2	O
,	O
3	O
,	O
5	O
-	O
triphenyltetrazolium	B-CHEMICAL
chloride	O
and	O
edema	B-DISEASE
Part	O
B	O
,	O
for	O
eight	O
different	O
rats	O
in	O
each	O
group	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
evaluated	O
by	O
measuring	O
the	O
amount	O
and	O
extent	O
of	O
extravasation	O
of	O
Evans	B-CHEMICAL
Blue	I-CHEMICAL
Brain	B-DISEASE
injury	I-DISEASE
Evans	B-CHEMICAL
Blue	I-CHEMICAL
This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion	O
,	O
a	O
short	O
interval	O
of	O
hypertension	B-DISEASE
decreases	O
brain	B-DISEASE
injury	I-DISEASE
and	O
edema	B-DISEASE
;	O
and	O
that	O
sustained	O
hypertension	B-DISEASE
increases	O
the	O
risk	O
of	O
vasogenic	O
edema	B-DISEASE
People	O
aged	O
over	O
75	O
in	O
atrial	B-DISEASE
fibrillation	I-DISEASE
on	O
warfarin	B-CHEMICAL
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B-DISEASE
and	O
stroke	B-DISEASE
OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B-DISEASE
and	O
stroke	B-DISEASE
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
on	O
adjusted	O
-	O
dose	O
warfarin	B-CHEMICAL
PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
on	O
warfarin	B-CHEMICAL
MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B-DISEASE
episodes	O
,	O
strokes	B-DISEASE
,	O
and	O
warfarin	B-CHEMICAL
Total	O
follow	O
-	O
up	O
on	O
warfarin	B-CHEMICAL
The	O
annual	O
stroke	B-DISEASE
rate	O
after	O
initiation	O
of	O
warfarin	B-CHEMICAL
CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B-DISEASE
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	B-DISEASE
rate	O
on	O
warfarin	B-CHEMICAL
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	B-CHEMICAL
Safety	O
of	O
celecoxib	B-CHEMICAL
in	O
patients	O
with	O
adverse	O
skin	B-DISEASE
reactions	O
to	O
acetaminophen	B-CHEMICAL
(	O
paracetamol	B-CHEMICAL
)	O
and	O
nimesulide	B-CHEMICAL
BACKGROUND	O
:	O
Acetaminophen	B-CHEMICAL
(	O
paracetamol	B-CHEMICAL
--	O
P	O
)	O
and	O
Nimesulide	B-CHEMICAL
The	O
rate	O
of	O
adverse	O
hypersensitivity	B-DISEASE
Celecoxib	B-CHEMICAL
METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B-DISEASE
The	O
diagnosis	O
of	O
P	O
and	O
N	O
-	O
induced	O
skin	B-DISEASE
The	O
placebo	O
was	O
blindly	O
administered	O
at	B-DISEASE
The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B-DISEASE
,	O
rush	O
or	O
urticaria	B-DISEASE
-	O
angioedema	B-DISEASE
Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B-DISEASE
CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B-DISEASE
Case	O
-	O
control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
use	O
and	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
BACKGROUND	O
:	O
Studies	O
on	O
the	O
association	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
aspirin	B-CHEMICAL
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
In	O
order	O
to	O
examine	O
this	O
association	O
,	O
a	O
case	O
-	O
control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	B-DISEASE
METHODS	O
:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	B-DISEASE
They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease	B-DISEASE
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	B-DISEASE
Odds	O
ratios	O
were	O
calculated	O
using	O
a	O
conditional	O
logistic	O
model	O
,	O
including	O
potential	O
confounding	O
factors	O
,	O
both	O
for	O
the	O
whole	O
study	O
population	O
and	O
for	O
the	O
various	O
underlying	O
diseases	B-DISEASE
For	O
specific	O
groups	O
of	O
drugs	O
,	O
the	O
risks	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
aspirin	B-CHEMICAL
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyrazolones	B-CHEMICAL
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
paracetamol	B-CHEMICAL
The	O
risk	O
of	O
ESRD	B-DISEASE
associated	O
with	O
aspirin	B-CHEMICAL
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	B-DISEASE
as	O
underlying	O
disease	B-DISEASE
CONCLUSION	O
:	O
Our	O
data	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	B-DISEASE
However	O
,	O
the	O
chronic	O
use	O
of	O
aspirin	B-CHEMICAL
may	O
increase	O
the	O
risk	O
of	O
ESRD	B-DISEASE
Two	O
cases	O
of	O
amisulpride	B-CHEMICAL
overdose	B-DISEASE
:	O
a	O
cause	O
for	O
prolonged	O
QT	O
syndrome	B-DISEASE
Two	O
cases	O
of	O
deliberate	O
self	O
-	O
poisoning	B-DISEASE
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amisulpride	B-CHEMICAL
calcium	B-CHEMICAL
gluconate	I-CHEMICAL
Growth	O
-	O
associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	B-DISEASE
rats	O
treated	O
with	O
cycloheximide	B-CHEMICAL
PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	B-DISEASE
To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43	O
-	O
ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43	O
-	O
ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B-DISEASE
epilepticus	I-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
(	O
Pilo	O
),	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	B-CHEMICAL
Nicotine	B-CHEMICAL
antagonizes	O
caffeine	B-CHEMICAL
-	O
but	O
not	O
pentylenetetrazole	B-CHEMICAL
RATIONALE	O
:	O
Nicotine	B-CHEMICAL
and	O
caffeine	B-CHEMICAL
are	O
widely	O
consumed	O
licit	O
psychoactive	B-CHEMICAL
drugs	I-CHEMICAL
Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B-DISEASE
OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	B-CHEMICAL
on	O
anxiety	B-DISEASE
induced	O
by	O
caffeine	B-CHEMICAL
and	O
another	O
anxiogenic	O
drug	O
,	O
pentylenetetrazole	B-CHEMICAL
The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B-DISEASE
METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	B-CHEMICAL
or	O
saline	O
10	O
min	O
before	O
caffeine	B-CHEMICAL
or	O
pentylenetetrazole	B-CHEMICAL
RESULTS	O
:	O
Nicotine	B-CHEMICAL
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B-CHEMICAL
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	B-CHEMICAL
Nicotine	B-CHEMICAL
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	B-CHEMICAL
-	O
but	O
not	O
pentylenetetrazole	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	B-CHEMICAL
on	O
caffeine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
is	O
specific	O
to	O
caffeine	B-CHEMICAL
Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	B-CHEMICAL
and	O
caffeine	B-CHEMICAL
It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
osteoporosis	B-DISEASE
and	O
dementia	B-DISEASE
OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
heart	B-DISEASE
disease	I-DISEASE
,	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
stroke	B-DISEASE
,	O
transient	O
ischaemic	O
attacks	O
,	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
colorectal	B-DISEASE
cancer	I-DISEASE
,	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
endometrial	B-DISEASE
cancer	I-DISEASE
,	O
gallbladder	B-DISEASE
disease	I-DISEASE
,	O
cognitive	O
function	O
,	O
dementia	B-DISEASE
,	O
fractures	B-DISEASE
SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
up	O
to	O
November	O
2004	O
:	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	B-DISEASE
SELECTION	O
CRITERIA	O
:	O
Randomised	O
double	O
-	O
blind	O
trials	O
of	O
HT	O
(	O
oestrogens	O
with	O
or	O
without	O
progestogens	O
)	O
versus	O
placebo	O
,	O
taken	O
for	O
at	B-DISEASE
In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
'	O
s	O
use	O
),	O
stroke	B-DISEASE
(	O
after	O
3	O
years	O
),	O
breast	B-DISEASE
cancer	I-DISEASE
(	O
after	O
5	O
years	O
)	O
and	O
gallbladder	B-DISEASE
disease	I-DISEASE
Long	O
-	O
term	O
oestrogen	O
-	O
only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	B-DISEASE
and	O
gallbladder	B-DISEASE
disease	I-DISEASE
Overall	O
,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B-DISEASE
and	O
colon	B-DISEASE
cancer	I-DISEASE
Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B-DISEASE
Among	O
women	O
with	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B-DISEASE
thromboembolism	I-DISEASE
AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	B-DISEASE
disease	I-DISEASE
Drug	O
-	O
induced	O
liver	B-DISEASE
injury	I-DISEASE
BACKGROUND	O
&	O
AIMS	O
:	O
Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug	O
-	O
induced	O
liver	B-DISEASE
injury	I-DISEASE
The	O
liver	B-DISEASE
damage	I-DISEASE
The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin	B-CHEMICAL
-	O
clavulanate	B-CHEMICAL
Indeed	O
,	O
the	O
incidence	O
of	O
liver	B-DISEASE
transplantation	O
and	O
death	B-DISEASE
in	O
this	O
group	O
was	O
11	O
.	O
7	O
%	O
if	O
patients	O
had	O
jaundice	B-DISEASE
at	B-DISEASE
Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	B-DISEASE
hepatic	I-DISEASE
failure	I-DISEASE
were	O
female	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
),	O
hepatocellular	O
damage	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
),	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	B-CHEMICAL
CONCLUSIONS	O
:	O
Patients	O
with	O
drug	O
-	O
induced	O
hepatocellular	O
jaundice	B-DISEASE
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
death	B-DISEASE
Amoxicillin	B-CHEMICAL
-	O
clavulanate	B-CHEMICAL
Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d	O
-	O
ribose	B-CHEMICAL
on	O
adriamycin	B-CHEMICAL
-	O
evoked	O
cardiotoxicity	B-DISEASE
The	O
influence	O
of	O
d	O
-	O
ribose	B-CHEMICAL
on	O
adriamycin	B-CHEMICAL
Adriamycin	B-CHEMICAL
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
evoked	O
fully	O
developed	O
cardiac	B-DISEASE
toxicity	I-DISEASE
D	O
-	O
ribose	B-CHEMICAL
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
influence	O
ADR	B-CHEMICAL
cardiotoxicity	B-DISEASE
In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
:	O
protection	O
by	O
erdosteine	B-CHEMICAL
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	B-CHEMICAL
(	O
VCM	O
)-	O
induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	B-CHEMICAL
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	O
-	O
induced	O
renal	B-DISEASE
Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	O
and	O
VCM	O
plus	O
erdosteine	B-CHEMICAL
Erdosteine	B-CHEMICAL
VCM	O
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	B-DISEASE
malondialdehyde	B-CHEMICAL
(	O
MDA	O
)	O
and	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
d	O
-	O
glucosaminidase	O
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B-DISEASE
tubular	O
injury	O
)	O
excretion	O
but	O
decreased	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
Erdosteine	B-CHEMICAL
administration	O
with	O
VCM	O
injections	O
caused	O
significantly	O
decreased	O
renal	B-DISEASE
MDA	O
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	B-DISEASE
Erdosteine	B-CHEMICAL
showed	O
histopathological	O
protection	O
against	O
VCM	O
-	O
induced	O
nephrotoxicity	B-DISEASE
There	O
were	O
a	O
significant	O
dilatation	B-DISEASE
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B-DISEASE
,	O
desquamation	O
,	O
and	O
necrosis	B-DISEASE
in	O
VCM	O
-	O
treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	B-CHEMICAL
Erdosteine	B-CHEMICAL
It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	O
-	O
induced	O
nephrotoxicity	B-DISEASE
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	B-CHEMICAL
reduces	O
the	O
VCM	O
-	O
induced	O
kidney	O
damage	O
both	O
at	B-DISEASE
Does	O
domperidone	B-CHEMICAL
potentiate	O
mirtazapine	B-CHEMICAL
-	O
associated	O
restless	B-DISEASE
legs	I-DISEASE
syndrome	I-DISEASE
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-DISEASE
legs	I-DISEASE
syndrome	I-DISEASE
(	O
RLS	B-DISEASE
For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B-DISEASE
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
agonists	I-CHEMICAL
,	O
whereas	O
central	O
dopamine	B-CHEMICAL
D2	I-CHEMICAL
receptor	I-CHEMICAL
antagonists	I-CHEMICAL
can	O
induce	O
or	O
aggravate	O
RLS	B-DISEASE
To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B-CHEMICAL
,	O
a	O
peripheral	O
dopamine	B-CHEMICAL
D2	O
receptor	O
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B-DISEASE
Mirtazapine	B-CHEMICAL
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	B-CHEMICAL
(	O
NaSSA	O
),	O
has	O
been	O
associated	O
with	O
RLS	B-DISEASE
The	O
authors	O
report	O
here	O
a	O
depressed	B-DISEASE
patient	O
comorbid	O
with	O
postprandial	O
dyspepsia	B-DISEASE
who	O
developed	O
RLS	B-DISEASE
after	O
mirtazapine	B-CHEMICAL
had	O
been	O
added	O
to	O
his	O
domperidone	B-CHEMICAL
Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	B-DISEASE
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B-CHEMICAL
,	O
and	O
his	O
RLS	B-DISEASE
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B-CHEMICAL
Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B-CHEMICAL
and	O
the	O
symptoms	O
of	O
RLS	B-DISEASE
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	O
on	O
mirtazapine	B-CHEMICAL
-	O
associated	O
RLS	B-DISEASE
However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B-CHEMICAL
can	O
be	O
associated	O
with	O
RLS	B-DISEASE
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B-CHEMICAL
D2	I-CHEMICAL
receptor	I-CHEMICAL
antagonists	I-CHEMICAL
Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	O
arterial	O
disease	B-DISEASE
AIM	O
:	O
To	O
study	O
the	O
change	O
of	O
lipid	B-DISEASE
metabolism	I-DISEASE
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	B-DISEASE
cancer	I-DISEASE
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
years	O
follow	O
-	O
up	O
the	O
changes	O
in	O
plasma	O
cholesterols	O
(	O
C	O
),	O
triglycerides	B-CHEMICAL
(	O
TG	B-DISEASE
),	O
lipoproteins	O
(	O
LP	O
),	O
and	O
apolipoproteins	O
(	O
Apo	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	B-DISEASE
cancer	I-DISEASE
(	O
stage	O
:	O
T1cN0M0	O
,	O
Gleason	O
score	O
:	O
2	O
-	O
5	O
)	O
during	O
treatment	O
with	O
cyproterone	B-CHEMICAL
acetate	I-CHEMICAL
(	O
CPA	B-CHEMICAL
RESULTS	O
:	O
Significant	O
decreases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
increase	O
of	O
triglyceride	O
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	B-CHEMICAL
After	O
a	O
period	O
of	O
2	O
.	O
5	O
years	O
on	O
CPA	B-CHEMICAL
treatment	O
,	O
four	O
patients	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
CONCLUSIONS	O
:	O
Ischaemic	O
coronary	B-DISEASE
arteriosclerosis	I-DISEASE
with	O
an	O
incidence	O
rate	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prolonged	O
CPA	B-CHEMICAL
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	B-CHEMICAL
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglyceridemic	O
effect	O
caused	O
by	O
estrogen	B-CHEMICAL
5	B-CHEMICAL
-	I-CHEMICAL
Fluorouracil	I-CHEMICAL
cardiotoxicity	B-DISEASE
induced	O
by	O
alpha	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
Cardiotoxicity	B-DISEASE
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
treatment	O
for	O
malignancies	B-DISEASE
We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
The	O
patient	O
,	O
who	O
had	O
unresectable	O
colon	B-DISEASE
cancer	I-DISEASE
metastases	O
to	O
the	O
liver	B-DISEASE
and	O
lung	B-DISEASE
After	O
admission	O
,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
(	O
1000	O
mg	O
/	O
day	O
),	O
during	O
which	O
precordial	O
pain	B-DISEASE
with	O
right	O
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
Both	O
the	O
precordial	O
pain	B-DISEASE
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
As	O
the	O
precordial	O
pain	B-DISEASE
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
,	O
the	O
administration	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
Instead	O
,	O
oral	O
administration	O
of	O
S	O
-	O
1	O
(	O
a	O
derivative	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
),	O
at	B-DISEASE
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	O
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	O
is	O
related	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
S	O
-	O
1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
doxorubicin	B-CHEMICAL
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	B-DISEASE
,	O
the	O
anthracyclin	O
doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
DOX	B-CHEMICAL
-	O
induced	O
cardiac	O
damage	O
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	B-CHEMICAL
radicals	I-CHEMICAL
by	O
DOX	B-CHEMICAL
Reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
The	O
semisynthetic	O
flavonoid	O
monohydroxyethylrutoside	O
(	O
monoHER	O
)	O
showed	O
cardioprotection	O
against	O
DOX	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
through	O
its	O
radical	O
scavenging	O
and	O
iron	B-CHEMICAL
Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	O
(	O
about	O
30	O
min	O
),	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	B-CHEMICAL
METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	O
were	O
treated	O
with	O
saline	O
,	O
DOX	B-CHEMICAL
alone	O
or	O
DOX	B-CHEMICAL
Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	O
damage	O
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	B-DISEASE
Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	B-CHEMICAL
RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	B-CHEMICAL
The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	B-CHEMICAL
The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	O
before	O
DOX	B-CHEMICAL
This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	B-CHEMICAL
CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	O
may	O
be	O
administered	O
shortly	O
before	O
DOX	B-CHEMICAL
Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	B-CHEMICAL
administration	O
for	O
atrial	B-DISEASE
fibrillation	I-DISEASE
BACKGROUND	O
:	O
Bepridil	B-CHEMICAL
hydrochloride	O
(	O
Bpd	O
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	B-DISEASE
fibrillation	I-DISEASE
(	O
AF	O
)	O
and	O
atrial	B-DISEASE
flutter	I-DISEASE
However	O
,	O
serious	O
adverse	O
effects	O
,	O
including	O
torsade	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
(	O
Tdp	B-DISEASE
There	O
was	O
marked	O
QT	O
prolongation	O
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
patients	O
,	O
bradycardia	B-DISEASE
less	O
than	O
40	O
beats	O
/	O
min	O
in	O
6	O
patients	O
,	O
dizziness	B-DISEASE
and	O
general	O
fatigue	B-DISEASE
In	O
4	O
of	O
13	O
patients	O
with	O
QT	O
prolongation	O
,	O
Tdp	B-DISEASE
The	O
major	O
triggering	O
factors	O
of	O
Tdp	B-DISEASE
were	O
hypokalemia	B-DISEASE
There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	B-DISEASE
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	B-DISEASE
CONCLUSION	O
:	O
Careful	O
observation	O
of	O
serum	O
potassium	B-CHEMICAL
Enhanced	O
isoproterenol	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	B-CHEMICAL
We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin	O
-	O
angiotensin	B-CHEMICAL
In	O
this	O
study	O
we	O
aimed	O
at	B-DISEASE
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta	O
-	O
adrenoceptor	O
(	O
beta	O
-	O
AR	O
)	O
agonist	O
isoproterenol	B-CHEMICAL
(	O
Iso	B-CHEMICAL
Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	B-CHEMICAL
In	O
isolated	O
hearts	O
,	O
Iso	B-CHEMICAL
LV	O
hypertrophy	B-DISEASE
induced	O
by	O
Iso	B-CHEMICAL
The	O
greater	O
LV	O
hypertrophy	B-DISEASE
The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta	O
-	O
AR	O
antagonist	O
metoprolol	B-CHEMICAL
-	O
18	O
.	O
1	O
+/-	O
1	O
.	O
5	O
%),	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	B-CHEMICAL
These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta	O
-	O
AR	O
agonist	O
-	O
induced	O
cardiac	O
inotropic	O
response	O
and	O
hypertrophy	B-DISEASE
Drug	O
-	O
induced	O
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B-CHEMICAL
BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
Methadone	B-CHEMICAL
prolongs	O
the	O
QT	B-DISEASE
interval	I-DISEASE
In	O
the	O
inpatient	O
setting	O
,	O
the	O
frequency	O
of	O
QT	B-DISEASE
interval	I-DISEASE
prolongation	O
with	O
methadone	B-CHEMICAL
treatment	O
,	O
its	O
dose	O
dependence	B-DISEASE
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B-CHEMICAL
and	O
those	O
not	O
receiving	O
methadone	B-CHEMICAL
A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	B-CHEMICAL
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B-CHEMICAL
In	O
addition	O
to	O
methadone	B-CHEMICAL
RESULTS	O
:	O
Among	O
167	O
methadone	B-CHEMICAL
Six	O
patients	O
(	O
3	O
.	O
6	O
%)	O
in	O
the	O
methadone	B-CHEMICAL
group	O
presented	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B-CHEMICAL
Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	B-CHEMICAL
dose	O
,	O
cytochrome	O
P	O
-	O
450	O
3A4	O
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	B-DISEASE
,	O
and	O
altered	O
liver	B-DISEASE
CONCLUSIONS	O
:	O
QT	B-DISEASE
interval	I-DISEASE
prolongation	O
in	O
methadone	B-CHEMICAL
Methadone	B-CHEMICAL
dose	O
,	O
presence	O
of	O
cytochrome	O
P	O
-	O
450	O
3A4	O
inhibitors	O
,	O
potassium	B-CHEMICAL
level	O
,	O
and	O
liver	B-DISEASE
Long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B-CHEMICAL
Mechanisms	O
of	O
hypertension	B-DISEASE
induced	O
by	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
)	O
in	O
hypertension	B-DISEASE
Experimental	O
hypertension	B-DISEASE
These	O
include	O
augmented	O
endothelin	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	O
-	O
nitro	O
-	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
(	O
LNNA	O
)	O
hypertension	B-DISEASE
Rats	O
were	O
treated	O
with	O
the	O
NO	O
synthase	O
inhibitor	O
LNNA	O
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinking	B-CHEMICAL
water	I-CHEMICAL
Maximal	O
contraction	O
to	O
norepinephrine	B-CHEMICAL
Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B-CHEMICAL
Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	O
hypertension	B-DISEASE
at	B-DISEASE
The	O
superoxide	B-CHEMICAL
scavenger	O
tempol	B-CHEMICAL
Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	B-CHEMICAL
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	O
hypertensive	B-DISEASE
Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	O
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-CHEMICAL
These	O
data	O
suggest	O
that	O
while	O
NO	O
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B-DISEASE
Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	B-CHEMICAL
-	O
induced	O
extrapyramidal	O
syndrome	B-DISEASE
in	O
Chinese	O
schizophrenic	B-DISEASE
AIM	O
:	O
Extrapyramidal	O
syndrome	B-DISEASE
(	O
EPS	B-DISEASE
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	B-CHEMICAL
drugs	I-CHEMICAL
Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B-DISEASE
In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	B-CHEMICAL
-	O
induced	O
EPS	B-DISEASE
in	O
schizophrenic	B-DISEASE
METHODS	O
:	O
We	O
identified	O
seven	O
SNP	B-CHEMICAL
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(-	O
141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	B-DISEASE
inpatients	O
(	O
59	O
with	O
EPS	B-DISEASE
and	O
87	O
without	O
EPS	B-DISEASE
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	B-CHEMICAL
CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	B-CHEMICAL
,	O
at	B-DISEASE
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	B-DISEASE
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	B-DISEASE
Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	B-DISEASE
In	O
order	O
to	O
elucidate	O
this	O
problem	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long	O
-	O
term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	B-DISEASE
Thereafter	O
,	O
seizures	B-DISEASE
were	O
induced	O
by	O
pilocarpine	B-CHEMICAL
During	O
the	O
acute	O
period	O
of	O
status	B-DISEASE
epilepticus	I-DISEASE
,	O
we	O
measured	O
:	O
(	O
1	O
)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensity	O
of	O
seizures	B-DISEASE
,	O
(	O
3	O
)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	B-CHEMICAL
All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	B-DISEASE
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
Tonic	B-DISEASE
Endogenous	O
dopamine	B-CHEMICAL
Administration	O
of	O
the	O
dopamine	B-CHEMICAL
precursor	O
levodopa	B-CHEMICAL
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B-DISEASE
Because	O
levodopa	B-CHEMICAL
increases	O
both	O
phasic	O
and	O
tonic	B-DISEASE
We	O
here	O
probed	O
how	O
selective	O
tonic	B-DISEASE
Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine	B-CHEMICAL
-	O
receptor	O
agonist	O
pergolide	B-CHEMICAL
The	O
dopamine	B-CHEMICAL
agonist	I-CHEMICAL
Subjects	O
treated	O
with	O
pergolide	B-CHEMICAL
The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergolide	B-CHEMICAL
These	O
findings	O
suggest	O
that	O
tonic	B-DISEASE
occupation	O
of	O
dopamine	B-CHEMICAL
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	B-CHEMICAL
Thus	O
,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	B-CHEMICAL
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B-DISEASE
Minocycline	B-CHEMICAL
-	O
induced	O
vasculitis	B-DISEASE
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	B-DISEASE
nodosa	I-DISEASE
A	O
47	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	B-CHEMICAL
for	O
palmoplantar	O
pustulosis	O
developed	O
fever	B-DISEASE
,	O
myalgias	O
,	O
polyneuropathy	B-DISEASE
,	O
and	O
testicular	O
pain	B-DISEASE
These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	B-DISEASE
nodosa	I-DISEASE
Stopping	O
minocycline	B-CHEMICAL
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline	B-CHEMICAL
-	O
induced	O
vasculitis	B-DISEASE
Differential	O
diagnosis	O
for	O
drug	O
-	O
induced	O
disease	B-DISEASE
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	B-DISEASE
nodosa	I-DISEASE
Intramuscular	O
hepatitis	B-DISEASE
B	I-DISEASE
immune	O
globulin	O
combined	O
with	O
lamivudine	B-CHEMICAL
in	O
prevention	O
of	O
hepatitis	B-DISEASE
B	I-DISEASE
recurrence	B-DISEASE
after	O
liver	B-DISEASE
BACKGROUND	O
:	O
Combined	O
hepatitis	B-DISEASE
B	I-DISEASE
immune	O
globulin	O
(	O
HBIg	O
)	O
and	O
lamivudine	B-CHEMICAL
in	O
prophylaxis	O
of	O
the	O
recurrence	B-DISEASE
of	O
hepatitis	B-DISEASE
B	I-DISEASE
after	O
liver	B-DISEASE
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	B-CHEMICAL
This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	B-DISEASE
transplantation	O
for	O
patients	O
with	O
hepatitis	B-DISEASE
B	I-DISEASE
METHODS	O
:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV	O
-	O
related	O
cirrhotic	O
diseases	B-DISEASE
RESULTS	O
:	O
At	B-DISEASE
a	O
median	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
months	O
,	O
the	O
overall	O
recurrence	B-DISEASE
A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	B-CHEMICAL
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	B-CHEMICAL
CONCLUSION	O
:	O
Lamivudine	B-CHEMICAL
combined	O
with	O
intramuscular	O
HBIg	O
can	O
effectively	O
prevent	O
allograft	O
from	O
the	O
recurrence	B-DISEASE
of	O
HBV	O
after	O
liver	B-DISEASE
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-CHEMICAL
acetate	I-CHEMICAL
(	O
BIA	O
2	O
-	O
093	O
)	O
on	O
seizures	B-DISEASE
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B-CHEMICAL
Eslicarbazepine	B-CHEMICAL
acetate	I-CHEMICAL
(	O
BIA	O
2	O
-	O
093	O
,	O
S	O
-(-)-	O
10	O
-	O
acetoxy	O
-	O
10	O
,	O
11	O
-	O
dihydro	O
-	O
5H	O
-	O
dibenzo	O
/	O
b	O
,	O
f	O
/	O
azepine	O
-	O
5	O
-	O
carboxamide	O
)	O
is	O
a	O
novel	O
antiepileptic	O
drug	O
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B-CHEMICAL
(	O
CBZ	B-CHEMICAL
)	O
and	O
oxcarbazepine	B-CHEMICAL
We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-CHEMICAL
acetate	I-CHEMICAL
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B-DISEASE
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B-DISEASE
In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B-CHEMICAL
,	O
the	O
average	O
number	O
of	O
seizures	B-DISEASE
was	O
2	O
.	O
3	O
+/-	O
1	O
.	O
2	O
,	O
and	O
average	O
seizure	B-DISEASE
Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	B-CHEMICAL
microperfusion	O
prevented	O
seizures	B-DISEASE
Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B-DISEASE
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	B-DISEASE
duration	O
(	O
24	O
.	O
3	O
+/-	O
6	O
.	O
8s	O
)	O
and	O
seizure	B-DISEASE
No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-CHEMICAL
acetate	I-CHEMICAL
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	B-DISEASE
Acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	B-CHEMICAL
Nephropathy	B-DISEASE
caused	O
by	O
Chinese	O
herbs	O
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	B-CHEMICAL
acids	I-CHEMICAL
We	O
report	O
a	O
23	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
The	O
renal	B-DISEASE
injury	I-DISEASE
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
diclofenac	B-CHEMICAL
Renal	B-DISEASE
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	B-DISEASE
Spontaneous	O
renal	B-DISEASE
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills	O
,	O
but	O
mild	O
interstitial	O
fibrosis	B-DISEASE
and	O
tubular	O
atrophy	B-DISEASE
Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone	O
-	O
containing	O
herbal	O
agent	O
and	O
renal	B-DISEASE
injury	I-DISEASE
remains	O
to	O
be	O
proven	O
,	O
phytotherapy	O
-	O
associated	O
interstitial	O
nephropathy	B-DISEASE
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	B-DISEASE
failure	I-DISEASE
Chloroacetaldehyde	B-CHEMICAL
as	O
a	O
sulfhydryl	O
reagent	O
:	O
the	O
role	O
of	O
critical	O
thiol	O
groups	O
in	O
ifosfamide	B-CHEMICAL
nephropathy	B-DISEASE
Chloroacetaldehyde	B-CHEMICAL
(	O
CAA	B-DISEASE
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	B-CHEMICAL
(	O
IFO	O
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-DISEASE
damage	I-DISEASE
following	O
anti	O
-	O
tumor	B-DISEASE
In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B-DISEASE
Toxicity	B-DISEASE
of	O
CAA	B-DISEASE
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	O
release	O
,	O
trypan	B-CHEMICAL
blue	I-CHEMICAL
CAA	B-DISEASE
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	O
and	O
an	O
increase	O
in	O
necrosis	B-DISEASE
CAA	B-DISEASE
but	O
not	O
acrolein	B-CHEMICAL
inhibited	O
the	O
cysteine	B-CHEMICAL
proteases	I-CHEMICAL
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
and	O
cathepsin	O
B	O
.	O
Caspase	O
activation	O
by	O
cisplatin	B-CHEMICAL
was	O
inhibited	O
by	O
CAA	B-DISEASE
In	O
cells	O
stained	O
with	O
fluorescent	B-CHEMICAL
dyes	I-CHEMICAL
targeting	O
lysosomes	O
,	O
CAA	B-DISEASE
The	O
effects	O
of	O
CAA	B-DISEASE
on	O
cysteine	B-CHEMICAL
Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B-DISEASE
with	O
thiol	O
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B-DISEASE
on	O
necrosis	B-DISEASE
markers	O
,	O
thiol	O
depletion	O
and	O
cysteine	B-CHEMICAL
Thus	O
,	O
CAA	B-DISEASE
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	O
,	O
mediating	O
its	O
toxicity	B-DISEASE
Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	O
nephropathy	B-DISEASE
Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
Following	O
status	B-DISEASE
epilepticus	I-DISEASE
It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	B-DISEASE
that	O
ultimately	O
develop	O
after	O
status	B-DISEASE
epilepticus	I-DISEASE
To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	B-DISEASE
different	O
times	O
after	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	B-DISEASE
epilepticus	I-DISEASE
Interestingly	O
,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	B-DISEASE
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	B-DISEASE
The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	B-CHEMICAL
model	O
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
A	O
prospective	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	B-CHEMICAL
in	O
autistic	B-DISEASE
disorder	I-DISEASE
OBJECTIVE	O
:	O
Post	O
-	O
mortem	O
studies	O
have	O
reported	O
abnormalities	B-DISEASE
of	O
the	O
cholinergic	O
system	O
in	O
autism	B-DISEASE
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	B-CHEMICAL
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator	O
,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B-DISEASE
METHODS	O
:	O
Thirteen	O
medication	O
-	O
free	O
children	O
with	O
autism	B-DISEASE
(	O
mean	O
age	O
,	O
8	O
.	O
8	O
+/-	O
3	O
.	O
5	O
years	O
)	O
participated	O
in	O
a	O
12	O
-	O
week	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	B-CHEMICAL
Patients	O
were	O
rated	O
monthly	O
by	O
parents	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
and	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
,	O
and	O
by	O
a	O
physician	O
using	O
the	O
Children	O
'	O
s	O
Psychiatric	B-DISEASE
RESULTS	O
:	O
Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent	O
-	O
rated	O
irritability	B-DISEASE
Similarly	O
,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children	O
'	O
s	O
Psychiatric	B-DISEASE
Overall	O
,	O
galantamine	B-CHEMICAL
CONCLUSION	O
:	O
In	O
this	O
open	O
trial	O
,	O
galantamine	B-CHEMICAL
was	O
well	O
-	O
tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B-DISEASE
,	O
particularly	O
aggression	B-DISEASE
Randomized	O
comparison	O
of	O
olanzapine	B-CHEMICAL
versus	O
risperidone	B-CHEMICAL
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B-DISEASE
OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4	O
-	O
month	O
treatment	O
outcomes	O
for	O
olanzapine	B-CHEMICAL
versus	O
risperidone	B-CHEMICAL
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	B-DISEASE
METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
years	O
[	O
SD	O
=	O
5	O
.	O
1	O
])	O
with	O
first	O
-	O
episode	O
schizophrenia	B-DISEASE
(	O
75	O
%),	O
schizophreniform	B-DISEASE
disorder	I-DISEASE
(	O
17	O
%),	O
or	O
schizoaffective	B-DISEASE
disorder	I-DISEASE
(	O
8	O
%)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	B-CHEMICAL
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	B-CHEMICAL
RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	B-CHEMICAL
(	O
43	O
.	O
7	O
%,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%-	O
58	O
.	O
6	O
%)	O
and	O
risperidone	B-CHEMICAL
Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	B-CHEMICAL
group	O
(	O
40	O
.	O
9	O
%,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%-	O
65	O
.	O
0	O
%)	O
than	O
in	O
the	O
risperidone	B-CHEMICAL
Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B-DISEASE
and	O
akathisia	B-DISEASE
Extrapyramidal	O
symptom	O
severity	O
scores	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperidone	B-CHEMICAL
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapine	B-CHEMICAL
Significantly	O
more	O
weight	B-DISEASE
gain	I-DISEASE
occurred	O
with	O
olanzapine	B-CHEMICAL
than	O
with	O
risperidone	B-CHEMICAL
:	O
the	O
increase	O
in	O
weight	O
at	B-DISEASE
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%-	O
20	O
.	O
5	O
%)	O
with	O
olanzapine	B-CHEMICAL
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%-	O
14	O
.	O
3	O
%)	O
with	O
risperidone	B-CHEMICAL
Body	O
mass	O
index	O
at	B-DISEASE
baseline	O
and	O
at	B-DISEASE
4	O
months	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapine	B-CHEMICAL
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidone	B-CHEMICAL
CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	B-CHEMICAL
were	O
equal	O
to	O
those	O
with	O
olanzapine	B-CHEMICAL
Olanzapine	B-CHEMICAL
Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-DISEASE
gain	I-DISEASE
,	O
but	O
weight	B-DISEASE
gain	I-DISEASE
was	O
greater	O
with	O
olanzapine	B-CHEMICAL
Early	O
paracentral	O
visual	O
field	O
loss	O
in	O
patients	O
taking	O
hydroxychloroquine	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	B-CHEMICAL
RESULTS	O
:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	B-CHEMICAL
Of	O
the	O
262	O
patients	O
,	O
14	O
(	O
18	O
%)	O
of	O
76	O
who	O
had	O
stopped	O
treatment	O
at	B-DISEASE
Thirty	O
-	O
five	O
patients	O
(	O
13	O
.	O
4	O
%)	O
had	O
visual	O
field	O
abnormalities	B-DISEASE
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	B-CHEMICAL
Three	O
of	O
the	O
4	O
patients	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
day	O
and	O
all	O
patients	O
had	O
normal	O
renal	B-DISEASE
and	O
liver	B-DISEASE
CONCLUSIONS	O
:	O
The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	B-DISEASE
assessment	O
,	O
funduscopy	O
,	O
and	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
Patients	O
taking	O
hydroxychloroquine	B-CHEMICAL
Peri	O
-	O
operative	O
atrioventricular	B-DISEASE
block	I-DISEASE
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	B-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
A	O
47	O
-	O
year	O
-	O
old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	B-DISEASE
In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
epirubicin	B-CHEMICAL
,	O
paclitaxel	B-CHEMICAL
(	O
Taxol	B-CHEMICAL
)	O
and	O
cyclophosphamide	B-CHEMICAL
She	O
was	O
found	O
to	O
be	O
bradycardic	O
at	B-DISEASE
Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	B-DISEASE
block	I-DISEASE
We	O
discuss	O
how	O
evidence	O
-	O
based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case	O
,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	B-DISEASE
We	O
suggest	O
that	O
patients	O
who	O
have	O
received	O
chemotherapy	O
at	B-DISEASE
OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
(	O
AMI	B-CHEMICAL
We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B-CHEMICAL
and	O
GI	O
bleeding	B-DISEASE
among	O
elderly	O
patients	O
using	O
COX	O
-	O
2	O
inhibitors	O
,	O
NS	O
-	O
NSAIDs	O
and	O
acetaminophen	B-CHEMICAL
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	B-CHEMICAL
RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	B-CHEMICAL
were	O
:	O
75	O
,	O
761	O
to	O
acetaminophen	B-CHEMICAL
,	O
42	O
,	O
671	O
to	O
rofecoxib	B-CHEMICAL
65	O
,	O
860	O
to	O
celecoxib	B-CHEMICAL
Among	O
users	O
of	O
aspirin	B-CHEMICAL
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxib	B-CHEMICAL
,	O
22	O
,	O
875	O
to	O
celecoxib	B-CHEMICAL
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38	O
,	O
048	O
to	O
acetaminophen	B-CHEMICAL
Among	O
non	O
-	O
users	O
of	O
aspirin	B-CHEMICAL
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B-CHEMICAL
/	O
GI	O
vs	O
the	O
acetaminophen	B-CHEMICAL
(	O
with	O
no	O
aspirin	B-CHEMICAL
)	O
group	O
were	O
:	O
rofecoxib	B-CHEMICAL
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
),	O
celecoxib	B-CHEMICAL
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
),	O
naproxen	B-CHEMICAL
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
),	O
diclofenac	B-CHEMICAL
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprofen	B-CHEMICAL
Among	O
users	O
of	O
aspirin	B-CHEMICAL
,	O
they	O
were	O
:	O
rofecoxib	B-CHEMICAL
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
),	O
celecoxib	B-CHEMICAL
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
),	O
ibuprofen	B-CHEMICAL
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
),	O
diclofenac	B-CHEMICAL
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
),	O
naproxen	B-CHEMICAL
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminophen	B-CHEMICAL
CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-CHEMICAL
,	O
naproxen	B-CHEMICAL
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B-CHEMICAL
/	O
GI	O
bleeding	B-DISEASE
The	O
AMI	B-CHEMICAL
/	O
GI	O
toxicity	B-DISEASE
of	O
celecoxib	B-CHEMICAL
was	O
similar	O
to	O
that	O
of	O
acetaminophen	B-CHEMICAL
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	B-CHEMICAL
Among	O
users	O
of	O
aspirin	B-CHEMICAL
,	O
both	O
celecoxib	B-CHEMICAL
and	O
naproxen	B-CHEMICAL
Quinine	B-CHEMICAL
-	O
induced	O
arrhythmia	B-DISEASE
in	O
a	O
patient	O
with	O
severe	O
malaria	B-DISEASE
It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	O
malaria	B-DISEASE
patient	O
with	O
jaundice	B-DISEASE
who	O
presented	O
with	O
arrhythmia	B-DISEASE
(	O
premature	O
ventricular	O
contraction	O
)	O
while	O
getting	O
quinine	B-CHEMICAL
A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B-DISEASE
,	O
chill	O
,	O
vomiting	B-DISEASE
,	O
jaundice	B-DISEASE
On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(++++),	O
total	O
bilirubin	B-CHEMICAL
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	B-CHEMICAL
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	B-CHEMICAL
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potassium	B-CHEMICAL
3	O
.	O
52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	O
malaria	B-DISEASE
with	O
jaundice	B-DISEASE
and	O
got	O
quinine	B-CHEMICAL
On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	O
,	O
diarrhea	B-DISEASE
,	O
tinnitus	B-DISEASE
After	O
30	O
hours	O
of	O
quinine	B-CHEMICAL
infusion	O
the	O
patient	O
felt	O
palpitation	O
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	O
ventricular	O
contraction	O
(	O
PVC	O
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
--	O
sinoatrial	B-DISEASE
block	I-DISEASE
He	O
was	O
treated	O
with	O
lidocaine	B-CHEMICAL
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	O
5	O
%/	O
24	O
hour	O
and	O
potassium	B-CHEMICAL
aspartate	B-CHEMICAL
Quinine	B-CHEMICAL
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	B-CHEMICAL
Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	O
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	B-CHEMICAL
Quinine	B-CHEMICAL
,	O
like	O
quinidine	B-CHEMICAL
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti	O
-	O
arrhythmic	O
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	O
that	O
can	O
cause	O
various	O
arrhythmias	B-DISEASE
,	O
including	O
severe	O
arrhythmia	B-DISEASE
Administration	O
of	O
parenteral	O
quinine	B-CHEMICAL
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	O
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B-DISEASE
diseases	I-DISEASE
or	O
patients	O
with	O
electrolyte	O
disorder	O
(	O
hypokalemia	B-DISEASE
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B-DISEASE
and	O
or	O
diarrhea	B-DISEASE
in	O
malaria	B-DISEASE
Penicillamine	B-CHEMICAL
-	O
related	O
lichenoid	O
dermatitis	B-DISEASE
and	O
utility	O
of	O
zinc	B-CHEMICAL
acetate	I-CHEMICAL
in	O
a	O
Wilson	O
disease	B-DISEASE
patient	O
with	O
hepatic	O
presentation	O
,	O
anxiety	B-DISEASE
and	O
SPECT	O
abnormalities	B-DISEASE
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	B-CHEMICAL
metabolism	B-DISEASE
with	O
consequent	O
copper	B-CHEMICAL
accumulation	O
and	O
toxicity	B-DISEASE
in	O
many	O
tissues	O
and	O
consequent	O
hepatic	O
,	O
neurologic	B-DISEASE
and	O
psychiatric	B-DISEASE
We	O
report	O
a	O
case	O
of	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
with	O
chronic	O
liver	B-DISEASE
disease	I-DISEASE
;	O
moreover	O
,	O
in	O
our	O
patient	O
,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	B-DISEASE
without	O
depression	B-DISEASE
During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patient	O
,	O
penicillamine	B-CHEMICAL
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	O
dermatitis	B-DISEASE
,	O
and	O
zinc	B-CHEMICAL
acetate	I-CHEMICAL
In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	B-CHEMICAL
acetate	I-CHEMICAL
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
patient	O
in	O
which	O
penicillamine	B-CHEMICAL
The	O
safety	O
of	O
the	O
zinc	B-CHEMICAL
acetate	I-CHEMICAL
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs	O
;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
Since	O
most	O
of	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
penicillamine	B-CHEMICAL
-	O
treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	B-DISEASE
Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
therapy	O
,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B-DISEASE
pain	I-DISEASE
awoke	O
with	O
chest	B-DISEASE
pain	I-DISEASE
The	O
patient	O
'	O
s	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	B-CHEMICAL
Several	O
minutes	O
after	O
the	O
GTN	O
the	O
patient	O
experienced	O
a	O
sudden	O
drop	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	B-CHEMICAL
The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold	O
-	O
Jarish	O
reflex	B-DISEASE
Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	O
episode	O
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	B-DISEASE
Acute	O
encephalopathy	B-DISEASE
and	O
cerebral	O
vasospasm	B-DISEASE
after	O
multiagent	O
chemotherapy	O
including	O
PEG	O
-	O
asparaginase	O
and	O
intrathecal	O
cytarabine	B-CHEMICAL
for	O
the	O
treatment	O
of	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
A	B-CHEMICAL
7	I-CHEMICAL
-	O
year	O
-	O
old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B	O
-	O
cell	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
The	O
patient	O
developed	O
acute	O
encephalopathy	B-DISEASE
evidenced	O
by	O
behavioral	O
changes	O
,	O
aphasia	B-DISEASE
,	O
incontinence	B-DISEASE
,	O
visual	B-DISEASE
hallucinations	I-DISEASE
,	O
and	O
right	O
-	O
sided	O
weakness	B-DISEASE
with	O
diffuse	O
cerebral	O
vasospasm	B-DISEASE
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	B-CHEMICAL
Vincristine	B-CHEMICAL
,	O
dexamethasone	B-CHEMICAL
,	O
and	O
polyethylene	B-CHEMICAL
Neurologic	B-DISEASE
Comparison	O
of	O
valsartan	B-CHEMICAL
/	O
hydrochlorothiazide	B-CHEMICAL
combination	O
therapy	O
at	B-DISEASE
doses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	B-DISEASE
BACKGROUND	O
:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	B-DISEASE
Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B-DISEASE
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	B-DISEASE
OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	B-CHEMICAL
(	O
VAL	O
)	O
or	O
hydrochlorothiazide	B-CHEMICAL
(	O
HCTZ	O
)-	O
monotherapy	O
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	O
with	O
essential	B-DISEASE
hypertension	I-DISEASE
Patients	O
with	O
essential	B-DISEASE
hypertension	I-DISEASE
Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	B-DISEASE
Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	B-DISEASE
The	O
incidence	O
of	O
hypokalemia	B-DISEASE
CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL	O
/	O
HCTZ	O
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B-DISEASE
Succimer	B-CHEMICAL
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead	B-CHEMICAL
-	O
exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B-DISEASE
impairment	I-DISEASE
in	O
the	O
absence	O
of	O
lead	B-CHEMICAL
BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	B-DISEASE
only	O
slightly	O
elevated	O
blood	O
lead	B-CHEMICAL
OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	O
exposure	O
and	O
treatment	O
with	O
succimer	B-CHEMICAL
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	O
poisoning	B-DISEASE
Succimer	B-CHEMICAL
In	O
contrast	O
,	O
succimer	B-CHEMICAL
CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-DISEASE
deficits	I-DISEASE
These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	B-CHEMICAL
However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	B-CHEMICAL
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	O
or	O
other	O
heavy	O
metals	B-CHEMICAL
Caffeine	B-CHEMICAL
challenge	O
test	O
in	O
panic	B-DISEASE
disorder	I-DISEASE
and	O
depression	B-DISEASE
with	O
panic	B-DISEASE
attacks	I-DISEASE
Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B-DISEASE
disorder	I-DISEASE
(	O
PD	B-DISEASE
)	O
and	O
patients	O
with	O
major	B-DISEASE
depression	I-DISEASE
with	O
panic	B-DISEASE
attacks	I-DISEASE
(	O
MDP	O
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-DISEASE
Disorders	I-DISEASE
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B-DISEASE
attacks	I-DISEASE
by	O
an	O
oral	O
caffeine	B-CHEMICAL
We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	B-DISEASE
,	O
27	O
with	O
MDP	O
,	O
25	O
with	O
major	B-DISEASE
depression	I-DISEASE
without	O
panic	B-DISEASE
attacks	I-DISEASE
(	O
MD	B-DISEASE
The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	B-DISEASE
In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	B-CHEMICAL
and	O
a	O
caffeine	B-CHEMICAL
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	B-CHEMICAL
form	O
and	O
anxiety	B-DISEASE
A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	B-DISEASE
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	O
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	B-DISEASE
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B-DISEASE
attack	I-DISEASE
after	O
the	O
480	O
-	O
mg	O
caffeine	B-CHEMICAL
The	O
patients	O
with	O
PD	B-DISEASE
and	O
MDP	O
were	O
more	O
sensitive	O
to	O
caffeine	B-CHEMICAL
than	O
were	O
patients	O
with	O
MD	B-DISEASE
No	O
panic	B-DISEASE
attack	I-DISEASE
was	O
observed	O
after	O
the	O
caffeine	B-CHEMICAL
The	O
patients	O
with	O
MD	B-DISEASE
Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B-DISEASE
attacks	I-DISEASE
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-DISEASE
or	O
MDP	O
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	B-CHEMICAL
BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
mitral	O
annuloplasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
and	O
functional	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
MR	B-DISEASE
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B-DISEASE
However	O
,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	B-DISEASE
The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	B-DISEASE
failure	I-DISEASE
Acute	O
heart	B-DISEASE
failure	I-DISEASE
was	O
induced	O
by	O
propranolol	B-CHEMICAL
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
;	O
an	O
absence	O
of	O
MR	B-DISEASE
Data	O
were	O
acquired	O
at	B-DISEASE
baseline	O
,	O
after	O
induction	O
of	O
acute	O
heart	B-DISEASE
failure	I-DISEASE
Decreases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastolic	O
pressure	O
(	O
from	O
17	O
+/-	O
7	O
to	O
15	O
+/-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tau	O
(	O
from	O
48	O
+/-	O
8	O
to	O
45	O
+/-	O
8	O
ms	B-DISEASE
,	O
p	O
<	O
0	O
.	O
01	O
),	O
while	O
fractional	O
shortening	O
at	B-DISEASE
After	O
MAP	O
,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	B-DISEASE
output	I-DISEASE
CONCLUSION	O
:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension	O
/	O
function	O
in	O
acute	O
heart	B-DISEASE
failure	I-DISEASE
,	O
even	O
in	O
the	O
absence	O
of	O
MR	B-DISEASE
However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B-DISEASE
failure	I-DISEASE
Piperacillin	B-CHEMICAL
/	O
tazobactam	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
Despite	O
popular	O
use	O
of	O
piperacillin	B-CHEMICAL
,	O
the	O
dire	O
neurotoxicity	B-DISEASE
associated	O
with	O
piperacillin	B-CHEMICAL
We	O
report	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
with	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
),	O
who	O
developed	O
slurred	O
speech	O
,	O
tremor	B-DISEASE
,	O
bizarre	O
behavior	O
,	O
progressive	O
mental	O
confusion	B-DISEASE
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic	B-DISEASE
-	I-DISEASE
clonic	I-DISEASE
seizure	I-DISEASE
(	O
GTCS	O
)	O
after	O
5	O
doses	O
of	O
piperacillin	B-CHEMICAL
/	O
tazobactam	B-CHEMICAL
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectasis	B-DISEASE
with	O
secondary	O
infection	B-DISEASE
The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	B-CHEMICAL
levels	O
but	O
leukocytosis	B-DISEASE
Neurologic	B-DISEASE
examinations	O
showed	O
dysarthria	B-DISEASE
Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	O
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin	B-CHEMICAL
/	O
tazobactam	B-CHEMICAL
Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	B-DISEASE
Initiation	O
of	O
high	O
-	O
flux	O
hemodialysis	O
rapidly	O
reversed	O
the	O
neurologic	B-DISEASE
Piperacillin	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	B-CHEMICAL
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
Frequency	O
of	O
transient	O
ipsilateral	O
vocal	B-DISEASE
cord	I-DISEASE
paralysis	I-DISEASE
BACKGROUND	O
:	O
Especially	O
because	O
of	O
improvements	O
in	O
clinical	O
neurologic	B-DISEASE
Temporary	O
ipsilateral	O
vocal	O
nerve	O
palsies	O
due	O
to	O
local	O
anesthetics	B-CHEMICAL
Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
contralateral	O
paralysis	B-DISEASE
Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ropivacaine	B-CHEMICAL
)	O
and	O
short	O
-	O
acting	O
(	O
prilocaine	B-CHEMICAL
Twelve	O
patients	O
(	O
43	O
%)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	B-DISEASE
cord	I-DISEASE
paralysis	I-DISEASE
There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	B-DISEASE
cord	I-DISEASE
paralysis	I-DISEASE
CONCLUSION	O
:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	B-DISEASE
cord	I-DISEASE
paralysis	I-DISEASE
Because	O
pre	O
-	O
existing	O
paralysis	B-DISEASE
is	O
of	O
a	O
relevant	O
frequency	O
(	O
up	O
to	O
3	O
%),	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	B-DISEASE
In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	B-DISEASE
cord	I-DISEASE
paralysis	I-DISEASE
Neuroprotective	O
effects	O
of	O
melatonin	B-CHEMICAL
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	B-CHEMICAL
-	O
induced	O
cortical	B-DISEASE
dysplasia	I-DISEASE
Cortical	B-DISEASE
dysplasia	I-DISEASE
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	B-CHEMICAL
-[	O
1	O
,	O
3	O
-	O
bis	O
(	O
2	O
-	O
chloroethyl	O
)-	O
1	O
-	O
nitrosoure	O
]	O
(	O
BCNU	B-CHEMICAL
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B-CHEMICAL
upon	O
cerebellar	O
BCNU	B-CHEMICAL
-	O
induced	O
cortical	B-DISEASE
dysplasia	I-DISEASE
Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
,	O
saline	O
-	O
control	O
,	O
melatonin	B-CHEMICAL
-	O
treated	O
,	O
BCNU	B-CHEMICAL
-	O
exposed	O
and	O
BCNU	B-CHEMICAL
-	O
exposed	O
plus	O
melatonin	B-CHEMICAL
Rats	O
were	O
exposed	O
to	O
BCNU	B-CHEMICAL
on	O
embryonic	O
day	O
15	O
and	O
melatonin	B-CHEMICAL
Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	B-CHEMICAL
and	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	B-CHEMICAL
-	O
exposed	O
cortical	B-DISEASE
dysplasia	I-DISEASE
There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	B-CHEMICAL
-	O
exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	B-CHEMICAL
fibrillary	I-CHEMICAL
acidic	I-CHEMICAL
protein	I-CHEMICAL
,	O
synaptophysin	B-CHEMICAL
and	O
transforming	B-CHEMICAL
growth	I-CHEMICAL
factor	I-CHEMICAL
beta1	I-CHEMICAL
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	B-CHEMICAL
Malondialdehyde	B-CHEMICAL
level	O
in	O
BCNU	B-CHEMICAL
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	B-CHEMICAL
decreased	O
malondialdehyde	B-CHEMICAL
levels	O
in	O
BCNU	B-CHEMICAL
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	B-CHEMICAL
dismutase	I-CHEMICAL
These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	B-CHEMICAL
during	O
pregnancy	B-DISEASE
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	B-CHEMICAL
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	B-CHEMICAL
Myo	O
-	O
inositol	B-CHEMICAL
-	O
1	O
-	O
phosphate	B-CHEMICAL
Lithium	B-CHEMICAL
and	O
valproate	B-CHEMICAL
Both	O
drugs	O
influence	O
inositol	B-CHEMICAL
metabolism	B-DISEASE
Lithium	B-CHEMICAL
inhibits	O
IMPase	O
and	O
valproate	B-CHEMICAL
This	O
study	O
shows	O
that	O
MIP	O
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	B-CHEMICAL
in	O
the	O
inositol	B-CHEMICAL
sensitive	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
synthesis	O
to	O
cellular	O
inositol	B-CHEMICAL
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de	O
-	O
novo	O
synthesis	O
by	O
lithium	B-CHEMICAL
Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
-	O
associated	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
Acute	O
tubulo	O
-	O
interstitial	B-DISEASE
nephritis	I-DISEASE
(	O
ATIN	O
)	O
is	O
an	O
important	O
cause	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
We	O
report	O
on	O
a	O
14	O
-	O
year	O
-	O
old	O
boy	O
who	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
2	O
weeks	O
after	O
aortic	B-DISEASE
valve	I-DISEASE
He	O
was	O
put	O
on	O
aspirin	B-CHEMICAL
following	O
surgery	O
and	O
took	O
ibuprofen	B-CHEMICAL
for	O
fever	B-DISEASE
He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	B-CHEMICAL
urea	I-CHEMICAL
nitrogen	I-CHEMICAL
(	O
BUN	O
)	O
concentration	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatinine	B-CHEMICAL
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
serum	O
potassium	B-CHEMICAL
He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	B-CHEMICAL
His	O
renal	B-DISEASE
recovery	O
and	O
disappearance	O
of	O
proteinuria	B-DISEASE
Rifampicin	O
-	O
associated	O
segmental	O
necrotizing	O
glomerulonephritis	B-DISEASE
in	O
staphylococcal	O
endocarditis	B-DISEASE
Segmental	O
necrotising	O
glomerulonephritis	B-DISEASE
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	O
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	B-DISEASE
Changing	O
epidemiology	O
of	O
infections	B-DISEASE
such	O
as	O
infective	O
endocarditis	B-DISEASE
(	O
IE	O
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	O
for	O
Staphylococcal	B-DISEASE
infections	I-DISEASE
We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	O
IE	O
who	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	B-DISEASE
Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-CHEMICAL
-	O
untreated	O
Iranian	O
patients	O
with	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	I-DISEASE
infection	I-DISEASE
BACKGROUND	O
:	O
Lamivudine	B-CHEMICAL
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(	O
resistant	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine	B-CHEMICAL
-	O
untreated	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-CHEMICAL
-	O
untreated	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	B-CHEMICAL
All	O
patients	O
were	O
also	O
tested	O
for	O
liver	B-DISEASE
enzymes	O
,	O
anti	O
-	O
HCV	O
,	O
HBeAg	B-CHEMICAL
HBeAg	B-CHEMICAL
YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	B-DISEASE
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	B-CHEMICAL
CONCLUSION	O
:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-CHEMICAL
-	O
untreated	O
patients	O
with	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
has	O
been	O
reported	O
,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine	B-CHEMICAL
-	O
untreated	O
chronic	O
hepatitis	B-DISEASE
B	I-DISEASE
Branch	O
retinal	B-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
and	O
fluoxetine	B-CHEMICAL
A	O
case	O
of	O
branch	O
retinal	B-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
associated	O
with	O
fluoxetine	B-CHEMICAL
-	O
induced	O
secondary	B-DISEASE
hypertension	I-DISEASE
Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
therapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	B-DISEASE
The	O
differential	O
effects	O
of	O
bupivacaine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
on	O
prostaglandin	O
E2	B-CHEMICAL
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	B-DISEASE
in	O
a	O
clinical	O
pain	B-DISEASE
BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	B-CHEMICAL
might	O
directly	O
modulate	O
inflammation	B-DISEASE
In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B-CHEMICAL
on	O
local	O
prostaglandin	O
E2	B-CHEMICAL
(	O
PGE2	O
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	O
pain	B-DISEASE
METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B-CHEMICAL
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-CHEMICAL
before	O
surgery	O
and	O
either	O
rofecoxib	B-CHEMICAL
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	B-CHEMICAL
.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	B-CHEMICAL
After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	B-DISEASE
the	O
surgical	O
site	O
for	O
PGE2	O
and	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
RESULTS	O
:	O
The	O
bupivacaine	B-CHEMICAL
/	O
rofecoxib	B-CHEMICAL
group	O
reported	O
significantly	O
less	O
pain	B-DISEASE
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h	B-CHEMICAL
.	O
However	O
,	O
the	O
bupivacaine	B-CHEMICAL
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B-DISEASE
at	B-DISEASE
24	O
h	B-CHEMICAL
and	O
PGE2	O
levels	O
during	O
the	O
first	O
4	O
h	B-CHEMICAL
Moreover	O
,	O
bupivacaine	B-CHEMICAL
significantly	O
increased	O
COX	O
-	O
2	O
gene	O
expression	O
at	B-DISEASE
48	O
h	B-CHEMICAL
as	O
compared	O
with	O
the	O
lidocaine	B-CHEMICAL
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B-CHEMICAL
stimulates	O
COX	O
-	O
2	O
gene	O
expression	O
after	O
tissue	O
injury	O
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	O
production	O
and	O
pain	B-DISEASE
p75NTR	O
expression	O
in	O
rat	O
urinary	B-DISEASE
bladder	I-DISEASE
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
A	O
role	O
for	O
nerve	B-CHEMICAL
growth	I-CHEMICAL
factor	I-CHEMICAL
(	O
NGF	B-CHEMICAL
)	O
in	O
contributing	O
to	O
increased	O
voiding	O
frequency	O
and	O
altered	O
sensation	O
from	O
the	O
urinary	B-DISEASE
bladder	I-DISEASE
Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	B-CHEMICAL
kinase	O
receptors	O
(	O
Trks	O
)	O
in	O
micturition	O
reflexes	O
with	O
urinary	B-DISEASE
bladder	I-DISEASE
inflammation	B-DISEASE
The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF	B-CHEMICAL
,	O
p75	O
(	O
NTR	O
),	O
after	O
various	O
durations	O
of	O
bladder	B-DISEASE
inflammation	I-DISEASE
induced	O
by	O
cyclophosphamide	B-CHEMICAL
CYP	O
-	O
induced	O
cystitis	B-DISEASE
The	O
number	O
of	O
p75	O
(	O
NTR	O
)-	O
immunoreactive	O
(-	O
IR	O
)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	O
-	O
induced	O
cystitis	B-DISEASE
Quantitative	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP	O
-	O
induced	O
cystitis	B-DISEASE
In	O
bladder	O
afferent	O
cells	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)-	O
IR	O
was	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
cystitis	B-DISEASE
Confocal	O
analyses	O
demonstrated	O
that	O
pericellular	O
p75	O
(	O
NTR	O
)-	O
IR	O
was	O
not	O
colocalized	O
with	O
the	O
glial	O
marker	O
,	O
glial	B-CHEMICAL
fibrillary	I-CHEMICAL
acidic	I-CHEMICAL
protein	I-CHEMICAL
These	O
studies	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	B-DISEASE
inflammation	I-DISEASE
Azathioprine	B-CHEMICAL
-	O
induced	O
suicidal	O
erythrocyte	O
death	B-DISEASE
BACKGROUND	O
:	O
Azathioprine	B-CHEMICAL
The	O
side	O
effects	O
of	O
azathioprine	B-CHEMICAL
include	O
anemia	B-DISEASE
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
Alternatively	O
,	O
anemia	B-DISEASE
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	B-DISEASE
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	O
(	O
PS	O
)	O
at	B-DISEASE
METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	B-CHEMICAL
According	O
to	O
annexin	O
V	O
binding	O
,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	O
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	B-CHEMICAL
RESULTS	O
:	O
Exposure	O
to	O
azathioprine	B-CHEMICAL
The	O
effect	O
of	O
azathioprine	B-CHEMICAL
CONCLUSIONS	O
:	O
Azathioprine	B-CHEMICAL
triggers	O
suicidal	O
erythrocyte	O
death	B-DISEASE
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	B-CHEMICAL
-	O
induced	O
anemia	B-DISEASE
BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	O
-	O
spinal	O
block	O
hypotension	B-DISEASE
METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	B-CHEMICAL
In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyperbaric	O
bupivacaine	B-CHEMICAL
Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	B-CHEMICAL
RESULTS	O
:	O
Three	O
patients	O
(	O
8	O
.	O
1	O
%)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13	O
.	O
5	O
%)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	B-DISEASE
Four	O
(	O
10	O
.	O
8	O
%)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2	O
.	O
7	O
%)	O
in	O
the	O
unilateral	O
group	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinephrine	B-CHEMICAL
infusion	O
to	O
treat	O
hypotension	B-DISEASE
Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	B-DISEASE
The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	B-CHEMICAL
Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	B-CHEMICAL
Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B-DISEASE
-	I-DISEASE
infected	I-DISEASE
To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-DISEASE
-	I-DISEASE
infected	I-DISEASE
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B-DISEASE
-	I-DISEASE
infected	I-DISEASE
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	B-DISEASE
The	O
most	O
common	O
regimens	O
were	O
3TC	O
+	O
d4T	O
+	O
nevirapine	B-CHEMICAL
(	O
NVP	O
)	O
(	O
54	O
.	O
8	O
%),	O
zidovudine	B-CHEMICAL
(	O
AZT	B-CHEMICAL
)	O
+	O
3TC	O
+	O
NVP	O
(	O
14	O
.	O
5	O
%),	O
3TC	O
+	O
d4T	O
+	O
efavirenz	B-CHEMICAL
(	O
EFV	O
)	O
(	O
20	O
.	O
1	O
%),	O
and	O
AZT	B-CHEMICAL
The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	B-DISEASE
time	O
of	O
event	O
were	O
rash	B-DISEASE
(	O
15	O
.	O
2	O
%;	O
CD4	O
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Clinically	O
significant	O
anemia	B-DISEASE
(	O
hemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B-DISEASE
(	O
clinical	O
jaundice	B-DISEASE
with	O
alanine	B-CHEMICAL
Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B-DISEASE
acidosis	I-DISEASE
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	O
reconstitution	O
syndrome	B-DISEASE
Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
,	O
NVP	O
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B-DISEASE
and	O
d4T	O
therapy	O
with	O
developing	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
Anemia	B-DISEASE
and	O
hepatitis	B-DISEASE
Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B-DISEASE
Thalidomide	B-CHEMICAL
and	O
sensory	O
neurotoxicity	B-DISEASE
BACKGROUND	O
:	O
Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	O
axonal	O
neuropathy	B-DISEASE
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	B-CHEMICAL
The	O
study	O
'	O
s	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(	O
SAP	O
)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	O
lupus	B-DISEASE
erythematosus	I-DISEASE
(	O
CLE	O
)	O
treated	O
with	O
thalidomide	B-CHEMICAL
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	B-DISEASE
potential	O
of	O
thalidomide	B-CHEMICAL
PATIENTS	O
AND	O
METHODS	O
:	O
Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	O
during	O
treatment	O
with	O
thalidomide	B-CHEMICAL
Five	O
patients	O
complained	O
of	O
paresthesias	O
and	O
leg	B-DISEASE
cramps	B-DISEASE
After	O
thalidomide	B-CHEMICAL
At	B-DISEASE
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
,	O
the	O
median	O
thalidomide	B-CHEMICAL
cumulative	O
dose	O
was	O
21	O
.	O
4	O
g	O
.	O
The	O
threshold	O
neurotoxic	B-DISEASE
This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	B-DISEASE
potential	O
of	O
thalidomide	B-CHEMICAL
Amiodarone	B-CHEMICAL
-	O
related	O
pulmonary	O
mass	O
and	O
unique	O
membranous	O
glomerulonephritis	B-DISEASE
in	O
a	O
patient	O
with	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
Amiodarone	B-CHEMICAL
is	O
an	O
anti	O
-	O
arrhythmic	O
drug	O
for	O
life	O
-	O
threatening	O
tachycardia	B-DISEASE
Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	B-DISEASE
mass	O
(	O
1	O
.	O
5	O
cm	B-DISEASE
in	O
diameter	O
)	O
and	O
proteinuria	B-DISEASE
(	O
2	O
.	O
76	O
g	O
/	O
day	O
)	O
after	O
treatment	O
with	O
amiodarone	B-CHEMICAL
The	O
lung	B-DISEASE
mass	O
was	O
highly	O
suspected	O
to	O
be	O
lung	B-DISEASE
cancer	I-DISEASE
on	O
CT	O
and	O
positron	O
emission	O
tomography	O
,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra	O
-	O
alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone	B-CHEMICAL
In	O
addition	O
,	O
the	O
lung	B-DISEASE
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	O
deposition	O
,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	O
lung	B-DISEASE
In	O
the	O
kidneys	O
,	O
glomeruli	O
had	O
membrane	O
spikes	O
,	O
prominent	O
swelling	B-DISEASE
Autoimmune	B-DISEASE
diseases	I-DISEASE
,	O
viral	O
hepatitis	B-DISEASE
,	O
malignant	O
neoplasms	B-DISEASE
or	O
other	O
diseases	B-DISEASE
with	O
a	O
known	O
relationship	O
to	O
membranous	O
glomerulonephritis	B-DISEASE
The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone	B-CHEMICAL
-	O
related	O
pulmonary	O
lesion	O
and	O
a	O
neoplasm	B-DISEASE
can	O
be	O
very	O
difficult	O
radiologically	O
,	O
and	O
suggests	O
that	O
membranous	O
glomerulonephritis	B-DISEASE
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	B-CHEMICAL
Risk	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
associated	O
with	O
initial	O
sulphonylurea	O
treatment	O
of	O
patients	O
with	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
(	O
CAD	O
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
METHODS	O
:	O
In	O
type	O
2	O
diabetic	B-DISEASE
The	O
20	O
-	O
year	O
risk	O
of	O
CAD	O
at	B-DISEASE
diagnosis	O
of	O
diabetes	B-DISEASE
The	O
hazard	O
of	O
developing	O
CAD	O
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glibenclamide	O
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
glipizide	B-CHEMICAL
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	B-CHEMICAL
The	O
hazard	O
decreased	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimepiride	B-CHEMICAL
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclazide	B-CHEMICAL
CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
with	O
glibenclamide	O
or	O
glipizide	B-CHEMICAL
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	O
in	O
comparison	O
to	O
gliclazide	B-CHEMICAL
or	O
glimepiride	B-CHEMICAL
Reduced	O
progression	O
of	O
adriamycin	B-CHEMICAL
nephropathy	B-DISEASE
in	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
treated	O
by	O
losartan	B-CHEMICAL
BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
type	O
-	O
1	O
receptor	O
blocker	O
,	O
losartan	B-CHEMICAL
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B-DISEASE
disease	B-DISEASE
progression	I-DISEASE
in	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	B-CHEMICAL
(	O
ADR	B-CHEMICAL
)	O
nephropathy	B-DISEASE
Groups	O
ADR	B-CHEMICAL
(	O
6	O
),	O
ADR	B-CHEMICAL
+	O
LOS	O
(	O
6	O
)	O
and	O
ADR	B-CHEMICAL
(	O
12	O
),	O
and	O
ADR	B-CHEMICAL
+	O
LOS	O
(	O
12	O
)	O
received	O
ADR	B-CHEMICAL
Group	O
ADR	B-CHEMICAL
+	O
LOS	O
(	O
6	O
)	O
received	O
losartan	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
./	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	B-CHEMICAL
+	O
LOS	O
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B-CHEMICAL
Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	B-DISEASE
RESULTS	O
:	O
Short	O
-	O
term	O
losartan	B-CHEMICAL
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B-DISEASE
resulting	O
in	O
decreased	O
proteinuria	B-DISEASE
Prolonged	O
treatment	O
with	O
losartan	B-CHEMICAL
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B-DISEASE
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B-DISEASE
and	O
interstitial	O
fibrosis	B-DISEASE
,	O
thus	O
preventing	O
heavy	O
proteinuria	B-DISEASE
and	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
Losartan	B-CHEMICAL
reduced	O
uraemia	O
and	O
increased	O
urea	B-CHEMICAL
clearance	O
in	O
advanced	O
ADR	B-CHEMICAL
nephropathy	B-DISEASE
Histological	O
examination	O
showed	O
that	O
losartan	B-CHEMICAL
could	O
prevent	O
tubular	O
atrophy	B-DISEASE
,	O
interstitial	O
infiltration	O
and	O
fibrosis	B-DISEASE
in	O
ADR	B-CHEMICAL
nephropathy	B-DISEASE
CONCLUSION	O
:	O
Losartan	B-CHEMICAL
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	B-CHEMICAL
-	O
induced	O
focal	B-DISEASE
segmental	I-DISEASE
glomerulosclerosis	I-DISEASE
to	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	B-DISEASE
complications	I-DISEASE
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patients	O
received	O
aprotinin	O
(	O
Group	O
A	O
);	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
Postoperatively	O
,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	B-DISEASE
Persistent	B-DISEASE
atrial	I-DISEASE
fibrillation	I-DISEASE
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
renal	B-DISEASE
failure	I-DISEASE
On	O
the	O
contrary	O
,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients	O
,	O
there	O
were	O
more	O
acute	O
myocardial	B-DISEASE
infarctions	I-DISEASE
and	O
renal	B-DISEASE
dysfunction	I-DISEASE
Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients	O
,	O
whereas	O
administration	O
of	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B-CHEMICAL
and	O
their	O
effects	O
on	O
cardiac	B-DISEASE
arrhythmias	I-DISEASE
The	O
optical	O
isomers	O
of	O
propranolol	B-CHEMICAL
In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	O
,	O
(+)-	O
propranolol	B-CHEMICAL
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(-)-	O
propranolol	B-CHEMICAL
At	B-DISEASE
dose	O
levels	O
of	O
(+)-	O
propranolol	B-CHEMICAL
The	O
metabolic	O
responses	O
to	O
isoprenaline	O
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	B-CHEMICAL
,	O
lactate	B-CHEMICAL
and	O
free	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
)	O
were	O
all	O
blocked	O
by	O
(-)-	O
propranolol	B-CHEMICAL
(+)-	O
Propranolol	B-CHEMICAL
had	O
no	O
effect	O
on	O
fatty	O
acid	O
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-CHEMICAL
and	O
glucose	B-CHEMICAL
Both	O
isomers	O
of	O
propranolol	B-CHEMICAL
The	O
isomers	O
of	O
propranolol	B-CHEMICAL
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	B-DISEASE
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B-CHEMICAL
Both	O
isomers	O
of	O
propranolol	B-CHEMICAL
were	O
capable	O
of	O
preventing	O
adrenaline	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
arrhythmias	I-DISEASE
in	O
cats	O
anaesthetized	O
with	O
halothane	B-CHEMICAL
,	O
but	O
the	O
mean	O
dose	O
of	O
(-)-	O
propranolol	B-CHEMICAL
was	O
0	O
.	O
09	O
+/-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(+)-	O
propranolol	B-CHEMICAL
At	B-DISEASE
the	O
effective	O
dose	O
level	O
of	O
(+)-	O
propranolol	B-CHEMICAL
Blockade	O
of	O
arrhythmias	B-DISEASE
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	B-CHEMICAL
Both	O
isomers	O
of	O
propranolol	B-CHEMICAL
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
caused	O
by	O
ouabain	B-CHEMICAL
The	O
dose	O
of	O
(-)-	O
propranolol	B-CHEMICAL
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(+)-	O
propranolol	B-CHEMICAL
Topotecan	B-CHEMICAL
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	B-DISEASE
Improving	O
glioblastoma	B-DISEASE
Topotecan	B-CHEMICAL
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	B-DISEASE
The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(	O
60	O
Gy	O
/	O
30	O
fractions	O
/	O
40	O
days	O
)	O
and	O
topotecan	B-CHEMICAL
The	O
incidence	O
of	O
non	O
-	O
hematological	O
toxicities	B-DISEASE
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	B-DISEASE
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	B-DISEASE
and	O
neutropenia	B-DISEASE
Topotecan	B-CHEMICAL
Long	O
-	O
term	O
lithium	B-CHEMICAL
therapy	O
leading	O
to	O
hyperparathyroidism	B-DISEASE
PURPOSE	O
:	O
This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	B-CHEMICAL
therapy	O
on	O
serum	O
calcium	B-CHEMICAL
level	O
and	O
parathyroid	B-DISEASE
glands	I-DISEASE
We	O
examined	O
the	O
case	O
of	O
a	O
lithium	B-CHEMICAL
-	O
treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	B-DISEASE
to	O
better	O
understand	O
the	O
disease	B-DISEASE
CONCLUSION	O
:	O
Primary	O
hyperparathyroidism	B-DISEASE
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
long	O
-	O
term	O
lithium	B-CHEMICAL
PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithium	B-CHEMICAL
By	O
routinely	O
monitoring	O
serum	O
calcium	B-CHEMICAL
BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions	O
,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	B-DISEASE
as	O
well	O
as	O
intraoperative	O
blood	O
pressure	O
,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(	O
FESS	O
)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(	O
FRLMA	O
)	O
versus	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
in	O
maintaining	O
controlled	O
hypotension	B-DISEASE
anesthesia	O
induced	O
by	O
propofol	B-CHEMICAL
-	O
remifentanil	B-CHEMICAL
METHODS	O
:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I	O
-	O
II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	B-DISEASE
anesthesia	O
caused	O
by	O
propofol	B-CHEMICAL
-	O
remifentanil	B-CHEMICAL
Hemorrhage	B-DISEASE
RESULTS	O
:	O
Controlled	O
hypotension	B-DISEASE
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	B-CHEMICAL
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	B-CHEMICAL
CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	B-DISEASE
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	B-DISEASE
loss	I-DISEASE
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	B-DISEASE
with	O
low	O
doses	O
of	O
remifentanil	B-CHEMICAL
Nonalcoholic	O
fatty	B-DISEASE
liver	I-DISEASE
disease	B-DISEASE
during	O
valproate	B-CHEMICAL
Valproic	B-CHEMICAL
acid	I-CHEMICAL
(	O
VPA	B-CHEMICAL
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	B-DISEASE
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	B-DISEASE
weight	I-DISEASE
We	O
report	O
a	O
case	O
of	O
nonalcoholic	O
fatty	B-DISEASE
liver	I-DISEASE
disease	B-DISEASE
(	O
NAFLD	O
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	B-DISEASE
during	O
VPA	B-CHEMICAL
Laboratory	O
data	O
revealed	O
hyperinsulinemia	O
with	O
insulin	B-DISEASE
resistance	I-DISEASE
After	O
the	O
withdrawal	O
of	O
VPA	B-CHEMICAL
therapy	O
,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	B-DISEASE
loss	I-DISEASE
The	O
present	O
case	O
suggests	O
that	O
obesity	B-DISEASE
,	O
hyperinsulinemia	O
,	O
insulin	B-DISEASE
resistance	I-DISEASE
,	O
and	O
long	O
-	O
term	O
treatment	O
with	O
VPA	B-CHEMICAL
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	O
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	B-CHEMICAL
Carbimazole	B-CHEMICAL
induced	O
ANCA	O
positive	O
vasculitis	B-DISEASE
Anti	O
-	O
thyroid	B-DISEASE
drugs	O
,	O
like	O
carbimazole	B-CHEMICAL
and	O
propylthiouracil	B-CHEMICAL
(	O
PTU	O
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	B-DISEASE
Antineutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	O
)--	O
associated	O
vasculitis	B-DISEASE
We	O
report	O
a	O
patient	O
with	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
who	O
developed	O
ANCA	O
positive	O
carbimazole	B-CHEMICAL
induced	O
vasculitis	B-DISEASE
The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	O
skin	B-DISEASE
rash	B-DISEASE
associated	O
with	O
large	O
joint	O
arthritis	B-DISEASE
,	O
pyrexia	O
and	O
parotiditis	O
but	O
no	O
renal	B-DISEASE
He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	B-DISEASE
Carbimazole	B-CHEMICAL
and	O
methimazole	B-CHEMICAL
To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	B-CHEMICAL
induced	O
vasculitis	B-DISEASE
Aspirin	B-CHEMICAL
BACKGROUND	O
:	O
Coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
and	O
cerebrovascular	O
disease	B-DISEASE
are	O
leading	O
causes	O
of	O
death	B-DISEASE
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	B-CHEMICAL
with	O
adults	O
who	O
are	O
at	B-DISEASE
increased	O
risk	O
for	O
coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
PURPOSE	O
:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	B-CHEMICAL
for	O
the	O
primary	O
prevention	O
of	O
myocardial	B-DISEASE
infarctions	I-DISEASE
,	O
strokes	B-DISEASE
,	O
and	O
death	B-DISEASE
STUDY	O
SELECTION	O
:	O
English	O
-	O
language	O
randomized	O
,	O
controlled	O
trials	O
(	O
RCTs	O
);	O
case	O
-	O
control	O
studies	O
;	O
meta	O
-	O
analyses	O
;	O
and	O
systematic	O
reviews	O
of	O
aspirin	B-CHEMICAL
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
(	O
CVD	O
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions	O
:	O
Does	O
aspirin	B-CHEMICAL
decrease	O
coronary	O
heart	O
events	O
,	O
strokes	B-DISEASE
,	O
death	B-DISEASE
from	O
coronary	O
heart	O
events	O
or	O
stroke	B-DISEASE
Does	O
aspirin	B-CHEMICAL
increase	O
gastrointestinal	B-DISEASE
bleeding	I-DISEASE
or	O
hemorrhagic	B-DISEASE
strokes	B-DISEASE
DATA	O
SYNTHESIS	O
:	O
New	O
evidence	O
from	O
1	O
good	O
-	O
quality	O
RCT	O
,	O
1	O
good	O
-	O
quality	O
meta	O
-	O
analysis	O
,	O
and	O
2	O
fair	O
-	O
quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	B-CHEMICAL
Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	B-DISEASE
infarctions	I-DISEASE
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	B-DISEASE
Aspirin	B-CHEMICAL
The	O
use	O
of	O
aspirin	B-CHEMICAL
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	B-DISEASE
events	O
,	O
primarily	O
gastrointestinal	B-DISEASE
bleeding	I-DISEASE
Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	B-DISEASE
strokes	B-DISEASE
with	O
aspirin	B-CHEMICAL
A	O
new	O
RCT	O
and	O
meta	O
-	O
analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	B-DISEASE
strokes	B-DISEASE
LIMITATIONS	O
:	O
New	O
evidence	O
on	O
aspirin	B-CHEMICAL
The	O
dose	O
of	O
aspirin	B-CHEMICAL
CONCLUSION	O
:	O
Aspirin	B-CHEMICAL
reduces	O
the	O
risk	O
for	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
men	O
and	O
strokes	B-DISEASE
Aspirin	B-CHEMICAL
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	B-DISEASE
Reducing	O
harm	O
associated	O
with	O
anticoagulation	O
:	O
practical	O
considerations	O
of	O
argatroban	B-CHEMICAL
therapy	O
in	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
Argatroban	B-CHEMICAL
is	O
a	O
hepatically	O
metabolized	O
,	O
direct	O
thrombin	B-CHEMICAL
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	B-DISEASE
in	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
(	O
HIT	B-DISEASE
)	O
and	O
for	O
patients	O
with	O
or	O
at	B-DISEASE
risk	O
of	O
HIT	B-DISEASE
The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	B-CHEMICAL
therapy	O
in	O
HIT	B-DISEASE
The	O
US	O
FDA	O
-	O
recommended	O
argatroban	B-CHEMICAL
dose	O
in	O
HIT	B-DISEASE
is	O
2	O
microg	O
/	O
kg	O
/	O
min	O
(	O
reduced	O
in	O
patients	O
with	O
hepatic	O
impairment	O
and	O
in	O
paediatric	O
patients	O
),	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	B-CHEMICAL
heart	B-DISEASE
failure	I-DISEASE
,	O
yet	O
are	O
unnecessary	O
for	O
renal	B-DISEASE
dysfunction	I-DISEASE
,	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B-DISEASE
Argatroban	B-CHEMICAL
For	O
PCI	O
,	O
argatroban	B-CHEMICAL
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients	O
;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B-DISEASE
Argatroban	B-CHEMICAL
prolongs	O
the	O
International	O
Normalized	O
Ratio	O
,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban	B-CHEMICAL
-	O
to	O
-	O
warfarin	B-CHEMICAL
Major	O
bleeding	B-DISEASE
with	O
argatroban	B-CHEMICAL
Argatroban	B-CHEMICAL
has	O
no	O
specific	O
antidote	O
,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs	O
,	O
argatroban	B-CHEMICAL
Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	B-CHEMICAL
therapy	O
in	O
HIT	B-DISEASE
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	B-DISEASE
fewer	O
argatroban	B-CHEMICAL
Rhabdomyolysis	B-DISEASE
and	O
brain	O
ischemic	B-DISEASE
stroke	I-DISEASE
in	O
a	O
heroin	B-CHEMICAL
-	O
dependent	O
male	O
under	O
methadone	B-CHEMICAL
OBJECTIVE	O
:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	B-DISEASE
abuse	I-DISEASE
Methadone	B-CHEMICAL
RESULTS	O
:	O
A	O
33	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyolysis	B-DISEASE
and	O
cerebral	O
ischemic	B-DISEASE
stroke	I-DISEASE
after	O
intravenous	O
heroin	B-CHEMICAL
He	O
had	O
used	O
heroin	B-CHEMICAL
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadone	B-CHEMICAL
He	O
was	O
found	O
unconsciousness	B-DISEASE
at	B-DISEASE
In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolysis	B-DISEASE
,	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
acute	O
respiratory	B-DISEASE
failure	I-DISEASE
After	O
transfer	O
to	O
an	O
internal	O
ward	O
,	O
we	O
noted	O
aphasia	B-DISEASE
and	O
weakness	B-DISEASE
After	O
MRI	O
,	O
we	O
found	O
cerebral	O
ischemic	O
infarction	B-DISEASE
CONCLUSION	O
:	O
Those	O
using	O
methadone	B-CHEMICAL
and	O
heroin	B-CHEMICAL
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	B-DISEASE
and	O
ischemic	B-DISEASE
stroke	I-DISEASE
Patients	O
under	O
methadone	B-CHEMICAL
Hypotheses	O
of	O
heroin	B-CHEMICAL
-	O
related	O
rhabdomyolysis	B-DISEASE
and	O
stroke	B-DISEASE
in	O
heroin	B-CHEMICAL
Increased	O
vulnerability	O
to	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxydopamine	I-CHEMICAL
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	B-DISEASE
Motor	O
impairment	O
,	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
neuronal	O
activity	O
and	O
proenkephalin	B-CHEMICAL
(	O
PENK	O
)	O
gene	O
expression	O
in	O
the	O
caudate	O
-	O
putamen	O
(	O
CPu	O
)	O
were	O
measured	O
in	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
-	O
lesioned	O
and	O
treated	O
(	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
+	O
benserazide	B-CHEMICAL
A	O
lesion	O
induced	O
by	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	B-CHEMICAL
Treatment	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
+	O
benserazide	B-CHEMICAL
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	B-DISEASE
The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	B-CHEMICAL
lesion	O
,	O
and	O
reduced	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
Animal	O
model	O
of	O
mania	B-DISEASE
induced	O
by	O
ouabain	B-CHEMICAL
The	O
intracerebroventricular	O
(	O
ICV	O
)	O
administration	O
of	O
ouabain	B-CHEMICAL
(	O
a	O
Na	B-CHEMICAL
(+)/	O
K	B-CHEMICAL
(+)-	O
ATPase	O
inhibitor	O
)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	B-DISEASE
mania	B-DISEASE
Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	B-DISEASE
disorder	I-DISEASE
may	O
be	O
related	O
to	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
Herein	O
,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	B-CHEMICAL
To	O
achieve	O
this	O
aim	O
,	O
the	O
effects	O
of	O
ouabain	B-CHEMICAL
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(	O
at	B-DISEASE
Additionally	O
,	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	I-CHEMICAL
substances	I-CHEMICAL
(	O
TBARSs	O
)	O
and	O
superoxide	B-CHEMICAL
Our	O
findings	O
demonstrated	O
that	O
ouabain	B-CHEMICAL
at	B-DISEASE
In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	B-CHEMICAL
levels	O
and	O
superoxide	B-CHEMICAL
In	O
conclusion	O
,	O
ouabain	B-CHEMICAL
-	O
induced	O
mania	B-DISEASE
-	O
like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	B-DISEASE
disorder	I-DISEASE
Intraoperative	O
dialysis	O
during	O
liver	B-DISEASE
transplantation	O
with	O
citrate	B-CHEMICAL
Liver	B-DISEASE
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	O
liver	B-DISEASE
failure	I-DISEASE
These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	O
liver	B-DISEASE
failure	I-DISEASE
can	O
lead	B-CHEMICAL
Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	B-CHEMICAL
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	B-DISEASE
carries	O
the	O
risk	O
of	O
citrate	B-CHEMICAL
toxicity	B-DISEASE
Citrate	B-CHEMICAL
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	B-CHEMICAL
acid	I-CHEMICAL
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
cannot	O
tolerate	O
heparin	B-CHEMICAL
or	O
regional	O
citrate	B-CHEMICAL
We	O
report	O
a	O
case	O
of	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
with	O
acetaminophen	B-CHEMICAL
-	O
induced	O
fulminant	O
liver	B-DISEASE
failure	I-DISEASE
with	O
associated	O
AKI	O
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	B-DISEASE
transplantation	O
anticoagulated	O
with	O
citrate	B-CHEMICAL
The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	B-CHEMICAL
toxicity	B-DISEASE
Citrate	B-CHEMICAL
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	B-DISEASE
transplantation	O
in	O
fulminant	O
liver	B-DISEASE
failure	I-DISEASE
Delirium	B-DISEASE
in	O
a	O
patient	O
with	O
toxic	O
flecainide	B-CHEMICAL
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B-CHEMICAL
OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	B-CHEMICAL
-	O
induced	O
delirium	B-DISEASE
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B-CHEMICAL
CASE	O
SUMMARY	O
:	O
A	O
69	O
-	O
year	O
-	O
old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	B-DISEASE
On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	B-CHEMICAL
12	O
mg	O
twice	O
daily	O
,	O
warfarin	B-CHEMICAL
2	O
mg	O
/	O
day	O
,	O
folic	B-CHEMICAL
acid	I-CHEMICAL
1	O
mg	O
/	O
day	O
,	O
levothyroxine	O
100	O
microg	O
/	O
day	O
,	O
pantoprazole	B-CHEMICAL
40	O
mg	O
/	O
day	O
,	O
paroxetine	B-CHEMICAL
40	O
mg	O
/	O
day	O
,	O
and	O
flecainide	B-CHEMICAL
Flecainide	B-CHEMICAL
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B-DISEASE
fibrillation	I-DISEASE
Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	B-CHEMICAL
A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	B-CHEMICAL
and	O
paroxetine	B-CHEMICAL
Paroxetine	B-CHEMICAL
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	B-CHEMICAL
Her	O
delirium	B-DISEASE
DISCUSSION	O
:	O
Flecainide	B-CHEMICAL
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	B-CHEMICAL
channels	I-CHEMICAL
may	O
cause	O
delirium	B-DISEASE
A	O
MEDLINE	O
search	O
(	O
1966	O
-	O
January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	B-CHEMICAL
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	B-CHEMICAL
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	B-CHEMICAL
-	O
induced	O
delirium	B-DISEASE
According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	B-CHEMICAL
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
'	O
s	O
delirium	B-DISEASE
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	B-CHEMICAL
and	O
paroxetine	B-CHEMICAL
CONCLUSIONS	O
:	O
Supratherapeutic	O
flecainide	B-CHEMICAL
plasma	O
concentrations	O
may	O
cause	O
delirium	B-DISEASE
Because	O
toxicity	B-DISEASE
may	O
occur	O
when	O
flecainide	B-CHEMICAL
is	O
prescribed	O
with	O
paroxetine	B-CHEMICAL
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	B-CHEMICAL
Efficacy	O
of	O
everolimus	B-CHEMICAL
(	O
RAD001	O
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-DISEASE
BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	B-DISEASE
cancer	I-DISEASE
(	O
NSCLC	B-DISEASE
RAD001	O
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
(	O
mTOR	O
),	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B-DISEASE
METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B-DISEASE
patients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	B-CHEMICAL
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	B-CHEMICAL
growth	I-CHEMICAL
factor	I-CHEMICAL
receptor	O
tyrosine	B-CHEMICAL
kinase	O
inhibitors	O
(	O
stratum	O
2	O
),	O
received	O
RAD001	O
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B-DISEASE
Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B-DISEASE
Overall	O
disease	B-DISEASE
Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B-DISEASE
,	O
dyspnea	B-DISEASE
,	O
stomatitis	B-DISEASE
,	O
anemia	B-DISEASE
,	O
and	O
thrombocytopenia	B-DISEASE
Pneumonitis	B-DISEASE
CONCLUSIONS	O
:	O
RAD001	O
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B-DISEASE
Evaluation	O
of	O
RAD001	O
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B-DISEASE
Posttransplant	O
anemia	B-DISEASE
:	O
the	O
role	O
of	O
sirolimus	B-CHEMICAL
Posttransplant	O
anemia	B-DISEASE
A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	B-DISEASE
,	O
of	O
which	O
the	O
level	O
of	O
renal	B-DISEASE
Sirolimus	B-CHEMICAL
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
inhibitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	B-DISEASE
This	O
review	O
considers	O
anemia	B-DISEASE
associated	O
with	O
sirolimus	B-CHEMICAL
Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low	O
-	O
risk	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
BACKGROUND	O
:	O
Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
are	O
admitted	O
for	O
at	B-DISEASE
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
acute	B-DISEASE
coronary	I-DISEASE
syndrome	I-DISEASE
In	O
patients	O
without	O
cocaine	B-CHEMICAL
use	O
,	O
coronary	O
computerized	O
tomography	O
angiography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	B-DISEASE
It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
,	O
as	O
coronary	B-DISEASE
vasospasm	I-DISEASE
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	B-DISEASE
We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
METHODS	O
:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low	O
-	O
risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	B-DISEASE
with	O
cocaineassociated	O
chest	B-DISEASE
pain	I-DISEASE
(	O
self	O
-	O
reported	O
or	O
positive	O
urine	B-DISEASE
Consecutive	O
patients	O
received	O
either	O
immediate	O
coronary	O
CTA	O
in	O
the	O
ED	B-DISEASE
(	O
without	O
serial	O
markers	O
)	O
or	O
underwent	O
coronary	O
CTA	O
after	O
a	O
brief	B-DISEASE
Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	B-DISEASE
The	O
main	O
outcome	O
was	O
30	O
-	O
day	O
cardiovascular	O
death	B-DISEASE
or	O
myocardial	B-DISEASE
infarction	I-DISEASE
RESULTS	O
:	O
A	O
total	O
of	O
59	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
associated	O
chest	B-DISEASE
pain	I-DISEASE
Twenty	O
patients	O
received	O
coronary	O
CTA	O
immediately	O
in	O
the	O
ED	B-DISEASE
Thirty	O
-	O
nine	O
received	O
coronary	O
CTA	O
after	O
a	O
brief	B-DISEASE
Six	O
patients	O
had	O
coronary	B-DISEASE
stenosis	I-DISEASE
During	O
the	O
30	O
-	O
day	O
follow	O
-	O
up	O
period	O
,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(	O
0	O
%;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	B-DISEASE
infarction	I-DISEASE
CONCLUSIONS	O
:	O
Although	O
cocaine	B-CHEMICAL
-	O
associated	O
myocardial	B-DISEASE
ischemia	I-DISEASE
can	O
result	O
from	O
coronary	O
vasoconstriction	O
,	O
patients	O
with	O
cocaine	B-CHEMICAL
associated	O
chest	B-DISEASE
pain	I-DISEASE
,	O
a	O
non	O
-	O
ischemic	O
ECG	O
,	O
and	O
a	O
TIMI	O
risk	O
score	O
<	O
2	O
may	O
be	O
safely	O
discharged	O
from	O
the	O
ED	B-DISEASE
Late	O
fulminant	O
posterior	O
reversible	O
encephalopathy	B-DISEASE
syndrome	B-DISEASE
after	O
liver	B-DISEASE
OBJECTIVES	O
:	O
Posterior	O
leukoencephalopathy	B-DISEASE
due	O
to	O
calcineurin	O
-	O
inhibitor	O
-	O
related	O
neurotoxicity	B-DISEASE
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	B-CHEMICAL
agents	I-CHEMICAL
(	O
primarily	O
those	O
administered	O
after	O
a	O
liver	B-DISEASE
CASE	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
46	O
-	O
year	O
-	O
old	O
woman	O
who	O
received	O
a	O
liver	B-DISEASE
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	O
cirrhosis	B-DISEASE
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	O
leukoencephalopathy	B-DISEASE
or	O
posterior	O
reversible	O
encephalopathy	B-DISEASE
syndrome	B-DISEASE
After	O
an	O
initially	O
uneventful	O
course	O
after	O
the	O
transplant	O
,	O
the	O
patient	O
rapidly	O
fell	O
into	O
deep	O
coma	B-DISEASE
Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	B-CHEMICAL
to	O
cyclosporine	B-CHEMICAL
CONCLUSIONS	O
:	O
Posterior	O
reversible	O
encephalopathy	B-DISEASE
syndrome	B-DISEASE
after	O
liver	B-DISEASE
Prolonged	O
hypothermia	B-DISEASE
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B-DISEASE
edema	I-DISEASE
and	O
intracranial	B-DISEASE
hypertension	I-DISEASE
associated	O
with	O
fulminant	B-DISEASE
hepatic	I-DISEASE
failure	I-DISEASE
BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B-DISEASE
edema	I-DISEASE
complicating	O
fulminant	B-DISEASE
hepatic	I-DISEASE
failure	I-DISEASE
(	O
FHF	O
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B-DISEASE
METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
female	O
with	O
FHF	O
from	O
acetaminophen	B-CHEMICAL
and	O
resultant	O
cerebral	B-DISEASE
edema	I-DISEASE
RESULTS	O
:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B-DISEASE
from	O
acetaminophen	B-CHEMICAL
The	O
patient	O
had	O
depressed	B-DISEASE
of	O
mental	O
status	O
lasting	O
at	B-DISEASE
least	O
24	O
h	B-CHEMICAL
Initial	O
evaluation	O
confirmed	O
FHF	O
from	O
acetaminophen	B-CHEMICAL
and	O
cerebral	B-DISEASE
edema	I-DISEASE
The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	B-DISEASE
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	B-DISEASE
We	O
then	O
initiated	O
therapeutic	O
hypothermia	B-DISEASE
At	B-DISEASE
re	O
-	O
warming	O
,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B-DISEASE
edema	I-DISEASE
and	O
intracranial	B-DISEASE
hypertension	I-DISEASE
At	B-DISEASE
CONCLUSION	O
:	O
In	O
patients	O
with	O
FHF	O
and	O
cerebral	B-DISEASE
edema	I-DISEASE
from	O
acetaminophen	B-CHEMICAL
overdose	B-DISEASE
,	O
prolonged	O
therapeutic	O
hypothermia	B-DISEASE
A	O
clinical	O
trial	O
of	O
hypothermia	B-DISEASE
Binasal	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
are	O
not	O
specific	O
to	O
vigabatrin	B-CHEMICAL
This	O
study	O
investigated	O
the	O
visual	O
defects	O
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	B-CHEMICAL
Two	O
hundred	O
four	O
people	O
with	O
epilepsy	B-DISEASE
Groups	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
,	O
and	O
seizure	B-DISEASE
Bilateral	O
visual	O
field	O
constriction	B-DISEASE
Bilateral	O
visual	O
field	O
abnormalities	B-DISEASE
are	O
common	O
in	O
the	O
treated	O
epilepsy	B-DISEASE
Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	O
toxicity	B-DISEASE
Smoking	B-CHEMICAL
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
as	O
a	O
risk	O
factor	O
for	O
HIV	O
infection	B-DISEASE
BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	B-CHEMICAL
crack	B-CHEMICAL
cocaine	I-CHEMICAL
has	O
on	O
the	O
incidence	O
of	O
HIV	O
infection	B-DISEASE
Given	O
the	O
increasing	O
use	O
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	O
infection	B-DISEASE
METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	B-DISEASE
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	O
-	O
negative	O
at	B-DISEASE
enrolment	O
and	O
completed	O
at	B-DISEASE
To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	O
seroconversion	O
among	O
daily	O
smokers	O
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
Of	O
these	O
,	O
137	O
acquired	O
HIV	O
infection	B-DISEASE
The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	B-CHEMICAL
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	O
seroconversion	O
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
INTERPRETATION	O
:	O
Smoking	B-CHEMICAL
of	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	B-DISEASE
people	O
who	O
smoke	B-CHEMICAL
crack	B-CHEMICAL
cocaine	I-CHEMICAL
Fluoxetine	B-CHEMICAL
improves	O
the	O
memory	O
deficits	O
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
Cancer	B-DISEASE
A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	O
antidepressant	B-CHEMICAL
Fluoxetine	B-CHEMICAL
In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	B-CHEMICAL
either	O
separately	O
or	O
in	O
combination	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
Animals	O
treated	O
only	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	B-CHEMICAL
administration	O
of	O
Fluoxetine	B-CHEMICAL
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	B-CHEMICAL
was	O
co	B-CHEMICAL
administered	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
Fluoxetine	B-CHEMICAL
These	O
findings	O
suggest	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	B-CHEMICAL
Fluoxetine	B-CHEMICAL
Liver	B-DISEASE
-	O
specific	O
ablation	O
of	O
integrin	O
-	O
linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	B-DISEASE
after	O
phenobarbital	B-CHEMICAL
We	O
have	O
recently	O
demonstrated	O
that	O
disruption	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)/	O
integrin	O
signaling	O
via	O
elimination	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
in	O
hepatocytes	O
interferes	O
with	O
signals	O
leading	O
to	O
termination	O
of	O
liver	B-DISEASE
This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	B-DISEASE
enlargement	O
induced	O
by	O
phenobarbital	B-CHEMICAL
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
liver	B-DISEASE
-/-	O
mice	O
were	O
given	O
PB	O
(	O
0	O
.	O
1	O
%	O
in	O
drinking	B-CHEMICAL
water	I-CHEMICAL
In	O
the	O
hepatocyte	O
-	O
specific	O
ILK	O
/	O
liver	B-DISEASE
-/-	O
mice	O
,	O
the	O
liver	B-DISEASE
:	O
body	B-DISEASE
weight	I-DISEASE
ratio	O
was	O
more	O
than	O
double	O
as	O
compared	O
to	O
0	O
h	B-CHEMICAL
at	B-DISEASE
day	O
2	O
(	O
2	O
.	O
5	O
times	O
),	O
while	O
at	B-DISEASE
There	O
were	O
slightly	O
increased	O
proliferating	B-CHEMICAL
cell	I-CHEMICAL
nuclear	I-CHEMICAL
antigen	I-CHEMICAL
-	O
positive	O
cells	O
in	O
the	O
ILK	O
/	O
liver	B-DISEASE
-/-	O
animals	O
at	B-DISEASE
Hepatocytes	O
of	O
the	O
ILK	O
/	O
liver	B-DISEASE
ILK	O
/	O
liver	B-DISEASE
-/-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	B-DISEASE
Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	B-DISEASE
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens	B-CHEMICAL
Decreased	O
Expression	O
of	O
Na	B-CHEMICAL
/	O
K	B-CHEMICAL
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin	B-CHEMICAL
-	O
induced	O
Nephropathy	B-DISEASE
The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
Sprague	O
-	O
Dawley	O
male	O
rats	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	B-CHEMICAL
Gentamicin	B-CHEMICAL
-	O
treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	B-CHEMICAL
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	B-CHEMICAL
Accordingly	O
,	O
the	O
fractional	O
excretion	O
of	O
sodium	B-CHEMICAL
Urine	B-DISEASE
volume	O
was	O
increased	O
,	O
while	O
urine	B-DISEASE
osmolality	O
and	O
free	O
water	B-CHEMICAL
Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na	B-CHEMICAL
(+)/	O
K	B-CHEMICAL
(+)-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin	B-CHEMICAL
Gentamicin	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
may	O
at	B-DISEASE
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na	B-CHEMICAL
(+)/	O
K	B-CHEMICAL
Longitudinal	O
association	O
of	O
alcohol	B-CHEMICAL
use	O
with	O
HIV	O
disease	B-DISEASE
progression	I-DISEASE
We	O
evaluated	O
the	O
association	O
of	O
alcohol	B-CHEMICAL
consumption	O
and	O
depression	B-DISEASE
,	O
and	O
their	O
effects	O
on	O
HIV	O
disease	B-DISEASE
progression	I-DISEASE
The	O
participants	O
had	O
physical	O
examination	O
,	O
medical	O
record	O
extraction	O
,	O
and	O
venipuncture	O
,	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
determination	O
,	O
measurement	O
of	O
depression	B-DISEASE
symptoms	O
(	O
using	O
the	O
self	O
-	O
report	O
Center	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	B-DISEASE
Scale	O
),	O
and	O
alcohol	B-CHEMICAL
use	O
assessment	O
at	B-DISEASE
There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	B-CHEMICAL
When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
association	O
between	O
alcohol	B-CHEMICAL
The	O
association	O
between	O
alcohol	B-CHEMICAL
consumption	O
and	O
depression	B-DISEASE
Depression	B-DISEASE
Our	O
findings	O
suggest	O
that	O
alcohol	B-CHEMICAL
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	B-DISEASE
Moreover	O
,	O
depression	B-DISEASE
is	O
associated	O
with	O
HIV	O
disease	B-DISEASE
progression	I-DISEASE
Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	B-CHEMICAL
Chemokine	B-CHEMICAL
CCL2	I-CHEMICAL
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
BACKGROUND	O
:	O
Neuroinflammation	O
occurs	O
after	O
seizures	B-DISEASE
In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
SE	B-DISEASE
)	O
induced	O
by	O
pilocarpine	B-CHEMICAL
METHODS	O
:	O
SE	B-DISEASE
was	O
induced	O
by	O
pilocarpine	B-CHEMICAL
Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B-CHEMICAL
Five	O
days	O
after	O
SE	B-DISEASE
RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B-DISEASE
Seizures	B-DISEASE
Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	B-DISEASE
Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2	O
-	O
labeled	O
cells	O
in	O
SE	B-DISEASE
In	O
addition	O
,	O
rats	O
that	O
experienced	O
SE	B-DISEASE
Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B-DISEASE
CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	B-CHEMICAL
-	O
induced	O
SE	B-DISEASE
Seizures	B-DISEASE
These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	O
changes	O
that	O
occur	O
following	O
seizures	B-DISEASE
Metallothionein	O
induction	O
reduces	O
caspase	O
-	O
3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	B-CHEMICAL
On	O
the	O
other	O
hand	B-DISEASE
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	O
induction	O
on	O
carmustine	B-CHEMICAL
(	O
BCNU	B-CHEMICAL
)-	O
induced	O
hippocampal	O
cognitive	B-DISEASE
dysfunction	I-DISEASE
A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
):	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	B-CHEMICAL
later	O
by	O
BCNU	B-CHEMICAL
The	O
second	O
group	O
administered	O
ZnSO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BCNU	B-CHEMICAL
solvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	B-CHEMICAL
.	O
Third	O
group	O
received	O
BCNU	B-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	B-CHEMICAL
Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	B-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	B-CHEMICAL
.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B-CHEMICAL
administration	O
resulted	O
in	O
deterioration	O
of	O
learning	O
and	O
short	O
-	O
term	O
memory	O
(	O
STM	O
),	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	B-CHEMICAL
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	B-CHEMICAL
reductase	I-CHEMICAL
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
Also	O
,	O
BCNU	B-CHEMICAL
administration	O
increased	O
serum	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
(	O
TNFalpha	O
),	O
hippocampal	O
MT	O
and	O
malondialdehyde	B-CHEMICAL
ZnSO	O
(	O
4	O
)	O
pretreatment	O
counteracted	O
BCNU	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	B-CHEMICAL
The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO	O
(	O
4	O
)	O
+	O
BCNU	B-CHEMICAL
compared	O
to	O
only	O
BCNU	B-CHEMICAL
In	O
conclusion	O
,	O
MT	O
induction	O
halts	O
BCNU	B-CHEMICAL
-	O
induced	O
hippocampal	O
toxicity	B-DISEASE
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	B-CHEMICAL
Fatal	O
carbamazepine	B-CHEMICAL
induced	O
fulminant	O
eosinophilic	O
(	O
hypersensitivity	B-DISEASE
)	O
myocarditis	B-DISEASE
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-DISEASE
hypersensitivity	I-DISEASE
The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B-CHEMICAL
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	B-DISEASE
A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-CHEMICAL
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B-DISEASE
)	O
myocarditis	B-DISEASE
We	O
report	O
a	O
case	O
of	O
hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
secondary	O
to	O
administration	O
of	O
carbamazepine	B-CHEMICAL
Acute	O
hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
Clinically	O
,	O
death	B-DISEASE
was	O
due	O
to	O
cardiogenic	B-DISEASE
shock	I-DISEASE
To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B-CHEMICAL
induced	O
myocarditis	B-DISEASE
Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	B-CHEMICAL
marmoset	O
model	O
of	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
OBJECTIVES	O
:	O
Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
PD	B-DISEASE
These	O
symptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisation	O
'	O
following	O
repeated	O
levodopa	B-CHEMICAL
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	B-CHEMICAL
on	O
the	O
disease	B-DISEASE
The	O
levodopa	B-CHEMICAL
-	O
treated	O
MPTP	B-CHEMICAL
-	O
lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	O
symptoms	O
in	O
PD	B-DISEASE
Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa	B-CHEMICAL
METHODS	O
:	O
Marmosets	O
were	O
administered	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyridine	I-CHEMICAL
for	O
five	O
days	O
,	O
resulting	O
in	O
stable	O
parkinsonism	B-DISEASE
Levodopa	B-CHEMICAL
(	O
15	O
mg	O
/	O
kg	O
and	O
benserazide	B-CHEMICAL
Animals	O
were	O
evaluated	O
for	O
parkinsonian	B-DISEASE
disability	O
,	O
dyskinesia	B-DISEASE
and	O
on	O
-	O
time	O
(	O
motor	O
fluctuations	O
)	O
and	O
neuropsychiatric	O
-	O
like	O
behaviors	O
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	B-CHEMICAL
As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	B-CHEMICAL
-	O
induced	O
motor	O
fluctuations	O
,	O
dyskinesia	B-DISEASE
and	O
wearing	O
-	O
off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	B-CHEMICAL
In	O
contrast	O
,	O
levodopa	B-CHEMICAL
-	O
induced	O
neuropsychiatric	O
-	O
like	O
behaviors	O
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	B-CHEMICAL
CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
neuropsychiatric	O
disorders	O
in	O
PD	B-DISEASE
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	B-CHEMICAL
and	O
the	O
disease	B-DISEASE
Contrast	O
medium	O
nephrotoxicity	B-DISEASE
after	O
renal	B-DISEASE
BACKGROUND	O
:	O
Renal	B-DISEASE
dysfunction	I-DISEASE
induced	O
by	O
iodinated	O
contrast	O
medium	O
(	O
CM	B-DISEASE
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	B-DISEASE
PURPOSE	O
:	O
To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	B-DISEASE
effect	O
of	O
CM	B-DISEASE
MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(	O
PTRA	O
group	O
,	O
mean	O
age	O
70	O
+/-	O
12	O
years	O
,	O
23	O
female	O
,	O
basal	O
creatinine	B-CHEMICAL
1	O
.	O
46	O
+/-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
group	O
),	O
matched	O
for	O
basal	O
creatinine	B-CHEMICAL
In	O
both	O
groups	O
postprocedural	O
(	O
48	O
h	B-CHEMICAL
)	O
serum	O
creatinine	B-CHEMICAL
RESULTS	O
:	O
Postprocedural	O
creatinine	B-CHEMICAL
Changes	O
in	O
serum	O
creatinine	B-CHEMICAL
This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	B-DISEASE
CONCLUSION	O
:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	B-DISEASE
damage	I-DISEASE
induced	O
by	O
CM	B-DISEASE
The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	B-DISEASE
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	B-DISEASE
toxicity	B-DISEASE
Medical	O
and	O
psychiatric	B-DISEASE
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
BACKGROUND	O
:	O
Acetaminophen	B-CHEMICAL
-	O
induced	O
hepatotoxicity	B-DISEASE
is	O
the	O
most	O
common	O
cause	O
of	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
(	O
ALF	B-DISEASE
Patients	O
often	O
consume	O
the	O
drug	O
with	O
suicidal	O
intent	O
or	O
with	O
a	O
background	O
of	O
substance	O
dependence	B-DISEASE
AIMS	O
AND	O
METHODS	O
:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness	O
,	O
psychiatric	B-DISEASE
co	B-CHEMICAL
-	O
morbidity	O
,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	B-DISEASE
transplantation	O
(	O
LT	O
)	O
emergently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
(	O
n	O
=	O
36	O
)	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non	O
-	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
(	O
n	O
=	O
35	O
)	O
and	O
elective	O
LT	O
for	O
chronic	O
liver	B-DISEASE
disease	I-DISEASE
RESULTS	O
:	O
Acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
Twenty	O
(	O
56	O
%)	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
patients	O
had	O
a	O
formal	O
psychiatric	B-DISEASE
diagnosis	I-DISEASE
before	O
LT	O
(	O
non	O
-	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
=	O
0	O
/	O
35	O
,	O
CLD	O
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%)	O
had	O
a	O
previous	O
suicide	B-DISEASE
During	O
follow	O
-	O
up	O
(	O
median	O
5	O
years	O
),	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
),	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
1	O
year	O
87	O
%,	O
5	O
years	O
75	O
%;	O
non	O
-	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
Two	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
patients	O
reattempted	O
suicide	B-DISEASE
CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	B-DISEASE
disturbance	O
,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non	O
-	O
acetaminophen	B-CHEMICAL
-	O
induced	O
ALF	B-DISEASE
Multidisciplinary	O
approaches	O
with	O
long	O
-	O
term	O
psychiatric	B-DISEASE
follow	O
-	O
up	O
may	O
contribute	O
to	O
low	O
post	O
-	O
transplant	O
suicide	B-DISEASE
Studies	O
of	O
synergy	O
between	O
morphine	B-CHEMICAL
and	O
a	O
novel	O
sodium	B-CHEMICAL
channel	O
blocker	O
,	O
CNSB002	O
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-DISEASE
pain	I-DISEASE
OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	O
,	O
a	O
sodium	B-CHEMICAL
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	B-CHEMICAL
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-DISEASE
pain	I-DISEASE
DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	B-CHEMICAL
and	O
CNSB002	O
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	B-DISEASE
models	O
:	O
carrageenan	B-CHEMICAL
-	O
induced	O
paw	O
inflammation	B-DISEASE
and	O
streptozotocin	B-CHEMICAL
(	O
STZ	O
)-	O
induced	O
diabetic	B-DISEASE
neuropathy	I-DISEASE
RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	B-CHEMICAL
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNSB002	O
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	O
with	O
morphine	B-CHEMICAL
The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B-DISEASE
(	O
ED50	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
carrageenan	B-CHEMICAL
model	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	O
-	O
induced	O
neuropathy	B-DISEASE
model	O
for	O
CNSB002	O
and	O
morphine	B-CHEMICAL
The	O
ED50	O
values	O
for	O
morphine	B-CHEMICAL
when	O
given	O
in	O
combination	O
with	O
CNSB002	O
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carrageenan	B-CHEMICAL
model	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
neuropathy	B-DISEASE
The	O
antinociception	O
after	O
morphine	B-CHEMICAL
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	B-CHEMICAL
-	O
administration	O
with	O
CNSB002	O
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
reversal	O
of	O
hyperalgesia	B-DISEASE
CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	B-CHEMICAL
Heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
Heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
(	O
HIT	B-DISEASE
It	O
begins	O
when	O
heparin	B-CHEMICAL
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin	B-CHEMICAL
-	O
platelet	B-CHEMICAL
factor	I-CHEMICAL
4	I-CHEMICAL
Thrombosis	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	B-DISEASE
The	O
prevalence	O
of	O
HIT	B-DISEASE
HIT	B-DISEASE
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	B-DISEASE
and	O
suspected	O
whenever	O
thrombosis	B-DISEASE
occurs	O
after	O
heparin	B-CHEMICAL
The	O
treatment	O
of	O
HIT	B-DISEASE
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	B-CHEMICAL
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	O
thrombin	B-CHEMICAL
Current	O
"	O
diagnostic	O
"	O
tests	O
,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	B-DISEASE
Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	B-CHEMICAL
Direct	O
thrombin	B-CHEMICAL
inhibitors	O
are	O
appropriate	O
,	O
evidence	O
-	O
based	O
alternatives	O
to	O
heparin	B-CHEMICAL
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	B-DISEASE
As	O
heparin	B-CHEMICAL
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	B-DISEASE
with	O
every	O
heparin	B-CHEMICAL
exposure	O
,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	B-CHEMICAL
Abductor	O
paralysis	B-DISEASE
after	O
botox	O
injection	O
for	O
adductor	O
spasmodic	O
dysphonia	B-DISEASE
OBJECTIVES	O
/	O
HYPOTHESIS	O
:	O
Botulinum	O
toxin	O
(	O
Botox	O
)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	O
spasmodic	O
dysphonia	B-DISEASE
Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness	O
,	O
throat	O
pain	B-DISEASE
Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	B-DISEASE
METHODS	O
:	O
Patients	O
that	O
received	O
Botox	O
injections	O
for	O
spasmodic	O
dysphonia	B-DISEASE
For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	B-DISEASE
,	O
age	O
,	O
sex	O
,	O
paralytic	O
Botox	O
dose	O
,	O
prior	O
Botox	O
dose	O
,	O
and	O
course	O
following	O
paralysis	B-DISEASE
Of	O
these	O
352	O
patients	O
,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	B-DISEASE
Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	B-DISEASE
and	O
continued	O
receiving	O
after	O
paralysis	B-DISEASE
Seven	O
patients	O
recovered	O
after	O
a	O
brief	B-DISEASE
The	O
incidence	O
of	O
abductor	O
paralysis	B-DISEASE
CONCLUSIONS	O
:	O
Bilateral	O
abductor	O
paralysis	B-DISEASE
The	O
likely	O
mechanism	O
of	O
paralysis	B-DISEASE
The	O
paralysis	B-DISEASE
Mitochondrial	O
impairment	O
contributes	O
to	O
cocaine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
We	O
hypothesized	O
that	O
cocaine	B-DISEASE
abuse	I-DISEASE
may	O
lead	B-CHEMICAL
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
Seven	O
days	O
of	O
cocaine	B-CHEMICAL
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	B-CHEMICAL
In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	B-CHEMICAL
This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short	O
-	O
term	O
exposure	O
to	O
cocaine	B-CHEMICAL
,	O
suggesting	O
that	O
these	O
mitochondrial	O
abnormalities	B-DISEASE
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	B-CHEMICAL
MitoQ	O
,	O
a	O
mitochondrial	O
-	O
targeted	O
antioxidant	O
,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	O
abnormalities	B-DISEASE
as	O
well	O
as	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
Taken	O
together	O
,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
Trimethoprim	B-CHEMICAL
-	O
induced	O
immune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	B-DISEASE
hemolytic	I-DISEASE
transfusion	I-DISEASE
reaction	I-DISEASE
A	O
10	O
-	O
year	O
-	O
old	O
male	O
with	O
acute	O
leukemia	B-DISEASE
presented	O
with	O
post	O
-	O
chemotherapy	O
anemia	B-DISEASE
During	O
red	O
cell	O
transfusion	O
,	O
he	O
developed	O
hemoglobinuria	B-DISEASE
Transfusion	B-DISEASE
reaction	I-DISEASE
Drug	O
-	O
induced	O
immune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	B-CHEMICAL
and	O
trimethoprim	B-CHEMICAL
-	O
sulfamethoxazole	B-CHEMICAL
but	O
negative	O
with	O
sulfamethoxazole	B-CHEMICAL
The	O
patient	O
recovered	O
after	O
discontinuing	O
the	O
drug	O
,	O
with	O
no	O
recurrence	B-DISEASE
Other	O
causes	O
of	O
anemia	B-DISEASE
should	O
be	O
considered	O
in	O
patients	O
with	O
worse	O
-	O
than	O
-	O
expected	O
anemia	B-DISEASE
Furthermore	O
,	O
hemolysis	B-DISEASE
during	O
transfusion	O
is	O
not	O
always	O
a	O
transfusion	B-DISEASE
reaction	I-DISEASE
Blockade	O
of	O
endothelial	O
-	O
mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
OBJECTIVE	O
:	O
A	O
multicenter	O
,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHEMICAL
system	O
in	O
patients	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	B-DISEASE
,	O
suggesting	O
that	O
other	O
mechanism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
(	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
We	O
have	O
previously	O
demonstrated	O
that	O
endothelial	O
-	O
mesenchymal	O
-	O
transition	O
(	O
EndoMT	O
)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	B-DISEASE
interstitial	O
fibrosis	B-DISEASE
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	B-CHEMICAL
(	O
STZ	O
)-	O
induced	O
diabetes	B-DISEASE
In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
induced	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
Immunoprecipitation	O
/	O
Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
induced	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT	O
,	O
reduced	O
renal	B-DISEASE
fibrosis	B-DISEASE
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	B-DISEASE
CONCLUSIONS	O
:	O
EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
and	O
other	O
diabetes	B-DISEASE
complications	I-DISEASE
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	B-CHEMICAL
in	O
refractory	O
mantle	O
cell	O
lymphoma	B-DISEASE
Mantle	O
cell	O
lymphoma	B-DISEASE
(	O
MCL	O
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	O
-	O
cell	O
non	O
-	O
Hodgkin	B-DISEASE
'	I-DISEASE
s	I-DISEASE
lymphoma	I-DISEASE
However	O
,	O
a	O
38	O
%	O
remission	B-DISEASE
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	O
treated	O
with	O
temsirolimus	B-CHEMICAL
,	O
a	O
mTOR	O
inhibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	O
who	O
had	O
tumor	B-DISEASE
regression	O
two	O
months	O
after	O
temsirolimus	B-CHEMICAL
In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-CHEMICAL
Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B-CHEMICAL
inhibited	O
tumor	B-DISEASE
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B-DISEASE
Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	B-CHEMICAL
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B-DISEASE
Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	B-DISEASE
tissue	O
repair	O
,	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	B-CHEMICAL
Thus	O
,	O
temsirolimus	B-CHEMICAL
reduced	O
tumor	B-DISEASE
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsirolimus	B-CHEMICAL
on	O
tumor	B-DISEASE
Syncope	B-DISEASE
caused	O
by	O
hyperkalemia	B-DISEASE
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	B-CHEMICAL
-	O
converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	B-CHEMICAL
A	O
76	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	O
of	O
consciousness	O
due	O
to	O
marked	O
bradycardia	B-DISEASE
caused	O
by	O
hyperkalemia	B-DISEASE
The	O
concentration	O
of	O
serum	O
potassium	B-CHEMICAL
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	B-CHEMICAL
The	O
cause	O
of	O
hyperkalemia	B-DISEASE
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	O
,	O
an	O
aldosterone	B-CHEMICAL
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	B-CHEMICAL
,	O
an	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B-DISEASE
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE	O
/	O
ARB	O
in	O
combination	O
with	O
potassium	B-CHEMICAL
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-DISEASE
Diffuse	O
skeletal	O
pain	B-DISEASE
after	O
administration	O
of	O
alendronate	B-CHEMICAL
BACKGROUND	O
:	O
Osteoporosis	B-DISEASE
is	O
caused	O
by	O
bone	B-DISEASE
resorption	I-DISEASE
in	O
excess	O
of	O
bone	O
formation	O
,	O
and	O
bisphosphonates	O
,	O
are	O
used	O
to	O
inhibit	O
bone	B-DISEASE
resorption	I-DISEASE
Alendronate	B-CHEMICAL
,	O
a	O
biphosphonate	O
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	B-DISEASE
Musculoskeletal	B-DISEASE
pain	I-DISEASE
We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out	O
-	O
patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	B-DISEASE
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	B-CHEMICAL
CONCLUSION	O
:	O
We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	B-DISEASE
can	O
report	O
pain	B-DISEASE
,	O
and	O
bisphosphonate	O
-	O
related	O
pain	B-DISEASE
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	B-DISEASE
Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	B-CHEMICAL
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	B-DISEASE
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	B-CHEMICAL
-	O
sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	B-DISEASE
with	O
suspected	O
MSSA	O
meningitis	B-DISEASE
treated	O
with	O
high	O
-	O
dose	O
daptomycin	B-CHEMICAL
CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B-DISEASE
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B-DISEASE
Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	B-CHEMICAL
,	O
levofloxacin	B-CHEMICAL
,	O
and	O
piperacillin	B-CHEMICAL
/	O
tazobactam	B-CHEMICAL
Blood	O
cultures	O
revealed	O
S	O
.	O
aureus	O
susceptible	O
to	O
oxacillin	B-CHEMICAL
Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	B-CHEMICAL
On	O
day	O
8	O
,	O
the	O
patient	O
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
serum	O
creatinine	B-CHEMICAL
The	O
patient	O
'	O
s	O
Glasgow	O
Coma	B-DISEASE
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	B-DISEASE
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	B-DISEASE
Nafcillin	B-CHEMICAL
was	O
discontinued	O
and	O
daptomycin	B-CHEMICAL
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B-DISEASE
and	O
was	O
continued	O
until	O
the	O
patient	O
'	O
s	O
death	B-DISEASE
Daptomycin	B-CHEMICAL
Creatine	B-CHEMICAL
kinase	I-CHEMICAL
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	B-CHEMICAL
DISCUSSION	O
:	O
Daptomycin	B-CHEMICAL
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	B-CHEMICAL
-	O
induced	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
and	O
relapsing	O
bacteremia	B-DISEASE
At	B-DISEASE
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	B-CHEMICAL
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B-DISEASE
Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	B-DISEASE
The	O
role	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
in	O
convulsions	B-DISEASE
induced	O
by	O
lindane	B-CHEMICAL
Lindane	B-CHEMICAL
It	O
evokes	O
convulsions	B-DISEASE
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	B-CHEMICAL
Nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
),	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
precursor	O
of	O
NO	O
syntheses	O
(	O
NOS	O
),	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
NAME	I-CHEMICAL
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B-DISEASE
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	O
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	B-CHEMICAL
-	O
induced	O
epilepsy	B-DISEASE
The	O
administration	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	B-DISEASE
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B-DISEASE
elicited	O
by	O
lower	O
lindane	B-CHEMICAL
On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
NAME	I-CHEMICAL
decreased	O
convulsion	B-DISEASE
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B-DISEASE
following	O
injection	O
with	O
a	O
convulsive	B-DISEASE
dose	O
of	O
lindane	B-CHEMICAL
EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
prior	O
to	O
lindane	B-CHEMICAL
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
NAME	I-CHEMICAL
These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	O
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	B-CHEMICAL
seizures	B-DISEASE
Long	O
-	O
term	O
oral	O
galactose	B-CHEMICAL
treatment	O
prevents	O
cognitive	B-DISEASE
deficits	I-DISEASE
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B-CHEMICAL
Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B-DISEASE
of	O
sporadic	O
Alzheimer	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
sAD	B-DISEASE
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	B-CHEMICAL
-	O
receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	B-CHEMICAL
transport	O
via	O
glucose	B-CHEMICAL
transporter	O
GLUT4	O
and	O
decreased	O
glucose	B-CHEMICAL
metabolism	B-DISEASE
An	O
alternative	O
source	O
of	O
energy	O
is	O
d	O
-	O
galactose	B-CHEMICAL
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	O
-	O
glucose	B-CHEMICAL
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	B-CHEMICAL
-	O
independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B-CHEMICAL
Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B-CHEMICAL
induce	O
memory	O
deterioration	O
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	B-DISEASE
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B-CHEMICAL
We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B-CHEMICAL
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-DISEASE
deficits	I-DISEASE
in	O
streptozotocin	B-CHEMICAL
-	O
induced	O
(	O
STZ	O
-	O
icv	O
)	O
rat	O
model	O
of	O
sAD	B-DISEASE
,	O
tested	O
by	O
Morris	O
Water	B-CHEMICAL
One	O
month	O
of	O
oral	O
galactose	B-CHEMICAL
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	O
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	O
-	O
icv	O
-	O
induced	O
cognitive	B-DISEASE
deficits	I-DISEASE
Beneficial	O
effect	O
of	O
oral	O
galactose	B-CHEMICAL
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	B-CHEMICAL
Additionally	O
,	O
oral	O
galactose	B-CHEMICAL
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B-CHEMICAL
The	O
increase	O
of	O
galactose	B-CHEMICAL
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B-CHEMICAL
Oral	O
galactose	B-CHEMICAL
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-DISEASE
deficits	I-DISEASE
associated	O
with	O
glucose	B-CHEMICAL
